<tstset trglang="any" setid="test" srclang="any">
<doc sysid="Edinburgh" docid="doc">
<seg id="1">"" "" "" "this document is a summary of the European Public Department report (EPAR), which explains how the Committee for Human Genetics (CHMP) evaluated the studies carried out to make recommendations regarding the use of the medicine." "" "" ""</seg>
<seg id="2">"" "" "" "if you need more information about your illness or their treatment, please read the package supplement (also part of the EPAR) or contact your doctor or pharmacist." "" "" ""</seg>
<seg id="3">"" "" "" "if you would like more information regarding the CHMP recommendations, please read the scientific discussion (also part of EPAR)." "" "" ""</seg>
<seg id="4">"" "" "" "it is available as a 5 mg, 10 mg, 15 mg and 30 mg tablets, as a solution for intake (1 mg / ml) and as an injection solution (7.5 mg / ml)." "" "" ""</seg>
<seg id="5">"" "" "" "B. wirres thinking and speaking, hallucinations (hearing or seeing things that are not present), distrust and delusions; • Bipolar-I disorder, in which patients have various episodes (periods of abnormal high spirits) with periods of normal mood." "" "" ""</seg>
<seg id="6">"" "" "" "in addition, Abilify is used to treat moderate to severe manic episodes and to prevent manic episodes in patients who have approached the medicine in the past." "" "" ""</seg>
<seg id="7">"" "" "" "the injection solution is used for rapid control of increased anxiety or behavioural disorders, if oral consumption of the medication is not possible." "" "" ""</seg>
<seg id="8">"" "" "" "in both diseases, the solution can be applied to intake or the melting tablets used in patients who prepare the swallowing of tablets." "" "" ""</seg>
<seg id="9">"" "" "" "in patients who are taking other medicines at the same time, the same as Abilify should be reduced, the dose of Abilify should be adjusted." "" "" ""</seg>
<seg id="10">"" "" "" "this impairs the signal transmission between brain cells by" neurotransmitters, "i.e. chemical substances that enable communication between neurotransmitters." "" "" ""</seg>
<seg id="11">Aripiprazole probably acts mainly as a "partial agonist" for the neurotransmitter dopamine and 5-hydroxytryptamin (also called serotonin).</seg>
<seg id="12">"" "" "" "this means that Aripiprazole, such as 5-hydroxytryptamin and dopamine, has a lower degree than neurotransmitters to activate the receptors." "" "" ""</seg>
<seg id="13">"" "" "" "as dopamine and 5-hydroxytryptamin play a role in schizophrenia and bipolar disorder, Aripiprazole helps to normalize the activity of the brain." "" "" ""</seg>
<seg id="14">"" "" "" "the effectiveness of Abilify, which prevents recurrence of symptoms, has been studied in three studies of up to one year." "" "" ""</seg>
<seg id="15">"" "" "" "the effectiveness of the injection solution was compared in two studies in 805 patients with schizophrenia or similar disorders, which led to increased agitation, over a period of two hours with a placebo." "" "" ""</seg>
<seg id="16">"" "" "" "in another study, Abilify was compared to 347 patients with haloperidol, in another study the efficacy of Abilify and placebo, in which the manic symptoms have already been stabilized with Abilify." "" "" ""</seg>
<seg id="17">The efficacy of Abilify injections was compared in a study of 301 patients with bipolar disorder that led to increased unrest led by Lorazepam (another anti-psychotic medication) and placebo over a period of two hours.</seg>
<seg id="18">"" "" "" "in all studies, the patient's symptoms were examined based on a standard scale for bipolar disorder or the number of patients receiving treatment." "" "" ""</seg>
<seg id="19">"" "" "" "the company also conducted studies to investigate how the body absorbs the melting tablets, and the solution for intake (absorbs)." "" "" ""</seg>
<seg id="20">"" "" "" "in both studies with the injection solution, patients who received Abilify in doses of 5,25 mg, 9.75 mg or 15 mg were significantly stronger in reducing symptoms than those receiving a placebo." "" "" ""</seg>
<seg id="21">"" "" "" "in applying for the treatment of bipolar disorder, Abilify decreased in four of the five short-time studies of manic symptoms more effective than placebo." "" "" ""</seg>
<seg id="22">"" "" "" "in addition, Abilify prevented up to 74 weeks more effective than placebo the recurrence of manic episodes in previously untreated patients and when administered in addition to an existing treatment." "" "" ""</seg>
<seg id="23">"" "" "" "in 10- or 15 mg doses, Abilify injections also reduced the symptoms of increased unrest and were similarly effective as Lorazepam." "" "" ""</seg>
<seg id="24">"" "" "" "the most common side effects of Abilify (observed in 1 to 10 of 100 patients) are extradipyramidal disorders (uncontrolled access), fatigue and exhaustion, nausea and exhaustion, restlessness, insomnia (sleep disorders) and anxiety." "" "" ""</seg>
<seg id="25">The Committee for Medicinal Drugs (CHMP) concluded that the advantages of Abilify in treating schizophrenia and from moderate to severe manic episodes in cases of bipolar-I disorder and the prevention of a new manic episode in patients with Aripizzol compared to the risks.</seg>
<seg id="26">"" "" "" "furthermore, the Committee came to the conclusion that the advantages of injection solution for fast control of increased unrest and behavioural disturbances in patients with schizophrenia or in patients with manic episodes in bipolar-I disorder should prevail over the risks." "" "" ""</seg>
<seg id="27">"" "" "" "in June 2004, the European Commission granted the company Otsuka Pharmaceutical Europe Ltd. approval for the placing of Abilify in the entire European Union." "" "" ""</seg>
<seg id="28">ABILIFY is indicated for the treatment of moderate to severe manic episodes of the bipolar disorder and for the prevention of a new manic episode in patients who had predominantly manic episodes and discussed their manic episodes on the treatment with Aripiprazole (see Section 5.1).</seg>
<seg id="29">"" "" "" "the recommended starting dose for ABILIFY amounts to 10 or 15 mg / day at a maintenance dose of 15 mg / day, regardless of meals." "" "" ""</seg>
<seg id="30">"" "" "" "increased effectiveness in dosages over a daily dose of 15 mg has not been proven, although individual patients may benefit from a higher dose." "" "" ""</seg>
<seg id="31">"" "" "" "the recommended starting dose for ABILIFY is 15 mg once a day, regardless of meals as a monotherapy or combination therapy (see Section 5.1)." "" "" ""</seg>
<seg id="32">The efficacy of ABILIFY in the treatment of schizophrenia and bipolar disorder in patients ≥ 65 years has not been proven.</seg>
<seg id="33">"" "" "" "with regard to the greater sensitivity of these patients, a lower initial dose should be considered if clinical factors justify this (see Section 4.4)." "" "" ""</seg>
<seg id="34">"" "" "" "if the CYP3A4 inductor is removed from the combination therapy, the recommended dose should be reduced to the recommended dose (see section 4.5)." "" "" ""</seg>
<seg id="35">"" "" "" "the occurrence of suicidal behavior belongs to psychotic diseases and affective disorders and was reported in some cases after onset, or after menopause, also in treatment with Aripiprazole (see section 4.8)." "" "" ""</seg>
<seg id="36">Results of an epidemiological study showed that there was no increased suicidal risk in patients with bipolar disorder compared to other antipsychotics.</seg>
<seg id="37">"" "" "" "Aripiprazole should be used with caution in patients with known cardiovascular diseases (myocardial infarction or ischemic heart disease, cardiac insufficiency), cerebrovascular diseases, conditions that are predisposing for hypotony." "" "" ""</seg>
<seg id="38">"" "" "" "3 Late dyskinesia: in clinical trials lasting one year or less, there were occasional reports of dyskinesia occurring during the treatment." "" "" ""</seg>
<seg id="39">"" "" "" "if symptoms and symptoms of late dyskinesia are treated with ABILIFY, consider reducing the dose or break the treatment." "" "" ""</seg>
<seg id="40">"" "" "" "if a patient develops signs and symptoms that indicate a mns or a clear high fever without an additional clinical manifestation of mns, all antipsychotics, including ABILIFY, must be removed." "" "" ""</seg>
<seg id="41">"" "" "" "therefore, Aripiprazole should be used with caution in patients with seizures in the anamnesis or at states associated with cramps." "" "" ""</seg>
<seg id="42">"" "" "" "56 - 99 years) with Aripiprazole in cases associated with Alzheimer's disease, patients treated with Aripiprazole had an increased risk of death compared to placebo." "" "" ""</seg>
<seg id="43">"" "" "" "there was however, in one of these studies, a study involving fixed dosage, a significant relationship between dosage and response for undesired cerebrovascular events in patients treated with Aripiprazole." "" "" ""</seg>
<seg id="44">"" "" "" "hyperglycemia, in some cases extremely and associated with ketoacidosis or hyperosmolar coma or death, was reported in patients treated with atypical antipsychotic drugs including ABILIFY." "" "" ""</seg>
<seg id="45">There are no precise risk assessments for hyperglycemia-related adverse events associated with ABILIFY and other atypical antipsychotic drugs to allow direct comparisons.</seg>
<seg id="46">"" "" "" "polydipoles, polyurine, polyphagia and weakness) are observed and patients with diabetes mellitus or with risk factors for diabetes mellitus should be regularly monitored regarding the deterioration of glucose levels." "" "" ""</seg>
<seg id="47">"" "" "" "weight gain is generally observed in schizophrenic patients and in patients with bipolar deficiency, the use of antipsychotics, in which weight gain is known as a side effect and could lead to serious complications." "" "" ""</seg>
<seg id="48">"" "" "" "due to the primary efficacy of Aripiprazole on the central nervous system, caution is recommended if Aripiprazole is used in combination with alcohol or other centrally administered medications containing superimposed side effects such as sedation (see Section 4.8)." "" "" ""</seg>
<seg id="49">"" "" "" "the H2 antagonist Famotidin, a gastric acid blocker, reduces the absorption rate of Aripiprazole, but this effect is considered clinically irrelevant." "" "" ""</seg>
<seg id="50">"" "" "" "in a clinical study involving healthy subjects, a highly effective CYP2D6 inhibitor (Chinidine) increased the AUC from Aripiprazole by 107% while the CMAx remained unchanged." "" "" ""</seg>
<seg id="51">"" "" "" "it is expected that other highly effective inhibitors of CYP2D6, such as fluoxetine and paroxetine, have similar effects and therefore should be carried out similar dosages." "" "" ""</seg>
<seg id="52">CYP2D6 'bad' (= 'poor') metabolism can result in joint application with high-effective inhibitors of CYP3A4 in higher plasma concentrations of Aripizzol compared to CYP2D6 Extensive metabolites.</seg>
<seg id="53">Considering the common gift of ketoconazol or other highly effective CYP3A4 inhibitors with ABILIFY the potential benefits should weigh the potential risks for the patient.</seg>
<seg id="54">"" "" "" "other highly effective inhibitors of CYP3A4, such as Itraconazole and HIV proteaseinase inhibitors, should have similar effects and should therefore be carried out similar doses." "" "" ""</seg>
<seg id="55">"" "" "" "after placing the CYP2D6- or 3A4 inhibitor, the dose of ABILIFY should be raised to the dose height before the beginning of the accompanying therapy." "" "" ""</seg>
<seg id="56">Diltiazem or escitalopram) or CYP2D6 together with ABILIFY can be calculated with a moderate rise in Aripiprazol- concentrations.</seg>
<seg id="57">In clinical studies doses of 10-30 mg of Aripivzol showed no significant effect on the metabolism of the substrates of CYP2D6 (Dextromethorphan / 3-methoxy morphine ratio) and 3A4 (Dextromethorphan).</seg>
<seg id="58">"" "" "" "patients should be advised to inform their doctor if they are pregnant, or plan pregnancy during treatment with Aripiprazole." "" "" ""</seg>
<seg id="59">"" "" "" "this drug may not be used in pregnancy because of the insufficient data storage for safety in humans and because of the concerns caused in the reproductive studies of the animal, unless the potential benefit justifies the potential risk for the foetus." "" "" ""</seg>
<seg id="60">"" "" "" "however, as with other antipsychotics, the patients should be warned against dangerous machines, including force vehicles, until they are sure that Aripiprazole has no negative influence on them." "" "" ""</seg>
<seg id="61">"" "" "" "the following side effects were more common (≥ 1 / 100) compared to placebo, or were classified as possible medically relevant adverse events (*):" "" "" ""</seg>
<seg id="62">"" "" "" "the frequency of the side effects listed below is defined according to the following criteria: frequent (&gt; 1 / 100, &lt; 1 / 10); occasionally (&gt; 1 / 1,000, &lt; 1 / 100)." "" "" ""</seg>
<seg id="63">Schizophrenia - In a controlled long-term study for 52 weeks a lower incidence (25.8%) of EPS including Parkinsonism and Dyskinesia was compared to patients treated with haloperidol (57.3%).</seg>
<seg id="64">"" "" "" "in a placebo-controlled long-term study over 26 weeks, the incidence of EPS 19% in patients under Aripizzol treatment and 13.1% in patients was placebo." "" "" ""</seg>
<seg id="65">"" "" "" "in another controlled long-term study over 26 weeks, the incidence of EPS 14.8% in patients treated with Aripiprazole was 15.1% in patients with Olanzapine therapy." "" "" ""</seg>
<seg id="66">Manic episodes in bipolar-I-disorder - in a controlled study of 12 weeks the incidence of EPS 23.5% in patients with Aripiprazol- treatment and 53.3% in patients with haloperidol therapy.</seg>
<seg id="67">"" "" "" "in another study of 12 weeks, the incidence of EPS 26,6% in patients under Aripizzol treatment and 17.6% for those under lithium." "" "" ""</seg>
<seg id="68">In the long-term follow-up period over 26 weeks in a placebo-controlled trial the incidence of EPS 18.2% was for patients under Aripiprazol- treatment and 15.7% for patients treated with placebo.</seg>
<seg id="69">"" "" "" "a comparison between the patient groups under Aripiprazole and placebo, with potentially clinically significant changes of routinely controlled laboratory parameters, did not reveal any medically significant differences." "" "" ""</seg>
<seg id="70">"" "" "" "increases of CPK (creatine phosphate kinase), generally temporary and asymptomatic, were observed in patients treated with Aripiprazole compared to 2.0% of patients treated with placebo." "" "" ""</seg>
<seg id="71">"" "" "" "the malignant neuroleptic syndrome, late dyskinesia and seizures, abnormal cerebrovascular events and increased mortality in older dementia patients, hyperglycemia and diabetes mellitus (see section 4.4)." "" "" ""</seg>
<seg id="72">"" "" "" "in clinical trials and since the market launch, unintentional or deliberate overdosages with Aripiprazole were observed alone in adult patients with estimated doses of up to 1260 mg and without a death sequence." "" "" ""</seg>
<seg id="73">"" "" "" "although there is no information on the efficacy of a hemodialysis in the treatment of overdosage with Aripiprazole, it is unlikely that Hemodialysis is beneficial in the treatment of overdosage as Aripiprazole has a high plasma protein binding." "" "" ""</seg>
<seg id="74">It is suspected that the efficacy of Aripiprazole in schizophrenia and bipolar-I disturbance on the combination of a partially antagonistic effect on dopamine dopamine and serotonin 5HT1 receptors and an antagonistic effect on serotonin 5HT2a receptors is mediated.</seg>
<seg id="75">Aripiprazole showed in vitro a high affinity to the dopamine D2- and D3 receptor and the serotonin 5HT1 and 5HT2a receptor as well as a moderate affinity with dopamine D4 and 5HT7- and to alpha-1-adrenergic and to the histamine-H1receptor.</seg>
<seg id="76">"" "" "" "in the application of Aripiprazole in dosages ranging from 0.5 to 30 mg once a day, the positron-emission tomography showed a dose-dependent decrease in the binding of 11C-Racloprid, a D2 / D3 receptor ligands, at the nucleus caudatus and at the putative." "" "" ""</seg>
<seg id="77">"" "" "" "in three placebo-controlled short-term studies (4 to 6 weeks) on 1,228 schizophrenic patients with positive or negative symptoms, Aripiprazole showed a statistically significant improvement in the psychotic symptoms." "" "" ""</seg>
<seg id="78">"" "" "" "in a haloperidol-controlled study, 52 was the proportion of responder patients receiving a response to study medication in both groups (Aripiprazole 77% and haloperidol 73%)." "" "" ""</seg>
<seg id="79">"" "" "" "current values from Messscales, defined as secondary study targets, including PANSS and the Montgomery-Asmine depression rate scale showed a significantly stronger improvement than with haloperidol." "" "" ""</seg>
<seg id="80">"" "" "" "in a placebo-controlled study of 26 weeks in stabilized patients with chronic schizophrenia, a significantly higher rate of relapse was found at 34% in the Aripizzol group and 57% in placebo." "" "" ""</seg>
<seg id="81">"" "" "" "in an Olanzapine-controlled, multinational double blind study for schizophrenia over 26 weeks, with significantly less patients a weight gain of at least 7% compared to the initial value (i.e. an increase of at least 5.6 kg with an average weight of ca.)." "" "" ""</seg>
<seg id="82">"" "" "" "in two placebo-controlled monotherapy studies with flexible dosage of 3 weeks with a manic or mixed episode of the bipolar-I disorder, Aripiprazole showed a superior efficacy compared to placebo over 3 weeks." "" "" ""</seg>
<seg id="83">"" "" "" "in a placebo-controlled monotherapy study, over 3 weeks with fixed doses of patients with a manic or mixed episode of bipolar I disorder showed no superior efficacy compared to placebo." "" "" ""</seg>
<seg id="84">"" "" "" "in two placebo and active controlled monotherapy studies for 12 weeks in patients with a manic or mixed episode of a bipolar I disorder, with or without psychotic characteristics, Aripiprazole showed a week 3 and an effect effect comparable to that of lithium or haloperidol in week 12." "" "" ""</seg>
<seg id="85">"" "" "" "in addition, Aripiprazole reported a comparable proportion of patients with symptomatic remission of the mania on such as lithium or haloperidol." "" "" ""</seg>
<seg id="86">"" "" "" "in a placebo-controlled study for 6 weeks with a manic or mixed episode of a bipolar-I disorder, with or without psychotic features, the companion therapy with Aripiprazole revealed a superior efficacy in reducing manic symptoms compared to monotherapy with lithium or valproat." "" "" ""</seg>
<seg id="87">10 In a placebo-controlled study over 26 weeks followed by a long-term expansion phase over 74 weeks in manian patients with Aripiprazole prior to randomization a remission was superior to the prevention of a bipolar recurrence.</seg>
<seg id="88">"" "" "" "based on in vitro studies, the CYP3A4 and CYP2D6 enzymes are responsible for Dehydration and hydroxyulation of Aripiprazole and the N-Dealkyulation is catalysed by CYP3A4." "" "" ""</seg>
<seg id="89">"" "" "" "in approximately 75 hours, the middle Elimination Halbal period is about CYP2D6 and approximately 146 hours with 'bad' (= 'poor') metabolites above CYP2D6." "" "" ""</seg>
<seg id="90">"" "" "" "in Aripiprazole, there are no differences in the pharmacokinetic between male and female healthy subjects, as well as showed no gender-related effects in a pharmacokinetic study of schizophrenic patients." "" "" ""</seg>
<seg id="91">A pop-up-specific analysis of pharmacokinetics did not reveal any clinically significant differences in respect to the ethnicity or the impact of smoking on the pharmacokinetics of Aripiprazole.</seg>
<seg id="92">The pharmacokinetic properties of Aripiprazole and Dehydro-Aripivzol were similar in patients with severe kidney failure compared to young healthy volunteers.</seg>
<seg id="93">"" "" "" "the study included only 3 patients with liver cirrhosis of the class C for liver cirrhosis, but the study included only 3 patients with liver cirrhosis of the class C, which is not sufficient to draw conclusions on their metabolic capacity." "" "" ""</seg>
<seg id="94">"" "" "" "based on conventional studies on safety macology, toxicity in repeated application, reproductive toxicity, genotoxicity and potential carcinogenic potential, the preclinical data could not be recognized by any particular danger to humans." "" "" ""</seg>
<seg id="95">"" "" "" "toxicologically significant effects were observed only in dosages or exposures, which significantly exceeded the maximum dosage or exposure to humans, so they have limited or no importance for clinical use." "" "" ""</seg>
<seg id="96">The effects included a dose-dependent ancillary toxicity (lipofuscin pigmentation and / or parenchymal loss) in rats after 104 weeks at the recommended maximum dose of 60 mg / kg / day (the average Steady State exposure (AUC) at the recommended maximum dose of humans).</seg>
<seg id="97">Also a cholelithiasis was detected as a result of the precipitation of the sulfate conjugates of the hydroxy- metabolites of Aripiprazol in the bile from 25 to 125 mg / kg / day (1 to 3 times the average Steady State exposure (AUC) at the recommended maximum dose of humans based on mg / m2).</seg>
<seg id="98">"" "" "" "however, the concentrations found in human gall at the highest recommended daily dose of 30 mg of Hydroxy- Aripiprazole found no more than 6% of the concentrations found in the study for 39 weeks in the Galle by monkeys." "" "" ""</seg>
<seg id="99">"" "" "" "in rabbits, these effects were observed following dosages, which led to positions of the 3 and 11ples of the average Steady State AUC at the recommended clinical maximum dose." "" "" ""</seg>
<seg id="100">"" "" "" "perforated blister packs for delivery of aluminium cans with 14 x 1, 28 x 1, 49 x 1, 56 x 1, 98 x 1 tablets." "" "" ""</seg>
<seg id="101">"" "" "" "15 Late dyskinesia: in clinical trials lasting one year or less, there were occasional reports of dyskinesia occurring during the treatment." "" "" ""</seg>
<seg id="102">It is suspected that the efficacy of Aripiprazole in schizophrenia and bipolar-I disturbance on the combination of a partially antagonistic effect on dopamine dopamine and serotonin 5HT1 receptors and an antagonistic effect on serotonin 5HT2a receptors is mediated.</seg>
<seg id="103">22 In a placebo-controlled study over 26 weeks followed by a long-term expansion phase over 74 weeks in manian patients with Aripiprazole prior to randomization a remission was superior to the prevention of a bipolar recurrence.</seg>
<seg id="104">"" "" "" "27 late-dyskinesia: in clinical trials lasting one year or less, there were occasional reports of dyskinesia occurring during the treatment." "" "" ""</seg>
<seg id="105">It is suspected that the efficacy of Aripiprazole in schizophrenia and bipolar-I disturbance on the combination of a partially antagonistic effect on dopamine dopamine and serotonin 5HT1 receptors and an antagonistic effect on serotonin 5HT2a receptors is mediated.</seg>
<seg id="106">34 In a placebo-controlled study over 26 weeks followed by a long-term expansion phase over 74 weeks in manian patients with Aripiprazole in front of randomization a remission was superior to the prevention of a bipolar incident.</seg>
<seg id="107">"" "" "" "39 late-dyskinesia: in clinical trials that lasted for one year or less, occasional reports of dyskinesia occurring during the treatment were performed." "" "" ""</seg>
<seg id="108">It is suspected that the efficacy of Aripiprazole in schizophrenia and bipolar-I disturbance on the combination of a partially antagonistic effect on dopamine dopamine and serotonin 5HT1 receptors and an antagonistic effect on serotonin 5HT2a receptors is mediated.</seg>
<seg id="109">46 In a placebo-controlled study over 26 weeks followed by a long-term expansion phase over 74 weeks in manian patients with Aripiprazole in front of randomization a remission was superior to the prevention of a bipolar incident.</seg>
<seg id="110">"" "" "" "the recommended starting dose for Aripiprazole is 10 or 15 mg / day at a maintenance dose of 15 mg / day, daily independent of meals." "" "" ""</seg>
<seg id="111">"" "" "" "patients who have difficulty swallowing ABILIFY tablets, can alternatively use the melting tablets as alternative to ABILIFY tablets (see Section 5.2)." "" "" ""</seg>
<seg id="112">"" "" "" "the occurrence of suicidal behaviors is related to psychotic diseases and affective disorders, in some cases after onset or after menopause, also in treatment with Aripiprazole (see section 4.8)." "" "" ""</seg>
<seg id="113">"" "" "" "late dyskinesia: in clinical trials lasting one year or less, there were occasional reports of dyskinesia occurring during the treatment." "" "" ""</seg>
<seg id="114">"" "" "" "clinical manifestations of a mn are high fever, rigidity, changing levels of consciousness and signs of autonomous instability (irregular pulse or blood pressure, tachycardia, sweating and heart rhythm disorders)." "" "" ""</seg>
<seg id="115">"" "" "" "weight gain is generally observed in schizophrenic patients and in patients with bipolar deficiency, the use of antipsychotics, in which weight gain is known as a side effect or lead to serious complications." "" "" ""</seg>
<seg id="116">"" "" "" "patients should be advised to inform their doctor if they are pregnant, or pregnancy during treatment with Aripiprazole" "" "" ""</seg>
<seg id="117">"" "" "" "the following side effects were more common (≥ 1 / 100) compared to placebo, or were classified as possible medically relevant side effects of the drug (*):" "" "" ""</seg>
<seg id="118">"" "" "" "in two placebo-controlled monotherapy studies with flexible dosage of 3 weeks with a manic or mixed episode of the bipolar-I disorder, Aripiprazole showed a superior efficacy compared to placebo over 3 weeks." "" "" ""</seg>
<seg id="119">"" "" "" "58 in a placebo-controlled study for 6 weeks with a manic or mixed episode of a bipolar-I disorder, with or without psychotic features, which sometimes did not apply to lithium or valproate monotherapy compared to monotherapy with lithium or valproat." "" "" ""</seg>
<seg id="120">"" "" "" "in a placebo-controlled study for 26 weeks followed by a long-term expansion phase over 74 weeks in manian patients with Aripiprazole prior to randomization, Aripiprazole was superior to placebo." "" "" ""</seg>
<seg id="121">"" "" "" "in rabbits, these effects were evaluated according to dosages, which were considered to be an extension of the 3 and 11x of the average Steady State AUC at the recommended clinical trials." "" "" ""</seg>
<seg id="122">"" "" "" "patients who have difficulty swallowing ABILIFY tablets, can alternatively use the melting tablets as alternative to ABILIFY tablets (see Section 5.2)." "" "" ""</seg>
<seg id="123">"" "" "" "late dyskinesia: in clinical trials lasting one year or less, there were occasional reports of dyskinesia occurring during the treatment." "" "" ""</seg>
<seg id="124">"" "" "" "71 In a placebo-controlled study for 6 weeks with a manic or mixed episode of a bipolar-I disorder, with or without psychotic features, which partially did not apply to lithium or valproate monotherapy compared to monotherapy with lithium or valproat." "" "" ""</seg>
<seg id="125">"" "" "" "patients who have difficulty swallowing ABILIFY tablets, can alternatively use the melting tablets as alternative to ABILIFY tablets (see Section 5.2)." "" "" ""</seg>
<seg id="126">"" "" "" "late dyskinesia: in clinical trials lasting one year or less, there were occasional reports of dyskinesia occurring during the treatment." "" "" ""</seg>
<seg id="127">"" "" "" "84 In a placebo-controlled study for 6 weeks with a manic or mixed episode of a bipolar-I disorder, with or without psychotic features, the accompanying therapy with Aripiprazole resulted in superior efficacy in reducing manic symptoms compared to monotherapy with lithium or valproat." "" "" ""</seg>
<seg id="128">200 mg of fructose per ml 400 mg Sucrose per ml 1.1.8 mg methyl-4 hydroxybenzoate (E218) per ml 0.2 mg propyl-4 hydroxybenzoate (E216) per ml.</seg>
<seg id="129">"" "" "" "the recommended starting dose for ABILIFY is 15 mg once a day, regardless of meals as a monotherapy or combination therapy (see Section 5.1)." "" "" ""</seg>
<seg id="130">"" "" "" "in order to prevent recurrence of manic episodes in patients receiving Aripiprazole, the therapy should be continued with the same dose." "" "" ""</seg>
<seg id="131">"" "" "" "late dyskinesia: in clinical trials lasting one year or less, there were occasional reports of dyskinesia occurring during the treatment." "" "" ""</seg>
<seg id="132">"" "" "" "hyperglycemia, in some cases extremely and associated with ketoacidosis or hyperosmolar coma or death, was reported in patients treated with atypical antipsychotic drugs including ABILIFY." "" "" ""</seg>
<seg id="133">There are no precise risk assessments for hyperglycemia-related adverse events associated with ABILIFY and other atypical antipsychotic drugs to allow direct comparisons.</seg>
<seg id="134">"" "" "" "92 In a clinical study involving healthy subjects, a highly effective CYP2D6 inhibitor (Chinidine) increased the AUC from Aripiprazole by 107% while the CMAx remained unchanged." "" "" ""</seg>
<seg id="135">Diltiazem or escitalopram) or CYP2D6 together with ABILIFY can be calculated with a moderate rise in Aripiprazol- concentrations.</seg>
<seg id="136">"" "" "" "manic episodes in bipolar-I disorder - in a controlled study of 12 weeks, the incidence of EPS 23,5% in patients under Aripiprazol-" "" "" ""</seg>
<seg id="137">It is suspected that the efficacy of Aripiprazole in schizophrenia and bipolar-I disturbance on the combination of a partially antagonistic effect on dopamine dopamine and serotonin 5HT1 receptors and an antagonistic effect on serotonin 5HT2a receptors is mediated.</seg>
<seg id="138">"" "" "" "in an Olanzapine-controlled, multinational double blind study for schizophrenia over 26 weeks, with significantly less patients a weight gain of at least 7% compared to the initial value (i.e. an increase of at least 5.6 kg with an average weight of ca.)." "" "" ""</seg>
<seg id="139">"" "" "" "97 In a placebo-controlled monotherapy study, over 3 weeks with fixed doses of patients with a manic or mixed episode of bipolar I disorder showed no superior efficacy compared to placebo." "" "" ""</seg>
<seg id="140">The ratio between the geometrical CMAx mean value of the solution and the value of the tablets was 122% (N = 30) in a relative bioavailability study.</seg>
<seg id="141">99 Furthermore a cholelithiasis was detected as a result of the precipitation of the sulfate conjugates of the Hydroxy- Metabolites in the Galle of apes after repeated oral administration of 25 to 125 mg / kg / day (from 1 to 3 times the recommended maximum dose of humans based on mg / m2).</seg>
<seg id="142">"" "" "" "in rabbits, these effects were observed following dosages, which led to positions of the 3 and 11ples of the average Steady State AUC at the recommended clinical maximum dose." "" "" ""</seg>
<seg id="143">ABILIFY injections solution is used for rapid control of intoxicity and behavioural disorders in patients with schizophrenia or in patients with manic episodes of bipolar I disorder if oral therapy is not appropriate.</seg>
<seg id="144">"" "" "" "once it is clinically attached, the treatment with Aripiprazole injections should be terminated and commenced with the oral application of Aripiprazole." "" "" ""</seg>
<seg id="145">"" "" "" "to increase the absorption and minimize variability, an injection in the M. Deltoideus or deep into the gluteus maximus muscle is recommended under bypass of adipous regions." "" "" ""</seg>
<seg id="146">A lower dose of 5.25 mg (0.7 ml) may be given depending on the individual clinical status taking into account the medicine used already for maintenance or acute treatment (see section 4.5).</seg>
<seg id="147">"" "" "" "if a further oral treatment with Aripiprazole is indicated, see the summary of the features of the drug to ABILIFY tablets, ABILIFY melt tablets or ABILIFY solution." "" "" ""</seg>
<seg id="148">There are no investigations into the efficacy of Aripiprazole injections in patients with atoxicity and behavioural disorders that have been caused by schizophrenia and manic episodes of bipolar I disorder.</seg>
<seg id="149">"" "" "" "if parenteral therapy with benzodiazepines is considered necessary in addition to the Aripiprazole injection solution, the patients should be observed with regard to extreme sedation or a blood pressure drop (see section 4.5)." "" "" ""</seg>
<seg id="150">Investigations on the safety and efficacy of Aripiprazole injection solution are not available for patients with alcohol or drug poisoning (prescribed or illegal medicines).</seg>
<seg id="151">"" "" "" "Aripiprazole should be used with caution in patients with known cardiovascular diseases (myocardial infarction or ischemic heart disease, cardiac insufficiency), cerebrovascular diseases, conditions that are predisposing for hypotony." "" "" ""</seg>
<seg id="152">"" "" "" "late dyskinesia: in clinical trials lasting one year or less, there were occasional reports of dyskinesia occurring during the treatment." "" "" ""</seg>
<seg id="153">"" "" "" "clinical manifestations of a mn are high fever, stiffness, changing levels of consciousness and signs of autonomous instability (irregular pulse or blood pressure, tachycardia, sweating and heart rhythm disorders)." "" "" ""</seg>
<seg id="154">"" "" "" "polydipoles, polyurine, polyphagia and weakness) are observed and patients with diabetes mellitus or with risk factors for diabetes mellitus should be regularly monitored regarding the deterioration of glucose levels." "" "" ""</seg>
<seg id="155">"" "" "" "a weight gain is generally observed in schizophrenic patients and patients with bipolar deficiency, the use of antipsychotics, in which weight gain is known as a side effect or lead to serious complications." "" "" ""</seg>
<seg id="156">"" "" "" "nevertheless, the intensity of the sedation was greater compared with the after sole administration of Aripiprazole, in a study where healthy volunteers Aripiprazole (15 mg dose) were intramuscular and at the same time received Lorazepam (2 mg dosage) intramuscular." "" "" ""</seg>
<seg id="157">"" "" "" "105 The H2 antagonist Famotidin, a gastric acid blocker, decreases the absorption rate of Aripiprazole, but this effect is considered clinically irrelevant." "" "" ""</seg>
<seg id="158">CYP2D6 'bad' (= 'poor') metabolites can result in joint application with high-effective inhibitors of CYP3A4 in higher plasma concentrations of Aripizzol compared to CYP2D6.</seg>
<seg id="159">"" "" "" "other highly effective inhibitors of CYP3A4, such as Itraconazole and HIV- protein inhibitors, should have similar effects and should therefore be carried out similar doses." "" "" ""</seg>
<seg id="160">"" "" "" "after placing the CYP2D6- or 3A4 inhibitor, the dose of ABILIFY should be raised to the dose height before the beginning of the accompanying therapy." "" "" ""</seg>
<seg id="161">"" "" "" "106 Lorazepam (2 mg dosage) received intramuscular, the intensity of the sedation was greater compared with the after sole administration of Aripiprazole." "" "" ""</seg>
<seg id="162">"" "" "" "the following side effects were more common in clinical trials involving Aripizole injections (≥ 1 / 100) compared to placebo, or were classified as possible medically relevant adverse events (*) (see Section 5.1):" "" "" ""</seg>
<seg id="163">"" "" "" "the frequency of the side effects listed below is defined according to the following criteria: frequently (≥ 1 / 100, &lt; 1 / 10); occasionally (≥ 1 / 1,000, &lt; 1 / 100)." "" "" ""</seg>
<seg id="164">"" "" "" "107 Side effects occurred more frequently (≥ 1 / 100) compared to placebo, or were classified as potential medically relevant adverse events (*) in clinical trials (see Section 5.1):" "" "" ""</seg>
<seg id="165">"" "" "" "in a placebo-controlled long-term study over 26 weeks, the incidence of EPS 19% in patients under Aripiprazol- treatment and 13.1% in patients was placebo." "" "" ""</seg>
<seg id="166">"" "" "" "in another study of 12 weeks, the incidence of EPS 26,6% in patients with Aripiquzol- treatment and 17.6% for those under lithium." "" "" ""</seg>
<seg id="167">"" "" "" "in the long-term development phase over 26 weeks in a placebo-controlled study, the incidence of EPS 18,2% for patients under Aripipezol treatment and 15.7% was treated with placebo." "" "" ""</seg>
<seg id="168">"" "" "" "a comparison between the patient groups under Aripiprazole and placebo, with potentially clinically significant changes of routinely controlled laboratory parameters, did not reveal any medically significant differences." "" "" ""</seg>
<seg id="169">"" "" "" "increases in CPK (Creatinphosphokinase), generally temporary and asymptomatic, were observed in patients treated with Aripiprazole compared to 2.0% of patients treated with placebo." "" "" ""</seg>
<seg id="170">"" "" "" "the malignant neuroleptic syndrome, late dyskinesia and seizures, abnormal cerebrovascular events and increased mortality in older dementia patients, hyperglycemia and diabetes mellitus (see section 4.4)." "" "" ""</seg>
<seg id="171">110 and behavioural disorders was the Aripiprazole injection solution associated with statistically significant improvements of intoxicity / behavioural disorders compared to placebo and was similar to haloperidol.</seg>
<seg id="172">In a placebo-controlled short-time study (24 h) with 291 patients with bipolar disorder as well as agititis and behavioural disorders the Aripiprazole injection solution was associated with a statistically significant improvement in the symptoms in comparison to placebo and similar to the Lorazepam- reference arm.</seg>
<seg id="173">The observed average recovery from the initial value on the PANSS Excitement Component score at the primary 2-hour end point was 5.8 for placebo and 9.6 for Lorazepam and 8.7 for Aripiprazole.</seg>
<seg id="174">"" "" "" "in analyses of sub-groups in patients with mixed episodes or patients with severe aspiration, a similar efficacy was observed in relation to the total population, but a statistical significance kanz could be detected due to a reduced number of patients." "" "" ""</seg>
<seg id="175">"" "" "" "in three placebo-controlled short-term studies (4 to 6 weeks) with positive or negative symptoms, Aripiprazole (oral) showed a statistically significant improvement in psychotic symptoms compared to placebo." "" "" ""</seg>
<seg id="176">"" "" "" "in a haloperidol-controlled study, 52 was the percentage of responder patients receiving a response to study medication in both groups (Aripiprazole 77% (oral) and haloperidol 73%)." "" "" ""</seg>
<seg id="177">"" "" "" "current values from Messscales, defined as secondary study targets, including PANSS and the Montgomery-Asberg depression rate scale showed significantly stronger improvement than with haloperidol." "" "" ""</seg>
<seg id="178">In a placebo-controlled study of 26 weeks in stabilized patients with chronic schizophrenia a significantly higher rate of relapse was reduced to 34% in the Aripiprazol- (oral) group and 57% in placebo.</seg>
<seg id="179">"" "" "" "in an Olanzapine-controlled, multinational double blind study for schizophrenia over 26 weeks, with significantly less patients a weight gain of at least 7% compared to the initial value (i.e. an increase of at least 5.6 kg with an average weight of ca.)." "" "" ""</seg>
<seg id="180">"" "" "" "111 In a placebo-controlled study for 6 weeks with a manic or mixed episode of a bipolar-I disorder, with or without psychotic features, the accompanying therapy with Aripiprazole resulted in superior efficacy in reducing manic symptoms compared to monotherapy with lithium or valproat." "" "" ""</seg>
<seg id="181">"" "" "" "in a placebo-controlled study for 26 weeks followed by a 74 weeks study extension for some patients with Aripiprazole prior to randomization, Aripiprazole was superior to placebo." "" "" ""</seg>
<seg id="182">The Aripiprazole AUC is in the first 2 hours after intramuscular injection 90% larger the AUC after receiving the same dose as a tablet; the systemic exposure was similar between the two formulations.</seg>
<seg id="183">"" "" "" "in 2 studies with healthy volunteers, average time was up to 3 hours to achieve maximum plasma levels." "" "" ""</seg>
<seg id="184">The gift of Aripiprazole Injection Solution was tolerated by rats and monkeys and resulted in no direct toxicity of a target organ after repeated application in a systemic exposure (AUC) which was 15- or 5 times above the maximum human therapeutic exposure of 30 mg intramuscular.</seg>
<seg id="185">"" "" "" "in studies on reproductive toxicity according to intravenous application, no safety-relevant concerns were found after maternal exposure involving 15- (rats) and 29 times (rabbits) above the maximum human therapeutic exposure of 30 mg." "" "" ""</seg>
<seg id="186">"" "" "" "based on conventional studies with Aripiprazole (oral) for safety macology, toxicity in repeated application, reproductive toxicity, genotoxicity and potential carcinogenic potential, the preclinical data could not be recognized by the human being." "" "" ""</seg>
<seg id="187">"" "" "" "toxicologically significant effects were observed only in dosages or exposures, which significantly exceeded the maximum dosage or exposure to humans; in this way they have limited or no importance for clinical use." "" "" ""</seg>
<seg id="188">The effects covered a dose-dependent ancillary toxicity (lipofuscin pigmentation and / or parenchymal loss) in rats after 104 weeks at the recommended maximum dose in humans) and an increase of adrenal glands with 60 mg / kg / day (the 10-fold mean-state exposure (AUC) at the recommended maximum dose of humans).</seg>
<seg id="189">In addition a cholelithiasis was detected as a result of the precipitation of the sulfate conjugates of the hydroxy- metabolites of Aripiprazole in the bile from 25 to 125 mg / kg / day (1 to 3 times the average level-state exposure (AUC) at the recommended maximum dose of people based on mg / m2.</seg>
<seg id="190">"" "" "" "in rabbits, these effects were observed following dosages which led to exposures of the 3 and 11-fold of the mid-state AUC at the recommended clinical maximum dose." "" "" ""</seg>
<seg id="191">"" "" "" "the authorisation holder must ensure that before and while the product is marketed, the pharmacovigilance system, as described in version 1.0 of module 1.8.1. the application for authorisation, is furnished and functional." "" "" ""</seg>
<seg id="192">"" "" "" "according to the CHMP Guideline on Risk Management Systems for human use, the updated risk management plan must be submitted simultaneously with the next Periodic Safety Update Report (PSUR)." "" "" ""</seg>
<seg id="193">"" "" "" "in addition, an updated risk management plan must be submitted if new information is known which may affect the risk minimization of the current safety data, the pharmacovigilance plan or the risk management measures." "" "" ""</seg>
<seg id="194">14 x 1 tablets 28 x 1 tablets 49 x 1 tablets 56 x 1 tablets 98 x 1 tablets</seg>
<seg id="195">EU / 1 / 04 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 005 98 x 1 Tablets</seg>
<seg id="196">EU / 1 / 04 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 010 98 x 1 Tablets</seg>
<seg id="197">EU / 1 / 04 / 276 / 012 28 x 1 tablets EU / 1 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 015 98 x 1 tablets</seg>
<seg id="198">EU / 1 / 04 / 276 / 017 28 x 1 tablets EU / 1 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 020 98 x 1 tablets</seg>
<seg id="199">"" "" "" "if one of the listed side effects affects you significantly or you may notice any side effects not specified in this information information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="200">"" "" "" "it is used for treating adults suffering from a disease characterized by symptoms such as hearing, seeing, or feeling of things that are not present, distrust, delusions, unrelated speech, wiry behaviour and flat mood." "" "" ""</seg>
<seg id="201">"" "" "" "ABILIFY is used in adults to treat a condition with auctioned high feeling, feeling excessive energy, requiring much less sleep than usual, very fast speech with fast changing ideas and sometimes strong irritability." "" "" ""</seg>
<seg id="202">"" "" "" "high blood sugar or cases of diabetes (diabetes) in the family are inarbitrary, irregular muscle movements, especially in the face heart or vascular disease in the family, stroke or temporary bleeding of the brain (transitory ischemic attack / TIA), abnormal blood pressure." "" "" ""</seg>
<seg id="203">"" "" "" "if you suffer from dementia (loss of memory or other mental capacity), you should tell your doctor if you have ever had a stroke or a temporary vascularization of the brain." "" "" ""</seg>
<seg id="204">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness combined with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="205">"" "" "" "children and young people ABILIFY do not apply to children and adolescents, since patients under the age of 18 have not been examined." "" "" ""</seg>
<seg id="206">"" "" "" "if you are using ABILIFY with other medicines, please inform your doctor or pharmacist if you are taking other medicines / applied or used recently, even if it is not prescription medicine." "" "" ""</seg>
<seg id="207">Medicines used to treat heart rhythm disorders antidepressants or herbal medicines that are used to treat depression and anxiety disorder medicine for treating HIV infection anticonvulsants that are used to treat epilepsy</seg>
<seg id="208">"" "" "" "pregnant and breastfeeding you should not take ABILIFY if you are pregnant, unless you have discussed this with your doctor." "" "" ""</seg>
<seg id="209">"" "" "" "traffic tightness and operation of machines you should not drive or operate tools or machines, until you know how ABILIFY works with you." "" "" ""</seg>
<seg id="210">"" "" "" "if you are aware of intolerance to certain sugars, please take this medicine only after consultation with your doctor." "" "" ""</seg>
<seg id="211">Please talk to your doctor or pharmacist if you have the impression that the effect of ABILIFY is too strong or too weak.</seg>
<seg id="212">"" "" "" "even if you feel better, change or set the daily dose of ABILIFY not to ask your doctor beforehand." "" "" ""</seg>
<seg id="213">If you have taken a larger amount of ABILIFY than you should notice that you have taken more ABILIFY tablets as recommended by your doctor (or if someone else has taken some of your ABILIFY tablets) contact your doctor promptly.</seg>
<seg id="214">"" "" "" "if you forgot the intake of ABILIFY, you should take the missed dose as soon as you think about it, but do not take a double dose every day." "" "" ""</seg>
<seg id="215">"" "" "" "frequent side effects (in case of more than 1 out of 100, less than 1 of 10 treatment) uncontrollable inflow movements, headache, fatigue, nausea, vomiting, increased saliva production, anxiety, anxiety, trembling, trembling and blurred vision." "" "" ""</seg>
<seg id="216">"" "" "" "occasional side effects (with more than 1 of 1,000 patients less than 1 out of 100 patients) may feel dizzy, especially when standing out of a lying or sitting position or they can determine an accelerated pulse." "" "" ""</seg>
<seg id="217">"" "" "" "please inform your doctor or pharmacist, if any of the side effects listed will affect you significantly or you may notice any side effects that are not stated in this information information." "" "" ""</seg>
<seg id="218">"" "" "" "like ABILIFY, the contents of the pack ABILIFY 5 mg tablets are rectangular and blue, with embossing A-007 and 5 on one side." "" "" ""</seg>
<seg id="219">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness combined with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="220">"" "" "" "even if you feel better, change or set the daily dose of ABILIFY not to ask your doctor beforehand." "" "" ""</seg>
<seg id="221">"" "" "" "like ABILIFY, the contents of the pack ABILIFY 10 mg tablets are rectangular and pink, with embossing A-008 and 10 on one side." "" "" ""</seg>
<seg id="222">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness combined with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="223">"" "" "" "even if you feel better, change or set the daily dose of ABILIFY not to ask your doctor beforehand." "" "" ""</seg>
<seg id="224">"" "" "" "how ABILIFY looks and content of the pack ABILIFY 15 mg tablets are round and yellow, with embossing A-009 and 15 on one page." "" "" ""</seg>
<seg id="225">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness combined with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="226">"" "" "" "even if you feel better, change or set the daily dose of ABILIFY not to ask your doctor beforehand." "" "" ""</seg>
<seg id="227">"" "" "" "how ABILIFY looks and content of the pack ABILIFY 30 mg tablets are round and pink, with embossing A-011 and 30 on one side." "" "" ""</seg>
<seg id="228">"" "" "" "171 If you suffer from dementia (loss of memory or other mental capacity), you should tell your doctor if you have ever had a stroke or a temporary vascularization of the brain." "" "" ""</seg>
<seg id="229">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness combined with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="230">Important information on certain other components of ABILIFY patients who are not allowed to take phenylalanine should note that ABILIFY is contained as a source of phenylalanine.</seg>
<seg id="231">"" "" "" "immediately after opening the blister pack, remove the tablet with dry hands and place the melt tablet in the whole on the tongue." "" "" ""</seg>
<seg id="232">"" "" "" "even if you feel better, change or set the daily dose of ABILIFY not to ask your doctor beforehand." "" "" ""</seg>
<seg id="233">If you have taken a larger amount of ABILIFY than you should notice that you have taken more ABILIFY melt tablets as recommended by your doctor (or if someone else has taken some of your ABILIFY melt tablets) contact your doctor promptly.</seg>
<seg id="234">"" "" "" "calcium trimetasilicate, Croscarmite sodium, cropovidon, silicon dioxide, aspartame, acetulfam potassium, vanilla, magnesium stearate, iron (III) - Oxide (E172)." "" "" ""</seg>
<seg id="235">"" "" "" "how ABILIFY looks and content of the pack The ABILIFY 10 mg processed tablets are round and pink, with embossing" A "over" 640 "on one side and" 10 "on the other." "" "" ""</seg>
<seg id="236">"" "" "" "177 If you suffer from dementia (loss of memory or other mental capacity), you should tell your doctor if you have ever had a stroke or a temporary vascularization of the brain." "" "" ""</seg>
<seg id="237">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness combined with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="238">"" "" "" "calcium-trimetasilicate, Croscarmite sodium, cropovidon, silicon dioxide, aspartame, acetulfam potassium, vanilla (III) - hydroxide oxide x H2O (E172)." "" "" ""</seg>
<seg id="239">"" "" "" "how ABILIFY looks and content of the pack The ABILIFY 15 mg processed tablets are round and yellow, with embossing" A "over" 641 "on one side and" 15 "on the other." "" "" ""</seg>
<seg id="240">"" "" "" "183 If you suffer from dementia (loss of memory or other mental capacity), you should tell your doctor if you have ever had a stroke or a temporary vascularization of the brain." "" "" ""</seg>
<seg id="241">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness combined with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="242">"" "" "" "how ABILIFY looks and content of the pack The ABILIFY 30 mg processed tablets are round and pink, with embossing" A "over" 643 "on one side and" 30 "on the other." "" "" ""</seg>
<seg id="243">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness combined with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="244">"" "" "" "traffic tightness and operation of machines you should not drive or operate tools or machines, until you know how ABILIFY works with you." "" "" ""</seg>
<seg id="245">190 Important information on certain other components of ABILIFY Each ml ABILIFY solution for intake contains 200 mg of fructose and 400 mg Sucrose.</seg>
<seg id="246">"" "" "" "if your doctor has told you that you are suffering from a intolerance to certain sugars, contact your doctor before taking this medicine." "" "" ""</seg>
<seg id="247">The dose of ABILIFY solution for intake must be measured with the calibrated measuring cup or the calibrated 2 ml dropper pipette that are contained in the package.</seg>
<seg id="248">Please talk to your doctor or pharmacist if you have the impression that the effect of ABILIFY is too strong or too weak.</seg>
<seg id="249">If you have taken a larger amount of ABILIFY than you should notice that you have taken more ABILIFY solution for intake than recommended by your doctor (or if someone else has taken ABILIFY solution for taking) contact your doctor promptly.</seg>
<seg id="250">"" "" "" "Dinatrium edetate, fructose, glycerol, lactic acid, methyl-4 hydroxybenzoate (E216), sodium hydroxide, sucrose, purified water and natural orange cream aroma with other natural flavours." "" "" ""</seg>
<seg id="251">How ABILIFY looks and content of the pack ABILIFY 1 mg / ml solution for taking is a clear, colourless to light yellow liquid in bottles with a child-safe polypropylene closures and 50 ml; 150 ml or 480 ml.</seg>
<seg id="252">"" "" "" "ABILIFY injections solution is used for rapid treatment of increased unrest and desperate behaviour that may appear as symptoms of a disease characterized by symptoms such as hearing, seeing or feeling of things that are not present." "" "" ""</seg>
<seg id="253">"" "" "" "people with this disease can also be depressed, feel guilty, anxious or tense. exaggerated feeling of feeling excessive energy requires much less sleep than usual, very fast speech with changing ideas and sometimes strong irritability." "" "" ""</seg>
<seg id="254">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness combined with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="255">"" "" "" "if you use ABILIFY with other medicines, please inform your doctor or pharmacist if you are taking other medicines / applied or used recently, even if it is not prescription medicine." "" "" ""</seg>
<seg id="256">Medicines used to treat heart rhythm disorders antidepressants or herbal medicines that are used to treat depression and anxiety disorder medicine for treating HIV infection anticonvulsants that are used to treat epilepsy.</seg>
<seg id="257">"" "" "" "196 pregnancy and breastfeeding you should not use ABILIFY if you are pregnant, unless you have discussed this with your doctor." "" "" ""</seg>
<seg id="258">"" "" "" "you should not drive or operate any tools or machines, if you feel behaved after using ABILIFY injections solution." "" "" ""</seg>
<seg id="259">"" "" "" "if you have concerns that you get more ABILIFY injection solution than you need to believe, please talk to your doctor or caregiver about it." "" "" ""</seg>
<seg id="260">"" "" "" "frequent side effects (with more than 1 out of 100, less than 1 of 10 treatments) of ABILIFY injections solution are tiredness, dizziness, headache, restlessness, nausea and vomiting." "" "" ""</seg>
<seg id="261">"" "" "" "occasional side effects (in case of more than 1 out of 1,000, less than 1 out of 100 treatment) Some people may feel dizzy or have a fast pulse, have a dry feeling in the mouth or feel downcast." "" "" ""</seg>
<seg id="262">"" "" "" "frequent side effects (in case of more than 1 out of 100, less than 1 of 10 treatment) uncontrollable inflow movements, headache, fatigue, nausea, vomiting, increased salivation, anxiety, anxiety, trembling, trembling and blurred vision." "" "" ""</seg>
<seg id="263">"" "" "" "if you need more information about your illness or their treatment, please read the package supplement (also part of the EPAR) or contact your doctor or pharmacist." "" "" ""</seg>
<seg id="264">"" "" "" "Abraxane should only be used under the supervision of a qualified oncologist, in the application of cytostatika (killing of cells) specialized departments." "" "" ""</seg>
<seg id="265">"" "" "" "in patients with certain side effects on the blood or nervous system, the dose can be reduced or the treatment is interrupted." "" "" ""</seg>
<seg id="266">(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: / / www.emea.europa.eu © EMEA 2007 Reproduction and / or distribution of this document is Authorised for non commercial purposes only.</seg>
<seg id="267">"" "" "" "the efficacy of Abraxane was examined in a major study, involving 460 women with metastatic breast cancer, of which about three quarters had received an anthracycline." "" "" ""</seg>
<seg id="268">The effect of Abraxane (in sole gift or as monotherapy) was compared with the drug containing a conventional paclitaxel (given in combination with other medicines to reduce side effects).</seg>
<seg id="269">"" "" "" "in total, 72 (31%) of 229 patients treated with Abraxane were treated to treatment, compared to 37 (16%) of 225 patients receiving conventional paclitaxel." "" "" ""</seg>
<seg id="270">"" "" "" "considering only the patients treated for metastatic breast cancer for the first time, there was no difference between drug efficacy indicators such as time to deterioration of disease and survival." "" "" ""</seg>
<seg id="271">"" "" "" "in contrast, in patients who had previously received other treatments of their metastatic breast cancer, Abraxane was more effective than conventional paclitaxel containing drugs." "" "" ""</seg>
<seg id="272">"" "" "" "in addition, it may not be used in patients who have low neutrophiles in the blood prior to the treatment." "" "" ""</seg>
<seg id="273">The Committee for Medicinal Products (CHMP) found that Abraxane was more effective in patients where the first treatment was no longer effective than conventional paclitaxel drugs did not have to be given to other medicines to reduce side effects.</seg>
<seg id="274">"" "" "" "January 2008, the European Commission granted the company Abraxis BioScience Limited a permit for the placing of Abraxane in the whole European Union." "" "" ""</seg>
<seg id="275">Abraxane-Monotherapy is indicated for the treatment of metastatic breast cancer in patients whose first-line treatment for metastatic disease has failed and is not shown for the treatment of a standard anthracycline-containing therapy (see section 4.4).</seg>
<seg id="276">In patients with severe neutropenia (neutrophilately &lt; 0.50 x 109 / l over a period of one week or longer) or severe sensory neuropathy during the Abraxane therapy the dose should be reduced to 220 mg / m2.</seg>
<seg id="277">"" "" "" "in sensory neuropathy degrees 3 the treatment is to be interrupted until an improvement is reached at grade 1 or 2, and the dose must be reduced in all subsequent cycles." "" "" ""</seg>
<seg id="278">"" "" "" "there is currently no adequate data for the recommendation of dose adjustments in patients with mild to moderate impairment of the liver function (see Section 4.4., and 5.2)." "" "" ""</seg>
<seg id="279">No studies with impaired renal function have been carried out and there is currently no adequate data on the recommendation of dose adjustments in patients with impaired renal function (see Section 5.2).</seg>
<seg id="280">"" "" "" "Abraxane is not recommended for use in children under the age of 18, due to insufficient data on safety and efficacy." "" "" ""</seg>
<seg id="281">Abraxane is an Albumin-bound nanoparticle formulation of paclitaxel which could have considerably different pharmacological characteristics than other formulations of paclitaxel (see Section 5.1 and 5.2).</seg>
<seg id="282">"" "" "" "if an allergic reaction occurs, the medicine should be removed immediately and a symptomatic treatment should be initiated and the patient must not be treated with paclitaxel again." "" "" ""</seg>
<seg id="283">"" "" "" "in patients, no renewed Abraxane treatment cycles should be initiated until the neutrophiles rose again to &gt; 1.5 x 109 / l and the thrombocyte number is increased again &gt; 100 x 109 / l." "" "" ""</seg>
<seg id="284">Patients with severe liver dysfunction (bilirubin &gt; 5 x ULN or ASL / ALT &gt; 10 x ULN) should not be treated with Abraxane.</seg>
<seg id="285">"" "" "" "during a unique cardiotoxicity associated with Abraxane, cardiac infestation in the indicated patient population is not unusual, especially in patients with previous anthracycline treatment or underlying heart disease or lung disease." "" "" ""</seg>
<seg id="286">"" "" "" "if there is nausea, vomiting and diarrhoea in the patients after the administration of Abraxane, they can be treated with the usual antiemetic and constiptive means." "" "" ""</seg>
<seg id="287">"" "" "" "Abraxane should not be used in pregnant women or women in childbearing age, who do not practise an effective contraception, except for the treatment of the mother with paclitaxel." "" "" ""</seg>
<seg id="288">"" "" "" "women in childbearing age should use a reliable contraception method, during and up to one month after the treatment with Abraxane." "" "" ""</seg>
<seg id="289">"" "" "" "male patients treated with Abraxane are advised, during and up to six months after treatment no child." "" "" ""</seg>
<seg id="290">"" "" "" "male patients should be advised to consult a sperm conservation before the treatment, as the treatment with Abraxane exists the possibility of irreversible infertility." "" "" ""</seg>
<seg id="291">Abraxane can cause side effects like tiredness (very common) and dizziness (often) that can affect the traffic tightness and the ability to operate machinery.</seg>
<seg id="292">"" "" "" "in the following, the most common and most important occurrences of side effects reported in 229 patients with metastatic breast cancer were treated with 260 mg / m2 of abrasion once every three weeks." "" "" ""</seg>
<seg id="293">Neutropenia was the most notable hematological toxicity (reported in 79% of the patients) and was rapidly reversible and dose-dependent; leukopenia was reported in 71% of the patients.</seg>
<seg id="294">Anaemia (Hb &lt; 10 g / dl) was observed in 46% of patients treated with Abraxane and was severe in three cases (Hb &lt; 8 g / dl).</seg>
<seg id="295">"" "" "" "table 1 shows the side effects that have occurred in conjunction with the administration of Abraxane as a monotherapy for each dose and indication in studies (N = 789)." "" "" ""</seg>
<seg id="296">"" "" "" "very common (≥ 1 / 100, &lt; 1 / 10); occasionally (≥ 1 / 1,000, &lt; 1 / 100); rare (≥ 1 / 10,000, &lt; 1 / 1000); very rare (≥ 1 / 10,000)." "" "" ""</seg>
<seg id="297">"" "" "" "occasionally: increased blood pressure, weight gain, increased lactate hydrogenase in the blood, increased creatine in the blood, increased blood sugar, increased phosphorus in the blood, reduced potassium in the blood heart disease:" "" "" ""</seg>
<seg id="298">"" "" "" "dysphagia, bloating, tongue burning, dry mouth, pain in the lower abdomen, pain in the lower abdomen, sores in the mouth, oral pain, rectal bleeding disorders of the kidneys and urinary tract:" "" "" ""</seg>
<seg id="299">"" "" "" "pain in the chest wall, weakness of the musculature, abdominal pain, muscle spasms, pain in skeletal muscles, chest pains, discomfort in the limbs, muscle weakness Very frequent:" "" "" ""</seg>
<seg id="300">"" "" "" "restlessness 1 The frequency of hypersensitivity reactions is calculated based on a definite in relation to a population of 789 patients," "" "" ""</seg>
<seg id="301">"" "" "" "since these events were reported on a voluntary basis during clinical practice, no estimates of the actual frequency are possible and no causal connection with these events was established." "" "" ""</seg>
<seg id="302">Paclitaxel is an antimicrobial agent that promotes the merging of microtubules from the granules and stabilises the microtubules by inhibiting its depolymerisation.</seg>
<seg id="303">This stabilization leads to inhibition of the normal dynamic reorganisation of the microtubular network which is essential for the vital phase and the mitotic cell functions.</seg>
<seg id="304">It is known that albumin mediates the transcytosis of plasma components into endothelial cells and demonstrated in vitro studies that the presence of albumin supports the transport of paclitaxel through endothelial cells.</seg>
<seg id="305">It is assumed that this improved transendothelial transport is mediated by the gp-60 albumbicreceptor and performs a paclitaxel accumulation in the area of the tumor due to the protein-binding protein SPARC (glutted protein acidic rich in cysteine).</seg>
<seg id="306">The application of Abraxane for metastatic breast cancer is supported by data of 106 patients in two randomised unaffiliated trials and of 454 patients treated in a randomized Phase III comparative study.</seg>
<seg id="307">"" "" "" "in one study, 43 patients with metastatic breast carcinoma were treated with Abraxane, which was given over 30 minutes with a dose of 175 mg / m2." "" "" ""</seg>
<seg id="308">"" "" "" "in the second study, a dose of 300 mg / m2 was used as an infusion of 63 patients with metastatic breast cancer." "" "" ""</seg>
<seg id="309">This multicenter study was conducted in patients with metastatic breast cancer which received a monotherapy with paclitaxel every 3 weeks or in the form of an allergic reaction (N = 225) or in the form of Abraxane 260 mg / m2 as a 30-minute infusion (N = 229).</seg>
<seg id="310">"" "" "" "in the study, 64% of patients had a reduced general condition (ECOG 1 or 2), 79% had visceral metastases and 76% had more than 3 meta cells." "" "" ""</seg>
<seg id="311">"" "" "" "14% of patients had previously not received chemotherapy, 27% had only a adjuvant chemotherapy, 40% only due to metastasis and 19% due to metastasis and adjuvant treatment." "" "" ""</seg>
<seg id="312">"" "" "" "9 The results for the general response rate and time to progression-free survival and survival for patients receiving first-line therapy, are explained below." "" "" ""</seg>
<seg id="313">Neurotoxicity versus paclitaxel was evaluated by the improvement of a degree for patients who experienced peripheral neuropathy degrees 3 at a time during therapy.</seg>
<seg id="314">The natural course of peripheral neuropathy for the sound on baseline because of the cumulative toxicity of Abraxane after &gt; 6 treatment courses was not evaluated and is still unknown.</seg>
<seg id="315">The pharmacokinetics of the total paclitaxel after 30- and 180-minute infusions of Abraxane with a dose of 80 to 375 mg / m2 was determined in clinical trials.</seg>
<seg id="316">The field of active substance exposition (AUC) increased linearly from 2653 to 16736 ng.h / ml similar to a dose of 80 to 300 mg / m2.</seg>
<seg id="317">"" "" "" "10 After the intravenous application of Abraxane in patients with metastatic breast cancer in the recommended clinical dose of 260 mg / m2, the paclitaxel plasma concentration decreased in multiphase manner." "" "" ""</seg>
<seg id="318">The average distribution volume was 632 l / m2; the high distribution volume points to a far-reaching extravascular distribution and / or transmission of paclitaxel.</seg>
<seg id="319">In a study of patients with advanced solid tumours the pharmacokinetic properties of paclitaxel were compared to intravenous 30-minute infusion of 260 mg / m2 of Abraxane with the values following a 3-hour injection of 175 mg / m2 of solvent containing paclitaxel.</seg>
<seg id="320">The clearing of paclitaxel was higher after the Abraxane administration (43%) than after a solvent containing paclitaxel injection and the distribution volume was higher with Abraxane (53%).</seg>
<seg id="321">In the published literature on in-vitro studies of human liver microsome and tissue coating is reported that paclitaxel is metabolized primarily to 6α-hydroxypaclitaxel and to two smaller metabolites (3 "-p hydroxypaclitaxel and 6α-3" -p-Dihydroxypaclitaxel).</seg>
<seg id="322">After a 30-minute infusion of 260 mg / m2 of Abraxane in patients with metastatic breast carcinoma the mean value of the unmodified total dose was 4% of the total dose of 6α-hydroxypaclitaxel and 3 "-p hydroxypaclitaxel.</seg>
<seg id="323">"" "" "" "however, only a few data are available about patients at the age of more than 75 years since only 3 patients of this age group participated in pharmacokinetic analysis." "" "" ""</seg>
<seg id="324">"" "" "" "the chemical and physical stability was proven at 2 ° C - 8 ° C in original box, protected against light light over 8 hours." "" "" ""</seg>
<seg id="325">Paclitaxel is a cytotoxic anticancer-carcinogenic drug and as well as other potentially toxic substances should be taken care of when dealing with Abraxane.</seg>
<seg id="326">Using a sterile syringe slowly over a period of at least 1 minute 20 ml of a 9 mg / ml (0.9%) sodium chloride infusion solution is injected into an Abraxane flow bottle.</seg>
<seg id="327">"" "" "" "after adding the solution, the bottle should rest for at least 5 minutes to ensure a good wetting of the solid material." "" "" ""</seg>
<seg id="328">"" "" "" "then the bottle should be slowly and cautiously tilted and / or inverted for at least 2 minutes, until complete reset of the powder is carried out." "" "" ""</seg>
<seg id="329">"" "" "" "if malformations or sinks are visible, the bottle must be inverted once again in order to achieve complete resusboard before applying." "" "" ""</seg>
<seg id="330">"" "" "" "the exact total dose volume of the 5 mg / ml suspension is calculated for the patient and injected in an empty, sterile PVC- or non-PVC infusion bag." "" "" ""</seg>
<seg id="331">"" "" "" "Pharmacovigilance System The holder of approval for placing on the market must ensure that the drug vigilance system, as described in version 2.0, is set up and works before and while the drug is brought into circulation." "" "" ""</seg>
<seg id="332">Risk management plan The owner of the authorisation for the marketing agency is obliged to carry out the studies and other pharmacovigilance activities described in version 4 of the risk management plan (RMP) and in module 1.8.2. the application for authorisation as well as all subsequent updates of the RMP that are agreed with the CHMP.</seg>
<seg id="333">"" "" "" "according to the CHMP directive on risk management systems for drug use, the updated RMP is to be submitted simultaneously with the next Periodic Safety Update Report (PSUR)." "" "" ""</seg>
<seg id="334">"" "" "" "in addition, an updated RMP is able to submit new information that may affect the current security classification, pharmacovigilance plan or risk management activities • On request of the EMEA" "" "" ""</seg>
<seg id="335">"" "" "" "8 hours in the refrigerator in the bottle, when stored in the box to protect the contents from light." "" "" ""</seg>
<seg id="336">"" "" "" "Abraxane is used to treat breast cancer if other therapies have been tried, but not successful, and if you are not interested in anthracycline-containing therapies." "" "" ""</seg>
<seg id="337">Abraxane may not be used: if you are hypersensitive to paclitaxel or any of the components of Abraxane if you are breastfeeding when your white blood cells are humbled (starting values for neutrophilates &lt; 1.5 x 109 / l - your doctor will inform you about it)</seg>
<seg id="338">"" "" "" "special caution when applying Abraxane is required: if you have a impaired renal function, tingling sensation, tingling sensation, tingness or muscle weakness occurs • if you suffer from severe liver problems • if you have heart problems." "" "" ""</seg>
<seg id="339">"" "" "" "if you use Abraxane with other medicines, please inform the doctor if you apply other medicines or have recently used it, even if it is not prescription drugs, since they might cause an interaction with Abraxane." "" "" ""</seg>
<seg id="340">"" "" "" "women in childbearing age should use a reliable contraception method, during and up to one month after the treatment with Abraxane." "" "" ""</seg>
<seg id="341">"" "" "" "in addition, they should be advised against the treatment of sparing because the Abraxane treatment offers the possibility of permanent infertility." "" "" ""</seg>
<seg id="342">Traffic tightness and the operation of machines Abraxane can cause side effects such as tiredness (very common) and dizziness (often) that can affect the traffic tightness and the ability to operate machinery.</seg>
<seg id="343">"" "" "" "if you are also receiving other medicines during your treatment, you should consult your doctor regarding driving or serving machines." "" "" ""</seg>
<seg id="344">"" "" "" "22 • Effect on peripheral nerves (pain and numbness) • pain in one or more joints • pain in the muscles • nausea, diarrhea • vomiting • weakness and fatigue" "" "" ""</seg>
<seg id="345">"" "" "" "• frequent side effects (with at least 1 of 100 patients reported) include skin rash, itching, dry skin, nail diseases, abdominal pain, abdominal pain, abdominal pain, sore throat, or sore throat, mouth soor • sleeping disorders" "" "" ""</seg>
<seg id="346">"" "" "" "the rare side effects (reported at least 1 of 10,000 patients) include: • lung infection • skin reaction to another substance after irradiation • Blood coagulation" "" "" ""</seg>
<seg id="347">"" "" "" "please inform your doctor or pharmacist, if any of the side effects listed will affect you significantly or you may notice any side effects that are not stated in this information information." "" "" ""</seg>
<seg id="348">"" "" "" "if not used immediately, it can be stored in the bottle up to 8 hours in the refrigerator (2 ° C - 8 ° C) to protect the contents from light." "" "" ""</seg>
<seg id="349">Each vial contains 100 mg of paclitaxel. • After the reconstitution every ml of the suspension contains 5 mg of paclitaxel. • The other component is albumina (containing sodium) sodium caprylate and N acetyltryptophan (Ph.Eur.))</seg>
<seg id="350">Precautions for preparation and application of paclitaxel is a cytotoxic anticancer-carcinogenic drug and as well as other potentially toxic substances should be considered when dealing with Abraxane.</seg>
<seg id="351">Using a sterile syringe slowly over a period of 1 minute 20 ml of a 9 mg / ml (0.9%) sodium chloride infusion solution should be injected into an Abraxane bottle.</seg>
<seg id="352">"" "" "" "after that, swing the bottle for at least 2 minutes and / or invert until complete reset of the powder is done." "" "" ""</seg>
<seg id="353">"" "" "" "the exact total dose volume of the 5 mg / ml suspension is calculated for the patient and injected in an empty, sterile PVC infusion bag type IV." "" "" ""</seg>
<seg id="354">"" "" "" "prior to using a visual inspection, parenteral drugs should be subjected to any particles and discolorations whenever the solution or the vessel can permit this." "" "" ""</seg>
<seg id="355">Stability unopened bottles with Abraxane are stable up to the date given on the packaging when the bottle is stored in the box to protect the contents from light.</seg>
<seg id="356">"" "" "" "after the first reconstitution, Suspension should immediately be filled into an infusion bag." "" "" ""</seg>
<seg id="357">"" "" "" "" "" "" "" "member states must ensure that the holder of approval for the market launch will provide medical professionals in dialysis centres and retail stores with the following information and materials:" "" "" ""</seg>
<seg id="358">• Training Brochure • Summary of the features of the medicine (specialist information); labeling and packaging supplement. • with unique pictorial representation of the correct application of the product provided coolers for transport by patients.</seg>
<seg id="359">"" "" "" "this means that Abseamed is similar to a biological medicine, which is already approved in the European Union (EU) and contains the same drug (also called" reference drug ")." "" "" ""</seg>
<seg id="360">"" "" "" "it is used in patients with normal blood vessels, in which complications of blood transfusion may occur if there is no bleeding or bleeding from 900 to 1 800 ml." "" "" ""</seg>
<seg id="361">The treatment with Abseamed must be initiated under the supervision of a doctor who has experience in the treatment of patients with diseases for which the medicine is shown.</seg>
<seg id="362">"" "" "" "in patients with kidney problems and for patients who want to make their own blood donation, Abseamed is injected into a vein." "" "" ""</seg>
<seg id="363">"" "" "" "the injection can also be performed by the patient or its caregiver, provided they have received appropriate guidance." "" "" ""</seg>
<seg id="364">"" "" "" "in patients with chronic kidney failure and for patients receiving chemotherapy, the hemoglobin values should always be at the recommended range (between 10 and 12 grams per deciliter in adults and between 9.5 and 11 g / dl in children)." "" "" ""</seg>
<seg id="365">"" "" "" "the iron values of all patients are to be checked before treatment to ensure that no iron deficiency exists, and iron supplements should be administered during the entire treatment." "" "" ""</seg>
<seg id="366">"" "" "" "in patients receiving chemotherapy, or in patients with kidney problems, anaemia can be caused by an erythropoietal deficiency or thereby indicating that the body does not adequately address the body's erythropoietin." "" "" ""</seg>
<seg id="367">Erythropoietin is also used before surgery to increase the number of red blood cells and thus reduce the consequences of a loss of blood.</seg>
<seg id="368">It is produced by a cell in which a gene (DNA) was incorporated into the formation of epoetin alfa.</seg>
<seg id="369">"" "" "" "Abseamed was compared with 479 patients in a major study involving 479 patients, which suffered anaemia due to kidney problems." "" "" ""</seg>
<seg id="370">All patients participating in this study had been injected in a vein for at least eight weeks before they were either converted to Abseamed or continue to receive Eprex / Erypo.</seg>
<seg id="371">The main indicator of efficacy was the change in hemoglobin values between the beginning of the study and the evaluation period in weeks 25 to 29.</seg>
<seg id="372">"" "" "" "the company also presented the results of a study, in which the effects of cutaneous abseamed with those of Eprex / Erypo were examined for 114 cancer patients receiving chemotherapy." "" "" ""</seg>
<seg id="373">"" "" "" "in the study involving patients suffering from anaemia caused by kidney problems, the hemoglobin values of patients who were converted to Abseamed were maintained in the same degree as with those patients who continued to receive Eprex / Erypo." "" "" ""</seg>
<seg id="374">"" "" "" "in comparison, the patients who continued receiving Eprex / Erypo showed an increase of 0.063 g / dl of the starting value of 12.0 g / dl." "" "" ""</seg>
<seg id="375">"" "" "" "the most common side effect of Abseamed is a rise in blood pressure, which occasionally leads to symptoms of encephalopathy (brain problems) like sudden, pungent migraine headaches and confusion." "" "" ""</seg>
<seg id="376">"" "" "" "Abseamed must not be used in patients, which may be hypersensitive to epoetin alfa or any of the other ingredients." "" "" ""</seg>
<seg id="377">"" "" "" "Abseamed as injections under the skin is not recommended for treating kidney problems, as further studies are required to ensure that there are no allergic reactions occurring." "" "" ""</seg>
<seg id="378">"" "" "" "the Committee for Medicinal Products (CHMP) concluded that for seamed according to the European Union regulations, the medicine has shown a comparable quality, safety and efficacy profile such as Eprex / Erypo." "" "" ""</seg>
<seg id="379">"" "" "" "the company that manufactures Abseamed will provide information packages for medical professionals across all Member States, including information on the safety of the drug." "" "" ""</seg>
<seg id="380">"" "" "" "August 2007, the European Commission granted the company Medice Medicaid Pütter GmbH & Co KG for the placing of Abseamed in the whole European Union." "" "" ""</seg>
<seg id="381">"" "" "" "treatment of anaemia and reduction of transfusion needs in adults with solid tumours, malignant lymphomas or multiplem myeloma, which is a risk of transfusion due to the general condition (e.g. cardiovascular status, preexisting anemia in the beginning of chemotherapy)." "" "" ""</seg>
<seg id="382">The treatment should only be carried out in patients with moderate anaemia (hemoglobin [Hb] 10 - 13 g / dl [6.2 - 8.1 mmol / l] if blood-saving measures are not available or insufficient in case of a large blood flow rate (4 or more units of blood in women; 5 or more units of blood in men).</seg>
<seg id="383">"" "" "" "for the reduction of foreign blood, Abseamed can be used before a large elective orthopedic procedure in adults with no iron deficiency, in which a high risk of transfusion complications can be expected." "" "" ""</seg>
<seg id="384">HB 10-13 g / dl) and an expected loss of blood from 900-1800 ml can be applied not to participate in an autologous blood donation program.</seg>
<seg id="385">The hemoglobin target concentration is between 10 and 12 g / dl (6.2 - 7.5 mmol / l) except for pediatric patients with the hemoglobin concentration between 9.5 and 11 g / dl (5.9 - 6.8 mmol / l).</seg>
<seg id="386">"" "" "" "symptoms of anemia and as a result may vary depending on age, gender and total disease burden; therefore, the assessment of the individual clinical course and condition of disease is required by the doctor." "" "" ""</seg>
<seg id="387">A rise in hemoglobin by more than 2 g / dl (1.25 mmol / l) over a period of four weeks should be avoided.</seg>
<seg id="388">"" "" "" "due to the variability between patients, individual hemoglobin values can occasionally be observed on or under the hemoglobin- target concentration." "" "" ""</seg>
<seg id="389">In view of these hemoglobin variability an appropriate dose management should be attempted to reach the hemoglobin target concentration of 10 g / dl (6.2 mmol / l) to 12 g / dl (7.5 mmol / l).</seg>
<seg id="390">If the hemoglobin value increases by more than 2 g / dl (1.25 mmol / l) per month or if the permanent hemoglobin value 12 g / dl (7.5 mmol / l) exceeds the epoetin alfa dosage is reduced by 25%.</seg>
<seg id="391">"" "" "" "patients should be closely monitored to ensure that epoetin alfa is applied in the lowest permitted dose, which is required for control of anaemia and anemia." "" "" ""</seg>
<seg id="392">The present clinical results suggest that patients with initially very low Hb-value (&lt; 6 g / dl or &lt; 3.75 mmol / l) may require higher maintenance doses than patients in which initial anemia is less severe (Hb &gt; 8 g / dl or &gt; 5 mmol / l).</seg>
<seg id="393">The present clinical results suggest that patients with initially very low Hb-value (&lt; 6.8 g / dl or &lt; 4.25 mmol / l) may require higher maintenance doses than patients with initial anaemia less difficult (Hb &gt; 6.8 g / dl or &gt; 4.25 mmol / l).</seg>
<seg id="394">Starting dose 50 I.U. / kg three times a week by an intravenous application if necessary with an increase of 25 I.U. / kg (three times a week) until the desired target value is reached (this should take steps of at least 4 weeks).</seg>
<seg id="395">"" "" "" "symptoms of anemia and subsequent symptoms may vary depending on age, gender and total disease burden; therefore, the assessment of the individual clinical course and condition of disease is required by the doctor." "" "" ""</seg>
<seg id="396">In view of these hemoglobin variability an appropriate dose management should be attempted to reach the hemoglobin target concentration of 10 g / dl (6.2 mmol / l) to 12 g / dl (7.5 mmol / l).</seg>
<seg id="397">"" "" "" "patients should be closely monitored to ensure that epoetin alfa is applied in the lowest permitted dose, which is required for controlling the anemia symptoms." "" "" ""</seg>
<seg id="398">"" "" "" "if the hemoglobin is increased by at least 1 g / dl (0,62 mmol / l) or the Reticular number by ≥ 40,000 cells / µl compared to the output value, the dose should be maintained three times a week or 450 I.U. / kg once a week." "" "" ""</seg>
<seg id="399">"" "" "" "if the hemoglobin increase &lt; 1 g / dl (&lt; 0,62 mmol / l) and the reticulozyte number &lt; 0,62 mmol / l is increased, the dose should be increased to 300 I.U. / kg three times a week." "" "" ""</seg>
<seg id="400">"" "" "" "if after further 4 weeks of treatment with 300 I.U. / kg three times a week the hemoglobin value by ≥ 1 g / dl (≥ 0.62 mmol / l) or the Reticular number of ≥ 40,000 cells / µl should be maintained three times a week." "" "" ""</seg>
<seg id="401">If the hemoglobin value has increased by &lt; 1 g / dl (&lt; 0.62 mmol / l) or the Reticular number by &lt; 40,000 cells / µl compared to the initial value the response to epoetin alfa therapy is unlikely and the treatment should be canceled.</seg>
<seg id="402">"" "" "" "patients with mild anemia (hematokrit 33-39%), in which the precautionary deposit of ≥ 4 blood congestions is required, should be kept in a dose of 600 I.U. / kg bodyweight twice weekly for 3 weeks prior to the surgical procedure." "" "" ""</seg>
<seg id="403">"" "" "" "iron substitution should be started as early as possible, for example a few weeks before the beginning of the autologous blood donation program, so that large iron reserves are available before the start of the seamed therapy." "" "" ""</seg>
<seg id="404">"" "" "" "6 The recommended dosage is 600 I.U. / kg epoetin alfa which should be given once a week for three weeks (day 21, 14 and 7) before the surgical procedure and on the day of the surgery (day 0)." "" "" ""</seg>
<seg id="405">"" "" "" "epoetin alfa should be given preoperatively 300 I.E. / kg each 10 consecutive days, on the day of the surgery and 4 days immediately afterwards." "" "" ""</seg>
<seg id="406">"" "" "" "alternatively, the injection can be given at the end of dialysis via the hose of a fistula, followed by 10 ml isotonic saline solution to rinse the hose and ensure sufficient injection of the drug in the circulation." "" "" ""</seg>
<seg id="407">Patients suffering from the treatment with any erythrodrtin (Pure Red Cell Aplasia (PRCA) should not receive a seamed or other erythropoetin (see section 4.4 - Erythroblasting).</seg>
<seg id="408">"" "" "" "heart attack or stroke within a month before treatment, unstable angina pectoris, increased risk of deep venous thromboses (e.g. anamnesia known venous thromboembosis)." "" "" ""</seg>
<seg id="409">"" "" "" "epoetin alfa is contraindicated in patients with severe coronary heart disease, peripheral vascular disease, peripheral vascular disease, vascular disease of the carotides or cerebrovascular diseases." "" "" ""</seg>
<seg id="410">Erythroblastoenie (PRCA) Very rarely was reported on the occurrence of an anti-body mediated PRCA after monate- to years of treatment with subcutaneous erythropoetin.</seg>
<seg id="411">"" "" "" "in patients with sudden loss of effect, defined as a reduction in hemoglobin values (1 - 2 g / dl per month) with increased need for transfusions, the reticulocyte value should be examined and the common causes of non-response (iron, folic acid or vitamin B12 deficiency, blood loss and hemolysis)." "" "" ""</seg>
<seg id="412">"" "" "" "if no other reason of an effective loss is found, the anti-erythropotin and leukocyte antibodies are determined and an examination of the bone cord for diagnosis of a PRCA should be measured." "" "" ""</seg>
<seg id="413">Data on immunogenicity in subcutaneous use of Abseamed in patients with a risk of an anti-body induced PRCA (patients with renal anemia) are not sufficient.</seg>
<seg id="414">"" "" "" "8 In patients with chronic kidney failure, maintenance therapy should not exceed the upper limit of hemoglobin target concentration under section 4.2." "" "" ""</seg>
<seg id="415">In clinical studies an increased risk of mortality and risk of severe cardiovascular events were observed when erythropoesis-stimulant drugs (ESA) were given with a hemoglobin target concentration of over 12 g / dl (7.5 mmol / l).</seg>
<seg id="416">Controlled clinical studies have shown no significant benefit that can be attributed to the administration of epoetins when the hemoglobin concentration is increased to the concentration of anaemia and the avoidance of blood transfusions.</seg>
<seg id="417">The hemoglobin increase should amount to approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of increasing blood pressure.</seg>
<seg id="418">In patients with chronic kidney failure and clinically evident coronary heart disease or insufficiency in maintenance therapy the upper limit of hemoglobin target concentration should not be exceeded.</seg>
<seg id="419">"" "" "" "according to the time available, anaemia associated with epoetin alfa in adults with kidney failure, which is not yet dialysis, will not accelerate the progression of renal insufficiency." "" "" ""</seg>
<seg id="420">For tumour patients under chemotherapy a 2 - 3-week delay between epoetin-alfa and the erythropoetin response should be considered (patients who may have to be transacted).</seg>
<seg id="421">If the Hb increase is higher than 2 g / dl (1.25 mmol / l) per month or a Hb-value of 13 g / dl (8.1 mmol / l) the dose must be adjusted in accordance with Section 4.2 to minimize the risk of possible thrombotic events (see section 4.2).</seg>
<seg id="422">"" "" "" "the decision to use recombinant erythropoetine should be based on a benefit-risk assessment under the participation of the respective patient, which should also take into account the specific clinical context." "" "" ""</seg>
<seg id="423">"" "" "" "in patients intended for a larger elective orthopaedic procedure, if possible, the cause of anaemia should be examined and treated accordingly." "" "" ""</seg>
<seg id="424">"" "" "" "patients undergoing a larger elective orthopaedic procedure should receive appropriate thrombosis prophylaxis, as they have an increased risk of thrombotic and vascular disease, especially in the underlying cardiovascular disease." "" "" ""</seg>
<seg id="425">"" "" "" "in addition, an increased risk of postoperative thrombotic / vascular events may not be excluded in treatment with epoetin alfa for patients with an initial hemoglobin value of &gt; 13 g / dl." "" "" ""</seg>
<seg id="426">"" "" "" "in several controlled studies, epoetine was not proven to improve overall survival in tumour patients with symptomatic anaemia or decrease the risk of tumour progression." "" "" ""</seg>
<seg id="427">"" "" "" "4 months in patients with metastatic breast cancer receiving chemotherapy, when hemoglobin target concentration of 12 - 14 g / dl (7.5 - 8.7 mmol / l) was targeted." "" "" ""</seg>
<seg id="428">"" "" "" "when applied with Ciclosporin, epoetin alfa should be controlled by Ciclosporin and the Ciclosporin dose should be adjusted to the rising hematokrit." "" "" ""</seg>
<seg id="429">"" "" "" "in vitro studies on tumor tissues, there are no indications of interactions between epoetin alfa and G-CSF or GM-CSF regarding hematological differentiation or proliferation." "" "" ""</seg>
<seg id="430">"" "" "" "over thrombotic, vascular events such as myocardial ischemia, myocardial infarction, arterial thrombosis, arterial thrombosis, aneurythromboses and 11 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="431">The most common side effect during treatment with epoetin alfa is a dose-dependent increase in blood pressure or the deterioration of an existing hypertension.</seg>
<seg id="432">Higher incidence of thrombovascular events (see section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="433">"" "" "" "regardless of erythropoetin treatment, it can occur in surgical patients with cardiovascular disease after repeated blood donations to thrombotic and vascular complications." "" "" ""</seg>
<seg id="434">The genetically recovered epoetin alfa is glycosides and is identical to the amino acids and carbohydrate part with the endogenous human erythropoetin that was isolated from the urine of anaesthesia.</seg>
<seg id="435">"" "" "" "with the help of cultures of human bone marrow cells, epoetin alfa specifically stimulates the erythropoesis and does not affect leukopoese." "" "" ""</seg>
<seg id="436">"" "" "" "389 patients with haemblastomosis (221 multiple myeloma, 144 non-Hodgkin- lymphomas and 24 other hemoblastomas, 23 breast carcinomas, 22 prostate cancer, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="437">"" "" "" "1895 patients with solid tumours (683 breast carcinomas, 260 bronchial carcinomas, 174 gynaecological tumors, 300 gastrointestinal tumors and 478 others) and 802 patients with haemblastomosis." "" "" ""</seg>
<seg id="438">Survival and tumor progression were studied in five large controlled trials involving a total of 2833 patients; four of these studies were double-blind placebo-controlled studies and</seg>
<seg id="439">"" "" "" "in the open study, there was no difference in overall survival between patients treated with recombinant human erythropoetin and patients." "" "" ""</seg>
<seg id="440">"" "" "" "in these studies, with recombinant human erythropoetin, patients treated with anaemia due to various common malignomas were consistent with significantly higher mortality than with the controls." "" "" ""</seg>
<seg id="441">Overall survival in the studies could not be explained by differences in the incidence of thromboses and related complications associated with recombinant human erythropoetin patients and at controls.</seg>
<seg id="442">There is an increased risk of thromboembolcal events in tumour patients treated with recombinant human erythropotin and a negative impact on overall survival cannot be ruled out.</seg>
<seg id="443">It is not clear how far these results are transmitted to the application of recombinant human erythropotin in tumour patients treated with chemotherapy with the aim of transferring a hemoglobin value below 13 g / dl as too few patients with these characteristics were included in the examined data.</seg>
<seg id="444">Epoetin-alfa-determinations after repeated intravenous application showed a half-life of about 4 hours in healthy volunteers and a somewhat prolonged half-life of about 5 hours in patients with kidney failure.</seg>
<seg id="445">"" "" "" "after subcutaneous injection, the serum levels of epoetin alfa are much lower than the serum levels that are achieved after intravenous injection." "" "" ""</seg>
<seg id="446">"" "" "" "there is no cumulation: the serum levels remain the same, regardless of whether they are determined 24 hours after the first gift or 24 hours after the last gift." "" "" ""</seg>
<seg id="447">(bone marrow fibrosis is a known complication of chronic kidney failure in humans and could be attributed to a secondary hyperparathyreoidism or unknown factors.</seg>
<seg id="448">In a study of hemodialysis patients who were treated three years with epoetin alfa was the incidence of bone marrow fibrosis compared to the control group with dialysis patients who were not treated with epoetin alfa.</seg>
<seg id="449">14. in animal experiments with approximately 20 times of the recommended weekly dose epoetin alfa led to reduced spherical body weight to a delay in the Ossification and to an increase in fetal mortality.</seg>
<seg id="450">"" "" "" "these reports are based on vitro findings with cells from human tumor tissue samples, which are of uncertain significance for the clinical situation." "" "" ""</seg>
<seg id="451">"" "" "" "as part of the outpatient application, the patient can store abseamed unique for a period of up to 3 days outside the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="452">"" "" "" "the syringes are provided with rank rings and the filling volume is indicated by a glued label, so that, if necessary, the measurement of partial quantities is possible." "" "" ""</seg>
<seg id="453">The treatment with Abseamed must be initiated under the supervision of doctors who have experience in treating patients with the above indications.</seg>
<seg id="454">"" "" "" "21 The recommended dosage is 600 I.U. / kg epoetin alfa which should be given once a week for three weeks (day 21, 14 and 7) before the surgical procedure and on the day of the surgery (day 0)." "" "" ""</seg>
<seg id="455">"" "" "" "23 In patients with chronic kidney failure, maintenance therapy should not exceed the upper limit of hemoglobin target concentration under section 4.2." "" "" ""</seg>
<seg id="456">The hemoglobin increase should amount to approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of increasing blood pressure.</seg>
<seg id="457">"" "" "" "over thrombotic, vascular events such as myocardial ischemia, myocardial infarction, arterial thrombosis, arterial thrombosis, aneurythromboses and 26 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="458">Higher incidence of thrombovascular events (see section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="459">"" "" "" "389 patients with haemblastomosis (221 multiple myeloma, 144 non-Hodgkin- lymphomas and 24 other hemoblastomas, 23 breast carcinomas, 22 prostate cancer, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="460">"" "" "" "29 in animal experiments with approximately 20 times of the recommended weekly dose used in humans, epoetin alfa has led to a decrease in obesity and an increase in fetal mortality." "" "" ""</seg>
<seg id="461">"" "" "" "as part of the outpatient application, the patient can store abseamed unique for a period of up to 3 days outside the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="462">"" "" "" "36 The recommended dosage is 600 I.U. / kg epoetin alfa which should be given once a week for three weeks (day 21, 14 and 7) before the surgical procedure and on the day of the surgery (day 0)." "" "" ""</seg>
<seg id="463">"" "" "" "38 For patients with chronic kidney failure, maintenance therapy should not exceed the upper limit of hemoglobin target concentration under section 4.2." "" "" ""</seg>
<seg id="464">The hemoglobin increase should amount to approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of increasing blood pressure.</seg>
<seg id="465">"" "" "" "over thrombotic, vascular events such as myocardial ischemia, myocardial infarction, arterial thrombosis, arterial thrombosis, aneurythromboses and 41 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="466">Higher incidence of thrombovascular events (see section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="467">"" "" "" "389 patients with haemblastomosis (221 multiple myeloma, 144 non-Hodgkin- lymphomas and 24 other hemoblastomas, 23 breast carcinomas, 22 prostate cancer, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="468">"" "" "" "44 in animal experiments with approximately 20 times of the recommended weekly dose used in humans, epoetin alfa has led to a decrease in obesity and an increase in fetal mortality." "" "" ""</seg>
<seg id="469">"" "" "" "as part of the outpatient application, the patient can store abseamed unique for a period of up to 3 days outside the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="470">"" "" "" "51 The recommended dosage is 600 I.U. / kg epoetin alfa which should be given once a week for three weeks (day 21, 14 and 7) before the surgical procedure and on the day of the surgery (day 0)." "" "" ""</seg>
<seg id="471">"" "" "" "53 In patients with chronic kidney failure, maintenance therapy should not exceed the upper limit of hemoglobin target concentration under section 4.2." "" "" ""</seg>
<seg id="472">The hemoglobin increase should amount to approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of increasing blood pressure.</seg>
<seg id="473">"" "" "" "over thrombotic, vascular events such as myocardial ischemia, myocardial infarction, arterial thrombosis, arterial thrombosis, aneurythrombosis and 56 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="474">Higher incidence of thrombovascular events (see section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="475">"" "" "" "389 patients with haemblastomosis (221 multiple myeloma, 144 non-Hodgkin- lymphomas and 24 other hemoblastomas, 23 breast carcinomas, 22 prostate cancer, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="476">"" "" "" "59 in animal experiments with approximately 20 times of the recommended weekly dose used in humans, epoetin alfa has led to a decrease in obesity and an increase in fetal mortality." "" "" ""</seg>
<seg id="477">"" "" "" "as part of the outpatient application, the patient can store abseamed unique for a period of up to 3 days outside the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="478">"" "" "" "66 The recommended dosage is 600 I.U. / kg epoetin alfa which should be given once a week for three weeks (day 21, 14 and 7) before the surgical procedure and on the day of the surgery (day 0)." "" "" ""</seg>
<seg id="479">"" "" "" "68 In patients with chronic kidney failure, maintenance therapy should not exceed the upper limit of hemoglobin target concentration under section 4.2." "" "" ""</seg>
<seg id="480">The hemoglobin increase should amount to approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of increasing blood pressure.</seg>
<seg id="481">"" "" "" "over thrombotic, vascular events such as myocardial ischemia, myocardial infarction, arterial thrombosis, arterial thrombosis, aneurythromboses and 71 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="482">Higher incidence of thrombovascular events (see section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="483">"" "" "" "389 patients with haemblastomosis (221 multiple myeloma, 144 non-Hodgkin- lymphomas and 24 other hemoblastomas, 23 breast carcinomas, 22 prostate cancer, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="484">"" "" "" "74 In animal experiments with approximately 20 times of the recommended weekly dose used in humans, epoetin alfa has led to a decrease in obesity and an increase in fetal mortality." "" "" ""</seg>
<seg id="485">"" "" "" "as part of the outpatient application, the patient can store abseamed unique for a period of up to 3 days outside the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="486">81 The recommended dosage is 600 I.U. / kg epoetin alfa which should be given once a week for three weeks (day 21: 14 and 7) before the surgical procedure and on the day of the surgery (day 0).</seg>
<seg id="487">"" "" "" "83 In patients with chronic kidney failure, maintenance therapy should not exceed the upper limit of hemoglobin target concentration under section 4.2." "" "" ""</seg>
<seg id="488">The hemoglobin increase should amount to approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of increasing blood pressure.</seg>
<seg id="489">"" "" "" "over thrombotic, vascular events such as myocardial ischemia, myocardial infarction, arterial thrombosis, arterial thrombosis, aneurythromboses and 86 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="490">Higher incidence of thrombovascular events (see section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="491">"" "" "" "389 patients with haemblastomosis (221 multiple myeloma, 144 non-Hodgkin- lymphomas and 24 other hemoblastomas, 23 breast carcinomas, 22 prostate cancer, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="492">"" "" "" "in animal experimental studies with approximately 20 times of the recommended weekly dose used in humans, epoetin alfa has led to a decrease in obesity and to increase the mortality rate." "" "" ""</seg>
<seg id="493">"" "" "" "as part of the outpatient application, the patient can store abseamed unique for a period of up to 3 days outside the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="494">"" "" "" "96 The recommended dosage is 600 I.U. / kg epoetin alfa which should be given once a week for three weeks (day 21, 14 and 7) before the surgical procedure and on the day of the surgery (day 0)." "" "" ""</seg>
<seg id="495">"" "" "" "98 In patients with chronic kidney failure, maintenance therapy should not exceed the upper limit of hemoglobin target concentration under section 4.2." "" "" ""</seg>
<seg id="496">The hemoglobin increase should amount to approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of increasing blood pressure.</seg>
<seg id="497">"" "" "" "over thrombotic, vascular events such as myocardial ischemia, myocardial infarction, arterial thrombosis, arterial thrombosis, aneurythromboses and 101 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="498">Higher incidence of thrombovascular events (see section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="499">"" "" "" "389 patients with haemblastomosis (221 multiple myeloma, 144 non-Hodgkin- lymphomas and 24 other hemoblastomas, 23 breast carcinomas, 22 prostate cancer, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="500">"" "" "" "epoetin alfa introduced in animal experiments with approximately 20 times of the recommended daily dose for use in humans. epoetin alfa has to be reduced, to a delay in Ossification and to increase the mortality rate." "" "" ""</seg>
<seg id="501">"" "" "" "as part of the outpatient application, the patient can store abseamed unique for a period of up to 3 days outside the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="502">111 The recommended dosage is 600 I.U. / kg epoetin alfa which should be given once a week for three weeks (day 21: 14 and 7) before the surgical procedure and on the day of the surgery (day 0).</seg>
<seg id="503">"" "" "" "113 Patients with chronic kidney failure should not be exceeded, in section 4.2, the upper limit of hemoglobin target concentration should not be exceeded." "" "" ""</seg>
<seg id="504">The hemoglobin increase should amount to approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of increasing blood pressure.</seg>
<seg id="505">"" "" "" "over thrombotic, vascular events such as myocardial ischemia, myocardial infarction, arterial thrombosis, arterial thrombosis, aneurythromboses and 116 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="506">Higher incidence of thrombovascular events (see section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="507">"" "" "" "389 patients with haemblastomosis (221 multiple myeloma, 144 non-Hodgkin- lymphomas and 24 other hemoblastomas, 23 breast carcinomas, 22 prostate cancer, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="508">"" "" "" "epoetin alfa introduced in animal experimental studies with approximately 20 times of the recommended weekly dose at humans, epoetin alfa to diminish the child's balance and to increase the mortality rate." "" "" ""</seg>
<seg id="509">"" "" "" "as part of the outpatient application, the patient can store abseamed unique for a period of up to 3 days outside the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="510">"" "" "" "126 The recommended dosage is 600 I.U. / kg epoetin alfa which should be given once a week for three weeks (day 21, 14 and 7) before the surgical procedure and on the day of the surgery (day 0)." "" "" ""</seg>
<seg id="511">"" "" "" "128 In patients with chronic kidney failure, maintenance therapy should not exceed the upper limit of hemoglobin target concentration under section 4.2." "" "" ""</seg>
<seg id="512">The hemoglobin increase should amount to approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of increasing blood pressure.</seg>
<seg id="513">"" "" "" "over thrombotic, vascular events such as myocardial ischemia, myocardial infarction, arterial thrombosis, arterial thrombosis, aneurythrombosis and 131 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="514">Higher incidence of thrombovascular events (see section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="515">"" "" "" "389 patients with haemblastomosis (221 multiple myeloma, 144 non-Hodgkin- lymphomas and 24 other hemoblastomas, 23 breast carcinomas, 22 prostate cancer, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="516">"" "" "" "epoetin alfa, recommended in animal experimental studies with approximately 20 times of the recommended daily dose for use in humans, led to a delay of the Ossification and an increase in infant mortality." "" "" ""</seg>
<seg id="517">"" "" "" "as part of the outpatient application, the patient can store abseamed unique for a period of up to 3 days outside the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="518">141 The recommended dosage is 600 I.U. / kg epoetin alfa which should be given once a week for three weeks (day 21: 14 and 7) before the surgical procedure and on the day of the surgery (day 0).</seg>
<seg id="519">"" "" "" "143 In patients with chronic kidney failure, maintenance therapy should not exceed the upper limit of hemoglobin target concentration under section 4.2." "" "" ""</seg>
<seg id="520">The hemoglobin increase should amount to approximately 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of increasing blood pressure.</seg>
<seg id="521">"" "" "" "over thrombotic, vascular events such as myocardial ischemia, myocardial infarction, arterial thrombosis, arterial thrombosis, aneurythromboses and 146 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="522">Higher incidence of thrombovascular events (see section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="523">"" "" "" "389 patients with haemblastomosis (221 multiple myeloma, 144 non-Hodgkin- lymphomas and 24 other hemoblastomas, 23 breast carcinomas, 22 prostate cancer, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="524">"" "" "" "epoetin alfa introduced 149 in animal experimental studies with approximately 20 times of the recommended weekly dose to diminish spherical body weight, to delay the oscillation and to increase the mortality rate." "" "" ""</seg>
<seg id="525">"" "" "" "as part of the outpatient application, the patient can store abseamed unique for a period of up to 3 days outside the fridge and not above 25 ° C." "" "" ""</seg>
<seg id="526">"" "" "" "prior to the market launch and according to agreement with the competent authorities of the member states, the holder of approval for the placing of the medicine in dialysis centres and retail stores with the following information and materials." "" "" ""</seg>
<seg id="527">"" "" "" "the owner of the authorisation procedure has to ensure that the pharmacovigilance system described in version 3.0 and implemented in module 1.8.1. is operational, before the drug is brought into circulation and as long as the drug used in traffic is applied." "" "" ""</seg>
<seg id="528">"" "" "" "the approval of the Risk Management Plan (RMP) specified in the pharmacovigilance plan, as well as in version 5 of the Risk Management Plan given in module 1.8.2., is obligated to carry out the Risk Management Plan adopted by the CHMP." "" "" ""</seg>
<seg id="529">An updated RMP should be provided at the same time as the next updated report on the safety of the drug (Periodic Safety Update Report, PSUR) according to the "CHMP Guideline on Risk Management Systems for human use."</seg>
<seg id="530">"" "" "" "in addition, an updated RMP should be submitted: • For obtaining new information that may have influence on current safety specifications (Safety Specification), the pharmaceutical vigilance plan or the risk reduction measures)" "" "" ""</seg>
<seg id="531">"" "" "" "• In a month before your treatment, you have suffered a heart attack or stroke - if you suffer from instable angina pectoris (for the first time occurring or increased chest pain) - the risk of blood clots occurring in the veins (deep venous thromboses) has occurred." "" "" ""</seg>
<seg id="532">"" "" "" "you suffer from severe bleeding disturbances of the heart (coronary artery disease), arteries of the legs or arms (peripheral arterial occlusion) or brain (cerebrovascular disease) or have recently suffered a heart attack or stroke." "" "" ""</seg>
<seg id="533">"" "" "" "during treatment with seamed amed, it can occur within the normal range to a slight dose-dependent increase in the number of platelets, which resumes after further treatment." "" "" ""</seg>
<seg id="534">"" "" "" "if necessary, your doctor will perform regular blood tests to check the number of platelets during the first 8 weeks of treatment." "" "" ""</seg>
<seg id="535">"" "" "" "iron deficiency, dissolution of the red blood cells (hemolysis), blood loss, vitamin B12 or folic acid deficiency should be considered and treated before the treatment with Abseamed." "" "" ""</seg>
<seg id="536">"" "" "" "very seldom, erythropoetin was reported about the occurrence of an antibody-mediated erythroblasting syndrome after monate- to years of treatment with subcutaneous (under the skin sprayed) erythropoetin." "" "" ""</seg>
<seg id="537">"" "" "" "if you suffer from erythroblasting, it will abort your therapy with seamed amed and determine how your anaemia is best treated." "" "" ""</seg>
<seg id="538">"" "" "" "therefore, Abseamed by injection must be given into a vein (intravenous) if you are treated for anaemia due to kidney disease." "" "" ""</seg>
<seg id="539">"" "" "" "a high hemoglobin value is the risk of problems with the heart or blood vessels, and the risk of death can be increased." "" "" ""</seg>
<seg id="540">"" "" "" "if you are elevated or rising in potassium, your doctor may consider an interruption of the treatment with seamed tonamed until the potassium values are back in normal range." "" "" ""</seg>
<seg id="541">"" "" "" "if you suffer from chronic kidney failure and clinically obvious coronary artery disease or congestion by insufficient heart performance, your doctor will ensure that your hemoglobin mirror does not exceed a certain value." "" "" ""</seg>
<seg id="542">"" "" "" "according to the findings, the treatment of anaemia in adults with chronic kidney failure (renal insufficiency), which is not yet dialysis, will not accelerate the progression of renal insufficiency." "" "" ""</seg>
<seg id="543">A 2 - 3-week delay between epoetin-alfa and the desired effect should be considered for assessing the effectiveness of Abseamed.</seg>
<seg id="544">200 Your doctor will regularly determine your values of the red blood dye (hemoglobin) and adapt your Abseamed dose to keep the risk of blood clots (thrombotic event) as low as possible.</seg>
<seg id="545">"" "" "" "this risk should be weighed very carefully compared to the benefits derived from the treatment with epoetin alfa, especially if you have an increased risk of thrombotic vascular events." "" "" ""</seg>
<seg id="546">"" "" "" "in case you are a cancer patient, remember that Abseamed acts as a growth factor for blood cells and may negatively affect the tumor." "" "" ""</seg>
<seg id="547">"" "" "" "if you have a larger orthopedic operation, you should investigate the cause of your anaemia before treatment with Abseamed and be treated accordingly." "" "" ""</seg>
<seg id="548">"" "" "" "if your values of the red blood dye (hemoglobin) are too high, you should not obtain Abseamed because there is an increased risk of blood clots after the surgery." "" "" ""</seg>
<seg id="549">"" "" "" "please inform your doctor or pharmacist if you are taking other medicines / applied / applied recently, even if it is not prescription medicine." "" "" ""</seg>
<seg id="550">"" "" "" "if you take Ciclosporin (funds to suppress the immune system) during your therapy with Abseamed, your doctor may arrange certain blood tests to measure the blood level of Ciclosporin." "" "" ""</seg>
<seg id="551">Laboratory tests have no interaction between epoetin alfa and G-CSF or GM-CSF (G-CSF and GM-CSF are means to establish the immune system (e.g. for cancer chemotherapy or HIV).</seg>
<seg id="552">"" "" "" "depending on how your anemia (anemia) refers to the treatment, the dose can be adjusted every four weeks until your condition is under control." "" "" ""</seg>
<seg id="553">Your doctor will be able to prescribe regular blood tests to verify the success of the treatment and ensure that the medicine works properly and does not exceed your hemoglobin value.</seg>
<seg id="554">"" "" "" "once you are well set, you get regular doses of seamed between 25 and 50 I.U. / kg twice a week, spread on two equally large injections." "" "" ""</seg>
<seg id="555">Your doctor will need regular blood tests to verify the success of your treatment and ensure that your hemoglobin value does not exceed a certain value.</seg>
<seg id="556">"" "" "" "depending on how anaemia is addressing the treatment, the dose can be adjusted every four weeks until the state is under control." "" "" ""</seg>
<seg id="557">"" "" "" "to ensure and ensure that the hemoglobin value does not exceed a certain value, the doctor will conduct regular blood tests." "" "" ""</seg>
<seg id="558">"" "" "" "if it is necessary to shorten treatment time prior to surgery, a dose of 300 I.U. / kg can be given on 10 consecutive days before the surgery, on the day of surgery and another 4 days after the surgery." "" "" ""</seg>
<seg id="559">"" "" "" "however, you can learn when your doctor is appropriate for it, also learn how to splash out abseamed yourself under the skin." "" "" ""</seg>
<seg id="560">"" "" "" "heart, heart attack, brain bleeding, stroke, temporary circulatory disorders, arterial thrombosis, arterial thrombosis, arterial thrombosis, arterial thrombosis and blood clots in artificial kidneys were reported in patients with erythropoetin treatment." "" "" ""</seg>
<seg id="561">"" "" "" "eye lids and lips (Quincke-Ödem) and shock-like allergic reactions with symptoms such as tingling, redness, itching, heat feeling and accelerated pulse have been reported in rare cases." "" "" ""</seg>
<seg id="562">Erythroblaendie means that there are no longer enough red blood cells to be formed in the bone marrow (see section called "Specific caution in the application of Abseamed is required").</seg>
<seg id="563">"" "" "" "after repeated blood donations, it can occur - regardless of the treatment with seamed - to a blood clots (thrombotic vascular events)." "" "" ""</seg>
<seg id="564">The treatment with Abseamed can be associated with an increased risk of blood prop after the operation (post-operative thrombotic vascular events) if your initial haemoglobin is too high</seg>
<seg id="565">Please inform your doctor or pharmacist if any of the side effects listed are significantly impaired or if you notice any side effects that are not stated in this information information.</seg>
<seg id="566">"" "" "" "when a syringe is taken out of the refrigerator and has reached room temperature (up to 25 ° C), it must be used either within 3 days or discarded." "" "" ""</seg>
<seg id="567">Aclasta is used to treat the following diseases: • Osteoporosis (a disease that makes the bones brittle) both in women after menopause and in men.</seg>
<seg id="568">"" "" "" "it is used in patients with a high fracture risk (fractures), including patients who recently suffered a lower traumatic hip fracture as in case of falling; • Morbus Paget of the bone, a disease that changes the normal course of bone growth." "" "" ""</seg>
<seg id="569">"" "" "" "additionally, patients with Morbus Paget should take at least 500 mg of calcium twice daily for at least 10 days after treatment; patients with hip fracture should have a large dose of vitamin D (50 000 to 125 000 IE) orally or by injection into a muscle." "" "" ""</seg>
<seg id="570">"" "" "" "the administration of paracetamol or ibuprofen (remedy against inflammation) shortly after use of Aclasta can reduce the symptoms occurring in the three days after infusion such as fever, muscle pain, flu-like symptoms, joint pain and headache." "" "" ""</seg>
<seg id="571">"" "" "" "for the treatment of the Morbus Paget, Aclasta can only be prescribed by doctors who have experience in treating this disease." "" "" ""</seg>
<seg id="572">"" "" "" "as the active ingredient in Aclasta is the same as in Zeta, a part of the data material for zometa was used to evaluate Aclasta." "" "" ""</seg>
<seg id="573">"" "" "" "in the first study, almost 8 000 elderly women with osteoporosis were involved, and the number of spinal and hip fractures over a period of three years was investigated." "" "" ""</seg>
<seg id="574">"" "" "" "the second study included 2 127 men and women with osteoporosis over 50 years, who recently suffered a hip fracture; the number of fractures over a period of up to five years was investigated." "" "" ""</seg>
<seg id="575">At Morbus Paget Aclasta was tested in two trials involving a total of 357 patients and compared with Risedron (another bisphosphonate) for six months.</seg>
<seg id="576">"" "" "" "the main indicator of the efficacy was whether the alkaline phosphatase in the serum (an enzyme that builds the bone substance) normalized in the blood, or decreased by at least 75% compared to the initial value." "" "" ""</seg>
<seg id="577">"" "" "" "in the study of older women, the risk of vertebrates in patients under Aclasta (without other osteoporosis) was reduced by 70% over a period of three years compared to the patients." "" "" ""</seg>
<seg id="578">"" "" "" "compared to all patients under Aclasta (with or without other osteoporosis), the risk of hip fractures was reduced by 41%." "" "" ""</seg>
<seg id="579">In the study involving men and women with hip fracture 9% of patients under Aclasta had a fracture (92 of 1 065) compared to 13% of patients under placebo (139 of 1 062).</seg>
<seg id="580">"" "" "" "most side effects of Aclasta occur within the first three days after infusion, and are less frequent with repeated infusions." "" "" ""</seg>
<seg id="581">"" "" "" "Aclasta must not be used in patients who may be hypersensitive to fluoric acid or other bisphosphonate, or any of the ingredients." "" "" ""</seg>
<seg id="582">"" "" "" "as with all bisphosphonates, patients with Aclasta are subject to the risk of kidney problems, reactions to the infusion spot and osteoecsis (death of bone tissue) in the jaw." "" "" ""</seg>
<seg id="583">"" "" "" "the manufacturer of Aclasta provides informational material for doctors who prescribe Aclasta to treat osteoporosis, as well as a similar material for patients where the side effects of the medicine are explained and indicated when they should contact the doctor." "" "" ""</seg>
<seg id="584">"" "" "" "April 2005, the European Commission granted Novartis Europharm Limited a permit for the placing of Aclasta across the European Union." "" "" ""</seg>
<seg id="585">Requirements OR Regulations regarding THE SICHERE AND effective FEWENDING OF THE GED OR ACCOMING OR ACCOUNDATION OR ACTIONS OF THE SICENDING OF THE EU member states ARE PROPHONE</seg>
<seg id="586">"" "" "" "treatment of osteoporosis in postmenopausal women and in men with increased risk of fractures, including patients with a recent low-traumatic hip fracture." "" "" ""</seg>
<seg id="587">"" "" "" "the patient information package is to be provided and the following core messages include: • The package supplement • contraindication in pregnancy and breastfeeding women • Required of adequate intake of calcium and vitamin D, appropriate signs and symptoms for serious side effects • When applying to medical or nursing care" "" "" ""</seg>
<seg id="588">"" "" "" "treatment of osteoporosis • in postmenopausal women • in men with an increased risk of fractures, including patients with a recent low-traumatic hip fracture." "" "" ""</seg>
<seg id="589">For the treatment of postmenopausal osteoporosis and osteoporosis in men an intravenous infusion of 5 mg Aclasta is recommended once a year.</seg>
<seg id="590">"" "" "" "in patients with low-traumatic hip fracture, the administration of the infusion of Aclasta is recommended two or more weeks after the correction of the hip fracture (see Section 5.1)." "" "" ""</seg>
<seg id="591">"" "" "" "for the treatment of the Morbus Paget, Aclasta should only be prescribed by doctors who have experience in treating the Morbus Paget." "" "" ""</seg>
<seg id="592">"" "" "" "following a treatment of the Morbus Paget with Aclasta, a long remission was observed in patients receiving treatment (see Section 5.1)." "" "" ""</seg>
<seg id="593">"" "" "" "in addition, it is very advisable to ensure sufficient intake of calcium in patients with Morbus Paget for at least 500 mg of elementary calcium, for at least 10 days after the gift of Aclasta (see section 4.4)." "" "" ""</seg>
<seg id="594">"" "" "" "in patients with a recently developed low-traumatic hip fracture, an initial dose of 50.000 to 125,000 I.U. is recommended prior to the first Aclasta infusion." "" "" ""</seg>
<seg id="595">"" "" "" "the frequency of symptoms occurring within the first three days after the administration of Aclasta, may be reduced by using paracetamol or ibuprofen, shortly after use by Aclasta." "" "" ""</seg>
<seg id="596">Patients with kidney function disorder (see section 4.4) In patients with a creatinin-clearing &lt; 35 ml / min Aclasta is not recommended as limited clinical experiences are available for this patient group.</seg>
<seg id="597">"" "" "" "older patients (≥ 65 years) A can adjustment is not necessary since the bioavailability, distribution and elimination of older patients is similar to younger patients." "" "" ""</seg>
<seg id="598">"" "" "" "children and young people Aclasta are not recommended for use in children and young people under the age of 18, as data is lacking for safety and efficacy." "" "" ""</seg>
<seg id="599">Aclasta is not recommended for patients with severe kidney failure (Creatinin-Clearance &lt; 35 ml / min) because only limited clinical experiences are available for this patient population.</seg>
<seg id="600">Preexisting hypokalemia is to be treated with Aclasta prior to the treatment of calcium and vitamin D (see Section 4.3).</seg>
<seg id="601">"" "" "" "a temporary, sometimes symptomatic hypocalcemia is able to develop over the first 10 days after the infusion of Aclasta (see Section 4.8)." "" "" ""</seg>
<seg id="602">"" "" "" "in addition, it is very advisable to ensure sufficient intake of calcium in patients with Morbus Paget for at least 500 mg of elementary calcium, for at least 10 days after the gift of Aclasta (see section 4.2)." "" "" ""</seg>
<seg id="603">"" "" "" "cancer, chemotherapy, treatment with corticosteroids, bad oral hygiene) should be induced before using bisphosphonates with appropriate preventive dental treatment." "" "" ""</seg>
<seg id="604">"" "" "" "for patients who need dental access, no data is available whether the interruption of treatment with bisphosphonates reduces the risk of osteonecrosis in the jaw area." "" "" ""</seg>
<seg id="605">The clinical evaluation by the treating physician should be the basis for the treatment plan of each patient and based on an individual benefit risk assessment.</seg>
<seg id="606">The frequency of symptoms occurring within the first three days after Aclasta administration may be reduced by using paracetamol or ibuprofen shortly after use of Aclasta (see section 4.2).</seg>
<seg id="607">The frequency of unreported cases of atrial fibrillation in patients receiving Aclasta was increased (1.3%) (51 of 3.862) compared to patients receiving placebo (0.6%) (22 of 3.852).</seg>
<seg id="608">In the osteoporosis studies (PFT) HORIZON - Recurrent Fracture Trial [RFT]) the overall frequency of atrial fibrillation between Aclasta (2.6%) and placebo (2.1%) was comparable.</seg>
<seg id="609">"" "" "" "common (≥ 1 / 100, &lt; 1 / 100), occasional (≥ 1 / 1,000, &lt; 1 / 1000), rare (≥ 1 / 1,000, &lt; 1 / 1000) adverse drug interactions are listed in Table 1." "" "" ""</seg>
<seg id="610">"" "" "" "renal dysfunction Zoledronylic acid was associated with renal function disorders, which expressed itself as a decrease in the renal function (i.e. an increase of serum creatine) and in rare cases referred to as acute renal failure." "" "" ""</seg>
<seg id="611">The change in the creatinin-clearing (measured annually before the administration) and the occurrence of kidney failure and a limited renal function were comparable between the Aclasta- and the placebo group in a clinical study of osteoporosis.</seg>
<seg id="612">A temporary increase of serum creatinins within 10 days after administration was observed at 1.8% of patients treated with Aclasta compared to 0.8% of patients treated with placebo.</seg>
<seg id="613">"" "" "" "based on the evaluation of laboratory findings, the temporary asymptomatic calcium levels were observed in 2.3% of patients treated with Aclasta in a large clinical study compared to 21% of patients treated with Aclasta in the Morbus Paget studies." "" "" ""</seg>
<seg id="614">"" "" "" "in addition, all patients received sufficient amounts of vitamin D and calcium in the postmenopausal osteoporosis study, in the study to prevent clinical fractures after a hip fracture and in the Morbus Paget studies (see Section 4.2)." "" "" ""</seg>
<seg id="615">"" "" "" "in the study to prevent clinical fractures after a recent hip fracture, the vitamin D levels were not routinely measured, but the majority of patients received an initial dose of vitamin D before the administration of Aclasta (see section 4.2)." "" "" ""</seg>
<seg id="616">"" "" "" "local reactions After the administration of zoledronylic acid in a large clinical study was reported via local reactions to the infusion spot, such as redness, swelling and / or pain, (0.7%)." "" "" ""</seg>
<seg id="617">"" "" "" "osteonecrosis in the jaw area has been treated, especially in cancer patients, about osteonecrosis (primarily in the jaw area), which were treated with bisphosphonate, including Zoledronylic acid." "" "" ""</seg>
<seg id="618">"" "" "" "many of these patients had signs of local infections including osteoelitis, and most of the reports refer to cancer patients after tooth extractions or other dental intervening." "" "" ""</seg>
<seg id="619">"" "" "" "7 study involving 7,736 patients showed osteoecsis in the jaw area of one with Aclasta and in patients treated with placebo." "" "" ""</seg>
<seg id="620">"" "" "" "in the case of overdosage, which leads to a clinically relevant hypokalemia, a compensation can be obtained by applying oral calcium and / or an intravenous infusion of calcium gluconate." "" "" ""</seg>
<seg id="621">Clinical efficacy in postmenopausal osteoporosis (PFT) The efficacy and safety of Aclasta 5 mg once a year for 3 consecutive years was demonstrated with either one bone density value (BMD) -T-Score for the femoral contracture (BMD) and at least two mild or a medium-heavy existing spine fracture (BMD).</seg>
<seg id="622">Effects on morphometric vertebral fractures Aclasta were significantly lowered over a period of three years and after one year the frequency of one or more new vertebrate fractures (see table 2).</seg>
<seg id="623">Aclasta-treated patients aged 75 years and older had a 60% reduced risk of vertebrate fractures compared to placebo patients (p &lt; 0.0001).</seg>
<seg id="624">Effects on hip fractures Aclasta showed a consistent effect over three years which resulted in a reduced risk for hip fractures in one by 41% (95% CI (17% to 58%).</seg>
<seg id="625">"" "" "" "effect on bone density (BMD) Aclasta increased bone density on lumbar vertebrates, hips and distal radius compared with placebo-treatment significantly at all times (6, 12, 24 and 36 months)." "" "" ""</seg>
<seg id="626">"" "" "" "9% increase in bone density of the lumbar spine by 6.7%, the entire hip at 6.0%, the femoral neck by 5.2% and the distal radius of 3.2%." "" "" ""</seg>
<seg id="627">"" "" "" "bone histology of 152 postmenopausal osteoporosis patients treated with Aclasta (N = 82) or placebo (N = 70) were taken from the pelvic ridge a year after the third annual dose." "" "" ""</seg>
<seg id="628">A microcomputer tomography (µCT) analysis showed an increase in trabecular bone volume in Aclasta compared to placebo.</seg>
<seg id="629">Bone turnover marker The bone-specific alkaline phosphatase (BSAP) in serum and beta-C Telopeptid (b-CTX) in serum and beta-C Telopeptid (b-CTX) were measured in subgroups of 517 to 1.246 patients during periods of study.</seg>
<seg id="630">"" "" "" "after 12 months, the treatment with an annual 5 mg dose Aclasta significantly reduced 30% compared to the initial value and was held at 28% below the starting value for up to 36 months." "" "" ""</seg>
<seg id="631">"" "" "" "P1NP was significantly reduced by 61% below the initial value after 12 months, and was held at 52% below the starting value for up to 36 months." "" "" ""</seg>
<seg id="632">"" "" "" "B-CTX was significantly reduced by 61% below the initial value after 12 months, and was kept at 55% below the starting value for up to 36 months." "" "" ""</seg>
<seg id="633">"" "" "" "the vitamin D levels were not routinely measured, but the majority of patients received an initial dose of vitamin D (50,000 to 125,000 I.U. oral or intramuscular) 2 weeks prior to infusion." "" "" ""</seg>
<seg id="634">Overall sinister mortality was 10% (101 patients) in the group treated with Aclasta compared to 13% (141 patients) in the placebo group.</seg>
<seg id="635">"" "" "" "effect on bone mineral density (BMD) In the HORIZON-RFT study, Aclasta treatment increased the BMD on the overall thigh and femoral neck at all times." "" "" ""</seg>
<seg id="636">"" "" "" "Aclasta treatment performed more than 24 months compared to placebo, increasing BMD by 5.4% on the overall hip and 4.3% on the femoral neck." "" "" ""</seg>
<seg id="637">"" "" "" "clinical efficacy in men In the HORIZON-RFT study, 508 men were randomised and the BMD was evaluated after 24 months." "" "" ""</seg>
<seg id="638">The study was not designed to show a reduction in clinical fractures in men; the incidence of clinical fractures was 7.5% in Aclasta-treated men compared to 8.7% in placebo.</seg>
<seg id="639">In another study in men (study CZOL446M2308) the once yearly administration of Aclasta was not inferior to the percentage change of the lumbar vertebra BMD after 24 months compared to the starting value.</seg>
<seg id="640">Clinical effectiveness of the treatment at Morbus Paget of the bone Aclasta was examined in patients aged over 30 years with radiologically confirmed (medium serum levels of alkaline phosphatase according to 2.6x to 3.0ples of the age-specific upper normal value when entering the study).</seg>
<seg id="641">11 The efficacy of an infusion of 5 mg of cichedron acid in comparison to the intake of 30 mg of Risedron once a day was proven in two six months of comparison studies.</seg>
<seg id="642">"" "" "" "after 6 months, the combined results showed a similar decrease in pain strength and pain influence compared to the baseline for Aclasta and Risedronat." "" "" ""</seg>
<seg id="643">"" "" "" "patients who were classified as Responds at the end of the 6-month trial, were able to be included in a follow-up phase." "" "" ""</seg>
<seg id="644">From the 143 with Aclasta and the 107 with Risedron treated patients who participated in the follow-up study the therapeutic response at 141 of patients treated with Aclasta was maintained at an average duration of the follow-up period of 18 months after the application.</seg>
<seg id="645">"" "" "" "infusion of 2, 4, 8 and 16 mg of fluoric acid in 64 patients showed the following pharmacokinetic data that proved to be a dose independent." "" "" ""</seg>
<seg id="646">"" "" "" "after that, the plasma level rapidly decreased to &lt; 10% of the maximum value after 4 hours and &lt; 1% after 24 h, followed by a long period of very low concentration, not more than 0.1% of the maximum value." "" "" ""</seg>
<seg id="647">Rapid biphasic disappearing from the large cycle with half-life time t ½ a 0.24 and t ½ to 1.87 hours followed by a long elimination phase with a terminal Eliminationshal lifetime t ½ g 146 hours.</seg>
<seg id="648">"" "" "" "the early distribution phases (α and β, with the above ½ -values) presumably represent the rapid absorption in the bones and excretion over the kidneys." "" "" ""</seg>
<seg id="649">"" "" "" "in the first 24 hours, 39 ± 16% of the administered dose in the urine occurs while the rest is mainly tied to bone tissue." "" "" ""</seg>
<seg id="650">"" "" "" "the total-body-clearing amounts to 5.04 ± 2.5 l / h regardless of the dose and remains unaffected by gender, age, race or body weight." "" "" ""</seg>
<seg id="651">An extension of the infusion period from 5 to 15 minutes led to the decrease in zinc-acid concentration by 30% at the end of the infusion but had no effect on the surface below the curve (plasma concentration versus time).</seg>
<seg id="652">"" "" "" "reduced clearing of mettochrome-P450 enzyme systems is unlikely to be metabolized in humans, because it is a weak or no direct and / or irreversible inhibitor of the P450-" "" "" ""</seg>
<seg id="653">Special patient groups (see section 4.2) The renal clearing of the Zoledron acid correlated with the creatinin-clearing with 75 ± 33% of the creatinin-clearing and was 84 ± 29 ml / min (range 22 to 143 ml / min).</seg>
<seg id="654">"" "" "" "this results in an easy (Clcr = 50- 80 ml / min) and a moderate kidney function disorder, down to a creatinin clearing up to 35 ml / min." "" "" ""</seg>
<seg id="655">"" "" "" "as for severe kidney function problems (Creatinin- Clearance &lt; 30 ml / min) only limited data are available, no statements are possible for this population." "" "" ""</seg>
<seg id="656">Acute toxicity The highest intravenous single dose for intravenous single dose was 10 mg / kg body weight and at rats 0.6 mg / kg body weight.</seg>
<seg id="657">"" "" "" "for studies in dogs single doses of 1,0 mg / kg (based on AUC the recommended human-therapeutic exposure) were administered over a period of 15 minutes, good and without a renal influence." "" "" ""</seg>
<seg id="658">Chronic and chronic toxicity In studies with intravenous application the renal tolerance of Zoledronylic acid in rats was determined in 3-day infusion in 3-day intervals of 6 times (a cumulative dose that corresponds to the 7fold of human-therapeutic exposure related to AUC).</seg>
<seg id="659">"" "" "" "in long-term studies with repeated use with accumulated expositions, which exceeded the maximum of intended human exposure, toxicological effects in other organs, including the gastrointestinal tract and the liver, as well as at the intravenous injection site." "" "" ""</seg>
<seg id="660">"" "" "" "the most frequent occurrence in studies with repeated use was an increased primary Spongiosa in the Metaphysis of the long bones of animals in the growth phase with almost all dosages, a findings that reflects the pharmacological, antioxidant effect of the substance." "" "" ""</seg>
<seg id="661">At rats one observed a teratogenicity in dosages from 0.2 mg / kg as external and internal (visceral) abnormalities and such of the skeleton.</seg>
<seg id="662">"" "" "" "no teratogenic effects or embryo-fetal effects were observed in rabbits, although the maternal toxicity was pronounced at 0.1 mg / kg as a result of the low serum calcium level." "" "" ""</seg>
<seg id="663">"" "" "" "if the medicine is not used immediately, the user is responsible for the storage period according to the preparation and conditions before the application; normally 24 hours at 2 ° C to 8 ° C should not be exceeded." "" "" ""</seg>
<seg id="664">"" "" "" "Aclasta is delivered as a package with a bottle of packing unit or bundle packing consisting of 5 packs, each containing a bottle." "" "" ""</seg>
<seg id="665">"" "" "" "treatment of osteoporosis in postmenopausal women and in men with increased risk of fractures, including patients with a recent low-traumatic hip fracture." "" "" ""</seg>
<seg id="666">"" "" "" "the patient information package is to be provided and the following core messages include: • The package supplement • contraindication in pregnancy and breastfeeding women • Required of adequate intake of calcium and vitamin D, appropriate physical activity, non-smoking and healthy nutrition 17" "" "" ""</seg>
<seg id="667">"" "" "" "July 2007, completed on 29 September 2006, in module 1.8.1 the drug vigilance system described in the module is and works before and while the product is marketed." "" "" ""</seg>
<seg id="668">Risko-Management-Plan The holder of approval of the marketing agency commits itself to the studies and the additional activities for pharmacovigilance which are presented in the pharmacovigilance plan of the approved version 004 of the risk management plan (RMP) approved by the CHMP approved versions of the RMP.</seg>
<seg id="669">"" "" "" "according to the CHMP guideline for risk management systems for human medicines, the revised RMP should be submitted together with the next" Periodic Safety Update "(PSUR)." "" "" ""</seg>
<seg id="670">"" "" "" "a revised RMP should be submitted, When new information is known, which may affect the current information on safety, pharmacovigilance plan or activities to minimize the risk." "" "" ""</seg>
<seg id="671">Zoledron acid is a representative of a substance called bisphosphonate and is used for the treatment of osteoporosis in postmenopausal women who use osteoporosis in men and the Morbus Paget of the bone.</seg>
<seg id="672">"" "" "" "decreasing blood levels of sex hormones, especially oestrogens being formed from androgens, play a role in the rather gradual loss of bone mass, which is observed in men." "" "" ""</seg>
<seg id="673">"" "" "" "at the Morbus Paget the bone structure takes place too quickly, and new bone material is unordered, which makes the bone material weaker than normal." "" "" ""</seg>
<seg id="674">"" "" "" "Aclasta helps to normalize the bone structure again, ensuring a normal bone formation and thus reinforces the bone." "" "" ""</seg>
<seg id="675">"" "" "" "if you are in dentistry or undergo a dental surgery, inform your doctor that you will be treated with Aclasta." "" "" ""</seg>
<seg id="676">"" "" "" "if you use Aclasta with other medicines, please inform your doctor, pharmacist or the nursing staff if you are taking other medicines / applied / applied recently, even if they are not prescription pharmaceuticals." "" "" ""</seg>
<seg id="677">"" "" "" "for your doctor, it is especially important to know if you are taking medicines that is known to the kidneys." "" "" ""</seg>
<seg id="678">"" "" "" "when using Aclasta, together with foods and drinks, worry that according to your doctor's instructions, you should take sufficient liquid before and after treatment with Aclasta." "" "" ""</seg>
<seg id="679">Osteoporosis The usual dose is 5 mg once a year which is administered to you by your doctor or nursing staff as infusion in a vein.</seg>
<seg id="680">"" "" "" "if you recently broke the hips, it is recommended to make the administration of Aclasta two or more weeks after the surgical treatment of the hip fracture." "" "" ""</seg>
<seg id="681">"" "" "" "Morbus Paget The usual dose is 5 mg, which is administered to you by your doctor or the nursing staff as an infusion in a vein." "" "" ""</seg>
<seg id="682">"" "" "" "since Aclasta has a long time, you may need a further dose after one year or longer." "" "" ""</seg>
<seg id="683">"" "" "" "it is important to follow these instructions carefully, so that the calcium level in your blood will not be too low in your blood after the infusion." "" "" ""</seg>
<seg id="684">"" "" "" "at Morbus Paget Aclasta can work longer than a year, and your doctor will inform you if you need a new treatment." "" "" ""</seg>
<seg id="685">"" "" "" "if missed by Aclasta, contact your doctor or hospital immediately to arrange a new appointment." "" "" ""</seg>
<seg id="686">"" "" "" "before ending the treatment with Aclasta If you are considering the termination of treatment with Aclasta, please take your next medical appointment and discuss this with your doctor." "" "" ""</seg>
<seg id="687">"" "" "" "side effects associated with the first infusion are very common (with more than 30% of patients), but are less frequent after subsequent infusion." "" "" ""</seg>
<seg id="688">"" "" "" "fever and chills, muscle or joint pain and headache occur within the first three days after the administration of Aclasta." "" "" ""</seg>
<seg id="689">"" "" "" "currently it is unclear whether Aclasta causes this irregular heartbeat, but you should report it to your doctor if you notice such symptoms after you have received Aclasta." "" "" ""</seg>
<seg id="690">"" "" "" "physical signs because of low calcium concentration in the blood, such as muscle cramps or tingling sensation or numbness, especially in the area around the mouth." "" "" ""</seg>
<seg id="691">"" "" "" "headache, sore throat, pain, sore throat, sore throat, sore throat, sore throat, sore throat, sore throat, skin rash, sore throat, skin rash, sore throats, skin rash, sore throats, skin rash, sore throat, skin rash, sore throat, sore throat, sore throat, sore throat, sore throat, sore throat, sore throat." "" "" ""</seg>
<seg id="692">Persistent pains and / or non-healing wounds in the mouth or in the jaw were reported mainly in patients treated with bisphosphonates because of other diseases.</seg>
<seg id="693">"" "" "" "allergic reactions, including rare cases of respiratory problems, hives and angioedema (such as swelling in the face, tongue or throat), has been reported." "" "" ""</seg>
<seg id="694">"" "" "" "please inform your doctor, pharmacist or nursing staff if any of the side effects listed will affect you significantly or you may notice any side effects not listed in this information information." "" "" ""</seg>
<seg id="695">"" "" "" "if the medicine is not directly used, the user is responsible for the storage time and conditions to the application; normally 24 hours should not be exceeded at 2 ° C to 8 ° C." "" "" ""</seg>
<seg id="696">"" "" "" "in patients with a recently developed low-traumatic hip fracture, it is recommended to make the infusion of Aclasta two or more weeks after the surgical treatment of the hip fracture." "" "" ""</seg>
<seg id="697">"" "" "" "before and after the administration of Aclasta, patients must be sufficiently supplied with liquid; this is especially important for patients receiving a diuretic therapy." "" "" ""</seg>
<seg id="698">"" "" "" "a temporary, sometimes symptomatic, hypokalzemia can develop, which usually occurs within the first 10 days after the infusion of Aclasta." "" "" ""</seg>
<seg id="699">"" "" "" "in addition, it is very advisable to ensure adequate intake of calcium in patients with Morbus Paget, according to at least twice a day 500 mg of elementary calcium, for at least 10 days after the gift of Aclasta." "" "" ""</seg>
<seg id="700">"" "" "" "in patients with a recently developed low-traumatic hip fracture, an initial dose of 50.000 to 125,000 I.U. is recommended before the infusion of Aclasta." "" "" ""</seg>
<seg id="701">"" "" "" "if you need more information about your illness or their treatment, please read the package supplement (also part of the EPAR) or contact your doctor or pharmacist." "" "" ""</seg>
<seg id="702">ACOMPLIA is used in addition to a diet and exercise for the treatment of adult patients with a body mass index (BMI) of 30 kg / m ² or about it or • which are overweight (BMI of 27 kg / m ² or above) and beyond one or more I</seg>
<seg id="703">"" "" "" "in addition, four studies have been conducted to over 7,000 patients in which ACOMPLIA was used as a supportive agent for setting up smoking." "" "" ""</seg>
<seg id="704">"" "" "" "on the other hand, the studies on the attitudes of smoking did not show uniform results so that the effect of ACOMPLIA was difficult to assess in this area of use." "" "" ""</seg>
<seg id="705">What risk is associated with ACOMPLIA? the most common side effects of ACOMPLIA observed during the studies (observed at more than 1 out of 10 patients) were Nausea (nausea) and infections of the upper respiratory tract.</seg>
<seg id="706">"" "" "" "it may also not be used in patients who suffer from an existing severe depression or be treated with antidepressants, since it can increase the risk of depression and can cause suicidal thoughts among others in a small minority of patients." "" "" ""</seg>
<seg id="707">Caution is recommended while using ACOMPLIA with medicines such as ketoconazole or Itraconazole (medicine against fungal infections) and kelierycin or Clarithromycin (antibiotics).</seg>
<seg id="708">The Committee for Human Use (CHMP) concluded that the efficacy of ACOMPLIA with regard to weight reduction in patients with obesity or obese people</seg>
<seg id="709">"" "" "" "medicine used in patients who need it from health and not for cosmetic reasons (by providing treatment packages for patients and physicians), and around the ARZ" "" "" ""</seg>
<seg id="710">"" "" "" "in addition to diet and exercise to treat obesity (BMI ≥ 30 kg / m ²) or obese patients (BMI &gt; 27 kg / m ²), which also have one or more risk factors, such as type 2 diabetes or dyslipidemia (see Section 5.1)." "" "" ""</seg>
<seg id="711">"" "" "" "ACOMPLIA is not recommended for use in children and adolescents under the age of 18, due to the lack of data on efficacy and harmlessness." "" "" ""</seg>
<seg id="712">"" "" "" "depression or mood changes with depressive symptoms have been reported in up to 10%, suicidal thoughts in up to 1% of patients receiving the Rimonabant (see Section 4.8)." "" "" ""</seg>
<seg id="713">"" "" "" "Rimonabant may not be used, unless the use of treatment in an individual case outweighs the risk (see Section 4.3 and 4.8)." "" "" ""</seg>
<seg id="714">"" "" "" "also in patients who have no noticeable risks in addition to obesity, depressive reactions can occur." "" "" ""</seg>
<seg id="715">"" "" "" "relatives or other related persons) are advised that it is necessary to monitor the recurrence of such symptoms and immediately obtain medical advice, if these symptoms occur." "" "" ""</seg>
<seg id="716">• Elderly patients The efficacy and harmlessness of Rimonabant in the treatment of patients over 75 years have not been shown sufficiently.</seg>
<seg id="717">Patients with a cardiovascular event (myocardial infarction or stroke etc.) were excluded from studies with Rimonabant less than 6 months ago.</seg>
<seg id="718">"" "" "" "rifampicin, phenobarbital, phenobarbital, carbamazepine, carob tree) is not examined, is assumed that the simultaneous injection of potent CYP3A4 inductors the plasma concentration of Rimonabant" "" "" ""</seg>
<seg id="719">"" "" "" "patients with obese patients and patients with obesity, plus 3800 patients in further indications." "" "" ""</seg>
<seg id="720">"" "" "" "the following table (Table 1) shows the unwanted effects of placebo-controlled trials in patients treated for weight reduction, and associated metabolic disorders." "" "" ""</seg>
<seg id="721">"" "" "" "if the incidence was statistically significant higher than the corresponding placebo (for undesired effects ≥ 1%) or if they were clinically relevant (for unwanted effects &lt; 1%)." "" "" ""</seg>
<seg id="722">"" "" "" "very common (≥ 10%); frequent (≥ 1, &lt; 10%); occasionally (≥ 0.01, &lt; 0.1%); very t)" "" "" ""</seg>
<seg id="723">"" "" "" "in a comparative study, in which a limited number of individuals were administered by up to 300 mg, only slight symptoms were observed." "" "" ""</seg>
<seg id="724">Patients had a BMI ≥ 30 kg / m ² or BMI &gt; 27 kg / m ² and an existing hypertension and / or dyslipidemia.</seg>
<seg id="725">N weight reduction after one year was for ACOMPLIA 20 mg 6.5 kg in relation to the output value compared to 1.6 kg for the placebo group (difference -4.9 kg CI95% -4.4 and p &lt; 0.001).</seg>
<seg id="726">The patient treated with ACOMPLIA 20 mg and 1.2 kg in the placebo group (difference -3.8 kg; CI95% -4.4; p &lt; 0.001).</seg>
<seg id="727">"" "" "" "after 2 years the difference in the total weight reduction between ACOMPLIA and placebo -4.2 kg (CI95% -5.0%; -3.4%, p &lt; 0.001)." "" "" ""</seg>
<seg id="728">"" "" "" "9 weight reduction and further risk factors in studies with patients without diabetes, in which a mixed population of patients with" "" "" ""</seg>
<seg id="729">"" "" "" "under Rimonabant 20 mg, an average rate of triglyceride was seen from 6.9% (baseline triglyceride 1.62 mmol / l) compared to an increase of 5.8%." "" "" ""</seg>
<seg id="730">In a second study in patients with obesity and previously untreated type 2 diabetes (Serenade) the absolute variation of the HbA1c value (with an initial value of 7.9% for both groups) was 6 months -0.8 for Rimonabant 20 mg and -0.3 under Placebo</seg>
<seg id="731">"" "" "" "the percentage of patients receiving HbA1c- value of &lt; 7%, was 51% in the Rimonabant Group and 35% in the placebo group." "" "" ""</seg>
<seg id="732">The difference in the mean weight change between the 20 mg- and the placebo group was 3.8 kg (CI95% -5.0 p &lt; 0.001).</seg>
<seg id="733">Improvement of the HbA1c value in patients who had received Rimonabant 20 mg were about 50% due to the direct effects of Rimonabant and explained about 50% by weight reduction. n eim ARZ</seg>
<seg id="734">2 hours reached and the Steady State plasma levels were reached after 13 days (CMAx = 196 ± 28,1 ng / ml; AUC0-24 = 2960 ± 268 ng.h / ml).</seg>
<seg id="735">Influence of food: it subjects who received the Rimonabant either in intimidating condition or after a fat-rich meal contrasted by 67% increased CMAx or by 48% increased ng AUC.</seg>
<seg id="736">Patients with black skin colour can reduce up to 31% less CMAx and a 43% lower AUC than patients of other ethnic populations.</seg>
<seg id="737">N-populating spatokinetic analyses (age range 18- 81 years) is estimated that a 75-year-old patient has a 21% higher CMAx and a 27% higher AUC than a 40-year-old</seg>
<seg id="738">"" "" "" "5.3 Preclinical data on the safety of the adverse reactions which were not observed in clinical studies, which occurred in animals after exposure to the human therapeutic sector, were evaluated as potentially relevant for clinical use:" "" "" ""</seg>
<seg id="739">"" "" "" "in some, but not in all cases, the beginning of convulsions seems to be associated with process-related stress such as dealing with the animals." "" "" ""</seg>
<seg id="740">"" "" "" "Rimonabant was given over a longer period prior to mating (9 weeks), which allowed recovery from the initial effects of Rimonabant so no unwanted effects were observed on fertility or cycline disruptions." "" "" ""</seg>
<seg id="741">The influence of Rimonabant on pre- and postnatal development was studied at the rat in dosages of up to 10 mg / kg / day.</seg>
<seg id="742">"" "" "" "in a study of rats for pre- and postnatal development, an exposition with Rimonabant in utero and lactation caused no changes in learning behaviour or memory." "" "" ""</seg>
<seg id="743">Detailed information about this medicine is available on the website of the European Medicines Agency (EMEA) http: / / www.emea.europa.eu / available.</seg>
<seg id="744">"" "" "" "La On the packaging supplement of the drug, name and address of the manufacturer, which are responsible for the release of the respective charge, must be stated." "" "" ""</seg>
<seg id="745">26 Healing of psychiatric events such as depression or mood changes were reported in patients receiving ACOMPLIA (see paragraph 2 which NEBENESS)</seg>
<seg id="746">"" "" "" "- If there are symptoms of depression (see below) during treatment with ACOMPLIA, contact your doctor and stop treatment." "" "" ""</seg>
<seg id="747">"" "" "" "dizziness, diarrhea, anxiety, itching, excessive sensation, tenderness, inclination to bruises, tenderness, sore throat (Ischialgia), tension loss, sore throes, camber, gripping infections, joint sweating." "" "" ""</seg>
<seg id="748">Please tell your doctor or pharmacist if any of the side effects listed will affect you significantly or you may notice any side effects that are not indicated in this information information.</seg>
<seg id="749">Summary of the EPAR for the public This document is a summary of the European Public Authoring Report (EPAR) which explains how the Committee for Human Genetics (CHMP) has evaluated the trials conducted in order to reach recommendations regarding the use of the medicine.</seg>
<seg id="750">Actos is used to treat type 2 diabetes (also known as non-insulin dependent diabetes). • It can be used alone (monotherapy) in patients (especially obese patients) when metformin (a diabetic drug) can be used.</seg>
<seg id="751">"" "" "" "it can be used in addition to metformin in patients (especially overweight patients), which cannot be satisfactorily adjusted using metformin alone in the highest tolerable dose." "" "" ""</seg>
<seg id="752">"" "" "" "in combination with a sulfonyl resnant or insulin, the previous dose of the sulfonyl harnant or insulin can be maintained with the beginning of the acetone treatment, except for patients with hypoglycemia (low blood sugar)." "" "" ""</seg>
<seg id="753">"" "" "" "this means that the body's insulin can be better utilized and the blood sugar level drops, which makes type 2 diabetes more effective." "" "" ""</seg>
<seg id="754">"" "" "" "in more than 1 400 patients, the efficacy of acetone was studied in tripleotherapy, in addition, the patients received a combination of metformin with a sulfonyl resin, in addition they received either Actos or placebo for up to 3.5 years." "" "" ""</seg>
<seg id="755">"" "" "" "the studies measured the concentration of a substance in the blood (glycosylated hemoglobin, HbA1c), which indicates how well the blood sugar is set." "" "" ""</seg>
<seg id="756">"" "" "" "Actos led to a lowering of the HbA1c value, which suggests that blood sugar levels were reduced by 15 mg, 30 mg and 45 mg." "" "" ""</seg>
<seg id="757">"" "" "" "at the end of the trial study, the effect of an additional administration with metformin and a sulfonyl harnfiller was reduced by 0.94% while the additional administration of placebo led to a decrease of 0.35%." "" "" ""</seg>
<seg id="758">"" "" "" "in a small study, in which the combination of acetyland insulin was examined in 289 patients, the patients receiving an additional insulin decrease of the HbA1c values decreased from 0.69% to 6 months, compared to 0.14% in patients receiving additional placebo." "" "" ""</seg>
<seg id="759">"" "" "" "the most common adverse events related to Actos were vision disorders, upper respiratory tract infections, weight gain and hypoaesthesia (reduced sensitivity to stimuli)." "" "" ""</seg>
<seg id="760">"" "" "" "Actos may not be used in patients who may be hypersensitive to pioglitazone or one of the other components, nor to patients with liver problems, heart failure or diabetic ketoacidosis (high ketone levels - in the blood)." "" "" ""</seg>
<seg id="761">"" "" "" "it was decided that in the context of a monotherapy, Actos should serve as an alternative to the standard treatment with metformin in patients where metformin is not shown." "" "" ""</seg>
<seg id="762">"" "" "" "October 2000, the European Commission granted the company Takeda Europe R & D Centre Limited a permit for placing Actos in the entire European Union." "" "" ""</seg>
<seg id="763">"" "" "" "the tablets are white to whitish, round, arched and on one side the mark" 15 "and on the other hand the inscription" Actos. "" "" "" ""</seg>
<seg id="764">Pioglitazon is also indicated for the combination with insulin for patients with type 2 diabetes mellitus whose blood sugar is insufficient with insulin and where metformin is unsuitable due to contraindications or intolerance (see Section 4.4).</seg>
<seg id="765">"" "" "" "for the use of pioglitazon in patients less than 18 years old no data is available, so the application in this age group is not recommended." "" "" ""</seg>
<seg id="766">"" "" "" "in patients who are endangered by the presence of at least one risk factor (e.g. earlier heart attack or symptomatic coronary heart disease), the doctor should start treatment with the lowest dose and gradually increase the dose gradually." "" "" ""</seg>
<seg id="767">"" "" "" "patients should be observed on signs and symptoms of cardiac insufficiency, weight gain or edema, especially those with reduced cardiac reserve." "" "" ""</seg>
<seg id="768">"" "" "" "patients should be observed on signs and symptoms of cardiac insufficiency, weight gain and edema if Pioglitazon is used in combination with insulin." "" "" ""</seg>
<seg id="769">A cardiovascular outcome study involving Pioglitazon in patients less than 75 years with type 2 diabetes mellitus and preexisting advanced macrovascular disease was performed.</seg>
<seg id="770">"" "" "" "this study showed an increase in the incidence of heart failure, which however did not lead to an increase in mortality in the study." "" "" ""</seg>
<seg id="771">"" "" "" "in patients with elevated output liver cells (ALT &gt; 2,5 x upper limit of the normal range) or with other signs of liver disease, Pioglitazon should not be used." "" "" ""</seg>
<seg id="772">"" "" "" "if the ALT levels are elevated up to 3 times the upper limit of the normal range, the liver cells are to be checked again as soon as possible." "" "" ""</seg>
<seg id="773">"" "" "" "if a patient develops symptoms that point to a hepatic dysfunction such as unclarified nausea, vomiting, upper stomach pain, fatigue, loss of appetite and / or dark harn, liver enzymes are to be examined." "" "" ""</seg>
<seg id="774">"" "" "" "the decision whether the treatment of the patient is continued with Pioglitazon, should be directed to the laboratory parameters of clinical evaluation." "" "" ""</seg>
<seg id="775">"" "" "" "in clinical trials with Pioglitazon, a dose-dependent weight gain was demonstrated that can stir from fatty deposits and in some cases linked to a fluid retention." "" "" ""</seg>
<seg id="776">A minor reduction of mean hemoglobin values (relative reduction by 4%) and the hematokrits (relative reduction by 4.1%) and the hematokrits (relative reduction by 4.1%).</seg>
<seg id="777">Similar changes were observed in comparative controlled trials with Pioglitazon in patients under metformin (relative reduction in hemoglobin by 3-4%) and hematokrits (relative reduction in hemoglobin by 1-2% and haemoglobin by 1-3.2%).</seg>
<seg id="778">"" "" "" "as a result of increased insulin sensitivity, patients who receive Pioglitazone as oral two or three-fold combination therapy with insulin, the risk of dose-dependent hypoglycemia." "" "" ""</seg>
<seg id="779">"" "" "" "after the market launch was reported under the treatment with thiazolidindions, including Pioglitazon, about an occurrence or worsening of diabetic macular edema with a decrease in visual acuity." "" "" ""</seg>
<seg id="780">"" "" "" "it is unclear whether there is a direct connection between the ingestion of pioglitazon and the occurrence of macular edema, but prescription physicians should be aware of the possibility of macular edema when patients talk about disturbances of visual acuity; an appropriate ophthalmological examination should be considered." "" "" ""</seg>
<seg id="781">"" "" "" "in a summary analysis of undesirable events regarding bone fractures from randomised, controlled, double-blind clinical studies over a period of up to 3.5 years with more than 8,100 patients treated with Pioglitazon" "" "" ""</seg>
<seg id="782">The calculated facture incidence was 1.9 fractures per 100 patient years with the women treated with Pioglitazon and 1.1 fractures per 100 patient years in women treated with a comparative meditate.</seg>
<seg id="783">"" "" "" "in the ProActive study, a study of 3.5 years for the examination of cardiovascular events, fractures in patients treated with Pioglitazon were compared to 23 / 905 (2.5%; 0.5 fractures per 100 patient years)." "" "" ""</seg>
<seg id="784">"" "" "" "patients should be aware of the possibility of a pregnancy, and if a patient wishes a pregnancy or this occurs, treatment is to be reduced (see Section 4.6)." "" "" ""</seg>
<seg id="785">"" "" "" "studies investigating the interactions have shown that Pioglitazon has no relevant effects on the pharmacokinetic or pharmaceutical dynamics of digoxin, warfarin, phenprocoumon and metformin." "" "" ""</seg>
<seg id="786">"" "" "" "interactions with medicines which are metabolized by these enzymes, such as oral contraceptives, cyclosporine, calcium channel blocker and HMGCoA reductase inhibitors are not expected." "" "" ""</seg>
<seg id="787">The simultaneous use of Pioglitazon with gemfibrozil (a cytochromium P450 2C8- Inhibitor) resulted in an increase in the AUC of Pioglitazon by 3 times.</seg>
<seg id="788">The simultaneous use of Pioglitazon with Rifampicin (a cytochrom P450 2C8 inductor) resulted in a reduction of the AUC of Pioglitazon by 54%.</seg>
<seg id="789">"" "" "" "this is due to the fact that under treatment with pioglitazon, the hyperinsulinemia resulting in pregnancy reduces the availability of the metabolic substrates for fetal growth." "" "" ""</seg>
<seg id="790">"" "" "" "very common &gt; 1 / 10; frequently &gt; 1 / 100, &lt; 1 / 100; occasionally &gt; 1 / 1000, &lt; 1 / 1000; very rare &lt; 1 / 10000, individual cases: unknown (from available data)." "" "" ""</seg>
<seg id="791">"" "" "" "these lead to a temporary alteration of the turgor and refractive index of the lens, as it can also be observed in other hypoglycemic agents." "" "" ""</seg>
<seg id="792">"" "" "" "in clinical trials with Pioglitazon, ALT ascents beyond the quadruple of the upper limit of the normal range were often similar to placebo, but less often than in comparison groups under Meta or Sulfonyl harnstoff." "" "" ""</seg>
<seg id="793">In an Outcome study in patients with pre-existing advanced macrovascular disease the frequency of severe cardiac insufficiency under Pioglitazon was 1.6% higher than placebo when Pioglitazon or respectively.</seg>
<seg id="794">"" "" "" "since the market launch has rarely been reported about heart failure under Pioglitazon, but more often when Pioglitazon was used in combination with insulin or in patients with heart failure in the anamnesis." "" "" ""</seg>
<seg id="795">"" "" "" "a summary analysis of undesirable events regarding bone fractures from randomised, controlled, double-blind clinical studies over a period of up to 3.5 years with more than 8,100 patients were performed in the groups treated with Pioglitazon." "" "" ""</seg>
<seg id="796">"" "" "" "over a period of 3.5 years, fractures in 44 / 870 (5.1%) of patients treated with Pioglitazon were compared with 23 / 905 (2.5%) in patients treated with a comparison meditate." "" "" ""</seg>
<seg id="797">"" "" "" "when taking the reported maximum dose of 120 mg / day over four days, then 180 mg / day over seven days there were no symptoms." "" "" ""</seg>
<seg id="798">"" "" "" "Pioglitazon seems to have an activation of specific nuclear receptors (PPAR-g), which leads to an increased insulin sensitivity of liver, fat and skeletal muscle cells." "" "" ""</seg>
<seg id="799">"" "" "" "it could be shown that Pioglitazon reduces glucoseproduction in the liver, and increases the peripheral glucose analysis in the event of insulin resistance." "" "" ""</seg>
<seg id="800">A clinical study with Pioglitazon versus Gliclavonic as monotherapy has been continued over two years to investigate the therapeutic effect (defined as HbA1c ≥ 8.0% after the first 6 months of treatment).</seg>
<seg id="801">"" "" "" "at the time of two years after the onset of therapy, blood sugar control (defined as HbA1c &lt; 8.0%) could be maintained by pioglitazon in 69% of patients treated under Gliclavonic." "" "" ""</seg>
<seg id="802">"" "" "" "in a placebo-controlled study for 12 months, patients whose blood sugar was insufficient with insulin for three months was randomised to Pioglitazon or placebo." "" "" ""</seg>
<seg id="803">In patients under Pioglitazon the mean HbA1c was reduced by 0.45% compared to the patients who continued to receive insulin. a reduction in insulin dose in the group treated with Pioglitazon was observed.</seg>
<seg id="804">"" "" "" "in clinical trials over a year, a statistically significant decrease in albumin / creatinin quotients proved to be statistically significant in comparison to the baseline values." "" "" ""</seg>
<seg id="805">"" "" "" "the effect of Pioglitazon (monotherapy with 45 mg versus placebo) was tested in a small, 18-week study of type 2 diabetics." "" "" ""</seg>
<seg id="806">"" "" "" "in most clinical trials compared to placebo, a reduction in total plasma triglycerides and free fatty acids and an increase in HDL cholesterol as well as a minor but clinically not significantly increased LDL cholesterol level were observed." "" "" ""</seg>
<seg id="807">"" "" "" "in clinical trials over a period of up to two years, Pioglitazon reduced total plasma levels and free fatty acids and increased the HDL Cholesterinspiegel." "" "" ""</seg>
<seg id="808">"" "" "" "compared to placebo, no statistically significant increase in LDL cholesterol was observed under Pioglitazon, while under metformin and Gliclavonic reduced values have been observed." "" "" ""</seg>
<seg id="809">"" "" "" "in a study of 20 weeks, Pioglitazon reduced not only the intimidation triglycerides but also improved the posterior increased triglyceride levels, which has an effect on triglyceride absorption and the hepatic triglyceride synthesis." "" "" ""</seg>
<seg id="810">"" "" "" "in the ProActive study, a cardioccult outcome study, 5238 patients with type 2 diabetes mellitus and preexisting advanced macrovascular disease in groups were randomised to receive either Pioglitazon or placebo over a period of up to 3.5 years." "" "" ""</seg>
<seg id="811">"" "" "" "after oral use, Pioglitazon is quickly absorbed, whereby the top concentrations of unchangeable pioglitazon can usually be achieved 2 hours after application." "" "" ""</seg>
<seg id="812">"" "" "" "on this basis, the contribution of M-IV is equivalent to the effectiveness of Pioglitazon, whereas the relative effectiveness of M-II is minimal." "" "" ""</seg>
<seg id="813">"" "" "" "in interaction studies, Pioglitazon has no relevant effect on the pharmacokinetic or pharmaceutical dynamics of digoxin, warfarin, phenprocoumon and metformin." "" "" ""</seg>
<seg id="814">The simultaneous application of Pioglitazon with gemfibrozil (a cytochromium P450 2C8- Inhibitor) or with Rifampicin (a cytochrom P450 2C8 inductor) or lowers the plasma concentration of Pioglitazon (see section 4.5).</seg>
<seg id="815">"" "" "" "after oral use of radioactively marked Pioglitazon in humans, the marker was found mainly in the wood (55%) and at a lower extent in the urine (45%)." "" "" ""</seg>
<seg id="816">"" "" "" "the mean plasma-elimination of immaculate Pioglitazon is 5-6 hours in humans, and the total active metabolism is 16-23 hours." "" "" ""</seg>
<seg id="817">"" "" "" "the plasma concentrations of Pioglitazon and its metabolites are lower than in healthy subjects in patients with impaired renal function, whereas the rates of oral clearing of the parent substance are similar." "" "" ""</seg>
<seg id="818">"" "" "" "in toxicological studies mice, rats, dogs and monkeys complied with hemodilution, anaemia and reversible external hypertrophy." "" "" ""</seg>
<seg id="819">This is due to the fact that under treatment with pioglitazone reduces the hyperinsulin- and increased insulin resistance of the mother animal and thereby reduces the availability of the metabolic substrates for fetal growth.</seg>
<seg id="820">"" "" "" "in long-term studies (up to 2 years), increased incidence of hyperplasia (male and female rats) and tumors (in male rats) of the urethral epithelium was induced." "" "" ""</seg>
<seg id="821">In an animal model of the family-adenomatous polyposis (FAP) the treatment with two other thiazolidindions led to an increased frequency of colonium tumors.</seg>
<seg id="822">"" "" "" "the tablets are white to whitish, round, flat and carry on one side the mark" 30 "and on the other hand the inscription" Actos. "" "" "" ""</seg>
<seg id="823">The calculated facture incidence was 1.9 fractures per 100 patient years with the women treated with Pioglitazon and 1.1 fractures per 100 patient years in women treated with a comparative meditate.</seg>
<seg id="824">"" "" "" "in the ProActive study, a study of 3.5 years for the examination of cardiovascular events, fractures in patients treated with Pioglitazon were compared to 23 / 905 (2.5%; 0.5 fractures per 100 patient years)." "" "" ""</seg>
<seg id="825">"" "" "" "in a further study of two years, the effects of a combination therapy of metformin with Pioglitazon or Gliclavonic were examined." "" "" ""</seg>
<seg id="826">"" "" "" "in clinical trials over 1 year, a statistically significant decrease in albumin / creatinin quotients proved to be statistically significant compared to the baseline values." "" "" ""</seg>
<seg id="827">"" "" "" "in a study of 20 weeks, Pioglitazon reduced not only the intimidation triglycerides but also improved the posterior increased triglyceride levels, which has an effect on the tryglyceride absorption and the hepatic trygliceride synthesis." "" "" ""</seg>
<seg id="828">"" "" "" "although the study showed the target with respect to its primary endpoint, a combination of the overall insulin, non-lethal myocardial infarction, stroke, acute coronary artery and revascularization of the leg arteries, the results suggest that there is no cardiovascular risk associated with taking Pioglitazon." "" "" ""</seg>
<seg id="829">"" "" "" "the tablets are white to whitish, round, flat and carry on one side the marking" 45 "and on the other hand the inscription" Actos. "" "" "" ""</seg>
<seg id="830">"" "" "" "in a summary analysis of undesirable events regarding bone fractures from randomised, controlled, double-blind clinical studies over a period of up to 3.5 years with more than 8,100 patients treated with Pioglitazon, increased incidence of fractures in women." "" "" ""</seg>
<seg id="831">"" "" "" "in the ProActive study, a study of 3.5 years for the examination of cardiovascular events, fractures in patients treated with Pioglitazon were compared to 23 / 905 (2.5%; 0.5 fractures per 100 patient years)." "" "" ""</seg>
<seg id="832">"" "" "" "in a study of more than 20 weeks, Pioglitazon reduced not only the intimidation triglycerides but also improved the posterior increased triglyceride levels, which has an effect on triglyceride absorption and the hepatic triglyceride synthesis." "" "" ""</seg>
<seg id="833">"" "" "" "on the packaging supplement of the drug, name and address of the manufacturer must be specified, which is responsible for the release of the respective charge." "" "" ""</seg>
<seg id="834">"" "" "" "in September 2005, the pharmaceutical company will submit an additional 6 month Periodic Safety Update Report (PSUR) and subsequent yearly PSURs, up to a different CHMP decision." "" "" ""</seg>
<seg id="835">An updated risk management plan must be presented in accordance with the CHMP-Guideline on Risk Management Systems for Medicinal Products for Human Use.</seg>
<seg id="836">"" "" "" "if you are suffering from type 2 diabetes, Actos takes 15 mg tablets to control your blood sugar levels by creating better recycling of your body's insulin." "" "" ""</seg>
<seg id="837">"" "" "" "if you are aware that you suffer from a sugar intolerance, please contact your doctor before taking Actos 15mg tablets." "" "" ""</seg>
<seg id="838">"" "" "" "please inform your doctor or pharmacist if you take further medicine or have taken it until recently, even if it is not prescription medicine." "" "" ""</seg>
<seg id="839">"" "" "" "if you take Actos 15 mg tablets in combination with other medicines for the treatment of diabetes (such as insulin, chlorpropene, gliaclamide, gliclavonamide, toleamide), your doctor will tell you if you need to reduce the dose of your medicine." "" "" ""</seg>
<seg id="840">"" "" "" "in some patients with type 2 diabetes mellitus and heart disease or earlier stroke, treated with Actos and insulin, a heart failure developed." "" "" ""</seg>
<seg id="841">"" "" "" "in clinical trials, in which Pioglitazon compared with other oral antidiabetic drugs or placebo (but not in men), the Pioglitazon obtained a higher number of fractures." "" "" ""</seg>
<seg id="842">"" "" "" "if you have accidentally taken too many tablets, or if someone else or a child has taken your medicine, you must contact a doctor or pharmacist promptly." "" "" ""</seg>
<seg id="843">"" "" "" "how Actos looks and content of the pack Actos 15 mg tablets are white to whitish, round, vaulted tablets with the marking" 15 "on one side and the inscription" Actos "on the other." "" "" ""</seg>
<seg id="844">"" "" "" "if you are suffering from type 2 diabetes, Actos takes 30 mg tablets to control your blood sugar levels by creating better recycling of your body's insulin." "" "" ""</seg>
<seg id="845">"" "" "" "if you are aware that you suffer from a sugar intolerance, please contact your doctor before taking Actos 30mg tablets." "" "" ""</seg>
<seg id="846">"" "" "" "if you take Actos 30 mg tablets in combination with other medicines for the treatment of diabetes (such as insulin, chlorpropene, gliaclamide, gliclavonamide, toleamide), your doctor will tell you if you need to reduce the dose of your medicine." "" "" ""</seg>
<seg id="847">61 inform your doctor as soon as possible if you notice signs of congestive heart failure such as unusual shortness or rapid weight gain or local swellings (edema).</seg>
<seg id="848">"" "" "" "in clinical trials, in which Pioglitazon compared with other oral antidiabetic drugs or placebo (but not in men), the Pioglitazon obtained a higher number of fractures." "" "" ""</seg>
<seg id="849">"" "" "" "how Actos looks and content of the pack Actos 30 mg tablets are white to whitish, round, flat tablets with marking 30" on one side and the inscription "Actos" on the other. "" "" "" "</seg>
<seg id="850">"" "" "" "if you are suffering from type 2 diabetes, Actos takes 45 mg tablets to control your blood sugar levels by creating better recycling of your body's insulin." "" "" ""</seg>
<seg id="851">"" "" "" "if you are aware that you suffer from a sugar intolerance, please contact your doctor before taking Actos 45mg tablets." "" "" ""</seg>
<seg id="852">"" "" "" "if you are taking Actos 45 mg tablets in combination with other medicines for the treatment of diabetes (such as insulin, chlorpropamid, gliaclamide, gliclavonamide, toleamide), your doctor will tell you if you need to reduce the dose of your medicine." "" "" ""</seg>
<seg id="853">"" "" "" "66 In some patients with type 2 diabetes mellitus and heart disease or earlier stroke treated with Actos and insulin, a heart failure developed." "" "" ""</seg>
<seg id="854">"" "" "" "inform your doctor as soon as possible, if you notice signs of heart failure, such as unusual shortness or rapid weight gain or local swellings (edema)." "" "" ""</seg>
<seg id="855">"" "" "" "in clinical trials, in which Pioglitazon compared with other oral antidiabetic drugs or placebo (but not in men), the Pioglitazon obtained a higher number of fractures." "" "" ""</seg>
<seg id="856">"" "" "" "67 If any of the side effects listed are significantly impaired or you may notice any side effects not specified in this information information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="857">"" "" "" "how Actos looks and content of the pack Actos 45 mg tablets are white to whitish, round, flat tablets with marking" 45 "on one side and the inscription" Actos "on the other." "" "" ""</seg>
<seg id="858">"" "" "" "this document is a summary of the European Public Department report (EPAR), which explains how the Committee for Human Genetics (CHMP) evaluated the studies carried out to make recommendations regarding the use of the medicine." "" "" ""</seg>
<seg id="859">"" "" "" "if you need more information on your medical condition or the treatment of your illness, please read the package supplement (which is also part of the EPAR) or contact a doctor or pharmacist." "" "" ""</seg>
<seg id="860">"" "" "" "if you would like more information on the basis of CHMP recommendations, please read the scientific discussion (which is also part of the EPAR)." "" "" ""</seg>
<seg id="861">Actraphane 10: soluble insulin 10% and isophan insulin with 90% Actraphane 20: soluble insulin with 30% and isophan insulin. 60% Actraphane 40: soluble insulin 50% and isophan insulin 50% Actraphane 50: soluble insulin 50% and isophan insulin</seg>
<seg id="862">"" "" "" "Actraphane is usually used once or twice a day, when a rapid initial effect is desired along with a longer lasting effect." "" "" ""</seg>
<seg id="863">(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 e-mail: mail @ emea.eu.int http: / / www.emea.eu.int © EMEA 2006 Reproduction and / or distribution of this document is Authorised for non commercial purposes only.</seg>
<seg id="864">"" "" "" "Actraphane has a total of 294 patients with type 1 diabetes, where the pancreas cannot produce insulin and type 2 diabetes, where the body is unable to use insulin effectively." "" "" ""</seg>
<seg id="865">"" "" "" "the study measured the concentration of a substance (glycosylated hemoglobin (HbA1c), which indicates how well the blood sugar is set." "" "" ""</seg>
<seg id="866">"" "" "" "Actraphane led to a decrease in the HbA1c mirror, which indicated that blood sugar levels were similar to another human insulin." "" "" ""</seg>
<seg id="867">"" "" "" "acetphane should not be used in patients, possibly hypersensitive (allergic) to human insulin (rDNA) or one of the other components." "" "" ""</seg>
<seg id="868">"" "" "" "in addition, doses of acetphane need to be adjusted if it is administered together with a number of other medicines that can affect blood sugar (the complete list is to be found in the package supplement)." "" "" ""</seg>
<seg id="869">"" "" "" "the Committee on Human Genetics (CHMP) concluded that the benefits of acetphane were outweighed in the treatment of diabetes, compared to the risks." "" "" ""</seg>
<seg id="870">"" "" "" "October 2002, the European Commission granted Novo Nordisk A / S a licence for placing Actraphane in the whole European Union." "" "" ""</seg>
<seg id="871">"" "" "" "premixed insulin products are usually applied once or twice a day, when a rapid initial effect is desired along with a longer lasting effect." "" "" ""</seg>
<seg id="872">"" "" "" "the injection needle must be left under the skin for at least 6 seconds, to ensure that the entire dose was injected." "" "" ""</seg>
<seg id="873">"" "" "" "patients whose blood sugar levels have improved significantly, for example, by intensified insulin therapy, can be observed in the hypoglycaemia warning symptoms and should be advised accordingly." "" "" ""</seg>
<seg id="874">"" "" "" "any change regarding strength, brand (manufacturer), insulin type (fast-acting, biphasic, long-acting insulin etc.), type of insulin (cell insulin, human insulin or insulin analog) and / or production method (due to recombinant DNA versus insulin in animal origin) can cause a change in dosage." "" "" ""</seg>
<seg id="875">"" "" "" "if a dose adjustment is required when changing to acetphane, it may be necessary during the first dosage or in the first weeks or months after the conversion." "" "" ""</seg>
<seg id="876">Some patients with hypoglycaemic reactions following a change from animal to human insulin reported that the early warning symptoms of hypoglycaemia were less pronounced or different from their previous insulin.</seg>
<seg id="877">"" "" "" "when travelling over several time zones, the patient should be advised to take the advice of his doctor as such trips can lead to that insulin and meals must be used or taken at other times." "" "" ""</seg>
<seg id="878">"" "" "" "therefore, the doctor must consider possible interactions during the therapy and ask his patients to ask for other medications taken by them." "" "" ""</seg>
<seg id="879">"" "" "" "4 Bless hypoglycemia and hyperglycemia, which may occur in inadequate controlled diabetes therapy, increase the risk of abnormalities and fertility in utero." "" "" ""</seg>
<seg id="880">"" "" "" "severe hypoglycemias may lead to unconsciousness and / or seizures, and may end with temporary or permanent disturbances of brain function and even death." "" "" ""</seg>
<seg id="881">Disorders of the nervous system Gelsomingly - Peripheral neuropathy A prompt improvement in blood sugar control may be associated with discomfort that is referred to as acute painful neuropathy and usually reversible.</seg>
<seg id="882">"" "" "" "5. intensification of insulin therapy with an abrupt improvement in blood sugar adjustment, however, may be associated with a temporary worsening of diabetic retinopathy." "" "" ""</seg>
<seg id="883">Disease of the skin and the subcutaneous tissue jelly - lipodystrophy at the injection site may arise a lipodystrophy if failed to switch the stitch branches inside the injection unit.</seg>
<seg id="884">"" "" "" "during insulin therapy local hypersensitivity reactions (redness, swelling, itching, soreness and hematoma can occur at the injection site)." "" "" ""</seg>
<seg id="885">"" "" "" "disorders of the immune system Gelsomingly - Urticaria, Exanthem Very rarely - anaphylactic reactions symptoms of generalized hypersensitivity, including generalized skin rash, itching, gastrointestinal edema, breathing difficulties, low blood pressure and impotence / unconsciousness." "" "" ""</seg>
<seg id="886">Hypoglycemia can develop gradually: • Easy hypoglycemia can be treated by the oral supply of glucose and sugary foods.</seg>
<seg id="887">Diabetics should therefore always have grape sugar, sweets, biscuits or sugary fruit juice. • Heavy Hypoglycemias with unconsciousness are treated with an intramuscular or subcutaneous injection of Glucagon (0.5 to 1.0 mg) or by glucose that is given intravenously by the doctor.</seg>
<seg id="888">"" "" "" "the effect begins within half an hour, the maximum efficiency is reached within 2 to 8 hours and total duration of operation is up to 24 hours." "" "" ""</seg>
<seg id="889">Resorption The resorption profile is based on the fact that the product is a mixture of insulin products with fast or delayed resorption.</seg>
<seg id="890">A number of fission (hydrolysis) locations on the human insuline molecule have been taken into consideration; none of the metabolites formed by the split is active.</seg>
<seg id="891">"" "" "" "based on conventional studies on safety macology, toxicity in repeated application, genotoxicity, carcinogenic potential and reproductive toxicity, the preclinical data do not allow specific dangers to humans." "" "" ""</seg>
<seg id="892">"" "" "" "it is recommended to increase the temperature of the insulin at room temperature (not above 25 ° C) before using the manual for the first use, according to the manual." "" "" ""</seg>
<seg id="893">Some patients with hypoglycaemic reactions following a change from animal to human insulin reported that the early warning symptoms of hypoglycaemia were less pronounced or different from their previous insulin.</seg>
<seg id="894">"" "" "" "therefore, the doctor must consider possible interactions during the therapy and ask his patients to ask for other medications taken by them." "" "" ""</seg>
<seg id="895">"" "" "" "12 Bless hypoglycemia and hyperglycemia, which may occur in inadequate controlled diabetes therapy, increase the risk of abnormalities and fertility in utero." "" "" ""</seg>
<seg id="896">"" "" "" "13. intensification of insulin therapy with an abrupt improvement in blood sugar adjustment, however, may be associated with a temporary worsening of diabetic retinopathy." "" "" ""</seg>
<seg id="897">The date half-life (t ½) is therefore more a measure of resorption than a measure of the elimination per se of insulin from the plasma (insulin has a t ½ a few minutes in the blood circulation).</seg>
<seg id="898">"" "" "" "it is recommended to increase the temperature of the insulin at room temperature (not above 25 ° C) before using the manual for the first use, according to the manual." "" "" ""</seg>
<seg id="899">Some patients with hypoglycaemic reactions following a change from animal to human insulin reported that the early warning symptoms of hypoglycaemia were less pronounced or different from their previous insulin.</seg>
<seg id="900">"" "" "" "20. both hypoglycemia and hyperglycemia, which may occur in inadequate controlled diabetes therapy, increase the risk of abnormalities and fertility in utero." "" "" ""</seg>
<seg id="901">"" "" "" "21. intensification of insulin therapy with an abrupt improvement in blood sugar adjustment, however, may be associated with a temporary worsening of diabetic retinopathy." "" "" ""</seg>
<seg id="902">"" "" "" "disorders of the immune system Gelsomingly - Urticaria, Exanthem Very rarely - anaphylactic reactions symptoms of generalized hypersensitivity, including generalized skin rash, itching, gastrointestinal edema, breathing difficulties, low blood pressure and impotence / unconsciousness." "" "" ""</seg>
<seg id="903">Cartridges may only be used together with products that are compatible with them and ensure a safe and effective cartridge function.</seg>
<seg id="904">It is recommended to increase the temperature of insulin at room temperature (not above 25 ° C) before it is stored in accordance with the operating instructions for the first use.</seg>
<seg id="905">Some patients with hypoglycaemic reactions following a change from animal to human insulin reported that the early warning symptoms of hypoglycaemia were less pronounced or different from their previous insulin.</seg>
<seg id="906">"" "" "" "28 Unless hypoglycemia and hyperglycemia, which may appear in inadequate controlled diabetes therapy, increase the risk of abnormalities and fertility in utero." "" "" ""</seg>
<seg id="907">"" "" "" "29. intensification of insulin therapy with an abrupt improvement in blood sugar adjustment, however, may be associated with a temporary worsening of diabetic retinopathy." "" "" ""</seg>
<seg id="908">Some patients with hypoglycaemic reactions following a change from animal to human insulin reported that the early warning symptoms of hypoglycaemia were less pronounced or different from their previous insulin.</seg>
<seg id="909">36. both hypoglycemia and hyperglycemia which may appear in a non-controlled Diabetesis therapy increase the risk of abnormalities and fertility in utero.</seg>
<seg id="910">37 An Intensification of insulin therapy with an abrupt improvement in blood sugar setting may be associated with a temporary worsening of diabetic retinopathy.</seg>
<seg id="911">"" "" "" "44 Unless hypoglycemia and hyperglycemia, which may appear in inadequate controlled diabetes therapy, increase the risk of abnormalities and fertility in utero." "" "" ""</seg>
<seg id="912">"" "" "" "45 A intensification of insulin therapy with an abrupt improvement in blood sugar adjustment, however, may be associated with a temporary worsening of diabetic retinopathy." "" "" ""</seg>
<seg id="913">Some patients with hypoglycaemic reactions following a change from animal to human insulin reported that the early warning symptoms of hypoglycaemia were less pronounced or different from their previous insulin.</seg>
<seg id="914">"" "" "" "52 As both hypoglycemia and hyperglycemia, which may occur in inadequate controlled disseretesis therapy, the risk of abnormalities and abnormalities in utero increases." "" "" ""</seg>
<seg id="915">"" "" "" "53. intensification of insulin therapy with an abrupt improvement in blood sugar adjustment, however, may be associated with a temporary worsening of diabetic retinopathy." "" "" ""</seg>
<seg id="916">"" "" "" "before injection, the injections must be prepared in such a way that the dose regulator is reduced to zero and an insulin drops at the tip of the injection needle appears." "" "" ""</seg>
<seg id="917">"" "" "" "59 patients whose blood sugar levels have improved significantly, for example, by intensified insulin therapy, can be observed in the hypoglycaemia warning symptoms and should be advised accordingly." "" "" ""</seg>
<seg id="918">"" "" "" "both hypoglycemia and hyperglycemia, which may occur in inadequate controlled disseretesis therapy, increase the risk of abnormalities and fertility in utero." "" "" ""</seg>
<seg id="919">"" "" "" "however, an intensification of insulin therapy with an abrupt improvement in blood sugar adjustment may be associated with a temporary worsening of diabetic retinopathy." "" "" ""</seg>
<seg id="920">"" "" "" "disorders of the immune system Gelsomingly - Urticaria, Exanthem Very rarely - anaphylactic reactions symptoms of generalized hypersensitivity, including generalized skin rash, itching, gastrointestinal edema, breathing difficulties, low blood pressure and impotence / unconsciousness." "" "" ""</seg>
<seg id="921">"" "" "" "these pens can only be used together with products, which are compatible with them and ensure a safe and effective functioning of the pens." "" "" ""</seg>
<seg id="922">It is recommended that after Actraphane NovoLet was removed from the refrigerator - the temperature of the insulin at room temperature (do not exceed 25 ° C) before it is resuserpended according to the operating instructions for the first use.</seg>
<seg id="923">"" "" "" "67 patients whose blood sugar levels have improved significantly, for example, by intensified insulin therapy, can be observed in the hypoglycaemia warning symptoms and should be advised accordingly." "" "" ""</seg>
<seg id="924">"" "" "" "75 patients whose blood sugar levels have improved significantly, for example, by intensified insulin therapy, can be observed in the hypoglycaemia warning symptoms and should be advised accordingly." "" "" ""</seg>
<seg id="925">"" "" "" "83 patients whose blood sugar levels have improved significantly, for example, by intensified insulin therapy, can be observed in the hypoglycaemia warning symptoms and should be advised accordingly." "" "" ""</seg>
<seg id="926">"" "" "" "91 patients whose blood sugar levels have improved significantly, for example, by intensified insulin therapy, can be observed in the hypoglycaemia warning symptoms and should be advised accordingly." "" "" ""</seg>
<seg id="927">"" "" "" "99 patients whose blood sugar levels have improved significantly, for example, by intensified insulin therapy, can be observed in the hypoglycaemia warning symptoms and should be advised accordingly." "" "" ""</seg>
<seg id="928">"" "" "" "any change in terms of strength, brand (manufacturer), insulin type (fast-acting, biphasic, long-acting insulin etc.), type of insulin (cell insulin, human insulin or insulin analog) and / or production method (due to recombinant DNA versus insulin in animal origin) can cause a change in dosage." "" "" ""</seg>
<seg id="929">It is recommended that after Actraphane Innoises was taken out of the refrigerator - the temperature of the insulin at room temperature (do not exceed 25 ° C) before it is resuserpended according to the operating instructions for the first use.</seg>
<seg id="930">It is recommended to increase the temperature of the insulin at room temperature (not above 25 ° C) before using the manual for the first use.</seg>
<seg id="931">"" "" "" "on the packaging supplement of the drug, name and address of the manufacturer must be specified, which is responsible for the release of the respective charge." "" "" ""</seg>
<seg id="932">Store in the fridge (2 ˚ C - 8 ˚ C) Do not freeze The bottle in the box to protect the contents from light After departure: do not store in the fridge or over 25 ° C</seg>
<seg id="933">Subcutaneous Application Peninsular Patrons are intended for use with Novo Nordisk insulin injections. use of the manual stress relief packages must be taken into account Actraphane 10 Pensefill may only be used by one person</seg>
<seg id="934">Store in the fridge (2 ˚ C - 8 ˚ C) Do not freeze the cartridge in the box to protect the contents from light After departure: do not store in the fridge or over 30 ° C</seg>
<seg id="935">Subcutaneous Application Peninsular Patrons are intended for use with Novo Nordisk insulin injections. use of the manual stress relief packages must be taken into account Actraphane 20 Pensefill may only be used by one person</seg>
<seg id="936">Subcutaneous Application Peninsular Patrons are intended for use with Novo Nordisk insulin injections. use of the manual stress relief packages must be taken into account Actraphane 30 Pensefill may only be used by one person</seg>
<seg id="937">Subcutaneous Application Peninsular Patrons are intended for use with Novo Nordisk insulin injections. use of the manual stress relief packages must be taken into account Actraphane 40 Pensefill may only be used by one person</seg>
<seg id="938">Subcutaneous Application Peninsular Patrons are intended for use with Novo Nordisk insulin injections. use of the manual stress relief packages must be taken into account Actraphane 50 Pensefill may only be used by one person</seg>
<seg id="939">Subcutaneous Application To use with Actraphane 10 NovoLet NovoFine injections are intended to be used to treat the guide resuspened packing instruction. Actraphane 10 Novolet may only be used by one person</seg>
<seg id="940">Store in the fridge (2 ˚ C - 8 ˚ C) Do not freeze ahead of light After departure: do not store in the fridge or over 30 ° C</seg>
<seg id="941">Subcutaneous Application To use with Actraphane 20 NovoLet NovoFine injection needles are intended to use the guide resuspende packing instruction. Actraphane 20 Novolet may only be used by one person</seg>
<seg id="942">Subcutaneous Application To use with Actraphane 30 NovoLet NovoFine injection needles are intended to use the guide resuspende packing instruction. Actraphane 30 Novolet may only be used by one person</seg>
<seg id="943">Subcutaneous Application To use with Actraphane 40 NovoLet NovoFine injection needles are intended to use the guide resuspende packing instruction. Actraphane 40 Novolet may only be used by one person</seg>
<seg id="944">Subcutaneous Application To use with Actraphane 50 NovoLet NovoFine injection needles are intended to use the guide resuspende packing instruction. Actraphane 50 Novolet may only be used by one person</seg>
<seg id="945">Subcutaneous Application To use with Actraphane 30 Innoises NovoFine S Innoises are intended to use the guide resuspende packing instruction. Actraphane 30 Innoises may only be used by one person</seg>
<seg id="946">"" "" "" "this means that approximately half an hour after you have applied it, your blood sugar begins to sink and that the effect will stop for about 24 hours." "" "" ""</seg>
<seg id="947">"" "" "" "► If you are allergic to this insulin product, metacresol or any of the other components (see section 7 for more information)." "" "" ""</seg>
<seg id="948">"" "" "" "be aware of the symptoms of an allergy, even if you feel the first signs of hypoglycemia (symptoms of fortification)." "" "" ""</seg>
<seg id="949">"" "" "" "if your doctor has caused a change from an insulin type or brand to another, possibly the dose must be adjusted by your doctor." "" "" ""</seg>
<seg id="950">"" "" "" "► Check the label, whether it's the right type of insulin, or disinfect the rubber membrane with a medical tampon." "" "" ""</seg>
<seg id="951">"" "" "" "if this is not completely undamaged, if you get the bottle of bottle, return the bottle to your pharmacy - if it was not stored correctly or frozen (see 6 How does Actraphane do not work evenly)." "" "" ""</seg>
<seg id="952">Use the injection technique that recommended your doctor or diabetes consultant. ► Let the injection needle under your skin for at least 6 seconds under your skin to ensure that the full dose was injected.</seg>
<seg id="953">"" "" "" "the warning signs of fortification can suddenly occur and may be: cold sweat, cold pale skin, headache, heart rate, nausea, large hunger, temporary blurredness, nausea, nervousness or trembling, anxiety, confusion, concentration difficulties." "" "" ""</seg>
<seg id="954">"" "" "" "tell your relatives, friends and colleagues that they will bring you into the stable side position in case of unconsciousness and immediately notify a doctor." "" "" ""</seg>
<seg id="955">"" "" "" "► If a severe fortification is not treated, this may lead to (temporary or permanent) brain damage or even death." "" "" ""</seg>
<seg id="956">"" "" "" "you can regain consciousness more quickly, if you injected the hormone Glucagon from a person familiar with its gift." "" "" ""</seg>
<seg id="957">"" "" "" "this may happen: if you injected too much insulin, if you eat too little or leave a meal, if you do more than otherwise physically." "" "" ""</seg>
<seg id="958">"" "" "" "increased urge to urinate, thirst, loss of appetite, nausea or vomiting, dizziness or fatigue, dry skin, dry mouth and fruity (after acetone) rifling breath." "" "" ""</seg>
<seg id="959">"" "" "" "• You have forgotten an insulin injections • Temporous injections of less insulin than you need • an infection or fever, more food than usual, less physical exercise than usual." "" "" ""</seg>
<seg id="960">"" "" "" "if you often have an injection at the same place, the subcutaneous fatty tissue can shrink (Lipatrophy) or increase (lipohypertrophy)." "" "" ""</seg>
<seg id="961">"" "" "" "if you notice depressions or thickening of your skin at the injection site, tell your doctor or diabetes consultant because these reactions can worsen or affect your insulin's intake when injected in such a place." "" "" ""</seg>
<seg id="962">"" "" "" "immediately seek a doctor if the symptoms of an allergy spread to other parts of the body, or if you suddenly feel uncomfortable and you have sweat-drops, nausea (vomiting), heart rate, you have dizzy or you have the impression to become unconscious." "" "" ""</seg>
<seg id="963">"" "" "" "you may have a very rare, allergic reaction to Actraphane or one of its components (a so-called systemic allergic reaction)." "" "" ""</seg>
<seg id="964">"" "" "" "if one of the listed side effects affects you significantly or you may notice side effects not specified in this information information, please inform your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="965">What Actraphane 30 contains - insulin produced by recombinant DNA technology (30% as soluble insulin and 70% as a isophan insulin).</seg>
<seg id="966">"" "" "" "as acetphane looks and contents of the package The injection suspension is delivered as opaque, white, aqueous Suspension in packs of 1 or 5 vials each 10 ml or a bundle wrapping with 5 vials of 10 ml." "" "" ""</seg>
<seg id="967">Use the injection technique that recommended your doctor or diabetes consultant. ► Let the injection needle under your skin for at least 6 seconds under your skin to ensure that the full dose was injected.</seg>
<seg id="968">"" "" "" "it is recommended, once removed from the refrigerator, to increase the temperature of the bottle at room temperature before the insulin is resuserpended according to the manual for the first use." "" "" ""</seg>
<seg id="969">"" "" "" "as acetphane looks and contents of the package The injection suspension is delivered as opaque, white, aqueous Suspension in packs of 1 or 5 vials each 10 ml or a bundle wrapping with 5 vials of 10 ml." "" "" ""</seg>
<seg id="970">"" "" "" "► Check the label, whether it's the right type of insulin, and always check the fill patrons including rubber piston (plugs)." "" "" ""</seg>
<seg id="971">Do not use it if any damage is to be seen or a gap between the rubber piston and the white tape of the label visible.</seg>
<seg id="972">"" "" "" "for more information on this, please refer to the manual of your insulin injection system. ► Do you disinfect the rubber membrane with a medical tupfer. ► Do you always use a new injection needle for each injection to avoid contamination." "" "" ""</seg>
<seg id="973">"" "" "" "► in insulin infusion pumps, if the fill or the device that contains the fill, has been dropped, damaged or crushed, even if it was not stored correctly or frozen (see 6 How does Actraphane do not work evenly)." "" "" ""</seg>
<seg id="974">"" "" "" "if you are treated with Actraphane 10 Penlines and a different insulin in Penfill cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="975">"" "" "" "before using the cartridge into the insulin injection system, move it at least 20 times between positions a and b (see figure), so that the glass ball moves from one end of the cartridge to the other." "" "" ""</seg>
<seg id="976">Use the injection technique that recommended your doctor or diabetes consultant and which is described in the manual of your injection system ► Let the injection needle be injected at least 6 seconds under your skin to ensure that the complete dose was injected.</seg>
<seg id="977">"" "" "" "183 Say your relatives, friends and close colleagues to bring you into the stable side position in case of unconsciousness and immediately notify a doctor." "" "" ""</seg>
<seg id="978">"" "" "" "• You have forgotten an insulin injections • Temporous injections of less insulin than you need • an infection or fever, more food than usual, less physical exercise than usual." "" "" ""</seg>
<seg id="979">"" "" "" "if one of the listed side effects affects you significantly or you may notice side effects not specified in this information information, please inform your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="980">"" "" "" "it is recommended to rise from the refrigerator - to increase the temperature of the fill-fill cartridge at room temperature, before the insulin is resuserpened in accordance with the manual for the first use." "" "" ""</seg>
<seg id="981">185 Keep the cartridges always in the box when you do not use them to protect them from light.</seg>
<seg id="982">What Actraphane 10 contains - insulin produced by recombinant DNA technology (10% as a soluble insulin and 90% as a isophan insulin).</seg>
<seg id="983">"" "" "" "as acetphane looks and contents of the package The injection suspension is delivered as a cloudy, white, aqueous suspension with 1, 5 or 10 cartridges per 3 ml." "" "" ""</seg>
<seg id="984">"" "" "" "for more information on this, please refer to the manual of your insulin injection system. ► Do you disinfect the rubber membrane with a medical tupfer. ► Do you always use a new injection needle for each injection to avoid contamination." "" "" ""</seg>
<seg id="985">"" "" "" "if you are treated with Actraphane 20 Penfill and another insulin in Penfill cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="986">"" "" "" "189 Say your relatives, friends and close colleagues to bring you into the stable side position in case of unconsciousness and immediately notify a doctor." "" "" ""</seg>
<seg id="987">"" "" "" "if one of the listed side effects affects you significantly or you may notice side effects not specified in this information information, please inform your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="988">"" "" "" "191 Keep the cartridges always in the box, if you do not use them to protect them from light." "" "" ""</seg>
<seg id="989">What Actraphane 20 contains - insulin produced by recombinant DNA technology (20% as soluble insulin and 80% as a isophan insulin).</seg>
<seg id="990">"" "" "" "as acetphane looks and contents of the package The injection suspension is delivered as a cloudy, white, aqueous suspension with 1, 5 or 10 cartridges per 3 ml." "" "" ""</seg>
<seg id="991">"" "" "" "for more information on this, please refer to the manual of your insulin injection system. ► Do you disinfect the rubber membrane with a medical tupfer. ► Do you always use a new injection needle for each injection to avoid contamination." "" "" ""</seg>
<seg id="992">"" "" "" "if you are treated with Actraphane 30 Pensefill and another insulin in Penfill cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="993">"" "" "" "195 Saw your relatives, friends and colleagues, that they will bring you into the stable side position in case of unconsciousness and immediately notify a doctor." "" "" ""</seg>
<seg id="994">"" "" "" "if one of the listed side effects affects you significantly or you may notice side effects not specified in this information information, please inform your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="995">197 Keep the cartridges always in the box when you do not use them to protect them from light.</seg>
<seg id="996">"" "" "" "manufacturers The manufacturer can be identified using the Chargen designation, which is printed on the lashings of the box and on the label:" "" "" ""</seg>
<seg id="997">"" "" "" "if on the second and third place of the batch name the character combination W5, S6, P5, K7 or ZF, the manufacturer Novo Nordisk A / S, Novo Allé, DK- 2880 Bagsvaerd, Denmark" "" "" ""</seg>
<seg id="998">"" "" "" "if on the second and third place of the Chargen name the character combination H7 or T6 appears, the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F-28002 Chartres, France." "" "" ""</seg>
<seg id="999">"" "" "" "for more information on this, please refer to the operating instructions of your Insul-Injection system. ► Do you disinfect the rubber membrane with a medical tupfer. ► Do you always use a new injection needle for each injection to avoid contamination." "" "" ""</seg>
<seg id="1000">"" "" "" "if you are treated with Actraphane 40 Penlines and a different insulin in Penfill cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="1001">"" "" "" "201 Tell your relatives, friends and colleagues, that they bring you into the stable side position in case of unconsciousness and immediately notify a doctor." "" "" ""</seg>
<seg id="1002">"" "" "" "if one of the listed side effects affects you significantly or you may notice side effects not specified in this information information, please inform your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1003">"" "" "" "203 Keep the cartridges always in the box, if you do not use them to protect them from light." "" "" ""</seg>
<seg id="1004">What Actraphane 40 contains - insulin produced by recombinant DNA technology (40% as a soluble insulin and 60% as a isophan insulin).</seg>
<seg id="1005">"" "" "" "for more information on this, please refer to the operating instructions of your Insul-Injection system. ► Do you disinfect the rubber membrane with a medical tupfer. ► Do you always use a new injection needle for each injection to avoid contamination." "" "" ""</seg>
<seg id="1006">"" "" "" "if you are treated with Actraphane 50 Penlines and a different insulin in Penfill cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="1007">"" "" "" "before placing the penetration cartridge into the insulin injection system, move it at least 20 times between positions a and b (see figure), so that the glass ball moves from one end of the cartridge to the other." "" "" ""</seg>
<seg id="1008">"" "" "" "207 Say your relatives, friends and close colleagues to bring you into the stable side position in case of unconsciousness and immediately notify a doctor." "" "" ""</seg>
<seg id="1009">"" "" "" "if one of the listed side effects affects you significantly or you may notice side effects not specified in this information information, please inform your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1010">"" "" "" "209 Keep the cartridges always in the box, if you do not use them to protect them from light." "" "" ""</seg>
<seg id="1011">What Actraphane 50 contains - insulin produced by recombinant DNA technology (50% as a soluble insulin and 50% as a isophan insulin).</seg>
<seg id="1012">"" "" "" "oral antidiabetic drugs (inhibitors), monoamine oxidase inhibitors (MAO inhibitors), beta-receptors, acetylsalicylic acid, anabolic steroids, beta carotenoids, beta carotenoids, beta carotenoids" "" "" ""</seg>
<seg id="1013">"" "" "" "► Check the label, whether it is the correct consul, and use a new injection needle for each injection to avoid contamination." "" "" ""</seg>
<seg id="1014">"" "" "" "► in insulin infusion pumps, if the Novolet has been dropped, damaged or crushed, is the risk of excretion of insulin if it was not stored correctly or frozen (see 6 How does Actraphane do not work evenly)." "" "" ""</seg>
<seg id="1015">"" "" "" "the warning signs of fortification can suddenly occur and may be: cold sweat, cold pale skin, headache, heart rate, nausea, large hunger, temporary blurredness, nausea, nervousness or trembling, anxiety, confusion, concentration difficulties." "" "" ""</seg>
<seg id="1016">"" "" "" "214 If any of the side effects listed are significantly impaired or you may notice any side effects not specified in this information information, please inform your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1017">"" "" "" "in use, NovoLet's pens and those that are soon used or used as replacements are not stored in the refrigerator." "" "" ""</seg>
<seg id="1018">"" "" "" "it is recommended, after removing from the refrigerator - the temperature of NovoLet's ready to rise to room temperature before the insulin is resuserpened in accordance with the manual for the first use." "" "" ""</seg>
<seg id="1019">"" "" "" "release the closing cap of your Novolet finished pens, when NovoLet is not in use to protect the insulin from light." "" "" ""</seg>
<seg id="1020">"" "" "" "as acetphane looks and contents of the package The injection suspension is delivered as opaque, white, aqueous suspension in packs of 5 or 10 finished pens to each 3 ml." "" "" ""</seg>
<seg id="1021">"" "" "" "before each injection, check if there are still at least 12 units of insulin in the cartridge so that an even blend is ensured." "" "" ""</seg>
<seg id="1022">Proceed as follows to avoid the injection of air and ensure proper dosage: • Keep Actraphane 10 NovoLet with the injection needle upwards • knocking a few times with your finger slightly against the cartridge.</seg>
<seg id="1023">"" "" "" "if air bubbles are present, they will keep up in the cartridge - While you keep Actraphane 10 NovoLet down with the injection needle, push the button in the direction of the arrow (Figure D) • Now you have to squeeze a drop of insulin from the tip of the injection needle." "" "" ""</seg>
<seg id="1024">"" "" "" "• Place the closing cap back to the finished pen, that the digit 0 is opposite the metering stamp (Figure E) • Check if the push button is pressed completely." "" "" ""</seg>
<seg id="1025">"" "" "" "if not, turn the closing cap until the push button is pressed down • Keep your Actraphane 10 NovoLet horizontally." "" "" ""</seg>
<seg id="1026">"" "" "" "if the push button can not move freely to the outside, insulin is pressed out of the injection needle • The scale on the closing cap indicates 0, 2, 4, 6, 10, 12, 14, 16 and 18 units." "" "" ""</seg>
<seg id="1027">"" "" "" "the push button moves outward while you rotate the closing cap • The scale below the push button shows 20, 40 and 60 units." "" "" ""</seg>
<seg id="1028">"" "" "" "check a set dose • Record the number on the closing cap next to the metering stamp • Record the highest number you have set on the button scale • If you have set a wrong dose, turn the closing cap forward or backward until you have set the correct number of units." "" "" ""</seg>
<seg id="1029">"" "" "" "otherwise, insulin from the injection needle will leak out and the inserted dose will not be correct • If you have tried to stop a dose of more than 78 units, follow these steps:" "" "" ""</seg>
<seg id="1030">"" "" "" "then remove the closing cap and set it up again, that the 0 of the metering stamp is opposite." "" "" ""</seg>
<seg id="1031">"" "" "" "be careful not to press the pressure button during the injection, until the injection needle was pressed out of the skin until the injection needle was pulled out of the skin." "" "" ""</seg>
<seg id="1032">"" "" "" "if not, turn the closing cap until the push button is pressed down and then proceed as described before use." "" "" ""</seg>
<seg id="1033">"" "" "" "it may not be accurate, you can't set a dose that is higher than the number of units remaining in the cartridge • You can use the residual amount scale to estimate how much insulin is remaining." "" "" ""</seg>
<seg id="1034">"" "" "" "oral antidiabetic drugs (inhibitors), monoamine oxidase inhibitors (MAO inhibitors), beta-receptors, acetylsalicylic acid, anabolic steroids, beta carotenoids, beta carotenoids, beta carotenoids" "" "" ""</seg>
<seg id="1035">"" "" "" "224 If any of the side effects listed are significantly impaired or you may notice any side effects not specified in this information information, please inform your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1036">"" "" "" "226 Before each injection, check if there are still at least 12 units of insulin in the cartridge so that an even blend is ensured." "" "" ""</seg>
<seg id="1037">Proceed as follows to avoid the injection of air and ensure proper dosage: • Keep Actraphane 20 NovoLet with the injection needle upwards • knocking a few times with your finger slightly against the cartridge.</seg>
<seg id="1038">"" "" "" "if air bubbles are present, they will keep up in the cartridge - While you keep Actraphane 20 NovoLet down with the injection needle, push the button in the direction of the arrow (Figure D) • Now you have to squeeze a drop of insulin from the tip of the injection needle." "" "" ""</seg>
<seg id="1039">"" "" "" "if not, turn the closing cap until the push button is pressed down • Keep your Actraphane 20 NovoLet horizontally." "" "" ""</seg>
<seg id="1040">"" "" "" "oral antidiabetic drugs (inhibitors), monoamine oxidase inhibitors (MAO inhibitors), beta-receptors, acetylsalicylic acid, anabolic steroids, beta carotenoids, beta carotenoids, beta carotenoids" "" "" ""</seg>
<seg id="1041">"" "" "" "234 If any of the side effects listed are significantly impaired or you may notice side effects not specified in this information information, please inform your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1042">"" "" "" "236 Before each injection, check if there are still at least 12 units of insulin in the cartridge so that an even blend is ensured." "" "" ""</seg>
<seg id="1043">Proceed as follows to avoid the injection of air and ensure proper dosage: • Keep Actraphane 30 NovoLet with the injection needle upwards • knocking a few times with your finger slightly against the cartridge.</seg>
<seg id="1044">"" "" "" "if air bubbles are present, they will keep up in the cartridge - While you keep Actraphane 30 NovoLet down with the injection needle, push the button in the direction of the arrow (Figure D) • Now you have to squeeze a drop of insulin from the tip of the injection needle." "" "" ""</seg>
<seg id="1045">"" "" "" "if not, turn the closing cap until the push button is pressed down • Keep your Actraphane 30 NovoLet horizontal." "" "" ""</seg>
<seg id="1046">"" "" "" "oral antidiabetic drugs (inhibitors), monoamine oxidase inhibitors (MAO inhibitors), beta-receptors, acetylsalicylic acid, anabolic steroids, beta carotenoids, beta carotenoids, beta carotenoids" "" "" ""</seg>
<seg id="1047">"" "" "" "244 If any of the side effects listed are significantly impaired or you may notice side effects not specified in this information information, please inform your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1048">"" "" "" "246 Before each injection, check if there are still at least 12 units of insulin in the cartridge so that an even blend is ensured." "" "" ""</seg>
<seg id="1049">Proceed as follows to avoid the injection of air and ensure proper dosage: • Keep Actraphane 40 NovoLet with the injection needle upwards • knocking a few times with your finger slightly against the cartridge.</seg>
<seg id="1050">"" "" "" "if air bubbles are present, they will keep up in the cartridge - While you keep Actraphane 40 NovoLet down with the injection needle, push the button in the direction of the arrow (Figure D) • Now you have to squeeze a drop of insulin from the tip of the injection needle." "" "" ""</seg>
<seg id="1051">"" "" "" "if not, turn the closing cap until the push button is pressed down • Keep your Actraphane 40 NovoLet horizontal." "" "" ""</seg>
<seg id="1052">"" "" "" "oral antidiabetic drugs (inhibitors), monoamine oxidase inhibitors (MAO inhibitors), beta-receptors, acetylsalicylic acid, anabolic steroids, beta carotenoids, beta carotenoids, beta carotenoids" "" "" ""</seg>
<seg id="1053">"" "" "" "254 If any of the side effects listed are significantly impaired or you may notice side effects not specified in this information information, please inform your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1054">"" "" "" "it is recommended, after removing from the refrigerator - the temperature of NovoLet's ready to rise to room temperature before the insulin is resuserpened in accordance with the manual for the first use." "" "" ""</seg>
<seg id="1055">"" "" "" "256 Before each injection, check if there are still at least 12 units of insulin in the cartridge so that an even blend is ensured." "" "" ""</seg>
<seg id="1056">Proceed as follows to avoid the injection of air and ensure proper dosage: • Keep Actraphane 50 NovoLet with the injection needle upwards • knocking a few times with your finger slightly against the cartridge.</seg>
<seg id="1057">"" "" "" "if air bubbles are present, they will keep up in the cartridge - While you keep Actraphane 50 NovoLet down with the injection needle, push the button in the direction of the arrow (Figure D) • Now you have to squeeze a drop of insulin from the tip of the injection needle." "" "" ""</seg>
<seg id="1058">"" "" "" "if not, turn the closing cap until the push button is pressed down • Keep your Actraphane 50 NovoLet horizontal." "" "" ""</seg>
<seg id="1059">"" "" "" "oral antidiabetic drugs (inhibitors), monoamine oxidase inhibitors (MAO inhibitors), beta-receptors, acetylsalicylic acid, anabolic steroids, beta carotenoids, beta carotenoids, beta carotenoids" "" "" ""</seg>
<seg id="1060">"" "" "" "► in insulin infusion pumps, if the Innox has been dropped, damaged or crushed, is the risk of excretion of insulin if it was not stored correctly or frozen (see 6 How does Actraphane do not work evenly)." "" "" ""</seg>
<seg id="1061">"" "" "" "the warning signs of fortification can suddenly occur and may be: cold sweat, cold pale skin, headache, heart rate, nausea, large hunger, temporary blurredness, nausea, nervousness or trembling, anxiety, confusion, concentration difficulties." "" "" ""</seg>
<seg id="1062">"" "" "" "264 If any of the side effects listed are significantly impaired or you may notice any side effects not specified in this information information, please inform your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1063">"" "" "" "in use, Innoises finished pens and those that are used shortly or are used as replacement are not stored in the refrigerator." "" "" ""</seg>
<seg id="1064">It is recommended that it is taken out of the refrigerator - to increase the temperature of the Innox prep to room temperature before the insulin is resuserpended according to the manual for the first use.</seg>
<seg id="1065">"" "" "" "release the closing cap of your Innox finished pens, whenever Innoislet is not used to protect the insulin from light." "" "" ""</seg>
<seg id="1066">"" "" "" "as acetphane looks and contents of the package The injection suspension is delivered as opaque, white, aqueous suspension in packs of 1, 5 or 10 finished pens to each 3 ml." "" "" ""</seg>
<seg id="1067">"" "" "" "the movement must be repeated until the liquid is evenly white and cloudy, following the reset, you perform all the following steps of the injection without delay." "" "" ""</seg>
<seg id="1068">• disinfect the rubber membrane with a medical tampon • Do always use a new injection needle to avoid contamination • Remove the injection needle straight and firmly on Actraphane 30 Innoises (figure 1B) • Drag the large external injection needle and the internal injection needle.</seg>
<seg id="1069">"" "" "" "• Keep check if the button is pressed completely, and the dose regulator is set to zero, specify the number of units you have to injected by turning the dose control clockwise (Figure 2)." "" "" ""</seg>
<seg id="1070">Do not use the residual quantity scale to measure your insulin dose • You can hear a click noise for each unit set individually.</seg>
<seg id="1071">"" "" "" "perform the injection technique that your doctor has shown to you • Give the dose, by pressing the push button (Figure 3)." "" "" ""</seg>
<seg id="1072">"" "" "" "the dosing needle must remain under the skin for at least 6 seconds after the injection, as the dose regulator has to be reset to zero if you press the injection needle after injection." "" "" ""</seg>
<seg id="1073">"" "" "" "medical personnel, family members and other supervisors must consider general precautions to remove and dispose of the injection needles to avoid accidental stitches with the injection needle." "" "" ""</seg>
<seg id="1074">"" "" "" "oral antidiabetic drugs (inhibitors), monoamine oxidase inhibitors (MAO inhibitors), beta-receptors, acetylsalicylic acid, anabolic steroids, beta carotenoids, beta carotenoids, beta carotenoids" "" "" ""</seg>
<seg id="1075">"" "" "" "► in insulin infusion pumps, if the flextaper has been dropped, damaged or crushed, the risk of withdrawal from insulin is, if it was not stored correctly or frozen (see 6 How does Actraphane do not work evenly)." "" "" ""</seg>
<seg id="1076">"" "" "" "if you notice depressions or thickening of your skin at the injection site, tell your doctor or diabetes consultant because these reactions can worsen or affect your insulin's intake when injected in such a place." "" "" ""</seg>
<seg id="1077">"" "" "" "274 If any of the side effects listed are significantly impaired or you may notice any side effects not specified in this information information, please inform your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1078">"" "" "" "in use flexPen finished pens and those that are used shortly, or used as replacements, are not stored in the refrigerator." "" "" ""</seg>
<seg id="1079">"" "" "" "it is recommended that it is taken out of the refrigerator - to increase the temperature of the flexpen finished pens to room temperature, before the insulin is resuserpened in accordance with the manual for the first use." "" "" ""</seg>
<seg id="1080">"" "" "" "if FlexPen is not used to protect the insulin from light, use the closing cap of your FlexPen finished pens." "" "" ""</seg>
<seg id="1081">"" "" "" "as acetphane looks and contents of the package The injection suspension is delivered as opaque, white, aqueous suspension in packs of 1, 5 or 10 finished pens to each 3 ml." "" "" ""</seg>
<seg id="1082">"" "" "" "manufacturers The manufacturer can be identified using the Chargen designation, which is printed on the lashings of the box and on the label:" "" "" ""</seg>
<seg id="1083">"" "" "" "275 • If at the second and third place of the Chargen name appears the character combination W5, S6, P5, K7 or ZF, the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F- 28002 Chartres, France." "" "" ""</seg>
<seg id="1084">"" "" "" "B Move the pen between positions 1 and 2 times and down, so that the glass ball moves from one end of the cartridge to the other." "" "" ""</seg>
<seg id="1085">"" "" "" "move the pen at least 10 times between positions 1 and 2, until the liquid appears uniformly white and opaque." "" "" ""</seg>
<seg id="1086">"" "" "" "• To reduce the risk of accidental conifers, never put the inner shell back on the injection needle after you have removed it once." "" "" ""</seg>
<seg id="1087">"" "" "" "279 g Keep the flexpen with the injection needle upwards and knock a few times with your finger against the cartridge, so that existing air bubbles will accumulate in the cartridge." "" "" ""</seg>
<seg id="1088">"" "" "" "the dose can be corrected both upwards and downwards, by turning the can pre-selection button in the appropriate direction until the correct dose is placed opposite the marker." "" "" ""</seg>
<seg id="1089">"" "" "" "this document is a summary of the European Public Department report (EPAR), which explains how the Committee for Human Genetics (CHMP) evaluated the studies carried out to make recommendations regarding the use of the medicine." "" "" ""</seg>
<seg id="1090">"" "" "" "the ineffectual ingredient in Actrapid, insulin humane (rDNA), is produced using the method of the so-called recombinant technology:" "" "" ""</seg>
<seg id="1091">© EMEA 2007 Reproduction and / or distribution of this document is Authorised for non commercial purposes only provided the EMEA is acknowledged How was Actrapid studied?</seg>
<seg id="1092">"" "" "" "Actrapid may not be used in patients who may be hypersensitive to insulin, human (rDNA) or any of the other ingredients." "" "" ""</seg>
<seg id="1093">"" "" "" "in addition, doses of acettpid may be adjusted if it is administered together with a number of other medicines that may affect blood sugar." "" "" ""</seg>
<seg id="1094">"" "" "" "October 2002, the European Commission issued a approval to the company Novo Nordisk A / S for placing Actrapid across the European Union." "" "" ""</seg>
<seg id="1095">"" "" "" "when two types of insulin are mixed, the quantity of the rapidly working insulin must first be raised, then the quantity of long acting insulin." "" "" ""</seg>
<seg id="1096">"" "" "" "3 In case of change to Actrapid in the patient, dosage adjustment is required, it may be necessary during the first dosage or in the first weeks or months after the conversion." "" "" ""</seg>
<seg id="1097">"" "" "" "when travelling over several time zones, the patient should be advised to take the advice of his doctor as such trips can lead to that insulin and meals must be used or taken at other times." "" "" ""</seg>
<seg id="1098">"" "" "" "5 General diseases and complaints at the administration of site Gelsomely - Local hypersensitivity reactions to the injection site During insulin therapy local hypersensitivity reactions (redness, swelling, itching, pain and haematoma occur at the injection site)." "" "" ""</seg>
<seg id="1099">Diabetics should therefore always have grape sugar, sweets, biscuits or sugary fruit juice. • Heavy Hypoglycemias with unconsciousness are treated with an intramuscular or subcutaneous injection of Glucagon (0.5 to 1.0 mg) or by glucose that is given intravenously by the doctor.</seg>
<seg id="1100">A clinical trial in an intensive care unit for the treatment of hyperglycemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients who underwent major surgical procedures (blood sugar 4.4 - 6.1 mmol / l) reduced mortality by 42% (8% compared to 4.6%).</seg>
<seg id="1101">"" "" "" "the effect begins within half an hour, the maximum working maximum is reached within 1.5 to 3.5 hours and total duration amounts to approximately 7 to 8 hours." "" "" ""</seg>
<seg id="1102">The pharmacokinetic profile of Actrapid was studied at a smaller number (n = 18) of diabetic children (aged between 6 and 12) and adolescent (ages 13 to 17).</seg>
<seg id="1103">"" "" "" "the data is limited, however, suggests that the pharmacokinetic profile is similar to children and adolescents from adults." "" "" ""</seg>
<seg id="1104">Infusion systems with acetpid in concentrations 0.05 I.E. / ml - 1.0 I.E. / ml Insulin human in the infusion fluids 0.9% sodium chloride and 10% D- glucose with 40 mmol / l potassium chloride are stable at room temperature for 24 hours at room temperature.</seg>
<seg id="1105">"" "" "" "11 In case of change to Actrapid in the patient, a dose adjustment is required, it may be necessary during the first dosage or in the first weeks or months after the conversion." "" "" ""</seg>
<seg id="1106">"" "" "" "when travelling over several time zones, the patient should be advised to take the advice of his doctor as such trips can lead to that insulin and meals must be used or taken at other times." "" "" ""</seg>
<seg id="1107">"" "" "" "13 General diseases and complaints at the administration of site Gelsomely - Local hypersensitivity reactions to the injection site During insulin therapy local hypersensitivity reactions (redness, swelling, itching, pain and haematoma occur at the injection site)." "" "" ""</seg>
<seg id="1108">Diabetics should therefore always have grape sugar, sweets, biscuits or sugary fruit juice. • Heavy Hypoglycemias with unconsciousness are treated with an intramuscular or subcutaneous injection of Glucagon (0.5 to 1.0 mg) or by glucose that is given intravenously by the doctor.</seg>
<seg id="1109">The pharmacokinetic profile of Actrapid was studied at a smaller number (n = 18) of diabetic children (aged between 6 and 12) and adolescent (ages 13 to 17).</seg>
<seg id="1110">"" "" "" "intravenous use of acetpid in pens or cartridges should be an exception, and only in situations where there are no bottles available." "" "" ""</seg>
<seg id="1111">"" "" "" "if a dose adjustment is required when changing to Actrapid, it may be necessary during the first dosage or in the first weeks or months after the conversion." "" "" ""</seg>
<seg id="1112">21 diseases of the skin and the subcutaneous tissue jelly - lipodystrophy at the injection site may arise a lipodystrophy if failed to switch the stitch branches inside the injection unit.</seg>
<seg id="1113">The pharmacokinetic profile of Actrapid was studied at a smaller number (n = 18) of diabetic children (aged between 6 and 12) and adolescent (ages 13 to 17).</seg>
<seg id="1114">29 diseases of the skin and the subcutaneous tissue jelly - lipodystrophy at the injection site may arise a lipodystrophy if failed to switch the stitch branches inside the injection unit.</seg>
<seg id="1115">"" "" "" "disorders of the immune system Gelsomingly - Urticaria, Exanthem Very rarely - anaphylactic reactions symptoms of generalized hypersensitivity, including generalized skin rash, itching, gastrointestinal edema, breathing difficulties, low blood pressure and impotence / unconsciousness." "" "" ""</seg>
<seg id="1116">The pharmacokinetic profile of Actrapid was studied at a smaller number (n = 18) of diabetic children (aged between 6 and 12) and adolescent (ages 13 to 17).</seg>
<seg id="1117">"" "" "" "disorders of the immune system Gelsomingly - Urticaria, Exanthem Very rarely - anaphylactic reactions symptoms of generalized hypersensitivity, including generalized skin rash, itching, gastrointestinal edema, breathing difficulties, low blood pressure and impotence / unconsciousness." "" "" ""</seg>
<seg id="1118">38 A clinical trial in an intensive care unit for the treatment of hyperglycemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients who underwent major surgical procedures (blood sugar 4.4 - 6.1 mmol / l) reduced mortality by 42% (8% compared to 4.6%).</seg>
<seg id="1119">"" "" "" "disorders of the immune system Gelsomingly - Urticaria, Exanthem Very rarely - anaphylactic reactions symptoms of generalized hypersensitivity, including generalized skin rash, itching, gastrointestinal edema, breathing difficulties, low blood pressure and impotence / unconsciousness." "" "" ""</seg>
<seg id="1120">46 A clinical trial in an intensive care unit for the treatment of hyperglycemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients who underwent major surgical procedures (blood sugar 4.4 - 6.1 mmol / l) reduced mortality by 42% (8% compared to 4.6%).</seg>
<seg id="1121">Store in the fridge (2 ° C - 8 ° C) Do not freeze The bottle in the cardboard box to protect the contents from light After departure: do not store in the fridge or over 25 ° C</seg>
<seg id="1122">Subcutaneous Application Peninsular Cartridges are intended for use with Novo Nordisk insulin injections and must be used only by one person to use Novo Nordisk insulin injections</seg>
<seg id="1123">Store in the fridge (2 ° C - 8 ° C) Do not freeze the cartridge in the box to protect the contents from light After departure: do not store in the fridge or over 30 ° C</seg>
<seg id="1124">Subcutaneous Application To use with Actrapid NovoLet NovoFine injections are intended to be used with treatment inserts. Actrapid Novolet may only be used by one person</seg>
<seg id="1125">"" "" "" "store in the fridge (2 ° C - 8 ° C) Do not freeze, Protect from light After departure: do not store in the fridge or over 30 ° C" "" "" ""</seg>
<seg id="1126">Subcutaneous Application To use with Actrapid Innoises NovoFine S Injection pins are intended to be used to observe Actrapid Innoises may only be used by one person</seg>
<seg id="1127">"" "" "" "this means that approximately half an hour after you have applied it, your blood sugar begins to sink and that the effect will stop for about 8 hours." "" "" ""</seg>
<seg id="1128">"" "" "" "► Check the label, whether it's the right type of insulin." "" "" ""</seg>
<seg id="1129">"" "" "" "if this is not completely undamaged, if you get the bottle of bottle, return the bottle to your pharmacy - if it was not stored correctly or frozen (see 6 How is Actupid to be stored?) ► if it doesn't look clear like water and colourless." "" "" ""</seg>
<seg id="1130">Use the injection technique that recommended your doctor or diabetes consultant. ► Let the injection needle under your skin for at least 6 seconds under your skin to ensure that the full dose was injected.</seg>
<seg id="1131">"" "" "" "83 Say your relatives, friends and colleagues, that they will bring you into the stable side position in case of unconsciousness and immediately notify a doctor." "" "" ""</seg>
<seg id="1132">You may have a very rare or allergic reaction to Actrapid or one of its constituents (a so-called systemic allergic reaction).</seg>
<seg id="1133">"" "" "" "the injection solution is delivered as clear, colorless, aqueous solution in packs of 1 or 5 vials each 10 ml or a bundle pack of 5 bottles of 10 ml." "" "" ""</seg>
<seg id="1134">"" "" "" "89 Say your relatives, friends and colleagues, that they will bring you into the stable side position in case of unconsciousness and immediately notify a doctor." "" "" ""</seg>
<seg id="1135">"" "" "" "► Check the label, whether it's the right type of insulin, and always check the cartridge including rubber piston (plugs)." "" "" ""</seg>
<seg id="1136">"" "" "" "► in insulin infusion pumps, if the fill or device that contains the fill is dropped, damaged or crushed; it is the risk of the insulin delivery (see 6 How does Actupid be stored or frozen) even if it does not look clear like water and colourless." "" "" ""</seg>
<seg id="1137">"" "" "" "if you are treated with Actrapid Penlines and another insulin in Penfill cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="1138">Use the injection technique that recommended your doctor or diabetes consultant and which is described in the manual of your injection system ► Do you need to remove the injection needle for at least 6 seconds under your skin to ensure that the complete dose was injected.</seg>
<seg id="1139">"" "" "" "• If on the second and third place of the Chargen name the character combination W5, S6, P5, K7 or ZF, the manufacturer Novo Nordisk A / S, Novo Allé, DK-2880 Bagsvaerd, Denmark" "" "" ""</seg>
<seg id="1140">"" "" "" "• If on the second and third place of the Chargen name the character combination H7 or T6 appears, the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F- 28002 Chartres, France." "" "" ""</seg>
<seg id="1141">"" "" "" "oral antidiabetic drugs (inhibitors), monoamine oxidase inhibitors (MAO inhibitors), beta-receptors, acetylsalicylic acid, anabolic steroids, beta carotenoids, beta carotenoids, beta carotenoids" "" "" ""</seg>
<seg id="1142">"" "" "" "► Check the label, whether it is the right type of insulin. ► Do not use a new injection needle for each injection to avoid contamination." "" "" ""</seg>
<seg id="1143">"" "" "" "► in insulin infusion pumps, if the Novolet has been dropped, damaged or crushed; there is a risk of withdrawal of insulin, if it has not been kept correctly or frozen (see 6 How does Actupid look like)." "" "" ""</seg>
<seg id="1144">"" "" "" "this may happen: if you injected too much insulin, if you eat too little or leave a meal, if you are more than otherwise physically demanding" "" "" ""</seg>
<seg id="1145">"" "" "" "always set up the closing cap of your Novolet finished pens, if it is not in use to protect it from light." "" "" ""</seg>
<seg id="1146">• Disinfect the rubber membrane with a medical tupfer • Do always use a new injection needle for each injection to avoid contamination. • Remove the injection needle straight and firmly on Actupid Novolet (Figure A) • Drag the large outer cap of the injection needle and the inner cap of the injection needle.</seg>
<seg id="1147">Proceed as follows to avoid the injection of air and ensure proper dosage: • Keep Actrapid NovoLet with the injection needle upwards • knocking a few times with your finger slightly against the cartridge.</seg>
<seg id="1148">"" "" "" "if air bubbles are present, these will be collected at the top of the cartridge • While the injection needle continues to keep up, press the button in the direction of the arrow (Figure C) • At the point of the injection needle a drop of insulin is required." "" "" ""</seg>
<seg id="1149">"" "" "" "• Place the closing cap back to the finished pen, that the digit 0 is opposite the metering stamp (Figure D) • Check if the push button is pressed completely." "" "" ""</seg>
<seg id="1150">"" "" "" "if the push button can not move freely, insulin is pressed out of the injection needle • The scale on the closing cap indicates 0, 2, 4, 6, 8, 10, 12, 14, 16 and 18 units." "" "" ""</seg>
<seg id="1151">"" "" "" "the push button moves outward while you rotate the closing cap • The scale below the push button (button scale) shows 20, 40 and 60 units." "" "" ""</seg>
<seg id="1152">"" "" "" "107 • Note the highest number you can see on the button scale • Adding the two numbers to get the recommended dose, if you have set a wrong dose, turn the cap forward or backward until you have set the correct number of units." "" "" ""</seg>
<seg id="1153">"" "" "" "turn it until the push button is at the bottom and you feel a resistance, then take the closing cap and set it up again that the 0 of the metering stamp is opposite." "" "" ""</seg>
<seg id="1154">"" "" "" "be careful not to press the pressure button during the injection, until you pressed the button after the injection until the injection needle was pulled out of the skin." "" "" ""</seg>
<seg id="1155">"" "" "" "it may not be accurate, you can't use a dose that is higher than the number of units remaining in the cartridge, but you can't use the residual quantity scale to estimate how much insulin is still remaining, but you can't use it to set or select your dose." "" "" ""</seg>
<seg id="1156">"" "" "" "oral antidiabetic drugs (inhibitors), monoamine oxidase inhibitors (MAO inhibitors), beta-receptors, acetylsalicylic acid, anabolic steroids, beta carotenoids, beta carotenoids, beta carotenoids" "" "" ""</seg>
<seg id="1157">"" "" "" "► in insulin infusion pumps, if the Innox has been dropped, damaged or crushed; there is a risk of withdrawal from insulin, if it has not been properly stored or frozen (see 6 How does Actupid look like)." "" "" ""</seg>
<seg id="1158">"" "" "" "always set the closing cap of your Innox finished pens, if it is not in use to protect it from light." "" "" ""</seg>
<seg id="1159">• disinfect the rubber membrane with a medical tampon • Do always use a new injection needle for each injection to avoid contamination. • Remove the injection needle straight and firmly on Actupid Innoises (Figure 1A) • Drag the large outer cap of the injection needle and the inner cap of the injection needle.</seg>
<seg id="1160">"" "" "" "after injection, the dose regulator has to remain under the skin for at least 6 seconds." "" "" "" • Assure that the dose regulator has to be stopped for at least 6 seconds. "" "" "" "</seg>
<seg id="1161">"" "" "" "oral antidiabetic drugs (inhibitors), monoamine oxidase inhibitors (MAO inhibitors), beta-receptors, acetylsalicylic acid, anabolic steroids, beta carotenoids, beta carotenoids, beta carotenoids" "" "" ""</seg>
<seg id="1162">"" "" "" "121 ► If it was not stored correctly or frozen (see 6, how does Actupid be stored?) ► if it doesn't look clear like water and colourless." "" "" ""</seg>
<seg id="1163">"" "" "" "if one of the listed side effects affects you significantly or you may notice side effects not specified in this information information, please inform your doctor, your diabetes consultant or your pharmacist." "" "" ""</seg>
<seg id="1164">"" "" "" "always set up the closing cap of your FlexPen finished pens, if it is not in use to protect it from light." "" "" ""</seg>
<seg id="1165">"" "" "" "F Keep the flexpen with the injection needle upwards and knock a few times with your finger against the cartridge, so that existing air bubbles will accumulate in the cartridge." "" "" ""</seg>
<seg id="1166">"" "" "" "the dose can be corrected both upwards and downwards, by turning the can pre-selection button in the appropriate direction until the correct dose is compared to the dose indicator." "" "" ""</seg>
<seg id="1167">"" "" "" "adenuric is used in patients who already have signs of crystallization, including arthritis (pain and inflammation in joints) or arthritis (" stones ")." "" "" ""</seg>
<seg id="1168">"" "" "" "if the uric acid level is still more than 6 mg per deciliter, the dose can be increased to 120 mg once a day." "" "" ""</seg>
<seg id="1169">"" "" "" "during the first treatment months there are still some cases of gout, so it is recommended that patients continue to use Adenuric for at least 6 months to prevent gout attacks." "" "" ""</seg>
<seg id="1170">"" "" "" "the drug is not recommended in children and for patients who had an organ transplantation, as it was not examined for these groups." "" "" ""</seg>
<seg id="1171">"" "" "" "in the first study, involving 1,072 patients, the efficacy of three different Adenuric dosages (80, 120 and 240 mg) was compared to that of a placebo (bogus medicine) and allopurinol (another medicine for the treatment of hyperuric leukemia)." "" "" ""</seg>
<seg id="1172">"" "" "" "in the second study, two doses of Adenuric (once daily 80 and 120 mg) were compared to 762 patients each with allopurinol." "" "" ""</seg>
<seg id="1173">"" "" "" "in both studies, Allopurinol was administered at a dose of 300 mg once a day; patients with kidney problems received only 100 mg per day." "" "" ""</seg>
<seg id="1174">"" "" "" "the main indicator for efficacy was the number of patients, whose acid levels in the blood were below 6 mg / dl in the last three measurements." "" "" ""</seg>
<seg id="1175">"" "" "" "in the first study 48% (126 of 262) of patients receiving Adenuric in a dose of once daily 80 mg, and 65% (175 of 269) received a uric acid level in the blood of less than 6 mg / dl." "" "" ""</seg>
<seg id="1176">"" "" "" "in comparison, this was 22% (60 of 268) of patients under Allopurinol and none of the 134 patients under placebo." "" "" ""</seg>
<seg id="1177">"" "" "" "the most common side effects of Adenuric (observed at 1 to 10 of 100 patients) are headaches, diarrhea, nausea (Nausea), rash and abnormal liver enzymes." "" "" ""</seg>
<seg id="1178">"" "" "" "in particular in patients with heart problems in prehistory, there may also be increased risk of certain side effects affecting the heart and blood vessels." "" "" ""</seg>
<seg id="1179">The Committee for Human Use (CHMP) concluded that Adenuric could be more effective in lowering the urine acid levels in the blood than Allopurinol but also a higher risk of side effects related to the heart and blood vessels.</seg>
<seg id="1180">"" "" "" "treatment of chronic hyperuric hyperuranaemia in diseases which have already led to urine deposits (including one of the medical records known or currently present, and / or arthritis)." "" "" ""</seg>
<seg id="1181">"" "" "" "if the serum concentrations exceed 2-4 weeks still &gt; 6 mg / dl (357 µmol / l), the dose increase to ADENURIC 120 mg 1 x can be considered daily." "" "" ""</seg>
<seg id="1182">"" "" "" "in patients with severe kidney function restrictions, efficacy and safety have not been fully studied (Creatinin- Clearance &lt; 30 ml / min, see Section 5.2)." "" "" ""</seg>
<seg id="1183">"" "" "" "children and young people Since there is no experience in children and adolescents, the use of februxostat in this group of patients is not recommended." "" "" ""</seg>
<seg id="1184">"" "" "" "since there is no experience in organ transplant recipients, the application of Febuxostat in this patient group is not recommended (see Section 5.1)." "" "" ""</seg>
<seg id="1185">Cardiovascular diseases In patients with ischemic heart disease or decompensated heart failure treatment with Febuxostat is not recommended (see Section 4.8).</seg>
<seg id="1186">"" "" "" "as with other harnessing drugs, it can occur during the treatment beginning with acute toxicity, because the lowering of serum concentration in tissues can initially be mobilised in tissues." "" "" ""</seg>
<seg id="1187">"" "" "" "B. in malignant diseases and their treatment, Lesch- Nyhan syndrome), the absolute concentration of Xanthin in the urine can increase so far that it comes to a deposit in the urinary tract." "" "" ""</seg>
<seg id="1188">"" "" "" "during Phase 3 clinical trials, slight abnormalities of liver function values were observed in patients treated with Febuxostat (3.5%)." "" "" ""</seg>
<seg id="1189">"" "" "" "therefore, it is recommended to perform a liver function test before beginning of filing and subsequent clinical findings (see Section 5.1)." "" "" ""</seg>
<seg id="1190">"" "" "" "theophyllin zinc has not been carried out at februxostat, but it is known that the XO inhibitory can lead to a rise in theophyllinic level (a inhibiting of the metabolism of theophylline was also reported for other XO inhibitors)." "" "" ""</seg>
<seg id="1191">At subjects the simultaneous administration of Febuxostat and naproxen was 250 mg 2 times daily with an increase in Febuxostat (CMAx 28% and AUC 41% and t1 / 2 26%).</seg>
<seg id="1192">"" "" "" "in clinical studies, the application of naproxen or other NSAR / Cox-2 inhibitors was not related to a clinically significant increase of adverse events." "" "" ""</seg>
<seg id="1193">Colchicin / Indometacin / Hydrochlorthiazide / Warfarin Febuxostat can be used together with colchicin or indometacin without a can adjustment for februxostat or the other active ingredient used at the same time.</seg>
<seg id="1194">In a study involving subjects 120 mg ADENURIC 1 x daily amounts to an average 22% increase in the AUC of Desipramine and a CYP2D6 Substrate which indicates a possible weak inhibitory effect of februxostat on the CYP2D6 enzyme in vivo.</seg>
<seg id="1195">"" "" "" "antacids There has been shown that the simultaneous intake of an antacids, the magnesium hydroxide and aluminium hydroxide, delayed the absorption of Febuxostat (about 1 hour) and a decrease in the CMAx by 32%, but no significant change in the AUC." "" "" ""</seg>
<seg id="1196">Pregnancy data on a very limited number of exposed pregnancies do not include side effects of februxostat on pregnancy or the health of the fetus / newborn.</seg>
<seg id="1197">"" "" "" "animal experimental studies do not include direct or indirect harmful effects on pregnancy, embryonic / fetal development or birth (see section 5.3)." "" "" ""</seg>
<seg id="1198">"" "" "" "patients should be careful when controlling a vehicle, operating machines or performing dangerous activities until they can reasonably be sure that ADENURIC does not adversely affect their performance." "" "" ""</seg>
<seg id="1199">A numerically higher incidence of cardiovascular events was observed in the total februxostadia compared to the Allopurinol group in the Pivotal Study of Phase 3 (1.4 versus 0.7 events per 100 patient years) and in long-term extension studies (1.4 versus 0.7 events per 100 patient years).</seg>
<seg id="1200">The risk factors identified in these patients were arteriosclerosis and / or a myocardial infarction or a decompensated heart failure in the medical history.</seg>
<seg id="1201">"" "" "" "frequent (≥ 1 / 100 to &lt; 1 / 100) and rare (≥ 1 / 1,000 to &lt; 1 / 1,000) and rare (≥ 1 / 10,000 to &lt; 1 / 1000) were reported in the treatment groups and reported in all the Febuxostat treatment groups more than once." "" "" ""</seg>
<seg id="1202">Diarrhea; nausea and vomiting are more common in patients treated at the same time with colchicine. * * In clinical studies no serious skin rash or severe hypersensitivity reactions were observed.</seg>
<seg id="1203">"" "" "" "7 Offered long-term extension studies In the open long-term extension studies 906 patients were treated up to 1 year, 57 patients up to 3 years and 53 patients up to 4 years with Febuxostat 80 mg / 120 mg." "" "" ""</seg>
<seg id="1204">"" "" "" "the events related to long-term extension studies were similar to those reported in Phase 3 studies (see Table 1)." "" "" ""</seg>
<seg id="1205">The following treatment-related events were reported in all of the Febuxostat treatment groups more than once and occurred in patients who received Febuxostat 80 mg / 120 mg in long-term extension studies (up to 4 years with an exposure time of &gt; 1.900 patient years).</seg>
<seg id="1206">"" "" "" "the following treatment-related events were either reported in the pivotal studies of Phase 3 for these doses, either at all or with a lower frequency:" "" "" ""</seg>
<seg id="1207">"" "" "" "diabetes, hyperlipidemia, sleeplessness, hypaesthesia, eye discomfort, skin lesions, bursitis, loss of potassium concentrations in the blood, decrease in lymphocytes, decrease in the number of white blood cells." "" "" ""</seg>
<seg id="1208">"" "" "" "the action mechanism of uric acid is the final product of Purinmetabolism in humans, resulting in the reaction skaskade hypoxanthin → Xanthin → uric acid." "" "" ""</seg>
<seg id="1209">"" "" "" "Febuxostat is a potent, non-purine-selective inhibitor of XO (NP-SIxO) with a Ki-value for in vitro inhibiting, which lies below the nanomolar area." "" "" ""</seg>
<seg id="1210">Clinical study results The efficacy of ADENURIC was shown in two pivotal studies of Phase 3 (APEX study and FACT study as described below) which were conducted with 1.832 patients with hyperuric aemia and gout.</seg>
<seg id="1211">"" "" "" "the primary efficacy endpoint was in every study the proportion of patients, where the last three month levels of serum concentration were &lt; 6.0 mg / dl (357 µmol / l)." "" "" ""</seg>
<seg id="1212">Placebo (n = 134) to ADENURIC 80 mg 1 x daily (n = 269) or ADENURIC 240 mg 1 x daily (n = 134) or Allopurinol 300 mg 1 x daily (n = 10) for patients with a serum incremental value at the beginning of studies of &gt; 1.5 mg / dl and ≤ 2.0 mg / dl.</seg>
<seg id="1213">The APEX study showed a statistically significant superiority in the treatment with ADENURIC 80 mg 1 x daily as well as with ADENURIC 120 mg 1 x a day compared to the treatment with conventional doses of Allopurinol 300 mg (n = 258) / 100 mg (n = 10).</seg>
<seg id="1214">The FACT study showed a statistically significant superiority in the treatment with ADENURIC 80 mg 1 x daily as well as with ADENURIC 120 mg 1 x a day compared to the conventional used dose Allopurinol 300 mg.</seg>
<seg id="1215">Patients with serum samples &gt; 1.5 and ≤ 2.0 mg / dl) or 300 mg 1 times daily (n = 509) were summarised for analyses. * p &lt; 0.001 versus Allopurinol; # p &lt; 0.001 versus 80 mg</seg>
<seg id="1216">The lowering of serum acid levels to &lt; 6.0 mg / dl (357 µmol / l) was observed during the visit visit in week 2 and continued throughout the entire treatment.</seg>
<seg id="1217">"" "" "" "509 patients received Allopurinol 300 mg 1 x daily, 10 patients with serum increment &gt; 1.5 and &lt; 2,0 mg / dl received 100 mg 1 x daily." "" "" ""</seg>
<seg id="1218">Primary endpoint in the group of patients with kidney function restrictions The APEX study evaluated the efficacy of 40 patients with kidney function restriction (i.e. h).</seg>
<seg id="1219">"" "" "" "with ADENURIC, the primary efficacy endpoint was 44% (80 mg 1 x daily), 45% (120 mg 1 x daily) and 60% (240 mg 1 x a day) of patients." "" "" ""</seg>
<seg id="1220">"" "" "" "there were no clinically significant differences in the percentage decline of serum concentrations in subjects, regardless of their renal function (58% in the group with normal renal function and 55% in the group with severe kidney function disorders)." "" "" ""</seg>
<seg id="1221">Primary endpoint in the subgroup of patients with serum concentrations ≥ 10 mg / dl Etwa 40% of patients (APEX- and FACT study) had a serum concentration of ≥ 10 mg / dl.</seg>
<seg id="1222">"" "" "" "the data collected in phase 3 showed that less than 3% of patients in the months 16-24 required a treatment against rheumatism (i.e. more than 97% of the patients needed no treatment against feeding)." "" "" ""</seg>
<seg id="1223">"" "" "" "this was associated with a reduction in the size of the pack, which resulted in 54% of patients a complete disappearance of the gigties up to month 24." "" "" ""</seg>
<seg id="1224">Increased TSH- values (&gt; 5.5 µIE / ml) were observed in patients receiving a long-term treatment with Febuxostat (5.0%) and in patients with Allopurinol (5.8%) in the open long-term extension studies (see section 4.4).</seg>
<seg id="1225">"" "" "" "in healthy subjects, the maximum plasma concentrations (CMAx) and the area under the plasma concentration time curve (AUC) from Febuxostat increased simply and multiple doses of 10 mg to 120 mg dose proportional." "" "" ""</seg>
<seg id="1226">"" "" "" "for doses between 120mg and 300 mg, an increase in the AUC is observed for Febuxostat, which is greater than the dose-proportional increase." "" "" ""</seg>
<seg id="1227">"" "" "" "after taking simple or multiple oral doses of 80 and 120 mg 1 x a day, the CMAx is about 2.8-3.2 µg / ml and 5.0-5.3 µg / ml." "" "" ""</seg>
<seg id="1228">"" "" "" "however, no clinically significant change was observed in the percentage decrease in serum concentration of serum (multiple doses of 80 mg)." "" "" ""</seg>
<seg id="1229">Distribution The apparent Steady state distribution volume (Vss / F) of februxostat is between 29 and 75 l after taking doses of 10-300 mg.</seg>
<seg id="1230">The plasma protein binding of Febuxostat is about 99.2% (primary attachment to albumin) and is constant over the concentration width obtained with doses of 80 and 120 mg.</seg>
<seg id="1231">In vitro studies in human liver microsomen showed that these oxidative metabolites are made predominantly by CYP1A1 and CYP2C8 or CYP2C9 and that Febuxostatglucuronid is mainly produced by UGT 1A1, 1A8 and 1A9.</seg>
<seg id="1232">After taking an 80 mg dose of 14C-marked februxostat around 49% of the dose in the urine found itself as immutable Febuxostat (3%) with known oxidative metabolites and their conjugate (13%) as well as other unknown metabolites (3%).</seg>
<seg id="1233">"" "" "" "apart from excretion over the urine, approximately 45% of the dose in the chair found itself as immutable Febuxostat (1%), known oxidative metabolites and their conjugate (25%) and other unknown metabolites (7%)." "" "" ""</seg>
<seg id="1234">Special patient groups renal insufficiency After taking multiple doses of 80 mg of ADENURIC in patients with mild or moderate or severe kidney failure the CMAx of Febuxostat did not change in relation to subjects with normal renal function.</seg>
<seg id="1235">The average total AUC of februxostat increased by about 1.8-times of 7.5 μ [0.2 g / ml in the group with normal renal function to 13.2 μ g / ml in the group with severe kidney function.</seg>
<seg id="1236">12 Liver dysfunction After taking multiple doses of 80 mg of ADENURIC in patients with mild (Child- Pugh classification B) Liver dysfunction the CMAx and AUC of Febuxostat and its metabolites did not change significantly compared to subjects with normal liver function.</seg>
<seg id="1237">Age There were no significant changes to the AUC of februxostat or its metabolites after taking multiple oral doses of ADENURIC in older patients compared to younger subjects.</seg>
<seg id="1238">"" "" "" "carcinogenesis, mutagenesis, impairment of fertility in male rats was found only in connection with Xanthin stones in the highly-dosed group, in approximately 11-times of exposure to humans." "" "" ""</seg>
<seg id="1239">"" "" "" "these findings are seen as a result of a specific purine metabolism and urine compound, and considered not relevant for clinical use." "" "" ""</seg>
<seg id="1240">It has been noted that februxostat in oral doses of up to 48 mg / kg / day has no effect on the fertility and reproductive performance of male and female rats.</seg>
<seg id="1241">"" "" "" "in high doses, which were about 4 times of human therapeutic exposure, maternal toxicity occurred which was accompanied by a decrease in expenditure and a development delay in the offspring of rats." "" "" ""</seg>
<seg id="1242">"" "" "" "teratological studies in supporting rats with exposures, approximately the 4.3-fold and in carrying rabbits with exposures, which excrete about the 13-fold of human therapeutic exposure showed no teratogenic effects." "" "" ""</seg>
<seg id="1243">Colchicin / Indometacin / Hydrochlorthiazide / Warfarin Febuxostat can be used together with colchicin or indometacin without a can adjustment for februxostat or the other active ingredient used at the same time.</seg>
<seg id="1244">Diarrhea; nausea and vomiting are more common in patients treated at the same time with colchicine. * * In clinical studies no serious skin rash or severe hypersensitivity reactions were observed.</seg>
<seg id="1245">21 Offene long-term extension studies In the open long-term extension studies 906 patients were treated up to 1 year in 57 patients up to 3 years and 53 patients up to 4 years with Febuxostat 80 mg / 120 mg.</seg>
<seg id="1246">"" "" "" "the primary efficacy endpoint was in every study the proportion of patients, where the last three month levels of serum concentration were &lt; 6.0 mg / dl (357 µmol / l)." "" "" ""</seg>
<seg id="1247">"" "" "" "the data collected in phase 3 showed that less than 3% of patients in the months 16-24 required a treatment against rheumatism (i.e. more than 97% of the patients needed no treatment against feeding)." "" "" ""</seg>
<seg id="1248">"" "" "" "26% Febuxostat (3%), Acylglucuronid of the active substance (30%), known as the known oxidative metabolites and their conjugate (13%) and other unknown metabolites (3%)." "" "" ""</seg>
<seg id="1249">Liver function Restriction After taking multiple doses of 80 mg of ADENURIC in patients with mild (Child- Pugh classification B) Liver dysfunction the CMAx and AUC of Febuxostat and its metabolites did not change significantly compared to subjects with normal liver function.</seg>
<seg id="1250">"" "" "" "carcinogenesis, mutagenesis, impairment of fertility in male rats was found only in connection with Xanthin stones in the highly-dosed group, in approximately 11-times of exposure to humans." "" "" ""</seg>
<seg id="1251">"" "" "" "the owner of the authorization for placing the drug has to make sure that a drug vigilance system is described in version 2.0 module 1.8.1 of the authorisation application, and is available for so long as the medicine is brought into circulation." "" "" ""</seg>
<seg id="1252">"" "" "" "according to the CHMP Guideline, an updated RMP is preferable to risk management systems for human medicines with the next Periodic Safety Update Report (PSUR)." "" "" ""</seg>
<seg id="1253">"" "" "" "additionally, an update of the RMP is required, if new information is available, which have an impact on the safety data, pharmacovigilance plan or risk minimization within 60 days" "" "" ""</seg>
<seg id="1254">"" "" "" "in some people, uric acid accumulates in the blood and can reach concentrations which are so high that uric acid becomes insoluble." "" "" ""</seg>
<seg id="1255">"" "" "" "if you keep the uric acid concentration low through the 1 x daily intake of ADENURIC, the formation of crystals is prevented and in this way a reduction of the discomfort is achieved." "" "" ""</seg>
<seg id="1256">ADENURIC must not be taken if you are hypersensitive to the active ingredient Febuxostat or any of the other components of ADENURIC.</seg>
<seg id="1257">Inform your doctor before you start taking this medicine if you have a heart weakness or suffer from another heart problem. • if you are treated with a high urinary acid concentration in the result of a cancer or lesch-nyhan syndrome (a rare innate disease in which there is too much uric acid in the blood).</seg>
<seg id="1258">"" "" "" "if you have a check in the moment (sudden onset of severe pain, pressure sensitivity, redness, feeling of warmth and joint swelling), wait until the check-in occurs before you begin treatment with ADENURIC." "" "" ""</seg>
<seg id="1259">"" "" "" "this does not have to be so, but could also occur with you, especially during the first treatment weeks or - months, if you are taking ADENURIC." "" "" ""</seg>
<seg id="1260">"" "" "" "your doctor will prescribe other medicines, if necessary, to prevent any injury or to treat the symptoms associated with it (such as pain and joint swelling)." "" "" ""</seg>
<seg id="1261">"" "" "" "please inform your doctor or pharmacist if you are taking other medicines / applied / applied recently, even if it is not prescription medicine." "" "" ""</seg>
<seg id="1262">It is particularly important to inform your doctor or pharmacist if you are taking medicine if you are taking medicines with ADENURIC (for the treatment of cancer) • Azathioprine (for the treatment of cancer) • Tophylline (for the treatment of asthma) • Warfarin (for the treatment of heart disease)</seg>
<seg id="1263">There were no studies on the effects of ADENURIC on the traffic tightness and the ability to operate machinery.</seg>
<seg id="1264">"" "" "" "therefore, please take ADENURIC only after consultation with your doctor if it is known that you suffer from intolerance to certain sugars." "" "" ""</seg>
<seg id="1265">"" "" "" "on the back of the blister pack, the individual weekdays are printed, so you can check if you have taken a tablet every day. • The tablets need to be swallowed and can be taken with or without food." "" "" ""</seg>
<seg id="1266">"" "" "" "if you have unintentionally taken an overdose, contact your doctor or emergency room at the nearest hospital." "" "" ""</seg>
<seg id="1267">"" "" "" "if you forgot to use ADENURIC, get it as soon as possible unless the next intake is imminent." "" "" ""</seg>
<seg id="1268">"" "" "" "when you break the intake of ADENURIC, your urinary acid concentration can increase again and your discomfort can worsen as new urine crystals can form in your joints and kidneys as well as their surroundings." "" "" ""</seg>
<seg id="1269">Frequent side effects (more than 1 of 100 treatments but less than 1 out of 10 dentists): • Ever liver tests • diarrhea • headache • rash • nausea</seg>
<seg id="1270">"" "" "" "rare side effects (more than 1 of 10,000 practitioners, but less than 1 out of 1000 treatments): • weakness • nervousness • Durstness • palpitations" "" "" ""</seg>
<seg id="1271">"" "" "" "please inform your doctor or pharmacist, if any of the side effects listed will affect you significantly or you may notice any side effects that are not stated in this information information." "" "" ""</seg>
<seg id="1272">ADENURIC is available in 2 bubble packs with 14 tablets each (pack of 28 tablets) or in 6 blister packs with 14 tablets each (pack of 84 tablets).</seg>
<seg id="1273">"" "" "" "approval by Ipsen Pharma 24 rue Erlanger F-75781 Paris Cedex 16 France Tél: + 33 - 1 - 44 96 13 13" "" "" ""</seg>
<seg id="1274">Danmark Norge and Norge (IPSEN) AB Kista Science Tower Farodatan 33 SE - 164 51 Kista Sverige / Ruotsi / Svíþjóller Tel / Tlf / Puh / Sími: + 46 8 588 370 70</seg>
<seg id="1275">ADROVANCE is used to treat osteoporosis (a disease in which the bones become brittle) in women after menopause when there is a risk of low vitamin D levels.</seg>
<seg id="1276">"" "" "" "the patient must take the tablet with a full glass of water (no mineral water) at least 30 minutes before eating, drinking or taking other medicines (including antacids, calcium and vitamin supplements)." "" "" ""</seg>
<seg id="1277">"" "" "" "to avoid irritation of the esophagus, the patient must not lie down until after the first food intake of the day, which should take place at least 30 minutes after taking the tablet." "" "" ""</seg>
<seg id="1278">"" "" "" "as Alendronate and vitamin D3 are already used separately in medicines which are approved in the European Union, the company presented data originating from previous studies and published literature." "" "" ""</seg>
<seg id="1279">The company also conducted a study of 35 men and 682 postmenopausal women with osteoporosis in order to demonstrate the efficacy of ADROVANCE in relation to increasing vitamin D levels.</seg>
<seg id="1280">"" "" "" "after a 15-week treatment, the proportion of patients with low vitamin D levels in patients treated with ADROVANCE was lower (11%) than those who only took Alendronate income (32%)." "" "" ""</seg>
<seg id="1281">"" "" "" "the company also presented data suggesting that the Alendronat dose contained in ADROVANCE corresponds exactly to the dose, which is required to prevent bone loss." "" "" ""</seg>
<seg id="1282">"" "" "" "the most common side effects (observed in 1 to 10 of 100 patients) are headaches, pain of the musculoskeletal system like abdominal pain, dysphagia, ulceration (ulceration), battered abdomen, diarrhea, as well as acidic irritation." "" "" ""</seg>
<seg id="1283">"" "" "" "in patients with any hypersensitivity to alendronate, vitamin D3 or any of the other components ADROVANCE must not be applied." "" "" ""</seg>
<seg id="1284">"" "" "" "it may not be used in diseases of the oesophagus, in patients with hypocalcemia (low calcium levels) or in patients who cannot stand or sit for at least 30 minutes." "" "" ""</seg>
<seg id="1285">"" "" "" "in January 2007, the European Commission granted the company Merck Sharp & Dohme Ltd. approval for placing ADROVANCE across the European Union." "" "" ""</seg>
<seg id="1286">"" "" "" "capsular, white to broken white tablets, marked with the outline of a bone on one side and" 710 "on the other side." "" "" ""</seg>
<seg id="1287">"" "" "" "ADROVANCE can only be taken with water (not with mineral water) at least 30 minutes before the first meal, drink or intake of medicines (including antacids, calcium and vitamin supplements) for the day." "" "" ""</seg>
<seg id="1288">"" "" "" "the following hints must be followed carefully, in order to reduce the risk of adverse reactions and associated side effects (see paragraph 4.4):" "" "" ""</seg>
<seg id="1289">• ADROVANCE should only be swallowed with a full glass of water (at least 200 ml) after getting up the day. • The patients should not chew the tablet or melt the tablet in the mouth because a risk for oropharyngeal ulcera is to take place.</seg>
<seg id="1290">"" "" "" "B. peptic ulcer, active gastrointestinal bleeding or surgical interventions in the upper gastrointestinal tract except pyloroplasty, can only be given with particular caution (see section 4.3)." "" "" ""</seg>
<seg id="1291">"" "" "" "esophageal reactions, such as esophagitis, esophageal ulcera and esophageal erosion, were rarely reported in patients under the seizure of Alendronat (some of them were severe and required hospitalization)." "" "" ""</seg>
<seg id="1292">The doctor should therefore pay attention to any signs and symptoms that point to possible allergic reactions such as dysphagia or pain when swallowing or retroviral pain or new or worsening heartburn the medicine and to get medical advice (see section 4.8).</seg>
<seg id="1293">"" "" "" "3 The risk of severe adverse side effects appears to be increased in patients who do not take the medicine correctly and / or, after the occurrence of symptoms that point to an esophageal irritation, continue to take." "" "" ""</seg>
<seg id="1294">It is very important that all dosage instructions are passed on to the patient and be understood by the patient (see Section 4.2).</seg>
<seg id="1295">"" "" "" "during large-scale clinical trials with alendronate no elevated risk was detected (after market introduction) stomach and duodenal ulcera, including some severe and complications (see Section 4.8)." "" "" ""</seg>
<seg id="1296">Osteoecsis of the jaw - commonly associated with tooth extraction and / or a local infection (including osteoelitis) was reported in cancer patients whose therapeutic regimen predominantly administered intravenous bisphosphonate.</seg>
<seg id="1297">"" "" "" "there are no data available to indicate whether the treatment of bisphosphonate therapy in patients who require a maxillary surgery, reduces the risk of osteoecsis of the jaw." "" "" ""</seg>
<seg id="1298">"" "" "" "the clinical assessment by the treating physician is decisive for therapy planning for each patient, based on an individual benefit risk assessment." "" "" ""</seg>
<seg id="1299">"" "" "" "patients need to be instructed that they should take a dose of ADROVANCE the tablet in the next morning, after having noticed their failure." "" "" ""</seg>
<seg id="1300">"" "" "" "you should not take two tablets the same day, but keep taking one tablet a week as originally planned for the day of the week." "" "" ""</seg>
<seg id="1301">Other diseases affecting the metabolism of minerals (such as vitamin D deficiency and hypoparathyreoidism) should also be adequately handled with ADROVANCE prior to treatment.</seg>
<seg id="1302">"" "" "" "alendronate foods and beverages (including mineral water), calcium supplements, antacids and some oral drugs can interfere with the absorption of alendronate if they are taken at the same time." "" "" ""</seg>
<seg id="1303">"" "" "" "therefore, after taking Alendronat, patients must wait at least 30 minutes before taking other medicines (see Sections 4.2 and 5.2)." "" "" ""</seg>
<seg id="1304">"" "" "" "although specific interaction studies were not carried out, alendronate was used in clinical trials together with a variety of commonly prescribed medicines without clinically relevant interactions." "" "" ""</seg>
<seg id="1305">ADROVANCE is intended only for use in postmenopausal women and is therefore not applicable during pregnancy or by nursing women.</seg>
<seg id="1306">Animal studies with alendronate leave no indication of directly damaging effects in relation to pregnancy that detect embryonic / fetal or postnatal development.</seg>
<seg id="1307">Osteoecsis of the jaw was reported in patients with bisphosphonates; most reports are from cancer patients but was also reported in osteoporosis.</seg>
<seg id="1308">"" "" "" "nevertheless, deviation from serum calcium to &lt; 8.0 mg / dl (2.0 mmol / l) and serum levels of serum up to ≤ 2.0 mg / dl (0,65 mmol / l) in both treatment groups with a similar frequency." "" "" ""</seg>
<seg id="1309">"" "" "" "alendronate Insequence of a oral overdose can occur hypocalcemia, hypophosphatemia and side effects in the upper Gastrointestinal tract such as stomach upset, heartburn, oesophagitis, gastritis or ulcera." "" "" ""</seg>
<seg id="1310">Colecalciferol (vitamin D3) Vitamin D3 is produced in the skin through UV light on the conversion of 7-Dehydromes to vitamin D3.</seg>
<seg id="1311">"" "" "" "the main effect of 1.25 Dihydroxyproxyprovitamin D3 is the increase in the intestinal absorption of calcium and phosphate, and the regulation of serum calcium, the renal excretion of calcium and phosphate, bone formation and bone resorption." "" "" ""</seg>
<seg id="1312">"" "" "" "in severe cases, secondary hyperparathyreoidism, hypophosphatemia, weakness of the proximal musculature and osteomalacia can lead to increased risk of falls and osteoporosis." "" "" ""</seg>
<seg id="1313">"" "" "" "bone mineral density) on spine or hip, the 2.5 standard deviations below average for a normal, young population, or irrespective of bone density as present pathological fracture." "" "" ""</seg>
<seg id="1314">Patients received ADROVANCE in lower strength (70 mg / 2.800 I.U.) (n = 350) or Fosamax (Alendronat) 70 mg once a week (n = 332); other vitamin D supplements were prohibited.</seg>
<seg id="1315">After 15 weeks of treatment the average serum levels of 25-hydroxylic D were significantly higher (26%) in the group under ADROVANCE (70 mg / 2.800 I.U.) than in the group below Alendronat alone (46 nmol / l [18.2 ng / ml]).</seg>
<seg id="1316">ADROVANCE (70 mg / 2.800 I.U.) significantly lowered the share of patients with vitamin D insufficiency (serum value of 25-hydroxylic D &lt; 37.5 nmol / l [&lt; 15 ng / ml]) by 62.5% compared to alendronate alone (12% vs.</seg>
<seg id="1317">The therapeutic equivalence of alendronate once a week 70 mg (n = 519) and alendronat 10 mg daily (n = 370) was demonstrated in a one-year multi-centre study of postmenopausal women with osteoporosis.</seg>
<seg id="1318">The effects of alendronate on bone mass and fracture in postmenopausal women were studied in two phase III studies of identical design (n = 944) as well as in the fracture intervention trial (FIT: n = 6.459).</seg>
<seg id="1319">"" "" "" "in the Phase III studies, the middle ascents of BMD amounted to 10 mg / day compared to placebo after 3 years 8.8% on the spine, 5.9% at the femur and 7.8% at the Trochanter." "" "" ""</seg>
<seg id="1320">"" "" "" "in the group treated with Alendronate, a reduction of 48% (Alendronat 3.2% compared to placebo 6.2%) was achieved in the proportion of patients suffering from one or more vertebrates." "" "" ""</seg>
<seg id="1321">"" "" "" "in the two-year extension of these studies, the ascents of the BMD of spine and trochanter continued to maintain; the BMD of the femur neck and the entire body was maintained." "" "" ""</seg>
<seg id="1322">"" "" "" "fit consisted of two placeboat trials, where Alendronate was taken daily (5 mg daily for 2 years and thereafter 10 mg daily, either over 1 or 2 years):" "" "" ""</seg>
<seg id="1323">"" "" "" "in this study, the daily administration of Alendronate reduced the appearance of at least one new vertebrate fracture by 47% (Alendronat 7.9% compared to placebo 15.0%)." "" "" ""</seg>
<seg id="1324">Resorption Behrined to an intravenous reference dose for women 0.64% for doses ranging from 5 to 70 mg after nocturnal fasting and two hours before taking a standardized breakfast.</seg>
<seg id="1325">Bio availability decreased accordingly to about 0.46% and 0.39% when Alendronat was taken one or half an hour before a standardised breakfast.</seg>
<seg id="1326">"" "" "" "in osteoporosis, alendronate was effective when it was taken at least 30 minutes before the first meal or drink of the day." "" "" ""</seg>
<seg id="1327">"" "" "" "in healthy subjects, oral prednisone (20 mg three times daily over five days) resulted in no clinically significant change in oral bio availability of alendronate (increase in average 20% to 44%)." "" "" ""</seg>
<seg id="1328">"" "" "" "9 distribution studies on rats have shown that Alendronate is distributed in soft tissue after intravenous administration of 1 mg / kg, but then quickly dispersed into the bone or excreted with the urine." "" "" ""</seg>
<seg id="1329">"" "" "" "after intravenous administration of a single dose of 14C-alendronate, about 50% of the radioactive substance identified within 72 hours with urine was excreted and little or no radioactivity was found in the feces." "" "" ""</seg>
<seg id="1330">"" "" "" "after intravenous administration of a single dose of 10 mg, the renal clearing of Alendronat was 71 ml / min and systemic clearing not exceeding 200 ml / min." "" "" ""</seg>
<seg id="1331">"" "" "" "in rats, Alendronate is not excreted via the kidneys or alkaline transport system of the kidneys and is therefore not accepted that it affects the excretion of other medicines by these transport systems." "" "" ""</seg>
<seg id="1332">Resorption In healthy adult subjects (women and men) after nightly fastings and two hours before taking a meal the middle surface below the serum concentration time curve (AUC0-120 h) for vitamin D3 296.4 ng • h / ml (without considering endogenous vitamin D3 levels).</seg>
<seg id="1333">The average maximum concentration in serum (CMAx) of vitamin D3 was 5.9 ng / ml and the median time until reaching the maximum serum concentration (Tmax) 12 hours.</seg>
<seg id="1334">"" "" "" "biotransformation Vitamin D3 is rapidly hydroxylic in the liver, and then metabolized in the kidneys to 1.25 Dihydroxyprovitamin D3, the biologically active form." "" "" ""</seg>
<seg id="1335">"" "" "" "excretion When using radioactively marked vitamin D3 in healthy subjects, the average excretion of radioactivity in the urine amounted to 2.4% in the urine after 4 days 4.9%." "" "" ""</seg>
<seg id="1336">"" "" "" "characteristics in patients Preclinical studies have shown that the portion of Alendronate, which is not deposited in the bone, is quickly excreted from the urine." "" "" ""</seg>
<seg id="1337">"" "" "" "although there are no clinical data on it, the elimination of alendronate as in animal experiments is also reduced in patients with reduced renal function." "" "" ""</seg>
<seg id="1338">"" "" "" "therefore, in patients with reduced renal function a slightly increased cumulation of alendronate can be expected in the bone (see section 4.2)." "" "" ""</seg>
<seg id="1339">"" "" "" "Alendronat non-clinical data based on conventional studies on safety macology, chronic toxicity, genotoxicity and carcinogenic potential do not allow specific dangers to humans." "" "" ""</seg>
<seg id="1340">Studies in rats showed that the gift of Alendronate was accompanied by pregnant rats with the appearance of dystokie in the mother animals that was due to a hypocalcemia.</seg>
<seg id="1341">Microcrystalline Cellulose (E 460) Lactose Low-chain triglyceride gelatine Croscarmless sodium hydroxylontoluene (E 321) starch, modified (corn) aluminum sodium silicate (E 554)</seg>
<seg id="1342">"" "" "" "case with sealed aluminium / aluminium blister packs in cartons with 2 tablets, 4 (1 equinis with 4 tablets), 6 (3 suretis with 4 tablets) or 40 (10 tuis with 4 tablets) tablets." "" "" ""</seg>
<seg id="1343">EU / 1 / 06 / 364 / 001 - 2 tablets EU / 1 / 06 / 364 / 002 - 6 tablets EU / 1 / 06 / 364 / 004 - 12 tablets EU / 1 / 06 / 364 / 005 - 40 tablets</seg>
<seg id="1344">"" "" "" "rectangular, white to broken white tablets, marked with the outline of a bone on one side and" 270 "on the other." "" "" ""</seg>
<seg id="1345">13. patients should not be allowed to take ADROVANCE for at least 30 minutes after taking ADROVANCE. • ADROVANCE should not be taken before bedtime or before the first rise of the day.</seg>
<seg id="1346">"" "" "" "the risk of severe adverse side effects appears to be increased in patients who do not take the medicine correctly and / or, after the occurrence of symptoms that point to an esophageal irritation, continue to take." "" "" ""</seg>
<seg id="1347">"" "" "" "during large-scale clinical trials with alendronate no elevated risk was detected (after market introduction) stomach and duodenal ulcera, including some severe and complications (see Section 4.8)." "" "" ""</seg>
<seg id="1348">18 colecalciferol (vitamin D3) Vitamin D3 is produced in the skin through UV light on the conversion of 7-Dehydromes to vitamin D3.</seg>
<seg id="1349">Patients received ADROVANCE in lower strength (70 mg / 2.800 I.U.) (n = 350) or Fosamax (Alendronat) 70 mg once a week (n = 332); other vitamin D supplements were prohibited.</seg>
<seg id="1350">Vitamin D3 (the amount of vitamin D3 in the higher dose of ADROVANCE) once a week was shown in a 24 week extension study involving 619 postmenopausal women with osteoporosis.</seg>
<seg id="1351">After 24 weeks treatment the average serum levels of 25-hydroxyvitamin D were significantly higher in the 5.600-I.E. vitamin D3 group (69 nmol / l [25.6 ng / l [25.6 ng / ml]).</seg>
<seg id="1352">There was no statistically significant difference between treatment groups in patients with hypercalciuria at the end of the 24 week extension.</seg>
<seg id="1353">"" "" "" "3.1% on the whole hip in the group with 70 mg once a week, and at 10 mg. a day." "" "" ""</seg>
<seg id="1354">"" "" "" "in this study, the daily administration of Alendronate reduced the appearance of at least one new vertebrate fracture by 47% (Alendronat 7.9% compared to placebo 15.0%)." "" "" ""</seg>
<seg id="1355">Bio availability decreased accordingly to about 0.46% and 0.39% if Alendronat was one or half an hour before a standardised breakfast.</seg>
<seg id="1356">"" "" "" "distribution studies on rats have shown that Alendronate is distributed in soft tissue after intravenous administration of 1 mg / kg, but then quickly dispersed into the bone or excreted with the urine." "" "" ""</seg>
<seg id="1357">Resorption In healthy adult subjects (women and men) after nocturnal fasting and two hours before taking a meal the middle surface below the serum concentration time curve (AUC0-80 h) for vitamin D3 490.2 ng • h / ml (without considering endogenous vitamin D3 levels).</seg>
<seg id="1358">Mean maximum concentration in serum (CMAx) of vitamin D3 was 12.2 ng / ml and the median time until reaching the maximum serum concentration (Tmax) 10.6 hours.</seg>
<seg id="1359">"" "" "" "smaller amounts are distributed in fat and muscle tissue, and are stored there as vitamin D3 to be released into the circulation afterwards." "" "" ""</seg>
<seg id="1360">"" "" "" "21 vitamin D3 is rapidly hydroxylic in the liver, and then metabolized in the kidneys to 1.25 Dihydroxyprovitamin D3, the biologically active form." "" "" ""</seg>
<seg id="1361">No evidence was found to satiate the absorption capacity of the bone after long-term dose of cumulative intravenous doses of up to 35 mg / kg in animals.</seg>
<seg id="1362">Case with sealed aluminium / aluminium blister packs in cartons to 2 (1 bucket with 2 tablets); 4 (1 case with 4 tablets) or 40 (10 tuis with 4 tablets) or 40 (10 tablets with 4 tablets) tablets.</seg>
<seg id="1363">"" "" "" "Pharmacovigilance System The holder of approval for the transport sector has to ensure that a drug vigilance system is described as described in version 2 module 1.8.1 of the approval documents, and so long is available how the marketed drug is brought into circulation." "" "" ""</seg>
<seg id="1364">Risk management plan The holder of approval for placing on the market is committed to carrying out studies and other pharmacovigilance activities of the pharmacovigilance plan described in the risk management plan (RMP) and its corresponding updates according to version 1 module 1.8.2 of the approval documents.</seg>
<seg id="1365">"" "" "" "according to the CHMP Guideline, an updated RMP is preferable to risk management systems for human medicines with the next Periodic Saftey Update Report (PSUR)." "" "" ""</seg>
<seg id="1366">"" "" "" "additionally an update of the RMP is required − when new information is available, which have an impact on the safety data, pharmacovigilance plan or risk minimization within 60 days (pharmaceutical vigilance or risk minimization) − on request of the EMEA" "" "" ""</seg>
<seg id="1367">Take an ADROVANCE tablet after getting up and before the first meal and drink and before taking any other medicines by swallowing the tablet with a full glass of water (not chewing and sputching).</seg>
<seg id="1368">"" "" "" "if you have any further questions, please contact your doctor or pharmacist." "" "" ""</seg>
<seg id="1369">"" "" "" "in the menopause, ovaries no longer produce female hormones, estrogen, more that help to preserve the skeleton of women healthily." "" "" ""</seg>
<seg id="1370">"" "" "" "the breaks are usually caused by hip, spine or wrist and can cause considerable problems such as bent posture (" widobuckel ") and a loss of flexibility." "" "" ""</seg>
<seg id="1371">"" "" "" "ADROVANCE does not only prevent loss of bone mass, but also helps reduce bone loss and reduce the risk of spinal and hip fractures." "" "" ""</seg>
<seg id="1372">Constriction of esophagus or swallowing problems (3) if it is not possible to sit or stand upright for at least 30 minutes (4) if your doctor has noticed that your calcium content is low in the blood.</seg>
<seg id="1373">"" "" "" "40 • If you have problems swallowing or with digesting, if you have cancer, • if you have cancer, if you have cancer, if you do not take steroids (corticosterate), if you do not routinely go to your dental provisioning." "" "" ""</seg>
<seg id="1374">"" "" "" "these complaints may occur in particular, if the patients do not take the ADROVANCE tablet with a full glass of water and / or sit before the expiry of 30 minutes after taking." "" "" ""</seg>
<seg id="1375">"" "" "" "taking ADROVANCE with other medicines calcium supplements, antacids and some other medicines to take in may obstruct the efficacy of ADROVANCE while taking medication." "" "" ""</seg>
<seg id="1376">"" "" "" "certain medicines or food additives may interfere with the absorption of vitamin D contained in ADROVANCE including artificial fat replacement materials, mineral oils, orlistat and the cholesterol lowering drug Cholestyramine and Colestipol." "" "" ""</seg>
<seg id="1377">"" "" "" "please inform your doctor or pharmacist if you are taking other medicines / applied / applied recently, even if it is not prescription medicine." "" "" ""</seg>
<seg id="1378">"" "" "" "if you are aware of intolerance to certain sugars, please take this medicine only after consultation with your doctor." "" "" ""</seg>
<seg id="1379">Please follow the instructions 2) (3) and 5) to facilitate the transport of the ADROVANCE tablet into the stomach and to reduce possible irritation of the esophagus (esophagus - the tube that connects your mouth with the stomach).</seg>
<seg id="1380">(2) Take the ADROVANCE tablet once before and before taking any foods or beverages as well as taking any other medicines with a full glass (at least 200 ml) water (not with mineral water). • Do not take with mineral water (with or without carbonic acid). • Do not take with juice or milk.</seg>
<seg id="1381">"" "" "" "(3) Do not lie down - stay completely erect (sitting, standing or walking) - at least 30 minutes after taking the tablet." "" "" ""</seg>
<seg id="1382">"" "" "" "(5) If there are difficulties or pain when swallowing, pain behind the sternum, new or worsening heartburn, use ADROVANCE and look for your doctor." "" "" ""</seg>
<seg id="1383">"" "" "" "(6) Wait after swallowing your ADROVANCE tablet at least 30 minutes before you take your first food, beverages or other medicines such as antacids (magenacidic medicines), calcium or vitamin supplements this day." "" "" ""</seg>
<seg id="1384">"" "" "" "if you have accidentally taken too many tablets at once, drink a full glass of milk and contact your doctor immediately." "" "" ""</seg>
<seg id="1385">"" "" "" "if you miss taking a tablet, just take one tablet the next morning after you noticed your failure." "" "" ""</seg>
<seg id="1386">"" "" "" "frequent pain when swallowing, swelling of the esophagus (esophagus - the tube that connects your mouth with your stomach), pain in chest, heartburn and pain or discomfort while swallowing." "" "" ""</seg>
<seg id="1387">"" "" "" "occasionally: nausea, vomiting, irritation and inflammation of the esophagus (esophagus - the tube that connects your mouth with your stomach) or the stomach mucosa, • black or teerlike chair; skin rash; itch; redness." "" "" ""</seg>
<seg id="1388">"" "" "" "following the market introduction the following side effects reported (frequency not known): • (rotation) dizziness, • fatigue, • Hair Loss, • jaw problems (osteoecsis), often after pulling teeth, • swelling of hands or legs." "" "" ""</seg>
<seg id="1389">"" "" "" "43 Dabei, it's helpful to note which complaints you had when they began and how long they stopped." "" "" ""</seg>
<seg id="1390">"" "" "" "the other components are microcrystalline Cellulose (E 460), lactose, medium-chain triglyceride, gelatine, elliphydroxytoluene (Ph.Eur.) (E 321), starch, modified (corn), and aluminium sodium silicate (E 554)." "" "" ""</seg>
<seg id="1391">The tablets are available in cartons with sealed aluminium / aluminium blister packs in cartons with 2 tablets (1 case with 4 tablets in aluminium blister packs) • 6 tablets (3 Etuis with 4 tablets in aluminium blister packs) • 40 tablets (10 tuis with 4 tablets in aluminium blister packs).</seg>
<seg id="1392">"" "" "" "in the menopause, ovaries no longer produce female hormones, estrogen, more that help to preserve the skeleton of women healthily." "" "" ""</seg>
<seg id="1393">"" "" "" "48 • If you have allergies, if you have problems with swallowing or with the digestion, if you have cancer, if you have cancer, if you have cancer, if you do not take steroids (corticosterate), if you do not routinely go to your dental provisioning." "" "" ""</seg>
<seg id="1394">"" "" "" "taking ADROVANCE with other medicines calcium supplements, antacids and some other medicines to take in may obstruct the efficacy of ADROVANCE while taking medication." "" "" ""</seg>
<seg id="1395">2) Take the ADROVANCE tablet once before and before taking any foods or beverages as well as taking any other medicines with a full glass (at least 200 ml) water (not with mineral water). • Do not take with mineral water (with or without carbonic acid). • Do not take with juice or milk.</seg>
<seg id="1396">"" "" "" "3) Do not lie down - stay fully erect (sitting, standing or walking) - at least 30 minutes after taking the tablet." "" "" ""</seg>
<seg id="1397">"" "" "" "5) If there are difficulties or pain when swallowing, pain behind the sternum, new or worsening heartburn, use ADROVANCE and look for your doctor." "" "" ""</seg>
<seg id="1398">"" "" "" "6) Wait after swallowing your ADROVANCE tablet at least 30 minutes before you take your first food, beverages or other medicines such as antacids (magenacidic medicines), calcium or vitamin supplements this day." "" "" ""</seg>
<seg id="1399">"" "" "" "• (turning) dizziness, • swellings, • fatigue, • hair loss, • jaw problems (osteoecsis) in connection with delayed wound healing and infections, often after pulling teeth, • swelling of hands or legs." "" "" ""</seg>
<seg id="1400">"" "" "" "tablets are available as rectangular, white to broken white tablets, marked with the outline of a bone on one side and" 270 "on the other." "" "" ""</seg>
<seg id="1401">"" "" "" "in addition, an adult patient is administered to allow kidney transplants to be repulsed by the immune system." "" "" ""</seg>
<seg id="1402">"" "" "" "since Tacrolimus and Prograf / Prograft are already used in the EU, the company has presented the results of previously carried out studies with Prograf / Prograft as well as data from published literature." "" "" ""</seg>
<seg id="1403">"" "" "" "in addition, the results of a clinical study were submitted to 668 patients with kidney transplant, compared with Prograf / Prograft or Ciclosporin." "" "" ""</seg>
<seg id="1404">"" "" "" "the main indicator of efficacy was the number of patients in which the graft was rejected after a period of treatment (for example, by examining how often a renewed organ transplant or resumption of dialysis was required)." "" "" ""</seg>
<seg id="1405">"" "" "" "in addition, shorter further studies in 119 patients with kidney transplant and 129 patients were performed with liver transplant and examined how Advagraf is absorbed by the body compared to Prograf / Prograft." "" "" ""</seg>
<seg id="1406">"" "" "" "tremor (tremor), headache, nausea, vomiting, diarrhoea (diarrhea), diabetes, increased potassium content (hypertension), high blood pressure (hypertension) as well as insomnia (insomnia)." "" "" ""</seg>
<seg id="1407">"" "" "" "in patients with any hypersensitivity (allergy) against tacrolimus, macrolide antibiotics (such as erythromycin) or any of the other ingredients may not be used." "" "" ""</seg>
<seg id="1408">"" "" "" "patients and doctors must be careful if other (especially some herbal) medicines have to be taken at the same time, as the dose or dose of the medication taken at the same time must be adjusted accordingly." "" "" ""</seg>
<seg id="1409">"" "" "" "hard capsules, retarded yellow-orange gelatine capsules, printed in red ink on the light yellow cape top with" 0.5 mg "and on the orange capsular bottom with" "" "" "" "647" "" "" "" "; they contain white powder." "" "" ""</seg>
<seg id="1410">Only doctors who are familiar with the immunosuppressive therapy and the treatment of transplant patients should prescribe this medicine or make changes in immunosuppressive therapy.</seg>
<seg id="1411">"" "" "" "due to clinically relevant differences in systemic exposure to tacrolimus, this can lead to graft rejection or increased incidence of side effects including under- or overimmunosuppression." "" "" ""</seg>
<seg id="1412">Patients should always keep the same tacrolimus formulation and daily dosage; Modification of the formulation or regime should only be carried out under the close control of a medical device experienced in the transplant (see Sections 4.4 and 4.8).</seg>
<seg id="1413">"" "" "" "as a result of a transition to an alternative formulation, a therapeutic monitoring and appropriate dose adjustments must be carried out to ensure that the systemic exposure to tacrolimus remains intact." "" "" ""</seg>
<seg id="1414">"" "" "" "the dose of Advagraf should be based primarily on the clinical assessment of rejection and tolerability in individual cases, and on blood-level provisions (see below" Recommendations "" "" "" ""</seg>
<seg id="1415">"" "" "" "after converting Prograf to Advagraf, the Tacrolimus valley level should be controlled before switching over and over two weeks after conversion." "" "" ""</seg>
<seg id="1416">"" "" "" "on Day 4, the systemic exposure measured as a valley mirror, comparable to both kidney and liver transplant patients." "" "" ""</seg>
<seg id="1417">Careful and repeated controls of the Tacrolimus valley level are recommended during the first two weeks after transplanting under Advagraf to ensure proper substance exposure in the immediate nocturnal transition phase.</seg>
<seg id="1418">"" "" "" "because tacrolimus is a substance with low clearing, an adjustment of the pre-dose can take several days until the Steady State is reached." "" "" ""</seg>
<seg id="1419">"" "" "" "if the patient's condition in the first postoperative period does not allow oral use of medicines, the Tacrolimus treatment can be initiated intravenously (Prograf 5 mg / ml concentrate for the production of an infusion solution) with a dose of ca." "" "" ""</seg>
<seg id="1420">"" "" "" "duration of application To suppress graft rejection, immunosuppression has to be maintained; consequently, maximum duration of oral therapy cannot be given." "" "" ""</seg>
<seg id="1421">"" "" "" "dose recommendations - kidney transplant prophylaxis of graft rejection. oral Adventurf treatment should start with 0,20 - 0,30 mg / kg / day as a daily gift in the morning." "" "" ""</seg>
<seg id="1422">"" "" "" "further can adjustments may be necessary later, as the pharmacokinetic of tacrolimus can change in the course of stabilisation of the patient after transplantation." "" "" ""</seg>
<seg id="1423">Dose recommendations - liver transplant prophylaxis of graft rejection The oral Adventurf therapy should start with 0.10 - 0.20 mg / kg / day as a daily gift in the morning.</seg>
<seg id="1424">"" "" "" "dosage recommendation - switching from Prograf to Adventurf must be converted to a daily dose of Prograf capsules on a daily intake of Prograf capsules, related to the total daily dose." "" "" ""</seg>
<seg id="1425">"" "" "" "after switching from other immunosuppressants to Advagraf once a day, the treatment with the oral initialdose of kidney and liver transplantation must begin once a day for the prevention of graft rejection." "" "" ""</seg>
<seg id="1426">"" "" "" "heart transplant At adult patients who are converted to Advagraf, an oral initial dose of 0,15 mg / kg / day is taken once daily in the morning." "" "" ""</seg>
<seg id="1427">Other graft recipients objected to an oral initial dose of 0.10 - 0.15 mg / kg / day in an oral initial dose of 0.2 mg / kg / day and with colorectal transplant recipients in an oral initial dose of 0.3 mg / kg / day.</seg>
<seg id="1428">"" "" "" "in patients with severe liver dysfunction in patients with severe liver dysfunction, dosage adjustment in specific patient groups can be necessary for patients with severe liver dysfunction." "" "" ""</seg>
<seg id="1429">Patients with reduced kidney function Since the renal function does not affect the pharmacokinetic of tacrolimus it can be assumed that a can adjustment is not necessary.</seg>
<seg id="1430">"" "" "" "however, due to the nephrotoxic potential of tacrolimus, careful observation of the renal function (including a regular determination of serum cholesterol and a calculation of the urine volume) is recommended." "" "" ""</seg>
<seg id="1431">Conversion from Ciclosporin to Advagraf In the conversion of a Ciclosporin to a tacrolimus-based therapy is advisable (see Sections 4.4 and 4.5).</seg>
<seg id="1432">"" "" "" "the dose should be based primarily on the clinical assessment of rejection and tolerability in individual cases, with the aid of full-blood-tacrolimus-talc controls." "" "" ""</seg>
<seg id="1433">"" "" "" "it is recommended to perform common monitoring of the Tacrolimus valley level during the first two weeks after transplant, followed by periodic checks during maintenance therapy." "" "" ""</seg>
<seg id="1434">"" "" "" "tacrolimus blood-level mirrors should also be controlled after switching from Prograf to Adventurf, dose adjustment, changes in immunosuppressive therapy or concurrent use of substances which could change the Tacrolimus-blood concentration." "" "" ""</seg>
<seg id="1435">"" "" "" "since advent is a medicine with a low clearing, adjustments of the dose may require several days until the Steady State has entered." "" "" ""</seg>
<seg id="1436">"" "" "" "the indications in clinical studies suggest that successful treatment is possible in most cases, if the blood level of the blood does not exceed 20 ng / ml." "" "" ""</seg>
<seg id="1437">"" "" "" "in clinical practice, tacrolimus and blood transplants usually lie within 5 - 20 ng / ml and heart transplanted patients at 10 - 20 ng / ml." "" "" ""</seg>
<seg id="1438">"" "" "" "during the subsequent maintenance therapy of liver, kidney and heart transplant recipients, blood concentrations in the range of 5 - 15 ng / ml were usually used." "" "" ""</seg>
<seg id="1439">"" "" "" "this has caused serious adverse events, including graft rejection or other side effects, which may result in tacrolimus under- or overexposure." "" "" ""</seg>
<seg id="1440">Patients should always keep the same tacrolimus formulation and daily dosage; Modification of the formulation or regime should only be carried out under the close control of a medical device experienced in the transplant (see Sections 4.2 and 4.8).</seg>
<seg id="1441">"" "" "" "5 For the treatment of adult patients with graft rejection, which proved to be resistant to other immunosuppressants, there are no clinical data for the retarated formulation Advagraf." "" "" ""</seg>
<seg id="1442">There are still no clinical data for the retarated formulation Advagraf available for prophylaxis of graft rejection in adult heart transplant recipients and graft recipients.</seg>
<seg id="1443">"" "" "" "because of possible interactions that may lead to lowering the Tacrolimus levels in the blood and weakening of the clinical effects of tacrolimus, the intake of herbal supplements containing St. John's wort (Hypericum perforatum) or other herbal remedies during a treatment with Advagraph (see section 4.5)." "" "" ""</seg>
<seg id="1444">"" "" "" "in patients with diarrhoea, a particularly careful monitoring of the Tacrolimus concentrations in the blood is advisable, as the Tacrolimus blood levels may be subject to considerable variations in such circumstances." "" "" ""</seg>
<seg id="1445">"" "" "" "in rare cases, a hypertrophy called cardiomyopathy was observed under Prograf, which can therefore also occur under Advagraf." "" "" ""</seg>
<seg id="1446">"" "" "" "other factors that increase the risk of such clinical disorders are an already existing heart disease, a treatment with corticosteroids, high blood pressure, kidney or liver dysfunction, infections, fluid overload and edema." "" "" ""</seg>
<seg id="1447">"" "" "" "as with other immunosuppressants, exposure to sunlight or UV light should be restricted due to the possible risk of malignant skin lesions due to suitable clothing or use of sun protection with a high protection factor." "" "" ""</seg>
<seg id="1448">"" "" "" "if patients suffering from tacrolimus, symptoms for PRES such as headaches, altered state of consciousness, cramps and blurred vision should show a radiological examination (e.g.." "" "" ""</seg>
<seg id="1449">"" "" "" "there are special caution in patients with rare hereditary lactose intolerance, lactase deficiency or glucose galactose malabsorption." "" "" ""</seg>
<seg id="1450">The simultaneous use of medicines or herbal remedies known as inhibitors or inductors of CYP3A4 can influence the metabolism of tacrolimus and therefore increase or lower the blood values of tacrolimus.</seg>
<seg id="1451">"" "" "" "therefore, it is recommended to monitor the Tacrolimus blood levels while using substances that can change the CYP3A's metabolism and adjust the Tacrolimus dose to maintain uniform concentrations (see Sections 4.2 and 4.4)." "" "" ""</seg>
<seg id="1452">A strongly pronounced alternation was associated with antimycotics such as ketoconazole and Itraconazole and Voriconazole as well as with the Macrolid antibiotic erythromycin and HIV proteasema (z.</seg>
<seg id="1453">"" "" "" "pharmacokinetic studies have resulted in the increase in blood levels mainly from the increased oral bioavailability of tacrolimus, due to the inhibition of gastrointestinal degradation." "" "" ""</seg>
<seg id="1454">"" "" "" "high-dose prednisolone or methylprednisolone, as used in acute rejection reactions, can increase or lower the concentration of tacrolimus in the blood." "" "" ""</seg>
<seg id="1455">The effect of tacrolimus on the metabolism of other medicines Tacrolimus is known as CYP3A4 inhibitor; therefore the simultaneous use of tacrolimus with medicines which are metabolized by CYP3A4 can interfere with their metabolism.</seg>
<seg id="1456">"" "" "" "because tacrolimus can reduce the clearing of steroid Contrictiva and thus increase hormone expositions, decisions regarding contraception can be particularly cautious." "" "" ""</seg>
<seg id="1457">The results of animal studies have shown that tacrolimus can potentially reduce the clearing of pentobarbital and phenazon and prolong their half-life.</seg>
<seg id="1458">The results of a small number of transplantation patients have no indication that under Tacrolimus there is an increased risk of adverse events with regard to the course and outcome of pregnancy.</seg>
<seg id="1459">"" "" "" "in utero exposure, a monitoring of the newborn is recommended for possible adverse effects of tacrolimus (especially for its effect on the kidneys)." "" "" ""</seg>
<seg id="1460">"" "" "" "there is the risk of premature birth (&lt; week 37) and a hypercalemia of the newborn (incidence 8 of 111 newborn, i.e.:" "" "" ""</seg>
<seg id="1461">The side effect profile of immunosuppressiva is often not exactly determined because of the disease of the patient and the simultaneous treatment with a variety of other medicines.</seg>
<seg id="1462">"" "" "" "the side effects following their frequency are outlined in descending order: very common (≥ 1 / 100, ≤ 1 / 100), rare (≥ 1 / 10,000, ≤ 1 / 100), very rare (≥ 1 / 10,000, ≤ 1 / 100)." "" "" ""</seg>
<seg id="1463">"" "" "" "ischemic disorders of the coronary vessels, tachycardia and cardiac arrest, heart failure, myocardiopathy, palpitatio, anomalies in ECG, abnormal heart rate and heart rate" "" "" ""</seg>
<seg id="1464">"" "" "" "diarrhea, nausea, intestinal inflammation, gastrointestinal ulcer and perforation, bleeding from the gastrointestinal tract, stomatitis and ulceration, dyspeptic signs and symptoms, obstpation, flatulence, flatulence, signs and symptoms in the gastrointestinal area" "" "" ""</seg>
<seg id="1465">"" "" "" "as known in other highly effective immunosuppressants, infections and parasitic diseases are often increased in patients treated with tacrolimus, susceptibility to infections (viral, bacterial, mycotic, protozoal)." "" "" ""</seg>
<seg id="1466">Cases of Nephropathy and JC virus associated progressive multifocal leukoencephalopathy (PML) were reported in patients with immunosuppression therapy including therapy with Advagraf.</seg>
<seg id="1467">"" "" "" "it was reported via benign or malignant neoplasms, including EBV- associated lymphoproliferative diseases and skin tumours in conjunction with tacrolimus." "" "" ""</seg>
<seg id="1468">"" "" "" "due to its high molecular weight, low water solubility and high binding of erythrocytes and plasma proteins, it is assumed that tacrolimus is not dialysis." "" "" ""</seg>
<seg id="1469">The action mechanism and pharmacodynamic effects on the molecular level are expected to mediate the effects of tacrolimus through its binding to a cytosole protein (FKBP12) that is responsible for enriching the connection in the cellular memory.</seg>
<seg id="1470">"" "" "" "this leads to a calcidal-dependent inhibiting of signal transductions in the T cell, preventing transcription of a certain number of lymphokin genes." "" "" ""</seg>
<seg id="1471">"" "" "" "tacrolimus suppresses the activation of T cells and the proliferation of the T cells, and the formation of lymphokines (such as interleukin-2, interleukin-3 and γ-interferon) and expression of the interleukin 2 receptor." "" "" ""</seg>
<seg id="1472">12 confirmed acute repulations were 32.6% in the first 24 weeks (N = 237) and 29.3% in the Prograf group (N = 234).</seg>
<seg id="1473">"" "" "" "patient survival rates after 12 months were at 89.2% for Prograf and 90,8% for Prograf; 25 women, 11 men, and 19 men were killed in the Prograf arm 24 (5 women, 19 men)." "" "" ""</seg>
<seg id="1474">"" "" "" "kidney transplant The efficacy and safety of Adventurf and Prograf was compared in combination with mycophenolate mofetil (MMF) and corticosteroids, at 667 de novo kidney transplant recipients." "" "" ""</seg>
<seg id="1475">"" "" "" "patients showed 10 (3 women, 7 men) and in the Prograf-Arm 8 (3 women, 5 men)." "" "" ""</seg>
<seg id="1476">"" "" "" "the efficacy and safety of Prograf, Ciclosporin and Advagraf was compared in combination with Basiliximab-antibody production, MMF and corticosteroids, at 638 de novo kidney transplant recipients." "" "" ""</seg>
<seg id="1477">"" "" "" "the incidence of treatment failure after 12 months (defined as death, graft loss, biopsy confirmed acute rejection or missing follow-up data) was 14.0% in the Prograf group (N = 212) and 17.0% in the Ciclosporin group (N = 212)." "" "" ""</seg>
<seg id="1478">The difference in the treatment was -3.0% (Advagraf- Ciclosporin) (95.2%)) for Advagraf vs Ciclosporin and -1.9% (5.2%)) for Prograf vs Ciclosporin.</seg>
<seg id="1479">"" "" "" "3 (3 women, 7 men) and in the Ciclosporin arm 6 (3 women, 3 men) died in the Adventurf arm." "" "" ""</seg>
<seg id="1480">Published results of primary immunosuppression with tacrolimus according to other primary transplants Prograf has become a recognized primary immunosuppressant based on pancreatic and lung and colorectal transplantation.</seg>
<seg id="1481">"" "" "" "175 of treatment transplanted patients, with 475 patients undergoing pancreatic transplantation, and in 630 cases treated as primary immunosuppressant in 630 cases." "" "" ""</seg>
<seg id="1482">"" "" "" "overall, the safety profile of oral prograf in these published studies was consistent with the observations in the major studies where Prograf was used for primary immunosuppression in liver, kidney and heart transplants." "" "" ""</seg>
<seg id="1483">Lung transplantation in an interim analysis of a recent multicenter study with oral prograf was reported over 110 patients receiving either tacrolimus or Ciclosporin within a 1: 1 randomization.</seg>
<seg id="1484">"" "" "" "in the first year after the transplant, chronic graft rejection, bronchiolitis was less frequent (2.86% vs. 8.57%)." "" "" ""</seg>
<seg id="1485">"" "" "" "the survival rate after one year was 80,8% in the Tacrolimus- and 83% in the Ciclosporin group (Treede et al., 3rd ICI San Diego, USA, 2004; abstract 22)." "" "" ""</seg>
<seg id="1486">"" "" "" "in the patients treated with tacrolimus, the incidence of a bronchiolitis was 21.7% compared to 38.0% less than Ciclosporin (p = 0,025)." "" "" ""</seg>
<seg id="1487">The number of cases in which Ciclosporin had to be converted to tacrolimus (n = 13) was significantly larger (p = 0.02) than the number of patients who were transferred from Tacrolimus to Ciclosporin (n = 2) (Keenan et al.; Ann Thoracic Surg 1995; 60: 580).</seg>
<seg id="1488">The number of cases in which there was no acute graft rejection after 6 months (57.7% vs. 45.8%) and after 1 year (50% versus 33.3%) and after 1 year (50% vs. 33.3%) and after 1 year (20: 511).</seg>
<seg id="1489">"" "" "" "in one study, the frequency of the emergence of a bronchiolitis was significantly lower in the patients treated with tacrolimus." "" "" ""</seg>
<seg id="1490">Pankreast Plantation A multicenter study with oral prograf was performed on 205 patients who were simultaneously receiving a pancreatic and kidney transplant that was randomised to a randomized procedure Tacrolimus (n = 103) or Ciclosporin (n = 102).</seg>
<seg id="1491">The oral initial dose (per minutes) of tacrolimus was 0.2 mg / kg / day and was then reached to achieve the desired level mirror of 8 to 15 ng / ml on 5.</seg>
<seg id="1492">Bowel transplantation The published clinical results of a monocentric study involving oral prograf as primary immunosuppressant after colorectal transplantation demonstrated an updated survival rate of 75% after 1 year and 5% after 5 years and 42% after 10 years.</seg>
<seg id="1493">Methods for early detection of Epstein-Barr (EBV) - and CMV infections such as bone marrow magnification and additional administration of the interleukin-2 antagonist Daclizumab in lower initial doses (Abu-Elmagne et al.; Ann Surg 2001; 234: 404).</seg>
<seg id="1494">Factors such as low haematocrit and low protein concentrations leading to an increase in the unbound faction of tacrolimus or a strengthening of metabolism in corticosteroids should be responsible for the higher clearing-rates observed after transplantation.</seg>
<seg id="1495">"" "" "" "this suggests that tacrolimus is almost completely metabolised before excretion, whereby the excretion is mainly done through bile." "" "" ""</seg>
<seg id="1496">"" "" "" "the systemic exposure of Tacrolimus (AUC0-24) was approximately 10% lower than under Prograf, for stable patients based on prograf (once a day) in ratio 1: 1 (mg: mg)." "" "" ""</seg>
<seg id="1497">"" "" "" "it is recommended to perform common monitoring of the Tacrolimus valley level during the first two weeks after transplant, followed by periodic checks during maintenance therapy." "" "" ""</seg>
<seg id="1498">"" "" "" "21 For the treatment of adult patients with graft rejection, which proved to be resistant to other immunosuppressants, there are no clinical data for the retarated formulation Advagraf." "" "" ""</seg>
<seg id="1499">"" "" "" "other factors that increase the risk of such clinical disorders are an already existing heart disease, a treatment with corticosteroids, high blood pressure, kidney or liver dysfunction, infections, fluid overload and edema." "" "" ""</seg>
<seg id="1500">28 confirmed acute repulations were 32.6% in the first 24 weeks (N = 237) and 29.3% in the Prograf group (N = 234).</seg>
<seg id="1501">"" "" "" "the efficacy and safety of Prograf, Ciclosporin and Advagraf was compared in combination with Basiliximab-antibody production, MMF and corticosteroids, at 638 de novo kidney transplant recipients." "" "" ""</seg>
<seg id="1502">"" "" "" "hard capsules, retarded gray-orange gelatine capsules, printed in red ink on the red capsular bottom with" 5 mg "and orange capsular bottom with" "" "" "" "687" "" "" "" "they contain white powder." "" "" ""</seg>
<seg id="1503">"" "" "" "it is recommended to perform common monitoring of the Tacrolimus valley level during the first two weeks after transplant, followed by periodic checks during maintenance therapy." "" "" ""</seg>
<seg id="1504">"" "" "" "37 For the treatment of adult patients with graft rejection, which proved to be resistant to other immunosuppressants, there are no clinical data for the retarated formulation Advagraf." "" "" ""</seg>
<seg id="1505">"" "" "" "other factors that increase the risk of such clinical disorders are an already existing heart disease, a treatment with corticosteroids, high blood pressure, kidney or liver dysfunction, infections, fluid overload and edema." "" "" ""</seg>
<seg id="1506">44 confirmed acupressure was 32.6% in the first 24 weeks in the Advent group (N = 237) and 29.3% in the Prograf group (N = 234).</seg>
<seg id="1507">"" "" "" "the efficacy and safety of Prograf, Ciclosporin and Advagraf was compared in combination with Basiliximab-antibody production, MMF and corticosteroids, at 638 de novo kidney transplant recipients." "" "" ""</seg>
<seg id="1508">"" "" "" "a total of 34 patients were converted from Ciclosporin to tacrolimus, while only 6 Tacrolimus patients needed another therapy (Bechstein et al., Transplantation 2004; 77: 1221)." "" "" ""</seg>
<seg id="1509">Bowel transplantation The published clinical results of a monocentric study involving oral prograf as primary immunosuppressant after colorectal transplantation demonstrated an updated survival rate of 75% after 1 year and 5% after 5 years and 42% after 10 years.</seg>
<seg id="1510">"" "" "" "this suggests that tacrolimus is almost completely metabolised before excretion, whereby the excretion is mainly done through bile." "" "" ""</seg>
<seg id="1511">"" "" "" "risk management plan The holder of approval of the marketing agency commits itself to perform the studies and additional pharmacovigilance activities described in version 3.2 of the risk management plan (RMP) and all other updates of the RMP, which are approved by CHMP." "" "" ""</seg>
<seg id="1512">"" "" "" "according to the CHMP guideline to the risk management systems for use on humans, the updated RMP must be submitted simultaneously with the next periodic safety report (Periodic Safety Update Report, PSUR)." "" "" ""</seg>
<seg id="1513">"" "" "" "you may also be eligible to treat your liver, kidney or heart transplant or any other transplanted organ or because the immune response of your body could not be ruled out by a prospective treatment." "" "" ""</seg>
<seg id="1514">"" "" "" "when taking Adventuri with other medicines, please inform your doctor or pharmacist if you take other medicines or have recently taken it, even if it is not a prescription medication or herbal origin." "" "" ""</seg>
<seg id="1515">"" "" "" "aporide, triamer or spironolactone), certain pain killers (called nonsteroidal antiphlogistica such as ibuprofen), anti-coagulants or medicines for the treatment of diabetes mellitus." "" "" ""</seg>
<seg id="1516">"" "" "" "pregnancy and lactation when a pregnancy is planned or already exists, ask your doctor or pharmacist for advice before taking any medication." "" "" ""</seg>
<seg id="1517">"" "" "" "if you feel dizzy or sleepy after taking Adventuri, you may feel drowsy or drowsy." "" "" ""</seg>
<seg id="1518">"" "" "" "important information about certain other ingredients of Advagraf Please contact your doctor only after consultation with your doctor, if it is known to you that you suffer from intolerance to certain sugars." "" "" ""</seg>
<seg id="1519">"" "" "" "make sure you always receive the same tacrolimus medication if you redeem your prescription, unless your specialist expressly approved a change of the Tacrolimus preparations." "" "" ""</seg>
<seg id="1520">"" "" "" "if you receive a medicine whose appearance is different from the usual deviation or the dosage instructions, please speak as fast as possible with your doctor or pharmacist." "" "" ""</seg>
<seg id="1521">"" "" "" "in order for your doctor to determine the correct dose and adjust it from time to time, he must then perform regular blood tests." "" "" ""</seg>
<seg id="1522">"" "" "" "if you have taken a larger quantity of lawyers than you should have inadvertently taken a larger quantity of advagraph, seek immediately your doctor or the emergency department of the nearest hospital." "" "" ""</seg>
<seg id="1523">"" "" "" "if you forgot taking Advagraf, if you forgot to take the capsules, please take it the same day at the earliest possible date." "" "" ""</seg>
<seg id="1524">"" "" "" "if you cancel the intake of Advagraf, the risk of rejection of your transplant may increase." "" "" ""</seg>
<seg id="1525">"" "" "" "Adventurf 0.5 mg of hard capsules, retarded, are hard gelatine capsules whose orange upper part is red with" "" "" "" "647" "" "" "". "" "" "" ""</seg>
<seg id="1526">"" "" "" "Adventurf 1 mg of hard capsules, retarded, are hard gelatine capsules whose white top is printed with" 1 mg "and their orange bottom with" "" "" "" "677" "" "" "". "" "" "" ""</seg>
<seg id="1527">"" "" "" "Adventurf 5 mg of hard capsules, retarded, are hard gelatine capsules with 5 mg." and their orange bottom with "" "" "" "" 687 "" "" "" "" and which are filled with white powder. "" "" "" "</seg>
<seg id="1528">România Astellas Pharma Internazionale Detalii de contact pentru România Ritoseaua Bucureş ti-Ploieş ti 42-44; Clă dire 1, Parter and 013696-Bucureş ti Tel: + 40 (0) 21 361 0495</seg>
<seg id="1529">Slovenská republika Astellas Pharma s.r.o.; organizač ná zlož named Galvániho 15 / C SK- 821 04 Bratislava 2 Tel: + 421 2 4444 2157</seg>
<seg id="1530">"" "" "" "Advance is used to treat and prevent bleeding in patients with haemophilia A (due to the lack of factor VIII, congenital bleeding disorders)." "" "" ""</seg>
<seg id="1531">"" "" "" "the dosage and frequency of use depend on whether Advance is used to treat bleeding, or to prevent bleeding in surgical procedures." "" "" ""</seg>
<seg id="1532">"" "" "" "patients with hemophilia A suffer from a factor VIII deficiency, causing blood clots such as bleeding in joints, muscles or internal organs." "" "" ""</seg>
<seg id="1533">"" "" "" "Octocog alfa is not extracted from human plasma, but produced according to a method described as recombinant DNA technology:" "" "" ""</seg>
<seg id="1534">"" "" "" "it is produced by a cell in which a gene (DNA) was incorporated, which enables the formation of the human coagulation factor VIII." "" "" ""</seg>
<seg id="1535">"" "" "" "Advance is similar to another in the European Union called Recombinate, but is produced differently, so that the drug does not contain proteins of human or animal origin." "" "" ""</seg>
<seg id="1536">"" "" "" "in three additional studies in patients with severe to moderate hemophilia A, including a study of 53 children under the age of six, the drug was examined for prevention of bleeding and surgical procedures." "" "" ""</seg>
<seg id="1537">"" "" "" "in the main study, the efficacy of Advance in prevention of bleeding in 86% of 510 new blood sepals was awarded" excellent "or" good. "" "" "" ""</seg>
<seg id="1538">"" "" "" "the most common side effects of Advance (observed at 1 to 10 of 100 patients) are dizziness, headaches, pyrexia (fever) and the formation of antibodies against factor VIII." "" "" ""</seg>
<seg id="1539">"" "" "" "Advance may not be used in patients who may be hypersensitive to the human coagulation factor VIII, mouse or hamster protein or any of the ingredients." "" "" ""</seg>
<seg id="1540">"" "" "" "in March 2004, the European Commission granted Baxter AG a permit for the placing of lawyers in the whole European Union." "" "" ""</seg>
<seg id="1541">"" "" "" "dosage The dosage and duration of substitution treatment depend on the severity of the factor VIII deficiency, the place and the extent of bleeding and the patient's clinical condition." "" "" ""</seg>
<seg id="1542">"" "" "" "in the following hemorrhagic events, factor VIII activity should not fall below the specified plasma level (in% of the standard or in I.E. / dl)." "" "" ""</seg>
<seg id="1543">"" "" "" "injection every 12-24 hours (8-24 hours in patients below 6 years) for 3-4 days or longer, until the pain and acute impairment are removed." "" "" ""</seg>
<seg id="1544">"" "" "" "injection every 8-24 hours (6-12 hours in patients below 6 years), until the risk is over for the patient." "" "" ""</seg>
<seg id="1545">"" "" "" "during treatment, the dose and frequency of the injections are recommended to determine the factor VIII plasma." "" "" ""</seg>
<seg id="1546">"" "" "" "in response to factor VIII, individual patients may differ in vivo recovery and have different half-value periods." "" "" ""</seg>
<seg id="1547">3 prophylaxis for long-term prophylaxis of bleeding in patients with severe hemophilia A should be given doses between 20 and 40 I.U. by factor VIII per kg body weight at a distance of 2-3 days.</seg>
<seg id="1548">"" "" "" "if the expected factor VIII plasma activity is not reached or if the bleeding is not controlled with a reasonable dose, a test must be carried out to prove an inhibitor." "" "" ""</seg>
<seg id="1549">"" "" "" "in patients with high inhibitors, it is possible that the factor VIII therapy is not effective so that other therapeutic interventions must be induced." "" "" ""</seg>
<seg id="1550">"" "" "" "the rate of administration is to be directed at the patient's condition, with a maximum injection rate of 10 ml / min should not be exceeded." "" "" ""</seg>
<seg id="1551">The formation of neutralizing antibodies (inhibitors) against factor VIII is a known complication in treating patients with haemophilia A.</seg>
<seg id="1552">These inhibitors are always against the prokoagulatory activity of factor VIII-orientated IgG immunoglobulins which are quantified in Bethesda units (B.E.) per ml plasma by modified Bethesda assay.</seg>
<seg id="1553">"" "" "" "the risk of developing inhibitors correlates with the extent of exposure to factor VIII, whereby the risk within the first 20 exposure days is greatest and depends on genetic and other factors." "" "" ""</seg>
<seg id="1554">"" "" "" "after switching from a recombinant factor VIII-product to another, the recurrence of (low-triangles) inhibitors was observed after switching from a recombinant factor VIII-product to another." "" "" ""</seg>
<seg id="1555">"" "" "" "due to the rare occurrence of hemophilia A in women, there are no experiences concerning the use of factor VIII during pregnancy and lactation." "" "" ""</seg>
<seg id="1556">"" "" "" "the ADRs in the largest number of patients were inhibitors of factor VIII (5 patients), which showed a higher risk to the formation of inhibitors, headache (5 patients), fever and dizziness (3 patients each)." "" "" ""</seg>
<seg id="1557">"" "" "" "very common (≥ 1 / 100 to &lt; 1 / 100), occasionally (≥ 1 / 1,000 to &lt; 1 / 1000), rare (≥ 1 / 10,000 to &lt; 1 / 1000), not known (frequency based on available data)." "" "" ""</seg>
<seg id="1558">A) The percentage of patients was calculated on the basis of the sum of the individual patients (234). the unexpected drop in blood coagulation factor VIII-level was observed postoperatively (10 - 14 postoperatively day) in a patient with continuous ADVATE infusion.</seg>
<seg id="1559">"" "" "" "blood clotting was maintained throughout the period, and both the factor VIII and the clearing rate showed sufficient values on the 15th postoperative day." "" "" ""</seg>
<seg id="1560">In clinical trials involving ADVATE to 145 children and adults 2 with diagnosed heavy to moderate hemophilia A (FVIII ≤ 2%) and previous exposure to factor VIII- concentrates (≥ 150 days) only one patient showed a low inhibitory (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1561">In addition no 53 papal patients with an age of under 6 years and diagnosed hard to moderate hemophilia A (FVIII ≤ 2%) after previous exposure to factor VIII- concentrates (≥ 50 days) found a FVIII inhibitor.</seg>
<seg id="1562">"" "" "" "in previously untreated patients, 5 out of 25 (20%) with ADVATE treated patients inhibitors against factor VIII." "" "" ""</seg>
<seg id="1563">"" "" "" "the patient's immune response to traces of contaminated proteins was analysed by examining the antibody titer against these proteins, laboratory parameters and reported side effects." "" "" ""</seg>
<seg id="1564">"" "" "" "one patient showed a statistically significant upward trend as well as a prolonged peak of anti-CHO cell protein, but there were no signs or symptoms that had an allergic reaction or hypersensitivity." "" "" ""</seg>
<seg id="1565">"" "" "" "in four patients the incidence of urticaria, pruritus, rash and increased number of eosinophils granulocytes were reported in several repeated product expositions within the study." "" "" ""</seg>
<seg id="1566">"" "" "" "7 As with other intravenous products, ADVATE was reported about hypersensitivity reactions from the allergic type, including anaphylactic / anaphylaktoid reactions (frequency not known)." "" "" ""</seg>
<seg id="1567">"" "" "" "the activated factor VIII acts as a factor factor for the activated factor IX, and accelerates the formation of activating factor X from factor X." "" "" ""</seg>
<seg id="1568">All pharmacokinetic studies with ADVATE were carried out in pre-treated patients with severe or moderate hemophilia A (basic value of factor VIII activity ≤ 2%).</seg>
<seg id="1569">Pharmacokinetic parameters are derived from a cross-over study with ADVATE in 100 previously treated patients or &gt; 10 years and are listed in table 3 below.</seg>
<seg id="1570">Table 3: summary of the pharmacokinetic parameters of ADVATE in 100 patients with severe to moderate hemophilia A (factor VIII &lt; 2%) PK parameters (Pharmacokinetics)</seg>
<seg id="1571">"" "" "" "non-clinical data, based on studies on safety macology, acute, repetitive and local toxicity and genotoxicity, show no specific risk to humans." "" "" ""</seg>
<seg id="1572">"" "" "" "each pack consists of a bottle containing powder, a bottle containing 5 ml of solvents (both types I with chlorobutyl rubber stoppers) and a device for reconstitution (BAXJECT II)." "" "" ""</seg>
<seg id="1573">"" "" "" "if the product is still in the refrigerator, remove both bottles with ADVATE powder and solvents from the refrigerator and heat them at room temperature (between 15 and 25 ° C)." "" "" ""</seg>
<seg id="1574">"" "" "" "a significant increase in the pulse rate can usually be lowered by slow or temporary interruption of the injection, (see Sections 4.4 and 4.8)." "" "" ""</seg>
<seg id="1575">14 prophylaxis for long-term prophylaxis of bleeding in patients with severe hemophilia A should be given doses between 20 and 40 I.U. by factor VIII per kg body weight at a distance of 2-3 days.</seg>
<seg id="1576">"" "" "" "due to the rare occurrence of hemophilia A in women, there are no experiences concerning the use of factor VIII during pregnancy and lactation." "" "" ""</seg>
<seg id="1577">"" "" "" "3 newborns (aged 0-1 month), infants (aged 1-12), children (aged 12-16), adults (aged 12-16), adults (over 16 years old)" "" "" ""</seg>
<seg id="1578">In clinical trials involving ADVATE to 145 children and adults 4 with diagnosed hard to moderate hemophilia A (FVIII ≤ 2%) and previous exposure to factor VIII- concentrates (≥ 150 days) only one patient showed a low inhibitory (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1579">"" "" "" "18 As with other intravenous products, ADVATE was reported about hypersensitivity reactions from the allergic type, including anaphylactic / anaphylaktoid reactions (frequency not known)." "" "" ""</seg>
<seg id="1580">Table 3: summary of the pharmacokinetic parameters of ADVATE in 100 patients with severe to moderate hemophilia A (factor VIII &lt; 2%) PK parameters (Pharmacokinetics)</seg>
<seg id="1581">"" "" "" "non-clinical data, based on studies on safety macology, acute, repetitive and local toxicity and genotoxicity, show no specific risk to humans." "" "" ""</seg>
<seg id="1582">25 prophylaxis for long-term prophylaxis of bleeding in patients with severe hemophilia A should be given doses between 20 and 40 I.U. by factor VIII per kg body weight at a distance of 2-3 days.</seg>
<seg id="1583">"" "" "" "5 newborns (aged 0-1 month), infants (aged 1-12), children (aged 12-16), adults (aged 12-16), adults (over 16 years old)" "" "" ""</seg>
<seg id="1584">In clinical trials involving ADVATE to 145 children and adults 6 with diagnosed hard to moderate hemophilia A (FVIII ≤ 2%) and previous exposure to factor VIII- concentrates (≥ 150 days) only one patient showed a low inhibitory (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1585">"" "" "" "29 As with other intravenous products, ADVATE was reported about hypersensitivity reactions from the allergic type, including anaphylactic / anaphylaktoid reactions (frequency not known)." "" "" ""</seg>
<seg id="1586">"" "" "" "non-clinical data, based on studies on safety macology, acute, repetitive and local toxicity and genotoxicity, show no specific risk to humans." "" "" ""</seg>
<seg id="1587">"" "" "" "36 Prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A, doses of between 20 and 40 I.U. should be given by factor VIII per kg body weight at a distance of 2-3 days." "" "" ""</seg>
<seg id="1588">"" "" "" "7 newborns (aged 0-1 month), infants (aged 1-12), children (aged 12-16), adults (aged 12-16), adults (over 16 years old)" "" "" ""</seg>
<seg id="1589">In clinical trials involving ADVATE to 145 children and adults 8 with diagnosed heavy to moderate hemophilia A (FVIII ≤ 2%) and previous exposure to factor VIII- concentrates (≥ 150 days) only one patient showed a low inhibitory (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1590">"" "" "" "40 As with other intravenous products, ADVATE was reported about hypersensitivity reactions from the allergic type, including anaphylactic / anaphylaktoid reactions (frequency not known)." "" "" ""</seg>
<seg id="1591">"" "" "" "non-clinical data, based on studies on safety macology, acute, repetitive and local toxicity and genotoxicity, show no specific risk to humans." "" "" ""</seg>
<seg id="1592">"" "" "" "47 prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A, doses of between 20 and 40 I.U. should be given by factor VIII per kg body weight at a distance of 2-3 days." "" "" ""</seg>
<seg id="1593">"" "" "" "9 infants (aged 0-1 month), infants (aged 2-12), children (aged 12-16), adults (aged 12-16), adults (over 16 years old)" "" "" ""</seg>
<seg id="1594">In clinical trials involving ADVATE to 145 children and adults 10 with diagnosed hard to moderate hemophilia A (FVIII ≤ 2%) and previous exposure to factor VIII- concentrates (≥ 150 days) only one patient showed a low inhibitory (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1595">"" "" "" "51 As with other intravenous products, ADVATE was reported about hypersensitivity reactions from the allergic type, including anaphylactic / anaphylaktoid reactions (frequency not known)." "" "" ""</seg>
<seg id="1596">"" "" "" "non-clinical data, based on studies on safety macology, acute, repetitive and local toxicity and genotoxicity, show no specific risk to humans." "" "" ""</seg>
<seg id="1597">"" "" "" "58 prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A, doses of between 20 and 40 I.U. should be given by factor VIII per kg body weight at a distance of 2-3 days." "" "" ""</seg>
<seg id="1598">"" "" "" "11 infants (aged 0-1 month), infants (aged 2-12), children (aged 12-16), adults (aged 12-16), adults (over 16 years old)" "" "" ""</seg>
<seg id="1599">In clinical trials involving ADVATE to 145 children and adults 12 with diagnosed hard to moderate hemophilia A (FVIII ≤ 2%) and previous exposure to factor VIII- concentrates (≥ 150 days) only one patient showed a low inhibitory (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1600">"" "" "" "62 As with other intravenous products, ADVATE was reported about hypersensitivity reactions from the allergic type, including anaphylactic / anaphylaktoid reactions (frequency not known)." "" "" ""</seg>
<seg id="1601">"" "" "" "non-clinical data, based on studies on safety macology, acute, repetitive and local toxicity and genotoxicity, show no specific risk to humans." "" "" ""</seg>
<seg id="1602">"" "" "" "the authorisation holder has to ensure that a pharmaceutical vigilance system, as described in Section 1.1 of the Chapel 1.8.1 of the Drug Application, has been established and that this system remains in force throughout the period in which the product is on the market." "" "" ""</seg>
<seg id="1603">"" "" "" "as defined in the CHMP directive on the risk management plan for human medicines, these updates should be submitted simultaneously with the next Periodic Safety Update Report (PSUR)." "" "" ""</seg>
<seg id="1604">"" "" "" "• if new information is available, the relevant safety instructions, the pharmacovigilance plan or the risk minimization, within 60 days of an important event (regarding drug vigilance or risk minimization)" "" "" ""</seg>
<seg id="1605">1 bottle bottle with ADVATE 500 i.e Octocog alfa; 1 bottle containing 5 ml sterilized water for injection purposes; 1 BAXJECT II medical product.</seg>
<seg id="1606">1 bottle bottle with ADVATE 1000 i.e Octocog alfa; 1 bottle containing 5 ml sterilized water for injection purposes; 1 BAXJECT II medical product</seg>
<seg id="1607">"" "" "" "particular caution when using ADVATE is required you should inform your doctor if you have recently been treated with factor VIII products, especially if you have developed inhibitors." "" "" ""</seg>
<seg id="1608">"" "" "" "these symptoms can represent early signs of an anaphylactic shock which can include the following symptoms: extreme dizziness, loss of consciousness, and extreme breathing difficulties." "" "" ""</seg>
<seg id="1609">"" "" "" "if you are taking other medicines, please inform your doctor if you take other medicines or have recently taken it, even if it is non-prescription drugs." "" "" ""</seg>
<seg id="1610">Your doctor will calculate your dose ADVATE (in international units or I.U.) depending on your physical condition and body weight and whether it is used to prevent or treat bleeding.</seg>
<seg id="1611">"" "" "" "patients suffering from factor VIII inhibitors If the expected factor VIII mirror cannot be reached in your plasma with ADVATE or the bleeding can not be controlled, this may be part of the development factor VIII-" "" "" ""</seg>
<seg id="1612">"" "" "" "in conjunction with catheter infections, lower number of red blood cells, swelling of limbs and joints, prolonged bleeding after removing a drainage, reduced factor VIII mirror and postoperative hematomas." "" "" ""</seg>
<seg id="1613">"" "" "" "rare side effects Since the introduction of the drug on the market, severe and potentially life-threatening reactions (anaphylaia) and other allergic reactions have been reported (see above)." "" "" ""</seg>
<seg id="1614">Tell your doctor if any of the side effects listed will affect you significantly or if you notice any side effects that are not listed in this treatment supplement.</seg>
<seg id="1615">Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira and Edifício 10 P-2710-089 Sintra Tel: + 351 21 925 25 00</seg>
<seg id="1616">"" "" "" "• Do not use BAXJECT II if its sterile barrier is broken, its packaging is damaged or signs of manipulation, as in the symbol" "" "" ""</seg>
<seg id="1617">"" "" "" "important Note: • Do not administer yourself, before you have received the special training from your doctor or nurse. • Check the product on suspended particles or discolouration before administered." "" "" ""</seg>
<seg id="1618">"" "" "" "the solution should slow down with an infusion velocity, which is beneficial to the patient and does not exceed 10 ml per minute." "" "" ""</seg>
<seg id="1619">"" "" "" "106 In the case of blood-occurrences, the factor VIII mirror should not fall under the specified plasma activity value (in% or in I.U. / ml)." "" "" ""</seg>
<seg id="1620">"" "" "" "these symptoms can represent early signs of an anaphylactic shock which can include the following symptoms: extreme dizziness, loss of consciousness, and extreme breathing difficulties." "" "" ""</seg>
<seg id="1621">"" "" "" "patients suffering from factor VIII inhibitors If the expected factor VIII mirror cannot be reached in your plasma with ADVATE or the bleeding can not be controlled, this may be part of the development factor VIII-" "" "" ""</seg>
<seg id="1622">"" "" "" "occasional side effects itching, increased sweating, unusual taste sensation, heat flushes, migraines, memory problems, shivers, sore throat, eye inflammations, skin rash, extreme sweating," "" "" ""</seg>
<seg id="1623">"" "" "" "116 In the case of blood-occurrences, the factor VIII mirror should not fall under the specified plasma activity value (in% or in I.U. / ml)." "" "" ""</seg>
<seg id="1624">"" "" "" "these symptoms can represent early signs of an anaphylactic shock which can include the following symptoms: extreme dizziness, loss of consciousness, and extreme breathing difficulties." "" "" ""</seg>
<seg id="1625">"" "" "" "patients suffering from factor VIII inhibitors If the expected factor VIII mirror cannot be reached in your plasma with ADVATE or the bleeding can not be controlled, this may be part of the development factor VIII-" "" "" ""</seg>
<seg id="1626">"" "" "" "126 In the case of blood-occurrences, the factor VIII mirror should not fall under the specified plasma activity value (in% or in I.U. / ml)." "" "" ""</seg>
<seg id="1627">"" "" "" "these symptoms can represent early signs of an anaphylactic shock which can include the following symptoms: extreme dizziness, loss of consciousness, and extreme breathing difficulties." "" "" ""</seg>
<seg id="1628">"" "" "" "patients suffering from factor VIII inhibitors If the expected factor VIII mirror cannot be reached in your plasma with ADVATE or the bleeding can not be controlled, this may be part of the development factor VIII-" "" "" ""</seg>
<seg id="1629">136 In case of blood-occurrences the factor VIII mirror should not fall under the specified plasma activity value (in% or in I.U. / ml).</seg>
<seg id="1630">"" "" "" "these symptoms can represent early signs of an anaphylactic shock which can include the following symptoms: extreme dizziness, loss of consciousness, and extreme breathing difficulties." "" "" ""</seg>
<seg id="1631">"" "" "" "patients suffering from factor VIII inhibitors If the expected factor VIII mirror cannot be reached in your plasma with ADVATE or the bleeding can not be controlled, this may be part of the development factor VIII-" "" "" ""</seg>
<seg id="1632">"" "" "" "146 In the case of blood-occurrences, the factor VIII mirror should not fall under the specified plasma activity value (in% or in I.U. / ml)." "" "" ""</seg>
<seg id="1633">"" "" "" "these symptoms can represent early signs of an anaphylactic shock which can include the following symptoms: extreme dizziness, loss of consciousness, and extreme breathing difficulties." "" "" ""</seg>
<seg id="1634">"" "" "" "patients suffering from factor VIII inhibitors If the expected factor VIII mirror cannot be reached in your plasma with ADVATE or the bleeding can not be controlled, this may be part of the development factor VIII-" "" "" ""</seg>
<seg id="1635">"" "" "" "occasional side effects itching, increased sweating, unusual taste sensation, heat flushes, migraines, memory problems, shivers, sore throat, eye inflammations, skin rash, extreme sweating," "" "" ""</seg>
<seg id="1636">"" "" "" "rare side effects Since the introduction of the drug on the market, severe and potentially life-threatening reactions (anaphylaia) and other allergic reactions have been reported (see above)." "" "" ""</seg>
<seg id="1637">"" "" "" "156 In the case of blood-occurrences, the factor VIII mirror should not fall under the specified plasma activity value (in% or in I.U. / ml)." "" "" ""</seg>
<seg id="1638">"" "" "" "based on the data available since initial approval, CHMP has continued to evaluate the benefit risk assessment as positive, but considered that the safety profile must be closely monitored for the following reasons:" "" "" ""</seg>
<seg id="1639">"" "" "" "therefore, the CHMP has decided on the basis of ADVATE's safety profile which necessitates filing of PSURs every 6 months." "" "" ""</seg>
<seg id="1640">"" "" "" "in December 2008, Gendux Molecular Limited officially approved the Committee on Human Use (CHMP) that the company rejects its application for authorisation of the advent of Advexin for the treatment of Li-Fraumeni cancer." "" "" ""</seg>
<seg id="1641">"" "" "" "normally, however, the breast, the brain, the bones, or the soft parts (tissue, the other structures in the body, surrounds and supports) are affected." "" "" ""</seg>
<seg id="1642">"" "" "" "this is a type of virus, which has been genetically modified so that it can carry a gene into the cells of the body." "" "" ""</seg>
<seg id="1643">"" "" "" "the virus in Advexin is a" adenovirus, "which has been modified so that it does not produce copies of itself and thus cannot trigger infections in humans." "" "" ""</seg>
<seg id="1644">"" "" "" "Advexin could have been injected directly into the tumors, allowing the cancer cells to form the normal p53 protein again." "" "" ""</seg>
<seg id="1645">"" "" "" "the p53 protein, which is formed from the non-defective p53 gene, normally contributes to the recovery of damaged DNA and killing the cells when the DNA cannot be recovered." "" "" ""</seg>
<seg id="1646">"" "" "" "in Li-Fraumeni-Krebs, in which the p53 gene is defective, the p53 protein does not work properly, and the cancer cells can grow and share." "" "" ""</seg>
<seg id="1647">"" "" "" "the company presented data from a study with a patient, in which Li-Fraumeni-cancer appeared in the area of the sub-building, in bones and in the brain." "" "" ""</seg>
<seg id="1648">"" "" "" "after the CHMP checked the answers from the company to the questions asked, there were still some questions unexplained." "" "" ""</seg>
<seg id="1649">"" "" "" "based on examining the initial submitted documents, the CHMP created a list of questions sent to the company on day 120." "" "" ""</seg>
<seg id="1650">"" "" "" "according to the CHMP, it was not sufficiently demonstrated that the injection of Advexin in Li-Fraumeni-Tumors has advantages for patients." "" "" ""</seg>
<seg id="1651">"" "" "" "the committee had further concerns regarding the processing of the drug in the body, the type of administration and the safety of the medicine." "" "" ""</seg>
<seg id="1652">"" "" "" "moreover, the company had not sufficiently demonstrated that Advexin could be manufactured in a reliable way and that it is harmful neither for the environment nor for people who come in close contact with the patient." "" "" ""</seg>
<seg id="1653">"" "" "" "the company did not inform the CHMP whether the recovery has consequences for patients, who are currently participating in clinical trials or" compassionate use "programs with Advexin." "" "" ""</seg>
<seg id="1654">"" "" "" "" "" "" "" "altered drug release" "" "" "" "means that the tablets are so composed that one of the effective components is released immediately and the other slowly over a few hours." "" "" ""</seg>
<seg id="1655">Aerinaze is used to treat symptoms of seasonal allergic rhinitis (hay fever caused by an allergy to pollen caused inflammation of the nasal passages) in patients with nasal mucous membranes (clogged nose).</seg>
<seg id="1656">"" "" "" "for adults and adolescents aged 12, the recommended dose of aerinaze is twice a day a tablet that should be taken completely with a glass of water with or without food." "" "" ""</seg>
<seg id="1657">"" "" "" "the duration of the treatment should be as short as possible and ended as soon as the symptoms, especially the swelling of the nasal mucosa (clogged nose), are clung." "" "" ""</seg>
<seg id="1658">"" "" "" "a treatment duration of more than 10 days is not recommended, because the effects of the drug can be followed by constipation of the nose." "" "" ""</seg>
<seg id="1659">The main efficacy measures were the changes in the severity of the hay fever symptoms which were reported by the patients before the treatment and during the 15-day treatment.</seg>
<seg id="1660">"" "" "" "during the study, patients carried out their symptoms every 12 hours in a diary and assessed with a standard scale how difficult the symptoms were in the last 12 hours." "" "" ""</seg>
<seg id="1661">"" "" "" "in case of all hay fever symptoms than the constipation of the nose, the patients who took aerinaze reported a decrease of the symptoms by 46.0% compared to 35.9% in the patients who received pseudoephedrine alone." "" "" ""</seg>
<seg id="1662">"" "" "" "if only the swelling of the nasal mucosa was seen, the patient showed a relief of the symptoms by 37.4% compared to 26,7% in the patients who received the Desolatadin alone." "" "" ""</seg>
<seg id="1663">"" "" "" "the most common side effects of aerinaze (observed in 1 to 10 of 100 patients) are tachycardia, mouth drying, dizziness, psychomotor hyperactivity (restlessness), somnolency (sleepiness), sleep disorders and nervousness." "" "" ""</seg>
<seg id="1664">"" "" "" "aerinaze may not be used in patients who may be hypersensitive to desloratadin, pseudoephedrine or one of the other ingredients, against adrenergic agents or lauatadin (other medicines for the treatment of allergies)." "" "" ""</seg>
<seg id="1665">"" "" "" "Aerinaze should also not be used in patients who suffer from hyperthyrosis (hypertension), hypertension (hypertension), hypertension (hypertension) or hypertension (hypertension) or have a hemorrhagic stroke." "" "" ""</seg>
<seg id="1666">"" "" "" "on 30 July 2007, the European Commission granted the company SP Europe a permit for the transport of aerinaze throughout the European Union." "" "" ""</seg>
<seg id="1667">"" "" "" "the tablet can be taken with a glass of water, but can be swallowed whole (i.e. without shatter or chewing)." "" "" ""</seg>
<seg id="1668">"" "" "" "because of the lack of data, aerinaze should not be used in children under 12 years of absence (see Section 5.1)." "" "" ""</seg>
<seg id="1669">"" "" "" "the duration of the application is as short as possible, and should not be continued after the symptoms are finished." "" "" ""</seg>
<seg id="1670">"" "" "" "it is recommended to limit the application time to 10 days, as with long-term application the activity of pseudoephedrine can decrease over time." "" "" ""</seg>
<seg id="1671">"" "" "" "after the swelling of the mucous membranes in the upper respiratory tract, the treatment can be continued when necessary with diloratadin as a monotherapy." "" "" ""</seg>
<seg id="1672">"" "" "" "since Aerinaze contains pseudoephedrine, the medicine is also contraindicated in patients treated with a monoamine oxidase (MAO) inhibitor within 2 weeks of termination of such therapy." "" "" ""</seg>
<seg id="1673">"" "" "" "this is due to alphamimetic activity in combined use of pseudoephedrine with other vasoconstrictors such as bromocripitin, pergolid, papurid, oxymetazoline, oxygenazoline, Naphazi, etc.)." "" "" ""</seg>
<seg id="1674">"" "" "" "the safety and efficacy of this combination therapy have not been reviewed for this patient study, and the data is not sufficient to address relevant recommendations for dosage." "" "" ""</seg>
<seg id="1675">"" "" "" "the safety and efficacy of aerinaze were not tested in patients with kidney or liver dysfunction, and the data is not sufficient to address relevant recommendations for dosage." "" "" ""</seg>
<seg id="1676">"" "" "" "patients need to be informed that treating hypertension or tachycardia or palpitations, heart rhythms, nausea or any other neurological symptoms (such as headaches or a strengthening of headaches) must be removed." "" "" ""</seg>
<seg id="1677">"" "" "" "caution: • Patients with cardiac arrhythmia • Patients with hypertonia • Patients with a myocardial infarction in the anamnesis, diabetes mellitus, hydatid clusion or bronchospasm in the amnesis." "" "" ""</seg>
<seg id="1678">"" "" "" "Aerinaze is at least 48 hours prior to performing dermatological tests, since antihistaminika otherwise reduces positive reactions to indicators for skin reactions or reduce them to their extent." "" "" ""</seg>
<seg id="1679">"" "" "" "in the context of clinical trials of diloratadin, where erythromycin or ketoconazole was additionally administered, no clinically relevant interactions or changes in the plasma concentration of Desloratadin were observed." "" "" ""</seg>
<seg id="1680">"" "" "" "in the results of the psychomotor test, no significant differences could be found between those treated with Desloratadin and the patients treated with placebo." "" "" ""</seg>
<seg id="1681">"" "" "" "the enzyme responsible for the metabolism of Desloratadin has not yet been identified, so that interactions with other medicines cannot be completely ruled out." "" "" ""</seg>
<seg id="1682">Desloratadin does not inhibit in-vivo CYP3A4 and in-vitro studies have shown that the drug CYP2D6 does not inhibit and neither a substrate nor an inhibitor of the P-glycoproteins.</seg>
<seg id="1683">The safety of the application of aerinaze during pregnancy is not assured; experience from a large number of affected pregnancies did not increase the frequency of abnormalities compared to the frequency of the normal population.</seg>
<seg id="1684">"" "" "" "since reproductive studies on animals are not always transmitted to humans and due to the vasoconstrictoric properties of pseudoephedrine, aerinaze should not be applied during pregnancy." "" "" ""</seg>
<seg id="1685">"" "" "" "however, patients should be informed that in very rare cases, it may result in a dizzlement that may result in impaired mobility or the ability to operate machinery." "" "" ""</seg>
<seg id="1686">"" "" "" "symptoms may vary between a CNS depression (sedation, apnea, decreased mental alertness, cyanosis, coma, cardiovascular collapse) and CNS stimulation (insomnia, hallucinations, tremor, convulsions) with potential lettering." "" "" ""</seg>
<seg id="1687">"" "" "" "headache, anxiety, created miction, muscle weakness and increased muscular tension, euphoria, excitement, heart rhythm disorders, tachycardia, palpitations, nausea, vomiting, nausea, vomiting, hypertonia or hypotony." "" "" ""</seg>
<seg id="1688">"" "" "" "CNS stimulation is particularly likely in children, as well as atropin-typical symptoms (mouth drying, pupil stiffness, and dilatation, skin comfort, hyperthermia and gastrointestinal symptoms)." "" "" ""</seg>
<seg id="1689">These include the inhibition of release of pro-inflammatory cytokines such as IL-4 and IL-8 and IL-13 from human mastcells / basophien as well as the inhibition of the expression of the Adalsionsmolecules P selectin to endothelial cells.</seg>
<seg id="1690">"" "" "" "in a single dose study with adults, Desloratadin 5 mg showed no influence on standard measurement ranges of the flight performance including amplification of subjective punctuality or the tasks associated with flying." "" "" ""</seg>
<seg id="1691">"" "" "" "in controlled clinical trials, the recommended dose of 5 mg daily did not detect an increased frequency of sleepiness compared to placebo." "" "" ""</seg>
<seg id="1692">"" "" "" "the oral application of pseudoephedrine in the recommended dosage can cause further symptomimetic effects, such as an increase in blood pressure, a tachycardia or manifestations of a CNS arousal." "" "" ""</seg>
<seg id="1693">"" "" "" "there were 1,248 patients aged between 12 and 78 years with seasonal allergic rhinitis, with 414 patients receiving Aerinaze tablets." "" "" ""</seg>
<seg id="1694">"" "" "" "in both studies, the histamine response of Aerinaze tablets was significantly higher than with pseudoephedrine compared to monotherapy with pseudoephedrine compared to the 2-week treatment period." "" "" ""</seg>
<seg id="1695">"" "" "" "the efficacy of Aerinaze tablets with regard to the swelling effect, determined by the nasal mucous membrane, was significantly higher than under a monotherapy with Desloratadin over the 2-week treatment period." "" "" ""</seg>
<seg id="1696">"" "" "" "the efficacy of Aerinaze tablets showed no significant differences in patients with regard to gender, age or ethnicity." "" "" ""</seg>
<seg id="1697">"" "" "" "as part of a single dose study on the pharmacokinetics of Aerinaze, Desloratadin is demonstrable within 30 minutes after the application in the plasma." "" "" ""</seg>
<seg id="1698">"" "" "" "after the perortal application of aerinaze in healthy subjects over 14 days, the flow balance of diloratadin, 3-hydroxydesloratadin and pseudoephedrine was reached day 10." "" "" ""</seg>
<seg id="1699">"" "" "" "in the framework of a pharmacokinetic multi-dose study, which was conducted with the formulation as a tablet in healthy adult subjects, four subjects of Desloratadin were badly confused." "" "" ""</seg>
<seg id="1700">A component interaction study shows that the exposure (CMAx and AUC) of pseudoephedrine after the sole administration of pseudoephedrine bioequivalent was to exposure to the gift of an aerinaze tablet.</seg>
<seg id="1701">"" "" "" "based on conventional studies on safety macology, toxicity in repeated application, genotoxicity and reproductive toxicity, the preclinical data with Desloratadin does not reveal any particular dangers to humans." "" "" ""</seg>
<seg id="1702">"" "" "" "the combination had no greater toxicity than their individual components, and the observed effects were generally related to the contents of pseudoephedrine." "" "" ""</seg>
<seg id="1703">In reproductive toxicological studies the combination of Loratadin / Pseudoephedrine was not teratogenic in the oral administration of rats in a dose of up to 150 mg / kg / day and rabbits in a dose of up to 120 mg / kg / day.</seg>
<seg id="1704">"" "" "" "in March 2007 and in module 1.8.1 the application for authorisation, the Pharmacovigilance System described and works before and while the product is on the market." "" "" ""</seg>
<seg id="1705">"" "" "" "antihistamines contribute to alleviating the allergic symptoms by preventing histamine, a body's substance, and its effect." "" "" ""</seg>
<seg id="1706">"" "" "" "Aerinaze tablets relieve symptoms associated with seasonal allergic rhinitis (hay fever), such as sneezing, running or itching nose and tears or itching eyes while constipation of the nose." "" "" ""</seg>
<seg id="1707">"" "" "" "20 In particular, it may be particularly sensitive to pseudoephedrine, which is contained in this medicine." "" "" ""</seg>
<seg id="1708">"" "" "" "(diabetes), a stenodizing stomach ulcer (ulcer, which leads to a narrowing of the stomach, the small intestine or the esophagus), a bladder neck closure, bronchospasm in the patient's history (breathlessness due to varicose of the lung musculature)." "" "" ""</seg>
<seg id="1709">"" "" "" "inform your doctor if under the application of Aerinaze you may experience or diagnose the following symptoms or diseases: • hypertension, palpitations, heart rhythm disorders • nausea and headache or strengthening existing headaches." "" "" ""</seg>
<seg id="1710">"" "" "" "when taking Aerinaze with other medicines, please inform your doctor or pharmacist if you take other medicines or have recently taken it, even if it is not prescription medicine." "" "" ""</seg>
<seg id="1711">"" "" "" "when applying in the recommended dosage, it is not to be expected that Aerinaze leads to dizziness or reduces the attention." "" "" ""</seg>
<seg id="1712">If you have taken a larger amount of aerinaze than you should inform your doctor or pharmacist if you have taken a larger amount of aerinaze than you should.</seg>
<seg id="1713">"" "" "" "if you forgot to take Aerinaze if you forgot to take a dose in time, take the application as soon as possible and apply the next dose at the appropriate time." "" "" ""</seg>
<seg id="1714">"" "" "" "please inform your doctor or pharmacist, if any of the side effects listed will affect you significantly or you may notice any side effects that are not stated in this information information." "" "" ""</seg>
<seg id="1715">"" "" "" "heart-hunting, restlessness with increased physical activity, dizziness, dizziness, neck pain, appetite, sugar in the urine, increased blood sugar levels, thirst, fatigue, headache, sleep disorders, nervousness and dizziness." "" "" ""</seg>
<seg id="1716">"" "" "" "heart palpitations, heart rhythm disorders, increased physical activity, skin redness, blurred vision, nasal irritation, nasal irritation, pain or difficulty passing urine, itching, shivering, anxiety, anxiety and irritability." "" "" ""</seg>
<seg id="1717">"" "" "" "after the market launch of Desloratadin, very rare cases of severe allergic reactions (breathing difficulties, whistling breathing, itching, hives and swelling) or skin rash are reported." "" "" ""</seg>
<seg id="1718">"" "" "" "about cases of palpitations, heart hunting, stomach pain, nausea, vomiting, stomach upset, nausea, hallucinations, nausea, hallucinations, dizziness, diarrhea and cases of conspicuous liver functions was also very rarely reported." "" "" ""</seg>
<seg id="1719">It is available as 5 mg tablet and 5 mg- lyophiisat (soluble tablet) and 2.5 mg / ml syrup and 0.5 mg / ml syrup and as 0.5 mg / ml solution for intake.</seg>
<seg id="1720">"" "" "" "for children aged one to five years, the dose is 1.25 mg once a day, which is in the form of 2.5 ml syrup." "" "" ""</seg>
<seg id="1721">"" "" "" "for children aged six to eleven years, the dose is 2.5 mg once a day, either in the form of 5 ml syrup or." "" "" ""</seg>
<seg id="1722">Aerius was examined in a total of eight studies involving around 4 800 adults and adolescents with allergic rhinitis (including four studies of seasonal allergic rhinitis and two studies in patients who had asthma).</seg>
<seg id="1723">"" "" "" "efficacy was measured by determining the symptoms (itching, number and size of the paddles, impairment of sleep and performance on the day) before and after six weeks of treatment." "" "" ""</seg>
<seg id="1724">"" "" "" "further studies have been presented to prove that the body uses the syrup, the solution for inserting and the melting tablets in the same way as the tablets and application in children is safe." "" "" ""</seg>
<seg id="1725">"" "" "" "in case of allergic rhinitis, when the results of all studies were taken together, the two-week treatment with 5 mg Aerius resulted in an average decrease of the symptom score (symptom score) by 25 to 32% compared to the decrease of 12 to 26% in patients receiving a placebo." "" "" ""</seg>
<seg id="1726">"" "" "" "in the two trials in Urticaria, the decrease of the symptom was 58 and 67%, compared to 40 and 33% in patients treated with placebo." "" "" ""</seg>
<seg id="1727">"" "" "" "Aerius may not be used in patients who may be hypersensitive to Desolatadin, Loratadin or any of the other ingredients." "" "" ""</seg>
<seg id="1728">"" "" "" "January 2001, the European Commission granted the company SP Europe a permit for the placing of Aerius in the entire European Union." "" "" ""</seg>
<seg id="1729">"" "" "" "one tablet once a day, with one or without a meal, to relieve the symptoms of allergic rhinitis (including intermittent and persisting allergic rhinitis) and urticaria (see section 5.1)." "" "" ""</seg>
<seg id="1730">"" "" "" "there is limited experience from clinical trials for efficacy in the use of diloratadin in adolescents from 12 to 17 years (see Sections 4.8 and 5.1)." "" "" ""</seg>
<seg id="1731">The treatment of the inhibiting allergic rhinitis (occurrence of symptoms for less than 4 days per week or less than 4 weeks) should be performed according to the previous illness.</seg>
<seg id="1732">"" "" "" "in the case of persistent allergic rhinitis (appearance of symptoms in 4 or more days a week and more than 4 weeks), the patient can be recommended for an ongoing treatment during the course of the allergy." "" "" ""</seg>
<seg id="1733">Clinically relevant interactions were not detected in clinical trials with Desloratadin tablets in which erythromycin or ketoconazole was additionally administered (see section 5.1).</seg>
<seg id="1734">"" "" "" "in a clinical pharmacological study, Aerius and alcohol have not increased the performance of alcohol (see Section 5.1)." "" "" ""</seg>
<seg id="1735">"" "" "" "however, patients should be informed that in very rare cases it can lead to dizziness, which may lead to impairment of traffic efficiency or the ability to operate machinery." "" "" ""</seg>
<seg id="1736">"" "" "" "in clinical trials in various indications including allergic rhinitis and chronic idiopathic urticaria, 3% more side effects were reported daily in patients with Aerius than in patients treated with placebo." "" "" ""</seg>
<seg id="1737">"" "" "" "the most common side effects reported more frequently than placebo were tiredness (1,2%), oral hygiene (0,8%) and headache (0,6%)." "" "" ""</seg>
<seg id="1738">"" "" "" "in a clinical study involving 578 youthful patients from 12 to 17 years, the most common side effect was headaches." "" "" ""</seg>
<seg id="1739">"" "" "" "in a multi-dose study, administered up to 45 mg of Desloratadin (nine-fold clinical dose), no clinically relevant effects were observed." "" "" ""</seg>
<seg id="1740">This includes the inhibition of release of pro-inflammatory cytokines such as IL-4 and IL-8 and IL-13 from human mastcells / basophien as well as the inhibition of the expression of the Adhesive-molecules P selectin to endothelial cells.</seg>
<seg id="1741">"" "" "" "no statistically significant or clinically relevant cardiovascular effect was described in a clinical study involving multiple doses, which was administered up to 20 mg daily in a dose of up to 20 mg daily." "" "" ""</seg>
<seg id="1742">"" "" "" "in a clinical pharmacological study, administered in the desloratadin in a dose of 45 mg. a day (the nine times the clinical dose) was administered over ten days, there was no extension of the Qtc interval." "" "" ""</seg>
<seg id="1743">"" "" "" "in a single dose study with adults, Desloratadin 5 mg showed no influence on standard measurement ranges of the flight performance, including amplification of subjective punctuality or the tasks associated with flying." "" "" ""</seg>
<seg id="1744">"" "" "" "in patients with allergic rhinitis, Aerius was effective in alleviating symptoms such as sneezing, nasal secretion and itching of the nose, itching and redness of the eyes as well as itching on the palate." "" "" ""</seg>
<seg id="1745">"" "" "" "in addition to the established classification in saisonal and perennial, allergic rhinitis can be classified as an alternative to the duration of symptoms alternatively also in intermittent allergic rhinitis and persistent allergic rhinitis." "" "" ""</seg>
<seg id="1746">Intermittent allergic rhinitis are defined as the onset of symptoms for less than 4 days per week or less than 4 weeks.</seg>
<seg id="1747">"" "" "" "allergic rhinitis are defined as symptoms of 4 or more days per week, and more than 4 weeks." "" "" ""</seg>
<seg id="1748">"" "" "" "as shown in the overall scores of the questionnaire for quality of life in Rhino-conjunctivitis, Aerius effectively reduces the strain caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1749">"" "" "" "Chronic Idiopathic Urticaria was representative for further forms of urticaria, as the underlying pathophysiology, regardless of etiology, is similar in the different forms and can be randomized to a simple prospectus." "" "" ""</seg>
<seg id="1750">"" "" "" "since the history of histamines is an causal factor in all ancient diseases, Desolatadin is also expected to improve the symptoms in other forms of urticaria. this is confirmed by the recommendations of clinical guidelines." "" "" ""</seg>
<seg id="1751">In two placebo-controlled trials over 6 weeks in patients with chronic idiopathic urticaria aperius was effective in improving pruritus and reduction of size and number of paddles at the end of the first dose interval.</seg>
<seg id="1752">"" "" "" "as in other studies with antihistaminika in Chronic Idiopathic Urticaria, the majority of patients who did not react to antihistaminika were excluded from the study." "" "" ""</seg>
<seg id="1753">An improvement of itching by more than 50% was observed in 55% of patients treated with Desloratadin compared to 19% of patients treated with placebo.</seg>
<seg id="1754">"" "" "" "treatment with Aerius significantly reduced the disturbance of sleep and wakefulness, as measured by a 4-point scale to evaluate these variables." "" "" ""</seg>
<seg id="1755">"" "" "" "in a pharmacokinetic study, where patients were comparable with the general seasonal allergic rhinitis population, 4% of patients had a higher concentration of Desolatadin." "" "" ""</seg>
<seg id="1756">"" "" "" "there are no indications for clinically relevant cumulation after once daily use of Desloratadin (5- 20 mg), over 14 days." "" "" ""</seg>
<seg id="1757">"" "" "" "however, the enzyme responsible for the metabolism of Desloratadin has not yet been identified so that interactions with other medicines are not completely excluded." "" "" ""</seg>
<seg id="1758">Desloratadin does not inhibit CYP3A4 and in-vitro studies have shown that the drug CYP2D6 does not inhibit and neither a substrate nor an inhibitor of the P-glycoproteins.</seg>
<seg id="1759">"" "" "" "in a single dose study with a total dose of 7.5 mg. meals (fatty, calorie-rich breakfast) did not affect the availability of Desloratadin." "" "" ""</seg>
<seg id="1760">"" "" "" "the preclinical studies carried out with Desloratadin and Loratadin showed no qualitative or quantitative differences in the toxicity profile of Desloratadin and Loratadin." "" "" ""</seg>
<seg id="1761">"" "" "" "based on conventional studies on safety macology, toxicity in repeated application, genotoxicity and reproductive toxicity, the preclinical data with Desloratadin reveal no particular dangers to humans." "" "" ""</seg>
<seg id="1762">"" "" "" "colorless film (contains lactose monohydrate, hypogol 400, Indigocarmin (E 132)), colourless film (contains Hypromless, Macrogol 400), carnauba wax, light wax." "" "" ""</seg>
<seg id="1763">"" "" "" "Aerius can be taken independently of meals, to relieve the symptoms of allergic rhinitis (including intermittent and persisting allergic rhinitis) and urticaria (see section 5.1)." "" "" ""</seg>
<seg id="1764">The prescribing physician should be aware that most cases of rhinitis in children under 2 years may be caused by an infection (see section 4.4) and that no data are available which support a treatment of infectious rhinitis with Aerius.</seg>
<seg id="1765">"" "" "" "in addition to exclusion of upper respiratory infections or anatomical anomalies, anamnesis, physical studies and appropriate laboratory and skin tests should play a role." "" "" ""</seg>
<seg id="1766">"" "" "" "about 6% of adults and children between 2 and 11 years metabolise Desloratadin, and experience a higher substance exposure (see section 5.2)." "" "" ""</seg>
<seg id="1767">"" "" "" "Aerius syrup's safety in children between 2 and 11 years, which can be metabolized, is identical to that in children who are normally metabolized." "" "" ""</seg>
<seg id="1768">"" "" "" "this medicine contains sucrose and sorbitol; therefore, patients with hereditary problems of fructose intolerance, glucose-galactose absorption or insufficiency of this drug should not be taken." "" "" ""</seg>
<seg id="1769">Clinically relevant interactions were not detected in clinical trials with Aerius tablets in which erythromycin or ketoconazole was additionally administered (see section 5.1).</seg>
<seg id="1770">"" "" "" "in a clinical pharmacological study, intake of Aerius tablets and alcohol did not increase the performance of alcohol (see section 5.1)." "" "" ""</seg>
<seg id="1771">The overall frequency of adverse events in children between 2 and 11 years was similar to the Aerius Sirup group similar to the placebo group.</seg>
<seg id="1772">"" "" "" "in clinical trials involving adults and adolescents in various indications including allergic rhinitis and chronic idiopathic urticaria, the recommended dose reported 3% more side effects in patients with Aerius than in patients treated with placebo." "" "" ""</seg>
<seg id="1773">No clinically relevant effects were observed in a multi-dose study of adults and adolescents with up to 45 mg of Desloratadin (nine-fold clinical dose).</seg>
<seg id="1774">Children aged between 1 and 11 years of age suffering from antihistamine therapy have received a daily diloratadine dose of 1.25 mg (aged between 1 and 5 years) or 2.5 mg (aged between 6 and 11 years).</seg>
<seg id="1775">"" "" "" "because the progression of allergic rhinitis / chronic idiopathic urticaria and the profile of diloratadin in adults and children are similar, the efficacy data of diloratadin in adults can be extrapolated to the children's population." "" "" ""</seg>
<seg id="1776">"" "" "" "as part of a clinical study involving multiple doses to adults and young people, in the desloratadin in a dose of up to 20 mg daily, no statistically significant or clinically relevant cardiovascular effect was described." "" "" ""</seg>
<seg id="1777">"" "" "" "in a clinical pharmacological study of adults and adolescents, in which a total dose of 45 mg. a day (the Neunary of the clinical dose) was applied over ten days in adults, there was no extension of the Qtc interval." "" "" ""</seg>
<seg id="1778">"" "" "" "in controlled clinical trials, the recommended dose of 5 mg daily for adults and adolescents reported no increased frequency of sleepiness compared to placebo." "" "" ""</seg>
<seg id="1779">"" "" "" "in case of a single daily dose of 7.5 mg, Aerius tablets in adults and adolescents in clinical trials did not affect psychomotor impairment." "" "" ""</seg>
<seg id="1780">"" "" "" "in clinical pharmacological studies in adults, the simultaneous intake of alcohol did not result in increasing the impairment of alcohol-induced impairment." "" "" ""</seg>
<seg id="1781">"" "" "" "in adult and adolescent patients with allergic rhinitis, Aerius tablets were effective in alleviating symptoms such as sneezing, nasal secretion and itching of the nose, itching and redness of the eyes as well as itching on the palate." "" "" ""</seg>
<seg id="1782">"" "" "" "as shown in the overall live scores of the questionnaire for quality of life in Rhino-conjunctivitis, Aerius tablets effectively reduce the caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1783">In two placebo-controlled trials over 6 weeks in patients with chronic idiopathic urticaria aperius was effective in improving pruritus and reduction of size and number of paddles at the end of the first dose interval.</seg>
<seg id="1784">The spread of this restricted metabolic phenotype was comparable to adults (6%) and children between 2 and 11 years (6%) and in both populations bigger in black (18% adults; 16% children) than with chewing (2% adults).</seg>
<seg id="1785">Similar pharmacokinetic parameters were observed in a pharmacokinetic multi-dose study with the syrup formation in children between 2 and 11 years with allergic rhinitis that are limited.</seg>
<seg id="1786">"" "" "" "after 3 to 6 hours, the strain (AUC) was about 6 times higher and the CMAx about 3 to 4 times higher with a terminal half-life of about 120 hours." "" "" ""</seg>
<seg id="1787">"" "" "" "there are no indications of clinically relevant drug congestion after once daily use of Desloratadin (5- 20 mg), over 14 days in adults and adolescents." "" "" ""</seg>
<seg id="1788">"" "" "" "12 In various single dose studies, AUC- and CMAx values were comparable with pediatric patients in the recommended doses with those of adults who received the Desolatadin syrup in a dose of 5 mg." "" "" ""</seg>
<seg id="1789">"" "" "" "however, the enzyme responsible for the metabolism of Desloratadin has not yet been identified so that interactions with other medicines cannot be completely ruled out." "" "" ""</seg>
<seg id="1790">"" "" "" "Aerius syrup is offered in type III brown bottles with child-safe polypropylene closures with 30, 50, 60, 100, 120, 225 and 300 ml." "" "" ""</seg>
<seg id="1791">"" "" "" "equipped with a rigid, transparent polystyrene measuring spoon, calibrated with 2.5 ml and 5 ml or with an application syringe for preparations for intake with 2.5 ml and 5 ml (only for the 150 ml bottle)." "" "" ""</seg>
<seg id="1792">"" "" "" "take a dose of Aerius Lyphilisat once a day to relieve the symptoms of allergic rhinitis (including intermittent and persisting allergic rhinitis) and urticaria (see section 5.1)." "" "" ""</seg>
<seg id="1793">"" "" "" "immediately prior to application, the blister must be carefully opened and the dose of the lyophiisat must be taken out without damaging it." "" "" ""</seg>
<seg id="1794">Clinically relevant interactions were not detected in clinical trials with Aerius tablets in which erythromycin or ketoconazole were additionally used (see section 5.1).</seg>
<seg id="1795">"" "" "" "in clinical trials in various indications including allergic rhinitis and chronic idiopathic urticaria, 3% more side effects were reported in patients with Aerius tablets a day than in patients treated with placebo." "" "" ""</seg>
<seg id="1796">"" "" "" "in a multi-dose study, where up to 45 mg of Desloratadin (nine-fold clinical dose) were used, no clinically relevant effects were observed." "" "" ""</seg>
<seg id="1797">"" "" "" "in two single dose studies, Aerius Lyphilisat was well tolerated; this was documented by clinical laboratory results, medical examinations, vital signs and ECG intervals." "" "" ""</seg>
<seg id="1798">"" "" "" "no statistically significant or clinically relevant cardiovascular effect was described as part of a clinical study involving multiple doses, which was administered up to 20 mg daily in a dose of up to 20 mg daily." "" "" ""</seg>
<seg id="1799">"" "" "" "in a clinical pharmacological study, in which the diloratadin was applied in a dose of 45 mg. a day (the nine times the clinical dose) was applied over ten days, there was no extension of the Qtc interval." "" "" ""</seg>
<seg id="1800">"" "" "" "in controlled clinical trials, the recommended dose of 5 mg daily did not detect an increased frequency of sleepiness compared to placebo." "" "" ""</seg>
<seg id="1801">"" "" "" "in a 17 single dose study with adults, Desloratadin 5 mg showed no influence on standard measurement ranges of the flight performance including amplification of subjective punctuality or the tasks associated with flying." "" "" ""</seg>
<seg id="1802">"" "" "" "in patients with allergic rhinitis, Aerius tablets were effective in alleviating symptoms such as sneezing, nasal secretion and itching of the nose, itching and redness of the eyes as well as itching on the palate." "" "" ""</seg>
<seg id="1803">"" "" "" "as shown in the overall scores of the questionnaire for quality of life in Rhino-conjunctivitis, Aerius effectively reduces the strain caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1804">"" "" "" "18 In a pharmacokinetic study, where patients were comparable with the general seasonal allergic rhinitis population, 4% of patients had a higher concentration of Desolatadin." "" "" ""</seg>
<seg id="1805">Food has no significant influence on AUC and CMAx from Aerius Lyphilisat for intake as food Tmax from Desloratadin from 2.5 to 4 hours and Tmax of 3-OH-Desloratadin from 4 to 6 hours extended.</seg>
<seg id="1806">Gelatine Mannitol aspartame (E 951) Polacrilin potassium dye opatint red (contains iron (III) -oxide (E 172) and Hypromless (E 464)) Aroma tutti-Frutti water-free citric acid</seg>
<seg id="1807">"" "" "" "aerius 2.5 mg of melt tablet once a day in the mouth, to relieve the symptoms of allergic rhinitis (including intermittent and persisting allergic rhinitis) and urticaria (see section 5.1)." "" "" ""</seg>
<seg id="1808">"" "" "" "two Aerius 2.5 mg of melted tablets daily in the mouth, to relieve the symptoms of allergic rhinitis (including intermittent and persisting allergic rhinitis) and urticaria (see section 5.1)." "" "" ""</seg>
<seg id="1809">"" "" "" "there is limited experience from clinical trials for efficacy in the use of diloratadin in adolescents from 12 to 17 years (see Sections 4.8 and 5.1)," "" "" ""</seg>
<seg id="1810">"" "" "" "immediately prior to application, the blister must be carefully opened and the dose of the melt tablet is removed without damaging it." "" "" ""</seg>
<seg id="1811">The efficacy and harmlessness of Aerius 2.5 mg of melting tablets in the treatment of children under 6 years have not been proven.</seg>
<seg id="1812">The overall frequency of adverse events between the siloratadine syrup and the placebo group was the same and did not significantly diminish any safety profile identified with adult patients.</seg>
<seg id="1813">At the recommended dose Aerius melted tablet turned out to be a bioequivalent to the Aerius 5 mg conventional tablets formulation and the Aerius 5 mg lyophilisate to the decomposition formulation of Desloratadin.</seg>
<seg id="1814">"" "" "" "in a clinical study involving multiple doses used in the desloratadin in a dose of up to 20 mg. daily over 14 days, no statistically significant or clinically" "" "" ""</seg>
<seg id="1815">"" "" "" "in a single dose study with adults, Desloratadin 5 mg showed no influence on standard measurement ranges of the flight performance including amplification of subjective punctuality or the tasks associated with flying." "" "" ""</seg>
<seg id="1816">"" "" "" "the spread of this badly metabolized phenotype was comparable to adult (6%) and paediatric patients between 2 and 11 years (adults 18%, children 16%), but the safety profile of these patients was not different from that of the general population." "" "" ""</seg>
<seg id="1817">In single dose-crossover studies of Aerius melt tablet with Aerius 5 mg conventional tablets or Aerius 5 mg lyophilisate the formulations were bioequivalent.</seg>
<seg id="1818">"" "" "" "Aerius 2.5 mg tablets were not examined in pediatric patients, in conjunction with the dose-finite studies in children, however, the pharmacokinetic data for Aerius melting tablets support the use of the 2.5 mg dosage in children from 6 to 11 years." "" "" ""</seg>
<seg id="1819">Food has no significant influence on AUC and CMAx of Aerius Aerius Lyphilisat for intake as food Tmax from Desloratadin from 2.5 to 4 hours and Tmax of 3-OH- Desloratadin from 4 to 6 hours extended.</seg>
<seg id="1820">The overall analysis of preclinical and clinical Irritation tests for the melting tablet revealed that this formulation is an unlikely risk for local irritation in clinical use.</seg>
<seg id="1821">Microcrystalline Cellulose Premiscellated starch Carboxymethyl ammethacrylate-Copolmethacrylate-Copolymer (Ph.Eur.) Crospovidon sodium hydrogen peroxide nitric oxide nitric oxide carnitine (E951) Aroma tutti Frutti</seg>
<seg id="1822">"" "" "" "the cold forming film consists of polyvinyl chloride (PVC) adhesive lamented onto a polyamide (OPA) film, lamented on an aluminium foil adhesive lamented on a polyvinyl chloride (PVC) film." "" "" ""</seg>
<seg id="1823">"" "" "" "an Aerius 5 mg of melt tablet once a day in the mouth, to relieve the symptoms of allergic rhinitis (including intermittent and persisting allergic rhinitis) and urticaria (see section 5.1)." "" "" ""</seg>
<seg id="1824">At the recommended dose Aerius 5 mg of melt tablet turned out to be a bioequivalent to the Aerius 5 mg conventional tablets formulation and the Aerius 5 mg lyophilisate to the decomposition formulation of Desloratadin.</seg>
<seg id="1825">"" "" "" "no statistically significant or clinically relevant cardiovascular effect was described as part of a clinical study involving multiple doses, which was administered up to 20 mg daily in a dose of up to 20 mg daily." "" "" ""</seg>
<seg id="1826">"" "" "" "in a 30 single dose study with adults, Desloratadin 5 mg showed no influence on standard measurement ranges of the flight performance including amplification of subjective punctuality or the tasks associated with flying." "" "" ""</seg>
<seg id="1827">"" "" "" "in patients with allergic rhinitis, Aerius tablets were effective in alleviating symptoms such as sneezing, nasal secretion and itching of the nose, itching and redness of the eyes as well as itching on the palate." "" "" ""</seg>
<seg id="1828">In single dose-crossover studies of Aerius 5 mg processed tablet with Aerius 5 mg conventional tablets or Aerius 5 mg lyophilisate the formulations were bioequivalent.</seg>
<seg id="1829">The overall analysis of preclinical and clinical Irritation tests for the melting tablet revealed that this formulation is an unlikely risk for local irritation in clinical use.</seg>
<seg id="1830">"" "" "" "the safety of diloratadin in children between 2 and 11 years, which can be metabolized, is identical to that in children who are normally metabolized." "" "" ""</seg>
<seg id="1831">"" "" "" "this medicine contains sorbitol; therefore, patients with hereditary problems of fructose intolerance, glucose-galactose absorption or insufficiase insufficiency of this drug should not use this medicine." "" "" ""</seg>
<seg id="1832">"" "" "" "the overall frequency of adverse events in children between 2 and 11 years was similar to the placebo group, similar to the placebo group." "" "" ""</seg>
<seg id="1833">"" "" "" "in infants aged 6 to 23 months, the most frequently encountered side-effects reported more frequently than placebo, diarrhea (3.7%), fever (2,3%) and insomnia (2,3%)." "" "" ""</seg>
<seg id="1834">"" "" "" "in an additional study, at a single dose of 2.5 mg of Desloratadin, no side effects were observed in patients aged between 6 and 11 years." "" "" ""</seg>
<seg id="1835">"" "" "" "at the recommended doses, the plasma concentrations of Desloratadin (see section 5.2) were comparable in the children's and adult population." "" "" ""</seg>
<seg id="1836">"" "" "" "in controlled clinical trials, the recommended dose of 5 mg daily for adults and adolescents reported no increased frequency of sleepiness compared to placebo." "" "" ""</seg>
<seg id="1837">"" "" "" "in addition to the established classification in saisonal and perennial, allergic rhinitis may alternatively also be in intermittent allergic rhinitis depending on the duration of symptoms." "" "" ""</seg>
<seg id="1838">"" "" "" "as shown in the overall scores of the questionnaire for quality of life in Rhino-conjunctivitis, Aerius tablets effectively reduce the strain caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1839">The spread of this restricted metabolic phenotype was comparable to adults (6%) and children between 2 and 11 years (6%) and in both populations bigger in black (18% adults; 16% children) than with chewing (2% adults).</seg>
<seg id="1840">"" "" "" "as Aerius solution for intake contains the same concentration of desloratadin, no bioequivalent study was required and it is expected that it corresponds to the syrup and the tablets." "" "" ""</seg>
<seg id="1841">"" "" "" "in various single dose studies, AUC- and CMAx values were comparable with pediatric patients in the recommended doses with those of adults who received the Desolatadin syrup in a dose of 5 mg." "" "" ""</seg>
<seg id="1842">"" "" "" "sorbitol, propylene glycol, sucralose E 955, Hypromless E 2910, sodium citric acid, sodium citric acid, sodium citric acid, sodium edetate (Ph.Eur.), purified water." "" "" ""</seg>
<seg id="1843">"" "" "" "Aerius solution for intake is offered with 30, 50, 60, 100, 150, 225 and 300 ml in type III brown bottles with a single-layer polyethylene coating." "" "" ""</seg>
<seg id="1844">"" "" "" "all sizes except the 150 ml package size are offered with a measuring spoon with markings for dosages of 2.5 ml, and 5 ml." "" "" ""</seg>
<seg id="1845">"" "" "" "the 150 ml packet size is a measuring spoon, or an application syringe for preparations to insert with scales of 2.5 ml and 5 ml." "" "" ""</seg>
<seg id="1846">"" "" "" "subsequently, the authorisation holder will submit the regularly updated reports on the unquestionability of a drug every two years, unless something else is decided by CHMP." "" "" ""</seg>
<seg id="1847">"" "" "" "1 Film tablets 2 film tablets, 3 film-tablets 5 film-tablets 10 film-tablets 20 film-tablets 30 film-tablets 30 film-tablets 100 film-tablets 100 film-tablets 100 film tablets" "" "" ""</seg>
<seg id="1848">"" "" "" "1 Film tablets 2 film tablets, 3 film-tablets 5 film-tablets 10 film-tablets 20 film-tablets 30 film-tablets 30 film-tablets 100 film-tablets 100 film-tablets 100 film tablets" "" "" ""</seg>
<seg id="1849">Syrup 30 ml with 1 measuring scoop 100 ml with 1 measuring scoop 100 ml with 1 measuring scoop 100 ml with 1 measuring spoon 150 ml with 1 measuring scoop 150 ml with 1 measuring scoop 300 ml with 1 measuring spoon 300 ml with 1 measuring spoon.</seg>
<seg id="1850">1 measuring scoop 100 ml with 1 measuring scoop 100 ml with 1 measuring scoop 100 ml with 1 measuring scoop 100 ml with 1 measuring scoop 150 ml with 1 measuring scoop 100 ml with 1 measuring scoop 300 ml with 1 measuring spoon 300 ml with 1 measuring spoon.</seg>
<seg id="1851">1 dose Lyphilisat for taking in 2 doses Lyphilisat for taking up 7 doses of lyophiisat for taking up 15 doses of lyophilisat for taking up 15 doses of lyophiisat for taking up of 50 doses Lyphilisat for taking up 100 doses Lyphilisat for taking up 100 doses of lyophilisat</seg>
<seg id="1852">"" "" "" "5 melting tablets 6 melt-coated tablets, 15 melting tablets 18 melting tablets." "" "" ""</seg>
<seg id="1853">1 measuring scoop 100 ml with 1 measuring scoop 100 ml with 1 measuring scoop 100 ml with 1 measuring scoop 100 ml with 1 measuring spoon 150 ml with 1 measuring scoop 100 ml with 1 measuring scoop 300 ml with 1 measuring spoon 300 ml with 1 measuring spoon.</seg>
<seg id="1854">"" "" "" "during pregnancy and lactation, consult your doctor or pharmacist for advice during pregnancy and lactation." "" "" ""</seg>
<seg id="1855">"" "" "" "when applying in the recommended dosage, it is not possible to reckon that Aerius leads to dizziness or diminishes attention." "" "" ""</seg>
<seg id="1856">"" "" "" "if you have been told by your doctor that you have a intolerance to certain sugars, consult your doctor before taking this medicine." "" "" ""</seg>
<seg id="1857">"" "" "" "regarding the duration of treatment, your doctor will determine the type of allergic rhinitis under which you are suffering and will determine how long you should take Aerius." "" "" ""</seg>
<seg id="1858">"" "" "" "if your allergic rhinitis is intermittent (symptoms less frequent than 4 days a week or less than 4 weeks), your doctor will recommend you a treatment scheme that depends on your previous illness." "" "" ""</seg>
<seg id="1859">"" "" "" "if your allergic rhinitis is persistent (the symptoms occur in 4 or more days a week and more than 4 weeks), your doctor may recommend you a lasting treatment." "" "" ""</seg>
<seg id="1860">"" "" "" "if you forgot taking Aerius If you forgot to take your dose in time, take it as soon as possible and then follow the normal treatment plan." "" "" ""</seg>
<seg id="1861">"" "" "" "71 By market introduction of Aerius, very rare cases of severe allergic reactions (difficulty breathing, whistling breathing, itching, hives, swelling) and rash are reported." "" "" ""</seg>
<seg id="1862">"" "" "" "about cases of palpitations, heart hunting, stomach pain, nausea, vomiting, stomach upset, diarrhea, hallucinations, hallucinations, diarrhea and unusual liver function values have also been reported very rarely." "" "" ""</seg>
<seg id="1863">"" "" "" "tablet coating consists of coloured film (contains lactose monohydrate, hypogol 400, Indigocarmin (E 132)), colourless film (contains Hypromless, Macrogol 400), carnauba wax, light wax." "" "" ""</seg>
<seg id="1864">"" "" "" "Aerius 5 mg tablets are individually packaged in blister packs including 1, 2, 3, 5, 10, 14, 15, 21, 30, 50, 90 or 100 tablets." "" "" ""</seg>
<seg id="1865">"" "" "" "Aerius Sirup is shown for children aged 1 to 11, teenagers (12 years and older) and adults, older people included." "" "" ""</seg>
<seg id="1866">"" "" "" "important information about certain other components of Aerius you should not take Aerius syrup, if you are allergic to the dye E 110." "" "" ""</seg>
<seg id="1867">"" "" "" "if your doctor has told you that you have an intolerance on some sugars, please contact your doctor before taking this medicine." "" "" ""</seg>
<seg id="1868">"" "" "" "if the syrup has an application syrup for preparation with scaling, you can use it alternatively to take the appropriate amount of syrup." "" "" ""</seg>
<seg id="1869">"" "" "" "regarding the duration of treatment, your doctor will determine the type of allergic rhinitis under which you are suffering and will determine how long you should take Aerius syrup." "" "" ""</seg>
<seg id="1870">"" "" "" "however, in children under 2 years diarrhea, fever and sleeplessness frequent side effects, while tiredness, oral hygiene and headache have been reported more often than with placebo." "" "" ""</seg>
<seg id="1871">"" "" "" "after the market introduction of Aerius, very rare cases of severe allergic reactions (difficulty breathing, whistling breathing, itching, hives, swelling) and rash are reported." "" "" ""</seg>
<seg id="1872">"" "" "" "77 Aerius Sirup is available in bottles with child-safe closing cap with 30, 50, 60, 100, 120, 225 and 300 ml." "" "" ""</seg>
<seg id="1873">"" "" "" "Aerius Lyphilisat will improve the symptoms of allergic rhinitis (through an allergy-induced inflammation of the nasal passages, e.g. hay fever or house dust mites allergy)." "" "" ""</seg>
<seg id="1874">"" "" "" "taking Aerius Lyphilisat intake, along with foods and drinks Aerius Lyphilisat, do not need to be taken with water or any other liquid." "" "" ""</seg>
<seg id="1875">"" "" "" "regarding the duration of treatment, your doctor will determine the type of allergic rhinitis under which you are suffering and will determine how long you should take Aerius Lyphilisat." "" "" ""</seg>
<seg id="1876">"" "" "" "81 If you forgot to take Aerius Lyphilisat, if you forgot to take your dose in time, take it as soon as possible and then follow the normal treatment plan." "" "" ""</seg>
<seg id="1877">"" "" "" "after the market introduction of Aerius, very rare cases of severe allergic reactions (difficulty breathing, whistling breathing, itching, hives, swelling) and rash are reported." "" "" ""</seg>
<seg id="1878">"" "" "" "Aerius Lyphilisat is packed individually in blister packs including 1, 2, 3, 5, 10, 14, 15, 21, 30, 50 or 100 doses of lyophiisat." "" "" ""</seg>
<seg id="1879">"" "" "" "Aerius melting tablet improves the symptoms of allergic rhinitis (through an allergy-induced inflammation of the nasal passages, e.g. hay fever or house dust mite allergy)." "" "" ""</seg>
<seg id="1880">"" "" "" "when taking Aerius melting tablets, with food and beverages Aerius melt tablet does not need to be taken with water or any other liquid." "" "" ""</seg>
<seg id="1881">"" "" "" "regarding the duration of treatment, your doctor will determine the type of allergic rhinitis under which you are suffering and will determine how long you should take Aerius melting tablets." "" "" ""</seg>
<seg id="1882">"" "" "" "86 If you forgot taking Aerius melting tablets If you forgot to take your dose in time, take it as soon as possible and then follow the normal treatment plan." "" "" ""</seg>
<seg id="1883">"" "" "" "Aerius melting tray is individually packaged in blister packs with 5, 6, 10, 12, 15, 20, 50, 60, 90 and 100 doses of the melting tablet." "" "" ""</seg>
<seg id="1884">"" "" "" "when taking Aerius melting tablets, with food and beverages Aerius melt tablet does not need to be taken with water or any other liquid." "" "" ""</seg>
<seg id="1885">"" "" "" "if you forgot taking Aerius melting tablets If you forgot to take your dose in time, take it as soon as possible and then follow the normal treatment plan." "" "" ""</seg>
<seg id="1886">"" "" "" "after the market introduction of Aerius, very rare cases of severe allergic reactions (difficulty breathing, whistling breathing, itching, hives, swelling) and rash are reported." "" "" ""</seg>
<seg id="1887">"" "" "" "Aerius solution for intake is indicated for children aged between 1 and 11 years, young people (12 years and older) and adults, older people included." "" "" ""</seg>
<seg id="1888">"" "" "" "if the solution for inserting an application syringe for preparations to take with scaling is attached, you can use it alternatively to take the appropriate amount of solution for taking." "" "" ""</seg>
<seg id="1889">"" "" "" "regarding the duration of treatment, your doctor will determine the type of allergic rhinitis under which you are suffering and will determine how long you should take Aerius solution for taking." "" "" ""</seg>
<seg id="1890">"" "" "" "however, in children under 2 years diarrhea, fever and sleeplessness frequent side effects while in adults fatigue, oral hygiene and headache have been reported more often than with placebo." "" "" ""</seg>
<seg id="1891">"" "" "" "97 Aerius solution for intake is available in bottles with child-safe closing cap with 30, 50, 60, 100, 120, 225 and 300 ml." "" "" ""</seg>
<seg id="1892">"" "" "" "the 150 ml packet size is a measuring spoon, or an application syringe for preparation with scales of 2.5 ml- and 5 ml doses." "" "" ""</seg>
<seg id="1893">June 2008 Novartis Vaccines and Diagnostics S.r.l. officially announced that the Committee for Human Use (CHMP) officially announced that the company takes its application for authorisation of the Aflunov permissions for the prevention of aviary H5N1 influenza in adults and elderly people.</seg>
<seg id="1894">Aflunov should be used in adults and elderly people to protect against flu caused by the trunk (type) H5N1 of the influenza A virus.</seg>
<seg id="1895">"" "" "" "this is a special kind of vaccine, which is to protect against a strain of the flu virus, which could cause a future pandemic." "" "" ""</seg>
<seg id="1896">"" "" "" "a pandemic erupts when a new stem of the flu virus appears, which can easily spread from man to person, because humans have no immunity (no protection) against it." "" "" ""</seg>
<seg id="1897">"" "" "" "after receiving the vaccine, the immune system recognizes the parts of the flu virus as" foreign, "and antibodies against it." "" "" ""</seg>
<seg id="1898">"" "" "" "as a result, the immune system is later able to produce antibodies in contact with a flu virus." "" "" ""</seg>
<seg id="1899">"" "" "" "subsequently, the membrane manure of the virus with the" surface antigens "(proteins on the membrane surface that recognizes the human body as a body foreign) has been purified and used as an integral part of the vaccine." "" "" ""</seg>
<seg id="1900">"" "" "" "a survey of some of the study centres showed that the study was not carried out according to" "" "" "" "good clinical practice" "" "" "" "(GCP)." "" "" ""</seg>
<seg id="1901">"" "" "" "as a result, the scope of the clinical data base for assessing the safety of the vaccine was not sufficient to meet the requirements of the EMEA guidelines for pre-pandemic vaccines." "" "" ""</seg>
<seg id="1902">"" "" "" "should you participate in a clinical examination and need more information about your treatment, please contact your doctor." "" "" ""</seg>
<seg id="1903">"" "" "" "if you would like more information regarding the CHMP recommendations, please read the scientific discussion (also part of EPAR)." "" "" ""</seg>
<seg id="1904">"" "" "" "it is used in combination with other antiviral medicines for the treatment of adults and children over four years, which are infected with the human immunodeficiency virus of type 1 (HIV-1), which causes the acquired immunodeficiency syndrome (AIDS)." "" "" ""</seg>
<seg id="1905">"" "" "" "for patients who cannot swallow the capsules, adenase is indeed available as a solution for intake, but this cannot be taken together with Ritonavir since the safety of this combination was not examined." "" "" ""</seg>
<seg id="1906">"" "" "" "atherosclerosis should only be prescribed if the doctor checked out which antiviral drugs the patient has previously taken, and the likelihood of the virus to be addressed to the medicine." "" "" ""</seg>
<seg id="1907">"" "" "" "the recommended dose for patients over twelve years amounts to 600 mg twice a day, which are taken with twice a day 100 mg Ritonavir and with other antiviral medicines." "" "" ""</seg>
<seg id="1908">"" "" "" "in children between four and twelve years and in patients with a body weight of less than 50 kg, the recommended dose of atherase depends on body weight." "" "" ""</seg>
<seg id="1909">"" "" "" "in combination with other antiviral medicines, atherase reduces the HIV-quantity of the blood and keeps it at a low level." "" "" ""</seg>
<seg id="1910">"" "" "" "not to cure AIDS, however, can delay the damage to the immune system and hence also the development of associated infections and diseases." "" "" ""</seg>
<seg id="1911">"" "" "" "Agenerase was studied in combination with other antiviral medicines, but without Ritonavir, in two main studies with 736 HIV infected adults who had previously not been treated with proteasants." "" "" ""</seg>
<seg id="1912">"" "" "" "the drug asgenerase, which was increased with low dose, was compared with other proteasinhibitors in 206 adults who formerly used proteasinhibitors." "" "" ""</seg>
<seg id="1913">Main indicator of efficacy was the proportion of patients with non-detectable concentrations of HIV in the blood (viral load) or the change in viral load after treatment.</seg>
<seg id="1914">"" "" "" "in the studies with patients who previously had no proteasinhibitors, more patients had a viral load among 400 copies / ml under Agenera than under placebo, but Agenera was less effective than indinavir." "" "" ""</seg>
<seg id="1915">"" "" "" "Agenera also reduced viral load in children, but with the children who had previously been treated with proteasant inhibitors, only very few addressed the treatment." "" "" ""</seg>
<seg id="1916">"" "" "" "in the study with adults who had previously been treated with proteasant inhibitors, the drug Agenera reinforced the viral load after 16-week treatment as effective as other proteasinhibitors:" "" "" ""</seg>
<seg id="1917">"" "" "" "in patients with HIV, which was resistant to four other proteasthenmer, there was a stronger decrease in the viral load after four weeks than in patients receiving their previous proteasinhibitors:" "" "" ""</seg>
<seg id="1918">"" "" "" "the most common side effects of Agenerase (observed in more than 1 out of 10 patients) are headaches, diarrhoea, flatulence, nausea, vomiting, rash and fatigue." "" "" ""</seg>
<seg id="1919">"" "" "" "2 / 3 Agenera must not be used in patients, which may be hypersensitive to amiravir or any of the other ingredients." "" "" ""</seg>
<seg id="1920">"" "" "" "atherosclerosis may not be used in patients, the St. John's wort (a herbal supplement for the treatment of depression) or medicines that are disposed of as atherase and are health-damaging in high concentrations in the blood." "" "" ""</seg>
<seg id="1921">"" "" "" "as with other medicines for HIV, there is a risk of lipodystrophy (changes in the distribution of body fat) or an immune reactivation syndrome (symptoms of infection caused by the restorative immune system)." "" "" ""</seg>
<seg id="1922">The Committee for Medicinal Products (CHMP) concluded that the benefits of atherosclerosis in combination with other antiretroviral medicines for the treatment of HIV-1 infected adults and children over four years outweigh the risks.</seg>
<seg id="1923">"" "" "" "Agenerase is usually taken together with the pharmacokinetic amplifier Ritonavir, but the committee found that the use of asgenerase in combination with kronyavir in patients who previously did not have proteasinhibitors is not proven." "" "" ""</seg>
<seg id="1924">"" "" "" "Agenera was originally supposed under" exceptional circumstances, "since the time of approval for scientific reasons only limited information was presented." "" "" ""</seg>
<seg id="1925">"" "" "" "in October 2000, the European Commission granted Glaxo Group Limited permission to transport Agenerase across the European Union." "" "" ""</seg>
<seg id="1926">"" "" "" "Agenerase is shown in combination with other antiretroviral medicines for the treatment of HIV-1 infected, proteasinhibitors (PI) -pretreated adults and children aged 4 years." "" "" ""</seg>
<seg id="1927">"" "" "" "usually, Agenerative Capsules should be administered to the pharmacokinetic booster of amponavir together with low doses of kritonavir (see Sections 4.2 and 4.5)." "" "" ""</seg>
<seg id="1928">"" "" "" "due to the individual viral resistance pattern and pretreatment of the patient, the use of ampleavir should be performed (see Section 5.1)." "" "" ""</seg>
<seg id="1929">The bioavailability of ampleavir as a solution for intake is 14% lower than from Ambroavir as capsule; therefore Agenera capsules and solution for intake on a milligram per milligram basis are not interchangeable (see Section 5.2).</seg>
<seg id="1930">The recommended dose for Agenerase capsules is 600 mg Ambroavir twice daily along with 100 mg Ritonavir twice a day in combination with other antiretroviral medicines.</seg>
<seg id="1931">"" "" "" "2 When Agenerative Capsules are used without the reinforcing addition of kronyavir (booster), higher doses of atherase (1200 mg twice a day) must be applied." "" "" ""</seg>
<seg id="1932">The recommended dose for Agenerase capsules is 20 mg of amponavir / kg bodyweight twice a day in combination with other antiretroviral drugs up to a daily dose of 2400 mg of ammonium that should not be exceeded (see Section 5.1).</seg>
<seg id="1933">"" "" "" "the pharmacokinetics, efficacy and safety of atherase in combination with low doses of kronyavir or other protein-inhibitors were not studied in children." "" "" ""</seg>
<seg id="1934">"" "" "" "Agenerase is not recommended for use in children under 4 years, due to the lack of data on the safety and efficacy (see Section 5.2)." "" "" ""</seg>
<seg id="1935">"" "" "" "based on pharmacokinetic data, the dose of Agenerase capsules was reduced to 450 mg twice daily and in patients with severe liver dysfunction at 300 mg twice daily." "" "" ""</seg>
<seg id="1936">"" "" "" "in patients with mild or moderate liver dysfunction, patients with severe liver dysfunction are contraindicated (see Section 4.3)." "" "" ""</seg>
<seg id="1937">"" "" "" "Agenera must not be given simultaneously with medicines which have a low therapeutic breadth, and also represent substrates of the cytochrom P450-Isoenzyme 3A4 (CYP3A4)." "" "" ""</seg>
<seg id="1938">Herbal preparations containing St. John's wort (hypericum perforatum) may not be used due to the risk of reduced plasma concentrations and a reduced therapeutic effect of ampleavir while taking aminoavir (see section 4.5).</seg>
<seg id="1939">Patients should be advised that atherosclerosis or any other antiretroviral therapy does not lead to a cure of HIV infection and that they can continue to develop opportunistic infections or other complications of an HIV infection.</seg>
<seg id="1940">"" "" "" "the current antiretroviral therapy, including treatment with atherosclerosis, does not prevent the risk of transmission from HIV to others through sexual contact or contamination with blood." "" "" ""</seg>
<seg id="1941">"" "" "" "usually, Agenerative Capsules should be used together with low doses of kronyavir and in combination with other antiretroviral medicines (see Section 4.2)." "" "" ""</seg>
<seg id="1942">"" "" "" "patients suffering from chronic hepatitis B or C and treated with antiretroviral therapy, have an increased risk of serious liver side effects with potentially fatal consequences." "" "" ""</seg>
<seg id="1943">"" "" "" "in case of simultaneous antiviral treatment of hepatitis B or C, please read the information on this medicine." "" "" ""</seg>
<seg id="1944">Patients with pre-existing liver function including chronically active hepatitis show increased incidence of liver function disorders under an antiretroviral therapy and should be monitored according to clinical practice.</seg>
<seg id="1945">Simultaneous use of Agenerase and Ritonavir with fluticason or other glucoco corticoids that are metabolized via CYP3A4 is not recommended unless the potential benefit of a treatment outweighs the risk of systemic corticosteroid effects including Morbus Cushing and Suppression of the adrenal function (see section 4.5).</seg>
<seg id="1946">Since the metabolism of the HMG-CoA-Reductase-Hemmer Lovastatin and Simvastatin is strongly dependent on CYP3A4 a simultaneous administration of agastatin and Simvastatin is not recommended because of the increased risk of myopathies including Rhabdomyolysis.</seg>
<seg id="1947">"" "" "" "4 For some medicines that can cause serious or life-threatening adverse events such as carbamazepine, phenobarbital, tricyclic antidepressants and warfarin (under surveillance of the International Norised Ratio), methods for determining the drug concentration are available." "" "" ""</seg>
<seg id="1948">"" "" "" "for patients who take these medicines at the same time, Agenera can be less effective because of diminished plasma levels of ampleavir (see section 4.5)." "" "" ""</seg>
<seg id="1949">"" "" "" "due to the possibility of metabolic interactions with ampleavir, the effectiveness of hormonal contraceptives can be altered, but the information is not sufficient to assess the type of interactions." "" "" ""</seg>
<seg id="1950">"" "" "" "if methadone is given at the same time with an amponavir, the patients should therefore be monitored for opium withdrawal symptoms especially if there are also low doses of kronyavir administered." "" "" ""</seg>
<seg id="1951">"" "" "" "because of the potential risk of a toxicity due to the high propylene glycol content of the Agenera solution, this formulation is contraindicated in children under an age of four years and should be used with caution in certain other patient groups." "" "" ""</seg>
<seg id="1952">"" "" "" "Agenerase should be removed in duration 5, when a rash of systemic or allergic symptoms is accompanied or the mucous membranes are involved (see Section 4.8)." "" "" ""</seg>
<seg id="1953">"" "" "" "in patients receiving antiretroviral therapy including proteasinhibitors, diabetes mellitus, hyperglycemia or an exadisation of an existing diabetes mellitus." "" "" ""</seg>
<seg id="1954">"" "" "" "many of the patients had other diseases, to which therapy medications were required to be associated with the development of diabetes mellitus or hyperglycemia." "" "" ""</seg>
<seg id="1955">"" "" "" "B. higher age, and associated with drug addicts, such as persistent antiretroviral treatment and associated metabolic disorders." "" "" ""</seg>
<seg id="1956">"" "" "" "in case of hemophile patients (type A and B) treated with protease inhibitors, reports of an increase in bleeding including spontaneous cutaneous hematomas and hematthrosis occur." "" "" ""</seg>
<seg id="1957">"" "" "" "in HIV-infected patients with severe immune defect, an anti-retroviral therapy (ART) may develop an inflammatory response to asymptomatic or residual opportunistic infections leading to severe clinical conditions or worsening symptoms." "" "" ""</seg>
<seg id="1958">"" "" "" "although multifactorial etiology is accepted (including use of corticosteroids, alcohol consumption, heavy immunosuppression, higher body mass index), in particular in patients with advanced HIV disease and / or long-term use of antiretroviral therapy (ART)." "" "" ""</seg>
<seg id="1959">CYP3A4 substrates with low therapeutic width Agenera must not be given simultaneously with medicines which have a low therapeutic breadth and also represent substrates of the cytochrom P450-Isoenzyme 3A4 (CYP3A4).</seg>
<seg id="1960">CYP2D6 substrates with low therapeutic width Agenerase with kpkavir must not be used together with medicines whose active ingredients are mainly mixed with CYP2D6 and are associated with severe and / or life-threatening adverse events.</seg>
<seg id="1961">"" "" "" "it has been shown that Rifampicin causes a 82% reduction in the AUC by Ambroavir, which can lead to a virological failure and a resistance development." "" "" ""</seg>
<seg id="1962">"" "" "" "in attempting to balance the lower plasma levels by a dose increase of other protease inhibitors in combination with kronyavir, adverse reactions have been observed on the liver." "" "" ""</seg>
<seg id="1963">St. John's wort (Hypericum perforatum) The serum levels of ammonium can be humiliated by the simultaneous use of herbal preparations with St. John's wort (Hypericum perforatum).</seg>
<seg id="1964">"" "" "" "if a patient already uses currants, the amphetavirus levels are and if possible to check the viral load and remove the St. John's wort." "" "" ""</seg>
<seg id="1965">A can adjustment for one of the medicines is not required if Nelfinavir is administered together with Ambroavir (see also Efavirenz below).</seg>
<seg id="1966">"" "" "" "by contrast, 508% increases, whereas kMAx is reduced by 30% if Ritonavir (100 mg twice a day) is administered in combination with ammonium capsules (600 mg twice a day)." "" "" ""</seg>
<seg id="1967">"" "" "" "in clinical trials, doses of 600 mg of amponavir were used twice a day and ritonavir 100 mg twice a day, confirming the efficacy and harmlessness of this treatment scheme." "" "" ""</seg>
<seg id="1968">"" "" "" "in combination with Kaletra (400 mg, Lopinavir + 100 mg Ritonavir twice a day), 52% is degraded in combination with Kaletra (400 mg of Lopinavir + 100 mg Ritonavir twice a day)." "" "" ""</seg>
<seg id="1969">The Cmin values of ampleavir in plasma that were obtained twice a day with Kaletra (600 mg twice daily) with Kaletra (600 mg twice daily) in combination with 100 mg Ritonavir twice a day are administered twice a day.</seg>
<seg id="1970">"" "" "" "a dosage recommendation for the simultaneous administration of Ambroavir and Kaletra can not be given, but a tight monitoring is recommended as the effectiveness and safety of this combination is unknown." "" "" ""</seg>
<seg id="1971">"" "" "" "not a pharmacokinetic study used to use atherosine in combination with didanosine is recommended, however, due to the antacids component of didanosine it is recommended that the revenues of didanosine and atherosclerosis are at least one hour apart (see Antazida below)." "" "" ""</seg>
<seg id="1972">Therefore the application of Efavirenz in combination with amponavir (600 mg twice a day) and kritonavir (100 mg twice daily) does not require dosage adjustment.</seg>
<seg id="1973">The treatment with Efavirenz in combination with Amprenavir and Saquinavir is not recommended as the exposure of both proteasinhibitors would decrease.</seg>
<seg id="1974">The effect of Nevidentin on other proteasinhibitors and existing limited data suggests that Nevips possibly lowers the serum concentration of amiravir.</seg>
<seg id="1975">"" "" "" "should these drugs be used at the same time, caution is advisable because Delavirus could be less effective because of the reduced or possibly subtherapeutic label." "" "" ""</seg>
<seg id="1976">"" "" "" "if these drugs are used together, caution is advisable; thorough clinical and virological surveillance should be made as an exact prediction of the effect of the combination of Amiravir and Ritonavir on Delavirdine is difficult." "" "" ""</seg>
<seg id="1977">The simultaneous injection of ammonium and riflabectin led to an increase in the plasma concentration (AUC) of rifabutin by 193% and therefore leads to an increase of the side effects associated with riflare.</seg>
<seg id="1978">"" "" "" "if it is required for clinical reasons, at least half of the recommended dosage will be reduced to at least half of the recommended dose, although there are no clinical data available." "" "" ""</seg>
<seg id="1979">"" "" "" "pharmacokinetic studies with arthromycin in combination with erythromycin have not been performed, but the plasma levels of both drugs could be increased in the case of simultaneous administration." "" "" ""</seg>
<seg id="1980">Simultaneous use of 700 mg of Foscarnitavir and 100 mg Ritonavir with 200 mg of ketoconazole once a day led to an increase in the CMAx of ketoconazole in plasma by 25% and the AUC (0-τ) once a day without simultaneous use of Fosamiravir with ketoconazole.</seg>
<seg id="1981">"" "" "" "other medicines that are listed below, including substrates, inhibitors or inductors of CYP3A4, can potentially lead to interactions with atherosclerosis." "" "" ""</seg>
<seg id="1982">"" "" "" "patients should therefore be monitored on toxic reactions associated with these drugs, when used in combination with atherosclerosis." "" "" ""</seg>
<seg id="1983">"" "" "" "based on the data of other proteasinhibitors, it is advisable that antacids are not taken at the same time as atherase as it can cause resorption disorders." "" "" ""</seg>
<seg id="1984">"" "" "" "the simultaneous use of anticonvulsants known as enzyme reducers (phenytoin, phenobarbital, carbamazepine), with ampleavir can lead to a degradation of the plasma levels of ampleavir." "" "" ""</seg>
<seg id="1985">"" "" "" "the serum concentrations of calcium channel blockers such as amlodipine, dipine, nifedipine, nifedipine, nifedipine, nivdipine, nivdipine, nivdipine and verapamil can be increased." "" "" ""</seg>
<seg id="1986">"" "" "" "simultaneous intake of atherosclerosis can considerably increase its plasma concentrations and strengthen associated side effects including hypotension, blurred vision and priapism (see section 4.4)." "" "" ""</seg>
<seg id="1987">"" "" "" "in a clinical study, in which Ritonavir 100 mg capsules were given twice daily along with 50 µg Fluticasonpropionate intranasal (4 times daily) over 7 days in subjects, the endogenous cortisol decreased by approximately 86% (90% -range from 82 to 89%)." "" "" ""</seg>
<seg id="1988">"" "" "" "as a result, the simultaneous gift of Agenerase with Ritonavir together with these glucoco corticoids is not recommended unless the potential benefit of a treatment outweighs the risk of systemic corticosteroid effects (see Section 4.4)." "" "" ""</seg>
<seg id="1989">"" "" "" "in the case of HMG-CoA reductase inhibitors such as Lovastatin and Simvastatin, their metabolism is strongly dependent on CYP3A4, significant increases in plasma levels can be expected with simultaneous administration of atherosclerosis." "" "" ""</seg>
<seg id="1990">"" "" "" "since plasma levels of these HMG-CoA reductase inhibitors can lead to myopathy, including Rhabdomyolysis, the combined use of this drug is not recommended." "" "" ""</seg>
<seg id="1991">"" "" "" "a more frequent monitoring of the therapeutic concentrations to stabilizing the mirror is recommended as the plasma concentrations of cyclosporine, rapamycin and tacrolimus can be increased with simultaneous injection of amiravir (see section 4.4)." "" "" ""</seg>
<seg id="1992">"" "" "" "therefore, atherosclerosis may not be used together with the oral mdazolam (see section 4.3), while at the same time it is advisable to use atherase with parenteral midazolam." "" "" ""</seg>
<seg id="1993">Data for simultaneous use of parenteral midazolam with other proteaseinase inhibitors indicate a possible increase in the plasma levels of Midazolam by 3 to 4 times.</seg>
<seg id="1994">"" "" "" "if methadone is administered together with amponavir, the patients should therefore be monitored for opium withdrawal symptoms especially if there are also low doses of kronyavir administered." "" "" ""</seg>
<seg id="1995">"" "" "" "due to the low reliability of historic comparisons, no recommendation can be given at the moment, as the AMP is administered at the same time with methadone." "" "" ""</seg>
<seg id="1996">An increased control of the INR (International Norised Ratio) is recommended because of the possibility of weakening or strengthening the anti-thrombotic effect (see section 4.4).</seg>
<seg id="1997">"" "" "" "the effect of an additional dose of kritonavir on hormonal contraceptives is not predictable, so alternative methods of contraception are also recommended." "" "" ""</seg>
<seg id="1998">A careful monitoring of the therapeutic effects and side effects of tricyclic antidepressants (for example Desipramine and nortryptilin) is recommended with simultaneous administration of atherosclerosis (see section 4.4).</seg>
<seg id="1999">"" "" "" "during pregnancy, this drug may only be used after careful weighing of the potential benefit for the mother compared to possible risks for the fetus." "" "" ""</seg>
<seg id="2000">"" "" "" "in the milk of lactate rats, ampleavir related substances have been detected; however, it is not known whether it passes into breast milk by people." "" "" ""</seg>
<seg id="2001">"" "" "" "a reproduction study of pregnant rats, which was administered by evaporation in the uterus until the end of the lactation period, showed a diminished increase of 12 body weight during follow-up." "" "" ""</seg>
<seg id="2002">"" "" "" "further development of seed, including fertility and reproductive capacity, was not affected by the administration of an ambulance." "" "" ""</seg>
<seg id="2003">The harmlessness of atheroma was examined in adults and children aged 4 years in controlled clinical trials in combination with various other antiretroviral medicines.</seg>
<seg id="2004">"" "" "" "most of the side effects associated with the Agenerase treatment were mild to moderate, very early and rarely lead to treatment cancerous." "" "" ""</seg>
<seg id="2005">"" "" "" "in many of these events, it is not clear whether or not they are drugs used to treat asterase or other medicines at the same time, or whether they are a consequence of the disease." "" "" ""</seg>
<seg id="2006">"" "" "" "most of the side effects listed below date from two clinical trials (PROAB3001, PROAB3006), in which patients with proteasant inhibitors were received twice daily." "" "" ""</seg>
<seg id="2007">"" "" "" "events (Grade 2 to 4), which were evaluated by the investigators as in connection with the study medication, were performed in more than 1% of the patients as well as in the treatment of occurring laboratory changes (grade 3 to 4)." "" "" ""</seg>
<seg id="2008">Antiretroviral therapy was associated with a redistribution of body fat (lipodystrophy) in HIV patients including a loss of peripheral and retinal fat tissue; increased intraabdominal and visceral fat tissue and hypertrophy of the breasts and dorsocervical fat accumulation (stem cells).</seg>
<seg id="2009">"" "" "" "under 113 antiretroviral non-treated individuals who had been treated with ammonia in combination with lamivudine / zidovudine over an average duration of 36 weeks, only one case (stem cells) was observed (&lt; 1%)." "" "" ""</seg>
<seg id="2010">"" "" "" "compared to 27 cases (11%) in 241 patients under indinavir, in combination with different NRTIs over a mean duration of 56 weeks (p &lt; 0.001)." "" "" ""</seg>
<seg id="2011">"" "" "" "skin rashes were usually mild to moderate, erythematous or makulopapulous nature, with or without itching and disappeared spontaneously during the second treatment week and disappeared spontaneously within two weeks without the treatment with ampleavir had to be canceled." "" "" ""</seg>
<seg id="2012">"" "" "" "osteoarthritis cases were reported in particular in patients with commonly known risk factors, advanced HIV disease or long-term use of antiretroviral therapy (ART)." "" "" ""</seg>
<seg id="2013">"" "" "" "in HIV-infected patients with severe immune defect, an anti-retroviral therapy (ART) may develop an inflammatory response to asymptomatic or residual opportunistic infections (see section 4.4)." "" "" ""</seg>
<seg id="2014">With PI pretreated patients who received 600 mg of ashease twice daily along with low dose kronyavir (grade 2 to 4) and laboratory changes (degrees 3 and 4) were observed very frequently in patients who received atherase along with low-dose Ritonavir.</seg>
<seg id="2015">"" "" "" "in case of overdose, the patient is to be observed on signs of intoxication (see section 4.8) if necessary, to initiate the necessary supporting measures." "" "" ""</seg>
<seg id="2016">"" "" "" "Ambroavir binds to the active centre of HIV-1 protease and thereby prevents the process pulsating viral gag- and gag-pol- polyproteins with the result of a formation of unripe, non-infectious viral particles." "" "" ""</seg>
<seg id="2017">The antiviral activity of Amiravir in vitro against HIV-1 IIIB was examined both in acute and chronic lymphoblastic cell lines (MT-4 and CEM-CCRF (H9) as well as peripheral blood lymphocytes.</seg>
<seg id="2018">The 50% Hemp concentration (IC50) of Ambroavir lies in the range from 0.12 to 0.08 µM in acute infected cells and is 0.41 µM in chronic infected cells.</seg>
<seg id="2019">The connection between the activity of the HIV-1 in vitro and the hibition of HIV-1 replication in humans is not yet defined.</seg>
<seg id="2020">In the treatment of antiretroviral retinavir / kronyavir dosages - as with other Ritonic inhibitors with proteaseinase inhibitors - the mutations described above are rarely observed.</seg>
<seg id="2021">"" "" "" "in sixteen of 434 antiretroviral non-treated patients with 100mg Ritonavir twice a day in the ESS100732 study, a virological failure occurred up to week 48, with 14 isolates could be genotypically examined." "" "" ""</seg>
<seg id="2022">Genotypic analysis of the isolates of 13 of 14 children in which a virological failure occurred within the 59 patients with proteasinhibitors revealed resistance patterns that were similar to those in adults.</seg>
<seg id="2023">"" "" "" "L10F / I / V, V11I, I54L, I54L, I54L, I54L, I54L, I84V, I84V, I84V, I85V, I93L / M / V, I84V, I93L / M." "" "" ""</seg>
<seg id="2024">In the APV30003 study and its extension APV30005 (700 mg of Fosaminoavir / 100 mg Ritonavir twice a day: n = 107) in patients with virological failure occurred over 96 weeks with the following proteasinhibitors:</seg>
<seg id="2025">Genotypic resistance testing based on genotypic resistance tests can be used to estimate the activity of Amiravir / Ritonavir or Fosamiravir / Ritonavir in patients with proteasinhibitor-resistant insulates.</seg>
<seg id="2026">The current (July 2006) ANRS-AC-11 algorithm for Fosamiravir / Ritonavir defines resistance as the presence of mutations V32I + 147a / V or I50V or at least 4 of the following mutations L10F / V or I50V / M / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / V / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F /</seg>
<seg id="2027">"" "" "" "the conclusions regarding the relevance of certain mutations or mutation patterns can be subject to changes by additional data, and it is recommended to always consult the current interpretation systems for analysis of the results of resistance tests." "" "" ""</seg>
<seg id="2028">Phenotypic resistance testing based analyses of clinical phenotypic interpretation systems can be used in conjunction with genotypic data for estimating the activity of Amiravir / Ritonavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritamprenavir / Ritam</seg>
<seg id="2029">Companies that drive diagnostic resistance tests have developed clinically-phenotypic cut-offs (separating points) for FPV / RTV that can be used to interpret the results of a resistance testing.</seg>
<seg id="2030">"" "" "" "each of these four genetic patterns associated with a reduced sensitivity to Amiravir creates a certain cross resistance against Ritonavir, sensitivity to indinavir, Nelfinavir and quinavir." "" "" ""</seg>
<seg id="2031">"" "" "" "there are currently data on cross resistance between ampleavir and other proteasinhibitors for all 4 Fosamiravir resistance paths, either alone or in combination with other mutations." "" "" ""</seg>
<seg id="2032">On the basis of twenty-five antiretroviral non-treated patients showing a resistance to Lopinavir / Ritonavir (one of 25 insulates), indinavir / Ritonavir (three out of 24 insulates) and zoonavir (three out of 24 insulates) and zoonavir (four out of 24 insulates).</seg>
<seg id="2033">"" "" "" "on the other hand, it retains its activity against some other proteasthenmer-resistant isolates; maintaining this activity seems to depend on the number and type of resistance mutations in the isolates." "" "" ""</seg>
<seg id="2034">Early departure of a failing therapy is recommended to hold the accumulation of a variety of mutations within borders which may have adverse effects on subsequent treatment.</seg>
<seg id="2035">The evidence of the efficacy of Agenerase in combination with kritonavir 100 mg twice daily is based on the study PRO30017 in a randomized open study where PI pre-treated adults after virological failure (100 mg twice a day) and nucleoside aloga (NRTI) and a standard therapy (standard of care and SOC) were obtained.</seg>
<seg id="2036">"" "" "" "one hundred threescore and sixty (n = 163) patients with proven virus sensitivity to Agenerase, at least one NRTI have been included in the A of PRO30017." "" "" ""</seg>
<seg id="2037">The primary analysis revealed the non-inferiority of APV / kronavir compared to the SOC-PI group in the viral load (HIV-1 RNA) in the plasma after 16 weeks with a non-undercover shaft of 0,4 log10 copies / ml.</seg>
<seg id="2038">"" "" "" "the evidence of the efficacy of unbleached genase is based on two uncontrolled studies with a total of 288 HIV-infected children aged 2 to 18, of which 152 were pre-treated with PI." "" "" ""</seg>
<seg id="2039">"" "" "" "in the studies Agenera was tested twice daily, 20 mg / kg three times daily, 20 mg / kg twice daily and 22.5 mg / kg twice daily, whereby the majority of patients received 20 mg / kg twice daily." "" "" ""</seg>
<seg id="2040">There was no low-dose kronyavir at the same time; the majority of patients treated with PI had previously received at least one (78%) or two (42%) of the NRTIs administered together with Agenerase.</seg>
<seg id="2041">"" "" "" "after 48 weeks, approximately 25% of patients enrolled in the study had a plasma HIV-1 RNA concentration of &lt; 10,000 copies / ml and 9% &lt; 400 copies / ml with a median increase in CD4 cell count of 26 cells / mm ³ (n = 74)." "" "" ""</seg>
<seg id="2042">"" "" "" "19 Based on this data, the benefits of" "" "" "" "unbundoosterous" "" "" "" "asgenera should be considered in therapy optimisation." "" "" ""</seg>
<seg id="2043">"" "" "" "after oral administration, the average duration (Tmax) is about 1 to 2 hours for the capsule and approximately 0.5 to 1 hour for the solution." "" "" ""</seg>
<seg id="2044">"" "" "" "by contrast, 508% increases, for CMAx by 30%, if Ritonavir (100 mg twice daily) was administered together with Ambroavir (600 mg twice a day)." "" "" ""</seg>
<seg id="2045">"" "" "" "the administration of ammonium with a meal leads to a 25% decrease in the AUC, but has no effect on the concentration of Ambroavir 12 hours after dosage (C12)." "" "" ""</seg>
<seg id="2046">"" "" "" "therefore, the minimum concentration in the Steady State (Cmin, ss) remained unaffected by the intake of food, although the simultaneous dietary intake influences the scale and rate of absorption." "" "" ""</seg>
<seg id="2047">The apparent distribution volume is approximately 430 l (6 l / kg in a body weight of 70 kg) and allows a large distribution volume as well as an unimpeded penetration of ammonium from the bloodstream into the tissue.</seg>
<seg id="2048">"" "" "" "this change results in a decrease in the total concentration of the active substance in the plasma, with the amount of ammonium that is active, probably remains unchanged." "" "" ""</seg>
<seg id="2049">"" "" "" "while the absolute concentration of untamed ammonium remains constant, the percentage of free active ingredient during the dosing interval varies depending on the total dose concentration in the steady state over the range of CMAx, ss to Cmin, ss." "" "" ""</seg>
<seg id="2050">"" "" "" "therefore, drugs that induce or inhibit CYP3A4 have to be administered with care if they are given simultaneously with atherosclerosis (see Sections 4.3, 4.4 and 4.5)." "" "" ""</seg>
<seg id="2051">"" "" "" "the gift of Agenerase capsules, either 20 mg / kg twice or 15 mg / kg three times daily, leads to a similar daily intoxicological exposition as in adults with a dose of 1200 mg twice daily." "" "" ""</seg>
<seg id="2052">"" "" "" "from the solution, Ambroavir is 14% less flexible than the capsules; therefore, Agenerative solution and Agenerase capsules are not interchangeable on a multi-gram basis." "" "" ""</seg>
<seg id="2053">"" "" "" "also, renal clearing of Ritonavir is negligible, hence the effect of kidney function disturbance on the elimination of amiravir and kronyavir is likely to be low." "" "" ""</seg>
<seg id="2054">"" "" "" "these treatment schemes show up to Ambroavir plasma levels, comparable to those that are achieved twice daily after a dose of 1200 mg of amponavir twice a day." "" "" ""</seg>
<seg id="2055">"" "" "" "in long-term studies for carcinogenicity in mice and rats, hepatoconular adenomas were present in male animals using the 2.0-fold (mice) or 3.8-fold (rat) of 1200 mg of amiravir." "" "" ""</seg>
<seg id="2056">The 21 underlying mechanism for the emergence of hepatocellular adenomas and carcinomas has not yet been clarified and the relevance of these observed effects for humans is unclear.</seg>
<seg id="2057">"" "" "" "however, there was little evidence for the adoption of clinical relevance of these findings from the present exposure data on humans, both from clinical trials and therapeutical purposes." "" "" ""</seg>
<seg id="2058">"" "" "" "in a standard battery of In-vivo- and in-vitro-genotoxicity tests, the bacterial reverse coupling tests (Ames test), mouse lymphom test, microkernel test on human peripheral lymphocytes, was neither mutagen nor genotoxic." "" "" ""</seg>
<seg id="2059">"" "" "" "this liver toxicity can be monitored and proven in clinical everyday life through measurement of AST, ALT and the activity of alkaline phosphatase." "" "" ""</seg>
<seg id="2060">"" "" "" "until now, no significant liver toxicity was observed in clinical trials, neither during the administration of atherosclerosis." "" "" ""</seg>
<seg id="2061">"" "" "" "studies on toxicity in young animals treated at an age of 4 days, showed high mortality in both the control animals and the treated animals." "" "" ""</seg>
<seg id="2062">"" "" "" "in a systemic plasma exposure which was significantly lower (rabbits) or not significantly higher (rats) than the expected exposure to therapeutic doses in humans, however, a number of minor changes including thymus gongation and minor skeletal changes have been observed." "" "" ""</seg>
<seg id="2063">"" "" "" "24 When Agenerative Capsules are used without the reinforcing addition of kronyavir (booster), higher doses of atherase (1200 mg twice a day) must be applied." "" "" ""</seg>
<seg id="2064">The recommended dose for Agenerase capsules is 20 mg of amponavir / kg bodyweight twice a day in combination with other antiretroviral drugs up to a daily dose of 2400 mg of ammonium that should not be exceeded (see Section 5.1).</seg>
<seg id="2065">"" "" "" "in patients with severe liver dysfunction, patients with severe liver dysfunction are contraindicated (see Section 4.3)." "" "" ""</seg>
<seg id="2066">"" "" "" "26 For some medicines that can cause serious or life-threatening adverse events such as carbamazepine, phenobarbital, tricyclic antidepressants and warfarin (under surveillance of the International Norised Ratio), methods for determining the drug concentration are available." "" "" ""</seg>
<seg id="2067">"" "" "" "Agenerase should be removed in duration 27, when a rash of systemic or allergic symptoms is accompanied or the mucous membranes are involved (see Section 4.8)." "" "" ""</seg>
<seg id="2068">"" "" "" "an increased risk of lipodystrophy was associated with individual factors, such as higher age, and with drug-related factors, such as prolonged antiretroviral treatment and associated metabolic disorders." "" "" ""</seg>
<seg id="2069">"" "" "" "it has been shown that Rifampicin causes a 82% reduction in the AUC by Ambroavir, which can lead to a virological failure and a resistance development." "" "" ""</seg>
<seg id="2070">"" "" "" "by contrast, 508% increases, whereas kMAx is reduced by 30% if Ritonavir (100 mg twice a day) is administered in combination with ammonium capsules (600 mg twice a day)." "" "" ""</seg>
<seg id="2071">The Cmin values of ampleavir in plasma that were obtained twice a day with Kaletra (600 mg twice daily) with Kaletra (600 mg twice daily) in combination with 100 mg Ritonavir twice a day are administered twice a day.</seg>
<seg id="2072">"" "" "" "a dosage recommendation for the simultaneous administration of Ambroavir and Kaletra can not be given, but a tight monitoring is recommended as the effectiveness and safety of this combination is unknown." "" "" ""</seg>
<seg id="2073">The treatment with Efavirenz in combination with Amprenavir and Saquinavir is not recommended as the exposure of both proteasinhibitors would decrease.</seg>
<seg id="2074">"" "" "" "if these drugs are used together, caution is advisable; thorough clinical and virological surveillance should be made as an exact prediction of the effect of the combination of Amiravir and Ritonavir on Delavirdine is difficult." "" "" ""</seg>
<seg id="2075">"" "" "" "if it is required for clinical reasons, at least half of the recommended dosage is recommended to reduce the dosage of riflare to at least half of the recommended dose." "" "" ""</seg>
<seg id="2076">"" "" "" "the serum concentrations of calcium channel blockers such as amlodipine, dipine, nifedipine, nifedipine, nivdipine, nivdipine, nivdipine, nivdipine and verapamil can be increased." "" "" ""</seg>
<seg id="2077">"" "" "" "in a clinical study, in which Ritonavir 100 mg capsules were given twice daily along with 50 µg Fluticasonpropionate intranasal (4 times daily) over 7 days in subjects, the endogenous cortisol decreased by approximately 86% (90% -range from 82 to 89%)." "" "" ""</seg>
<seg id="2078">An increased control of the INR (International Norised Ratio) is recommended because of the possibility of weakening or strengthening the anti-thrombotic effect (see section 4.4).</seg>
<seg id="2079">The simultaneous administration of Ortho-Novum 1 / 35 (0.035 mg ethinylepundiol plus 1.0 mg of Norethindron) resulted in a decrease in AUC and Cmin from Ambroavir by 22% respectively.</seg>
<seg id="2080">"" "" "" "during pregnancy, this drug may only be used after careful weighing of the potential benefit for the mother compared to possible risks for the foetus." "" "" ""</seg>
<seg id="2081">"" "" "" "a reproduction study of pregnant rats, which was administered by the evaporation in the uterus until the end of the lactation period, showed a diminished increase in body weight during follow-up." "" "" ""</seg>
<seg id="2082">The harmlessness of atheroma was examined in adults and children aged 4 years in controlled clinical trials in combination with various other antiretroviral medicines.</seg>
<seg id="2083">"" "" "" "in case of overdose, the patient is to be observed on signs of intoxication (see section 4.8) if necessary, to initiate the necessary supporting measures." "" "" ""</seg>
<seg id="2084">The antiviral activity of Amiravir in vitro against HIV-1 IIIB was examined both in acute and chronic lymphoblastic cell lines (MT-4 and CEM-CCRF (H9) as well as peripheral blood lymphocytes.</seg>
<seg id="2085">The 50% Hemp concentration (IC50) of Ambroavir lies in the range from 0.12 to 0.08 µM in acute infected cells and is 0.41 µM in chronic infected cells (1 µM = 0.50 µg / ml).</seg>
<seg id="2086">"" "" "" "on the other hand, it retains its activity against some other proteasthenmer-resistant isolates; maintaining this activity seems to depend on the number and type of resistance mutations in the isolates." "" "" ""</seg>
<seg id="2087">"" "" "" "based on these data, the benefits of" "" "" "" "unbundoosterous" "" "" "" "asgeneracy should be considered in the treatment optimisation with PI pre-treated children." "" "" ""</seg>
<seg id="2088">"" "" "" "while the absolute concentration of untamed ammonium remains constant, the percentage of free active ingredient during the dosing interval varies depending on the total dose concentration in the steady State over the range of CMAx, ss to Cmin, ss." "" "" ""</seg>
<seg id="2089">"" "" "" "therefore, drugs that induce or inhibit CYP3A4 have to be administered with care if they are given simultaneously with atherosclerosis (see Sections 4.3, 4.4 and 4.5)." "" "" ""</seg>
<seg id="2090">"" "" "" "also, renal clearing of Ritonavir is negligible; therefore, the effect of kidney function disturbance on the elimination of amiravir and kronyavir is likely to be low." "" "" ""</seg>
<seg id="2091">In long-term studies for carcinogenicity in mice and rats in male animals benign hepatoconular adenomas (mice) or 3.8-times (rat) of the exposure to the human after twice daily administration of 1200 mg of ampleavir.</seg>
<seg id="2092">The underlying mechanism for the emergence of hepatocytic adenomas and carcinomas has not yet been clarified and the relevance of these observed effects for humans is unclear.</seg>
<seg id="2093">"" "" "" "however, there was little evidence for the adoption of clinical relevance of these findings from the present exposure data on the human being, both from clinical studies and therapeutical purposes." "" "" ""</seg>
<seg id="2094">"" "" "" "in a standard battery of In-vivo- and in-vitro-genotoxicity tests, the bacterial reverse coupling tests (Ames test), mouse lymphom test, microkernel test on human peripheral lymphocytes, was neither mutagen nor genotoxic." "" "" ""</seg>
<seg id="2095">"" "" "" "studies on toxicity in young animals treated at an age of 4 days, showed high mortality in both the control animals and the treated animals." "" "" ""</seg>
<seg id="2096">"" "" "" "these results suggest that in juveniles the metabolisation paths are not fully matured, so that ampleavir or other critical components of the formulation (z)." "" "" ""</seg>
<seg id="2097">"" "" "" "Agenerase solution for intake is indicated in combination with other antiretroviral medicines for the treatment of HIV-1 infected, proteasinhibitors (PI) -pretreated adults and children aged 4 years." "" "" ""</seg>
<seg id="2098">The benefit of using Ritonavir "boodie" Agenerase solution to intake was not proven neither in patients treated with PI nor with PI pre-treated patients.</seg>
<seg id="2099">The bioavailability of ampleavir as a solution for intake is 14% lower than from Ambroavir as capsule; therefore Agenera capsules and solution for intake on a milligram per milligram basis are not interchangeable (see Section 5.2).</seg>
<seg id="2100">"" "" "" "as soon as they are able to swallow the capsules, stop taking the solution to stop (see section 4.4)." "" "" ""</seg>
<seg id="2101">The recommended dose for Agenerase solution amounts to 17 mg (1.1 ml) Amiravir / kg body weight three times a day in combination with other antiretroviral drugs up to a daily dose of 2800 mg of ampavir that should not be exceeded (see Section 5.1).</seg>
<seg id="2102">"" "" "" "in addition, as no dose recommendation must be given for the simultaneous use of asgenerase solution for intake and low dose kritonavir, this combination can be avoided in these patient groups." "" "" ""</seg>
<seg id="2103">"" "" "" "although it is not deemed necessary for amiravir, an application of atherosclerosis is contraindicated in patients with kidney failure (see Section 4.3)." "" "" ""</seg>
<seg id="2104">"" "" "" "due to the potential risk of toxic reaction as a result of high propylene glyphs, Agenera is contraindicated in patients with reduced liver function or liver failure and patients with kidney failure." "" "" ""</seg>
<seg id="2105">Simultaneous administration may lead to a competitive inhibition of the drug's metabolism and potentially cause serious and / or life-threatening adverse events such as cardiac arrhythmias (z).</seg>
<seg id="2106">Patients should be advised that atherosclerosis or any other antiretroviral therapy does not lead to a cure of HIV infection and that they continue to develop opportunistic infections or other complications of an HIV infection.</seg>
<seg id="2107">"" "" "" "the current antiretroviral therapy, including treatment with atherosclerosis, does not prevent HIV from transmitting HIV to others through sexual contact or contamination with blood." "" "" ""</seg>
<seg id="2108">"" "" "" "for some medicines that can cause serious or life-threatening adverse events such as carbamazepine, phenobarbital, tricyclic antidepressants and warfarin (under surveillance of the International Norised Ratio), methods for determining the drug concentration are available." "" "" ""</seg>
<seg id="2109">"" "" "" "atherosclerosis should be removed, if a rash of systemic or allergic symptoms is accompanied or the mucous membranes are involved (see Section 4.8)." "" "" ""</seg>
<seg id="2110">"" "" "" "an increased risk of lipodystrophy was associated with individual factors such as higher age, and with drug-49 dependent factors, such as prolonged antiretroviral treatment and associated metabolic disorders." "" "" ""</seg>
<seg id="2111">"" "" "" "in case of hemophile patients (type A and B) treated with protease inhibitors, reports of an increase in bleeding including spontaneous cutaneous hematomas and hematthrosis occur." "" "" ""</seg>
<seg id="2112">"" "" "" "it has been shown that Rifampicin causes a 82% reduction in the AUC by Ambroavir, which can lead to a virological failure and a resistance development." "" "" ""</seg>
<seg id="2113">"" "" "" "by contrast, 508% increases, whereas kMAx is reduced by 30% if Ritonavir (100 mg twice a day) is administered in combination with ammonium capsules (600 mg twice a day)." "" "" ""</seg>
<seg id="2114">"" "" "" "simultaneous intake of atherosclerosis can considerably increase their plasma concentrations and lead to PDE5 inhibitors related side effects including hypotension, blurred vision and priapism (see section 4.4)." "" "" ""</seg>
<seg id="2115">"" "" "" "based on the data on 54 other CYP3A4 inhibitors, Midazolam has significantly higher plasma concentrations according to the oral administration of Midazolam." "" "" ""</seg>
<seg id="2116">"" "" "" "the potential risk for the human being is not known, because of possible toxic reactions of the fetus to the contained propylene glycol cannot be applied during pregnancy (see Section 4.3)." "" "" ""</seg>
<seg id="2117">"" "" "" "in the milk of lactate rats, ampleavir related substances have been detected; however, it is not known whether it passes into breast milk by people." "" "" ""</seg>
<seg id="2118">"" "" "" "a reproduction study of pregnant rats, which was administered by the evaporation in the uterus until the end of the lactation period, showed a diminished increase in the 55 body weight during follow-up." "" "" ""</seg>
<seg id="2119">The harmlessness of atheroma was examined in adults and children aged 4 years in controlled clinical trials in combination with various other antiretroviral medicines.</seg>
<seg id="2120">"" "" "" "in many of these events, it is not clear whether or not they are drugs used to treat asterase or other medicines at the same time, or whether they are a consequence of the disease." "" "" ""</seg>
<seg id="2121">In the treatment of antiretroviral retinavir / kronyavir dosages - as with other Ritonic inhibitors with proteaseinase inhibitors - the mutations described above are rarely observed.</seg>
<seg id="2122">Early departure of a failing 60 therapy is recommended to hold the accumulation of a variety of mutations within borders which may have adverse effects on subsequent treatment.</seg>
<seg id="2123">"" "" "" "62 Based on this data, the benefits of" "" "" "" "unbundoosterous" "" "" "" "asgenera should be considered in therapy optimisation." "" "" ""</seg>
<seg id="2124">The apparent distribution volume is approximately 430 l (6 l / kg in a body weight of 70 kg) and allows an unimpeded penetration of ammonium from the bloodstream into the tissue.</seg>
<seg id="2125">The underlying mechanism for the emergence of hepatocellular adenomas and carcinomas has not yet been clarified and the relevance of these observed effects for humans is unclear.</seg>
<seg id="2126">"" "" "" "in a systemic plasma exposure which was significantly lower (rabbits) or not significantly higher (rats) than the expected exposure to therapeutic doses in humans, however, a number of minor changes including thymus gongation and minor skeletal changes have been observed." "" "" ""</seg>
<seg id="2127">"" "" "" "- If you have any further questions, please contact your doctor or pharmacist. - This drug was personally prescribed to you personally." "" "" ""</seg>
<seg id="2128">"" "" "" "it can harm other people, even if they have the same discomfort as you. − If any of the listed side effects you have significantly impaired or you may notice side effects that are not stated in this information information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="2129">Your doctor will normally instruct you to use atherase capsules along with low doses Ritonavir to reinforce the effect of atherosclerosis.</seg>
<seg id="2130">"" "" "" "the use of atherosclerosis is based on the individual viral resistance test carried out by your doctor, based on your medical history." "" "" ""</seg>
<seg id="2131">"" "" "" "tell your doctor if you are suffering from any of the above mentioned conditions, or taking any of the above medicines." "" "" ""</seg>
<seg id="2132">"" "" "" "if your doctor recommends that you are taking Agenerase capsules along with low doses of kronavir to strengthen the effect (booster), make sure you have read the use information on Ritonavir before starting the treatment." "" "" ""</seg>
<seg id="2133">"" "" "" "furthermore, no adequate information is available to recommend the use of Agenerase capsules along with kronyavir for strengthening effect in children aged 4 to 12 years or in general in patients less than 50 kg." "" "" ""</seg>
<seg id="2134">"" "" "" "therefore, it is important that you read the section" When taking asgenerase with other medicines, before you start taking asgenerase. "" "" "" "</seg>
<seg id="2135">"" "" "" "you may need additional factor VIII to control hemorrhage. − On patients receiving antiretroviral therapy, redistribution, accumulation or loss of body fat can occur." "" "" ""</seg>
<seg id="2136">"" "" "" "if you are certain medicines that can cause serious side effects, such as carbamazepine, phenobarbital, phenobarbital, cyclosporin, tacrolimus, tricyclic antidepressants and warfarin, at the same time as agenerase, your doctor may perform additional blood tests to minimize possible security problems." "" "" ""</seg>
<seg id="2137">"" "" "" "it is recommended that HIV-positive women should not breastfeed their children under no circumstances, in order to avoid the transfer of HIV." "" "" ""</seg>
<seg id="2138">"" "" "" "traffic tightness and operation of machines There have been no studies on the influence of atherosclerosis on the driving ability, or the ability to operate machinery." "" "" ""</seg>
<seg id="2139">"" "" "" "if you are aware of intolerance to certain sugars, please take this medicine only after consultation with your doctor." "" "" ""</seg>
<seg id="2140">"" "" "" "when taking Didano, it is advisable that you take this more than an hour before or after Agenera, otherwise the effects of atherosclerosis may be reduced." "" "" ""</seg>
<seg id="2141">Dosage of Agenerase Capsules is 600 mg twice daily along with 100 mg Ritonavir twice a day in combination with other antiretroviral medicines.</seg>
<seg id="2142">"" "" "" "if your doctor decides that the intake of kpkavir is not suitable for you, you will have to take higher doses (1200 mg Ambroavir twice a day)." "" "" ""</seg>
<seg id="2143">"" "" "" "85. it is very important that you take the total daily dose, prescribed by your doctor." "" "" ""</seg>
<seg id="2144">"" "" "" "if you have taken a larger quantity of asgenerase when you should have taken more than the prescribed dose of atherase, you should contact your doctor or pharmacist immediately." "" "" ""</seg>
<seg id="2145">"" "" "" "if you forgot the intake of atherase if you forgot taking asgenerase, take it as soon as you think about it and then continue taking the intake as before." "" "" ""</seg>
<seg id="2146">"" "" "" "in the treatment of an HIV infection, it is not always possible to tell if any side effects through atherase are caused by other medicines which are taken at the same time, or caused by the HIV infection itself." "" "" ""</seg>
<seg id="2147">"" "" "" "headache, drowsiness, diarrhea, disease feeling, vomiting, bloating skin rash (redness, blisters or itching) - occasionally the rash may be serious nature and you will force you to stop taking this medicine." "" "" ""</seg>
<seg id="2148">"" "" "" "mood disorders, depression, sleep disorders, loss of appetite, tingling in the lips and in the mouth, uncontrolled movements pain, discomfort or overaciated stomach, soft chairs, increase in liver enzymes called amylase" "" "" ""</seg>
<seg id="2149">Increased blood values for sugar or cholesterol (a certain blood fat) Increased blood levels of a substance called bilirubin swelling of the face and lips and tongue (angioedema or angioedema).</seg>
<seg id="2150">"" "" "" "this can include fat loss on legs, arms and in the face, fat increase in the abdomen and in other internal organs, breast augmentation and fat purge in the neck." "" "" ""</seg>
<seg id="2151">"" "" "" "please inform your doctor or pharmacist, if any of the side effects listed will affect you significantly or you may notice any side effects that are not stated in this information information." "" "" ""</seg>
<seg id="2152">"" "" "" "therefore, it is important that you read the section" When taking asgenerase with other medicines, before you start taking asgenerase. "" "" "" "</seg>
<seg id="2153">"" "" "" "in some patients receiving antiretroviral therapy, osteoarthritis (loss of bone tissue due to insufficient blood supply of the bone) can develop bone disease." "" "" ""</seg>
<seg id="2154">"" "" "" "when taking Didano, it is advisable that you take this more than an hour before or after Agenera, otherwise the effects of atherosclerosis may be reduced." "" "" ""</seg>
<seg id="2155">"" "" "" "94 For this purpose, it is very important that you take the total daily dose prescribed by your doctor." "" "" ""</seg>
<seg id="2156">"" "" "" "if you forgot the intake of atherase if you forgot taking asgenerase, take it as soon as you think about it and then continue taking it as before." "" "" ""</seg>
<seg id="2157">"" "" "" "headache, drowsiness, diarrhea, disease feeling, vomiting, bloating skin rash (redness, blisters or itching) - occasionally the rash may be serious nature and you will force you to stop taking this medicine." "" "" ""</seg>
<seg id="2158">"" "" "" "please inform your doctor or pharmacist, if any of the side effects listed will affect you significantly or you may notice any side effects that are not stated in this information information." "" "" ""</seg>
<seg id="2159">Dosage of Agenerase Capsules is 600 mg twice daily along with 100 mg Ritonavir twice a day in combination with other antiretroviral medicines.</seg>
<seg id="2160">"" "" "" "to make asgenera as much as possible, it is very important that you take the total daily dose prescribed by your doctor." "" "" ""</seg>
<seg id="2161">"" "" "" "if you have taken larger quantities of atherase than you should have taken if you have taken more than the prescribed dose of atherase, you should contact your doctor or pharmacist immediately." "" "" ""</seg>
<seg id="2162">The benefit of using Ritonavir "boodie" Agenera solution for intake was not documented in patients treated with proteasant inhibitors or with proteasant inhibitors.</seg>
<seg id="2163">"" "" "" "for use low doses of kronyavir (usually used to amplify the effect [Boost] of Agenerase capsules) along with Agenerase solution for intake, no dosage recommendations can be given." "" "" ""</seg>
<seg id="2164">"" "" "" "kronavir solution for intake), or in addition propylglycol while taking Agenerase solution (see also Agenera must not be taken)." "" "" ""</seg>
<seg id="2165">"" "" "" "your doctor may observe any side effects that are related to the propylene glycol content of the Agenerase solution for intake, especially if you have kidney or liver disease." "" "" ""</seg>
<seg id="2166">"" "" "" "111 If you are certain medicines that can cause serious side effects, such as carbamazepine, phenobarbital, liquamycin, tricyclic antidepressants and warfarin, your doctor might carry out additional blood tests to minimize possible security problems." "" "" ""</seg>
<seg id="2167">"" "" "" "do not use kronycol, or add an additional propylene glycol while taking ashease (see Agenera must not be taken)." "" "" ""</seg>
<seg id="2168">Important information on certain other components of Agenerase solution to intake The solution to intake contains propylene glycol which can lead to side effects in high doses.</seg>
<seg id="2169">"" "" "" "propylglycol can cause a number of side effects including seizures, dizziness, heart rate and reduction in red blood cells (see also Agenera must not be taken, special caution when taking agenera is necessary precautions)." "" "" ""</seg>
<seg id="2170">"" "" "" "if you forgot the intake of atherase if you forgot taking asgenerase, take it as soon as you think about it and then continue taking the intake as before." "" "" ""</seg>
<seg id="2171">"" "" "" "headache, drowsiness, diarrhea, disease feeling, vomiting, bloating skin rash (redness, blisters or itching) - occasionally the rash may be serious nature and you will force you to stop taking this medicine." "" "" ""</seg>
<seg id="2172">"" "" "" "this can include fat loss on legs, arms and in the face, fat increase in the abdomen and in other internal organs, breast augmentation and fat purge in the neck." "" "" ""</seg>
<seg id="2173">"" "" "" "other components are propylene glycol, acetylglycol 400), tocofersolan (TPGS), acetylglycol 400), sodium chloride, artificial chewing minence, citric acid, sodium citric acid, purified water." "" "" ""</seg>
<seg id="2174">The application frequency and duration of treatment with Aldara depend on the condition to be treated with Aldara for up to 16 weeks. • For small basal cell carcinomas the cream is to be carried out three times a week during one or two weeks of treatment.</seg>
<seg id="2175">"" "" "" "prior to bedtime, the cream is diluted to the affected areas of the skin, so that it remains sufficiently long (about eight hours) before it is washed off." "" "" ""</seg>
<seg id="2176">"" "" "" "in all studies, Aldara was compared to a placebo (same cream, but without the active ingredient). • Aldara was tested in four main studies of 923 patients with warts in the genital area for 16 weeks." "" "" ""</seg>
<seg id="2177">The main indicator of efficacy was the number of patients with complete healing of treated warts. • Aldara was also studied in 724 patients with small basal cell carcinomas in two studies in which patients were treated for six weeks.</seg>
<seg id="2178">The main indicator of efficacy was the number of patients with complete healing of the tumors after twelve weeks. • Aldara was also tested in two trials involving a total of 505 patients with actinic keratosis.</seg>
<seg id="2179">In all studies Aldara was more effective than placebo. • In the treatment of warts in the genital area the complete recovery rate in all four main studies was 15% to 52% in patients treated with Aldara compared to 0% to 3% in the placebo group.</seg>
<seg id="2180">The most common side effects of Aldara (observed in more than 1 out of 10 patients) are reactions to the application of the cream (pain or itching).</seg>
<seg id="2181">"" "" "" "clinically typical, non-hypertrophic, non-hypertrophic aktinic keratosis (AKs) in the face or on the scalp in immunocompetent adults if the size or number of lesions limit the efficacy and / or the acceptance of cryotherapy and other topical treatments are contraindicated or less appropriate." "" "" ""</seg>
<seg id="2182">"" "" "" "apply Monday, Wednesday and Friday or Tuesday, Thursday and Saturday before bedtime and leave for 6 to 10 hours on the skin." "" "" ""</seg>
<seg id="2183">"" "" "" "treatment with imiquimod cream is to continue until all visible feet in the genital or peripheral area have disappeared, or up to a maximum of 16 weeks per treatment period." "" "" ""</seg>
<seg id="2184">"" "" "" "an interruption in the treatment process described above should be considered when intensive local inflammatory reactions occur (see Section 4.4), or if an infection is observed in the treatment area." "" "" ""</seg>
<seg id="2185">"" "" "" "if the lesions are not completely healed during follow-up examination 4 to 8 weeks after the second treatment period, another therapy should be started (see section 4.4)." "" "" ""</seg>
<seg id="2186">"" "" "" "if a dose is omitted, the patient should apply the cream as soon as he / she notices this and then proceed with the usual therapy plan." "" "" ""</seg>
<seg id="2187">"" "" "" "Imiquimod cream is applied in a thin layer and in the purified, infected area of the skin, until the cream is completely drained." "" "" ""</seg>
<seg id="2188">"" "" "" "in these patients, there should be an attenuation between the benefits of a treatment with imiquimod and the risk associated with worsening their autoimmune disease." "" "" ""</seg>
<seg id="2189">"" "" "" "there should be an absorption in these patients between the benefit of a treatment with imiquimod, and the risk associated with a possible organ rejection or graft versus host reaction." "" "" ""</seg>
<seg id="2190">"" "" "" "in other studies, in which no daily inauthygiene was performed, two cases of severe phimosis and a case with a circumcision are observed." "" "" ""</seg>
<seg id="2191">"" "" "" "with an application of imiquimod cream in higher than the recommended doses there is an increased risk of severe local skin irritation (see Section 4.2.) In rare cases, severe local skin irritation were observed even under proper application." "" "" ""</seg>
<seg id="2192">"" "" "" "in cases where such reactions occurred at the exit of the urethra, some women had difficulty passing urine catheterisation and treatment of the affected area." "" "" ""</seg>
<seg id="2193">"" "" "" "so far, no clinical experience is available for the use of imiquimod-creme following treatment with other kutan treatments in the genital and peripheral areas." "" "" ""</seg>
<seg id="2194">"" "" "" "limited data suggest an increased rate of inclination reductions in HIV positive patients, imiquimod cream has shown a lower efficacy in this group of patients with regard to the removal of the paddles." "" "" ""</seg>
<seg id="2195">"" "" "" "treatment of basal cell carcinoma with imiquimod within 1 cm around the eyelids, nose, lips, or hair attachment has not been studied." "" "" ""</seg>
<seg id="2196">"" "" "" "local skin reactions are frequent, but the intensity of these reactions usually decreases during therapy or the reactions are back after completion of the treatment with imiquimod cream." "" "" ""</seg>
<seg id="2197">"" "" "" "if it is necessary due to the complaints of the patient or due to the severity of the local skin reactions, a treatment break can be made of several days." "" "" ""</seg>
<seg id="2198">"" "" "" "after the regeneration of the treated skin, the clinical outcome of the therapy may be judged approximately 12 weeks after the end of the treatment." "" "" ""</seg>
<seg id="2199">"" "" "" "as there is currently no data on long-term healing rates of more than 36 months of treatment available, other suitable therapy forms should be considered in case of superficient basal cell carcinomas." "" "" ""</seg>
<seg id="2200">"" "" "" "in patients with recurrent and pre-treated BCCs there is no clinical experience, therefore the application is not recommended for pre-treated tumors." "" "" ""</seg>
<seg id="2201">Data from an open clinical trial point out that large tumours (&gt; 7.25 cm2) have a lower likelihood of response to imiquimod therapy.</seg>
<seg id="2202">Imiquimod was not examined for treatment of acute keratosis on eyelids inside the nose or on the lip area within the lip area.</seg>
<seg id="2203">"" "" "" "there are only very limited data on the use of imiquimod, for the treatment of actinic keratoses on anatomical spots outside the face and scalp." "" "" ""</seg>
<seg id="2204">"" "" "" "the available data on the aktinic keratosis on arms and hands does not support the effectiveness of this application, therefore such an application is not recommended." "" "" ""</seg>
<seg id="2205">"" "" "" "local skin reactions occur frequently, but these reactions normally decrease in intensity during therapy or go back after the treatment with imiquimod cream." "" "" ""</seg>
<seg id="2206">"" "" "" "if the local skin reactions to the patient cause great discomfort or are very strong, the treatment may be exposed for a few days." "" "" ""</seg>
<seg id="2207">"" "" "" "from the data of an open clinical study, patients with more than 8 ac- lesions showed a lower overall healing rate than patients with less than 8 lesions." "" "" ""</seg>
<seg id="2208">"" "" "" "due to the immune-stimulating properties, imiquimod cream should be used with caution in patients receiving an immunosuppressive treatment (see 4.4)." "" "" ""</seg>
<seg id="2209">"" "" "" "animal studies show no direct or indirect harmful effects on pregnancy, embryonic / fetal development, debonding or postnatal development (see 5.3)." "" "" ""</seg>
<seg id="2210">"" "" "" "although neither after one-time topical application quantifiable serum levels (&gt; 5ng / ml) were obtained, no recommendation can be obtained during the lactation period." "" "" ""</seg>
<seg id="2211">The most frequently communicated and as probable or possibly with the application of Imiquimod-creme in connection-related side effects in the trials involving three times weekly treatment were local reactions at the location of the treatment of the psalwarts (33.7% of patients treated with imiquimod treated patients).</seg>
<seg id="2212">"" "" "" "among the most commonly reported and considered probable, or possibly with the application of the Imiquimod cream in relation to side effects, complaints at the application location with a frequency of 28.1%." "" "" ""</seg>
<seg id="2213">"" "" "" "the side-side effects reported by 185 with imiquimod-cream, treated from a placebo-controlled clinical trial phase III." "" "" ""</seg>
<seg id="2214">"" "" "" "in these studies, the most common, probably or possibly with the application of the Imiquimod cream in relation to the side effect were a response to the application location (22% of patients treated with imiquimod)." "" "" ""</seg>
<seg id="2215">"" "" "" "the side effects reported by 252 in placebo-controlled clinical trials of Phase III with imiquimod cream treated patients with actinic keratosis, are listed below." "" "" ""</seg>
<seg id="2216">"" "" "" "according to the review plan, clinical evidence shows that in these placebo-controlled clinical trials with Imiquimod cream often results in local skin reactions including erythema (30%), exkoriation / leaves (23%) and edema (14%)." "" "" ""</seg>
<seg id="2217">"" "" "" "according to the test plan, the clinical indication predicts that in these studies, five times weekly treatment with imiquimod cream often leads to severe erythema (31%), heavy erosion (13%)." "" "" ""</seg>
<seg id="2218">In clinical trials investigating the use of imiquimod for the treatment of actinic keratosis alopecia was diagnosed with a frequency of 0.4% (5 / 1214) at the treatment centre or in the surrounding area.</seg>
<seg id="2219">"" "" "" "the accidental one-time oral recording of 200 mg imiquimod, which corresponds to the contents of approximately 16 bags, could lead to nausea, vomiting, headache, myalgia and fever." "" "" ""</seg>
<seg id="2220">"" "" "" "the clinically severe side effect, which occurred after several oral doses of &gt; 200 mg, consisted of hypotony which normalized after orally or intravenous fluids." "" "" ""</seg>
<seg id="2221">"" "" "" "after topical application of imiquimod, systemic concentrations of alpha-interferon and other cytokines were detected in a pharmacokinetic study." "" "" ""</seg>
<seg id="2222">"" "" "" "in 3 pivotal Phase 3 efficacy studies, efficacy is clearly superior to a complete healing of the fetuses in an imiquimod treatment over 16 weeks of placebo." "" "" ""</seg>
<seg id="2223">"" "" "" "at 60% of the patients treated with imiquimod, the patients treated completely; this was the case with 20% of the patients treated with placebo (95% CI):" "" "" ""</seg>
<seg id="2224">"" "" "" "a complete healing could be achieved at 23% of 157 with imiquimod treated male patients, compared to 5% of 161 with placebo treated male patients (95% CI):" "" "" ""</seg>
<seg id="2225">"" "" "" "the effectiveness of imiquimod over 6 weeks was examined in two double-blind, placebo-controlled clinical studies." "" "" ""</seg>
<seg id="2226">"" "" "" "the target tumors were histologically confirmed single primary superficient basal cell carcinomas, with a minimum size of 0.5 cm2 and a maximum diameter of 2 cm." "" "" ""</seg>
<seg id="2227">"" "" "" "the data presented in an open, uncontrolled long-term study after four years show that approximately 79.3% [73.7%, 84.9%)] were clinically cured and this remained for 48 months." "" "" ""</seg>
<seg id="2228">"" "" "" "the effectiveness of imiquimod during three weeks of use in one or two treatment periods of 4 weeks, interrupted by a four-week, treatment-free period, was examined in two double-blind, placebo-controlled clinical studies." "" "" ""</seg>
<seg id="2229">"" "" "" "patients had clinically typical, visible, discrete, non-hyperkeratotic, non-hypertrophic ions within a connected 25 cm2 large treatment area on the uncomfortable heatskin or face." "" "" ""</seg>
<seg id="2230">One-year data from two combined monitoring studies show a recurrence rate of 27% (35 / 128 patients) for patients with clinical recovery after one or two treatment periods.</seg>
<seg id="2231">"" "" "" "as a rule, paediatric patients do not usually arise and were therefore not examined." "" "" ""</seg>
<seg id="2232">Aldara cream was studied in four randomised double-blind placebo-controlled studies in children aged 2 to 15 years with Molluscum contagiosum (Imiquimod n = 576; placebo n = 313).</seg>
<seg id="2233">"" "" "" "in these studies, the efficacy of imiquimod could not be shown in these studies (3x / week for a period of ≤ 16 weeks or less." "" "" ""</seg>
<seg id="2234">Minimal systemic absorption of the 5% imiquimod cream by the skin of 58 patients with actinic keratosis was observed during the three-week use during 16 weeks.</seg>
<seg id="2235">"" "" "" "the highest drug concentrations in serum at the end of the week 16 were observed between 9 and 12 hours and bettermed 0.1, 0.2 and 1,6 ng / ml in the face (25 mg, 2 bags) and on the hands / arms (75 mg, 6 bags)." "" "" ""</seg>
<seg id="2236">The estimated half-life time was about 10 times higher than the 2-hour half-life after subcutaneous use in an earlier study; this indicates an extended retention of the drug in the skin.</seg>
<seg id="2237">The data on systemic exposure showed that the absorption of Imiquimod after topical application on MC-diseased skin was low and comparable to that in healthy adults and adults with actinic keratosis or superficient basal cell carcinoma.</seg>
<seg id="2238">"" "" "" "in a four-month study on the current toxicity at the rat, doses of 0.5 and 2.5 mg / kg KG resulted in significantly reduced body weight and increased Milz weight." "" "" ""</seg>
<seg id="2239">"" "" "" "a two-year study on carcinogenicity in mice on three days a week, did not induce tumors at the application site." "" "" ""</seg>
<seg id="2240">"" "" "" "the appropriate mechanism is not known, but since imiquimod has only a low systemic absorption from the human skin and is not presumed, a risk for man is to be regarded as very low due to systemic exposure." "" "" ""</seg>
<seg id="2241">"" "" "" "tumors performed in the group of mice that were treated with the active-free cream, earlier and in larger numbers than in the control group with low UVR." "" "" ""</seg>
<seg id="2242">"" "" "" "it can harm other people even if these same symptoms have the same symptoms as you. − If any of the listed side effects are significantly impaired or you may notice side effects that are not stated in this information information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="2243">● Feigwarts (condylomata acuminata) formed on the skin in the area of genitals (sexual organs) and anus (after); superficial basal cell carcinoma This is a common and slowly growing form of skin cancer with very low probability of spreading to other parts of the body.</seg>
<seg id="2244">"" "" "" "if it remains untreated, it may lead to deformations, especially in the face - therefore early detection and - treatment is important." "" "" ""</seg>
<seg id="2245">"" "" "" "actinic keratoses are rough areas of the skin, which occur in people who were exposed to exposure to sunlight during their lives." "" "" ""</seg>
<seg id="2246">Aldara should only be used in the face and scalp in patients with a healthy immune system where your doctor has decided that Aldara is the most suitable treatment for you.</seg>
<seg id="2247">Aldara cream supports your body's immune system in the production of natural substances that help your body combat the superficial basal cell carcinoma to combat actinic keratosis or the virus responsible for infection.</seg>
<seg id="2248">"" "" "" "if you have previously used Aldara cream or other similar supplements, please inform your doctor before you have problems with your immune system." "" "" ""</seg>
<seg id="2249">"" "" "" "in case of reactions to the treated area, do not use cream as your doctor prescribes you. o Use the cream with a mild soap and water after applying Aldara cream." "" "" ""</seg>
<seg id="2250">"" "" "" "as soon as the reactions are cleared, you can continue the treatment. o inform your doctor if they do not have a normal blood picture" "" "" ""</seg>
<seg id="2251">"" "" "" "if this daily cleaning is not performed under the foreskin, swelling, thinning of the skin or difficulty can be expected when withdrawing the foreskin." "" "" ""</seg>
<seg id="2252">Do not apply Aldara cream in the urethra (urethra) in the vagina (vagina) that cervix (cervix) or within the anus (after).</seg>
<seg id="2253">"" "" "" "if other medicines have serious problems with your immune system, you should use this medication for no more than a treatment cycle." "" "" ""</seg>
<seg id="2254">"" "" "" "if you have intercourse with genital warts in the genital area, the treatment with Aldara cream after sexual intercourse (not previously) is to be performed." "" "" ""</seg>
<seg id="2255">"" "" "" "please inform your doctor or pharmacist if you apply other medicines or have recently been applied, even if it is not prescription medicine." "" "" ""</seg>
<seg id="2256">"" "" "" "breastfeed your infant during treatment with Aldara cream, as it is not known whether imiquimod interferes in breast milk." "" "" ""</seg>
<seg id="2257">"" "" "" "the frequency and duration of the treatment are different in case of stroke, basal cell carcinoma and actinic keratosis (see specific directions for each application area)." "" "" ""</seg>
<seg id="2258">"" "" "" "apply a thin layer of Aldara cream onto the clean, dry skin area with the feet and rub the cream gently on the skin until the cream is completely drained." "" "" ""</seg>
<seg id="2259">"" "" "" "men with paddles under the foreskin need to withdraw the foreskin every day and wash the skin area beneath them (see section 2, What do you need to consider before using Aldara cream?"). "" "" "" "</seg>
<seg id="2260">"" "" "" "please talk to your doctor or pharmacist, if you have the impression that the effect of Aldara is too strong or too weak." "" "" ""</seg>
<seg id="2261">Apply a sufficient quantity of Aldara cream for 6 weeks in a row to cover the affected area and 1 cm around this area.</seg>
<seg id="2262">"" "" "" "very common side effects (with more than 1 out of 10 patients to expect) side effects (with less than 1 out of 100 patients to expect) rare side effects (with less than 1 out of 1,000 patients expected) Very rare side effects (with less than 1 of 10,000 patients expected)" "" "" ""</seg>
<seg id="2263">Tell your doctor / health care professional or pharmacist immediately if you feel uncomfortable during the use of Aldara cream.</seg>
<seg id="2264">"" "" "" "if your skin reacts strongly to the treatment with Aldara cream, you should not use the cream to wash the affected area with water and a mild soap and communicate your doctor or pharmacist." "" "" ""</seg>
<seg id="2265">"" "" "" "a humiliated number of blood cells can make you more vulnerable to infection; it can cause you to create a blue stain faster, or you can cause discomfort." "" "" ""</seg>
<seg id="2266">Tell your doctor or pharmacist if any of the side effects listed will affect you significantly or you may notice any side effects that are not indicated in this information information.</seg>
<seg id="2267">"" "" "" "in addition, you can feel itching (32% of patients), burning (26% of patients) or pain in the areas you applied Aldara cream (8% of the patients)." "" "" ""</seg>
<seg id="2268">"" "" "" "most of the time, these are easier skin reactions occurring within 2 weeks after the treatment is removed." "" "" ""</seg>
<seg id="2269">"" "" "" "occasionally some patients notice changes at the application location (wound secretion, inflammation, swelling, shading, dermatitis) or irritability, nausea, dry mouth, flu-like symptoms and fatigue." "" "" ""</seg>
<seg id="2270">"" "" "" "occasionally, some patients suffer from changes at the application location (bleeding, inflammation, wound secretion, ulceration, flushing and scarring), inflammation of the nose-mucosa, inflammation of the nasal mucosa, redness, eyelids, fever, weakness or shivers." "" "" ""</seg>
<seg id="2271">Aldurazyme is used for the enzyme substitute therapy in patients with confirmed diagnosis of a Mucopolysaccharidosis I (MPS I; α-L-Iduronidase deficiency) in order to treat the non-neurological manifestations of the disease (the symptoms that are not related to brain or nerves).</seg>
<seg id="2272">"" "" "" "this means that certain substances (glycosaminoglykane, gags) are not broken down, thus accumulating in most organs in the body and damaging them." "" "" ""</seg>
<seg id="2273">"" "" "" "the following non neurological symptoms of the MPS I can occur: enlarged liver, stiff joints, aggravated movements, reduced lung volume, heart disease and eye disease." "" "" ""</seg>
<seg id="2274">Treatment with Aldurazyme should be monitored by a doctor who has experience in treating patients with MPS I or other hereditary metabolic diseases.</seg>
<seg id="2275">"" "" "" "the administration of Aldurazyme should take place in a hospital or a clinic with rehabilitation equipment, and patients may require appropriate medicines to prevent allergic reactions." "" "" ""</seg>
<seg id="2276">© EMEA 2007 Reproduction and / or distribution of this document is Authorised for non commercial purposes only provided the EMEA is acknowledged How does Aldurazyme work?</seg>
<seg id="2277">"" "" "" "the study was primarily examined for the safety of the drug, but it was also measured by its effectiveness (by affecting its effect regarding the reduction in GAG concentrations in the urine and regarding the size of the liver)." "" "" ""</seg>
<seg id="2278">"" "" "" "in children under the age of five Aldurazyme lowered the GAG concentrations in the urine by about 60%, and half of the children treated had a normal liver." "" "" ""</seg>
<seg id="2279">"" "" "" "the most common side effects of Aldurazyme in patients aged over five years (observed in more than 1 out of 10 patients) are headaches, nausea, stomach pain, arthropathy, pain in the limbs (in hands and feet), heat feeling, fever and reactions to the infusion spot." "" "" ""</seg>
<seg id="2280">"" "" "" "very common side effects in patients less than five years are elevated blood pressure, reduced oxygen saturation (a measurement size of lung function), tachycardia (accelerated heart rate), fever and shivers." "" "" ""</seg>
<seg id="2281">Aldurazyme may not be used in patients who may be hypersensitive (allergic) to laronidase or one of the other components (anaphylactic reaction).</seg>
<seg id="2282">"" "" "" "the European Medicines Agency (EMEA) will review every year all new information, which may be known, and if necessary update this summary." "" "" ""</seg>
<seg id="2283">"" "" "" "the manufacturer of Aldurazyme will receive patients who receive aldurazyms, with regard to reactions to the infusion and development of antibodies." "" "" ""</seg>
<seg id="2284">"" "" "" "in June 2003, the European Commission granted Genzyme Europe B.V. a permit for placing Aldurazyme across the European Union." "" "" ""</seg>
<seg id="2285">Laronidase is a recombinant form of the human α-L-Iduronidase and is produced using recombinant DNA-technology using CHO mammal cell cultures (Chinese hamster Ovary).</seg>
<seg id="2286">Aldurazyme is indicated for long-term enzyme treatment in patients with confirmed diagnosis of a Mucopolysaccharidosis I (MPS I, α-L-Iduronidase deficiency) in order to treat the non-neurological manifestations of the disease (see Section 5.1).</seg>
<seg id="2287">Treatment with Aldurazyme should be performed by a doctor who has experience in the treatment of patients with MPS I or other hereditary metabolic diseases.</seg>
<seg id="2288">The initial infusion rate of 2 E / kg / h can be increased every 15 minutes in individual stages to a maximum dose of 43 E / kg / h.</seg>
<seg id="2289">"" "" "" "the safety and efficacy of Aldurazyme in adults over 65 years has not been determined, and no dosage schedule can be recommended for these patients." "" "" ""</seg>
<seg id="2290">"" "" "" "the safety and efficacy of Aldurazyme in patients with kidney or liver failure was not determined, and no dosage schedule can be recommended for these patients." "" "" ""</seg>
<seg id="2291">Patients treated with Aldurazyme can develop infusion-related reactions which are defined as any side effect that occurs during infusion or until the end of the infusion-day (see Section 4.8).</seg>
<seg id="2292">"" "" "" "for this reason, especially these patients should continue to be closely monitored and the infusion of Aldurazyme should only be carried out in an appropriate clinical environment in which rehabilitation facilities are immediately available for medical emergencies." "" "" ""</seg>
<seg id="2293">"" "" "" "due to the clinical phase 3 study, nearly all patients with IgG antibodies against laronidase usually occur within 3 months from the beginning of treatment." "" "" ""</seg>
<seg id="2294">Patients who develop antibodies or symptoms of an infusion-related reaction have to be treated with care when using Aldurazyme (see Sections 4.3 and 4.8).</seg>
<seg id="2295">"" "" "" "since there is little experience regarding the resumption of the treatment after a longer interruption, the risk of hypersensitivity after an interruption of the treatment must be handled with caution." "" "" ""</seg>
<seg id="2296">"" "" "" "60 minutes before the beginning of infusion with medication (antihistaminika and / or anti-pyractica), to minimize the potential occurrence of infusion-related reactions." "" "" ""</seg>
<seg id="2297">"" "" "" "in case of a slight or moderate infusion-related reaction, the treatment with antihistaminika and paracetamol / ibuprofen should be induced and / or reduction of the infusion rate to half of the infusion rate in which reaction has occurred." "" "" ""</seg>
<seg id="2298">"" "" "" "in case of a single severe infusion-related reaction the infusion must be stopped until the symptoms are reduced, a treatment with antihistaminika and paracetamol / ibuprofen is to be considered." "" "" ""</seg>
<seg id="2299">"" "" "" "infusion can be resumed with a reduction of the infusion rate to 1 / 2 - 1 / 4 of the infusion rate, in which the reaction has occurred." "" "" ""</seg>
<seg id="2300">3 are treated (antihistaminika and paracetamol / ibuprofen and / or corticosteroids) as well as a reduction of the infusion rate to 1 / 2 - 1 / 4 of the infusion rate.</seg>
<seg id="2301">"" "" "" "Aldurazyme should not be used at the same time with Chloroquin or Procain, because a potential risk of interference with the intracellular absorption of Laronidase exists." "" "" ""</seg>
<seg id="2302">"" "" "" "animal experimental studies do not allow direct or indirect harmful effects on pregnancy that include embryonic / fetal development, birth and postnatal development (see section 5.3)." "" "" ""</seg>
<seg id="2303">"" "" "" "since no data on newborns originating from laronidase over the mother's milk is recommended, it is recommended not to breastfeed with Aldurazyme." "" "" ""</seg>
<seg id="2304">Adverse events in clinical trials were predominantly classified as infusion-related reactions which were observed in 53% of patients in Phase 3 (treatment duration up to 4 years) and 35% of patients in the study with participants under 5 years (treatment duration up to 1 year).</seg>
<seg id="2305">Adverse drug reactions related to Aldurazyms that were observed during the phase-3- study and their extension in a total of 45 patients aged 5 years or older during a treatment duration of up to 4 years (≥ 1 / 10); frequently (≥ 1 / 100 to &lt; 1 / 10).</seg>
<seg id="2306">"" "" "" "in some patients with severe MPS-I-related involvement of upper respiratory tract and lungs in prehistory, severe reactions, including bronchospasm, respiration and facial edema (see section 4.4)." "" "" ""</seg>
<seg id="2307">Children Unwanted drug interactions related to Aldurazyme which were reported during a phase 2 study with a total of 20 patients at the age of 5 with predominantly severe duration and duration of treatment up to 12 months.</seg>
<seg id="2308">"" "" "" "100 E / kg intravenously once a week (recommended dose), 200 E / kg intravenously once a week, 200 E / kg intravenously every 2 weeks or 300 E / kg intravenously every 2 weeks." "" "" ""</seg>
<seg id="2309">"" "" "" "in most patients it occurred within 3 months after the start of the treatment to a serokonogram, whereby it was a serokonogram in patients aged 5 years (average after 26 days compared to 45 days in patients at the age of 5 years and older)." "" "" ""</seg>
<seg id="2310">"" "" "" "by the end of the phase 3 trial (or until early retirement from the study), antibodies demonstrated by radioimmunopthalate (RIP) assay, including 3 patients, had never come to Serokonversion." "" "" ""</seg>
<seg id="2311">Patients with a lack of low antibody levels showed a robust reduction in the GAG mirror in the urine while in patients with high antibody titers a variable reduction of GAG in urine was observed.</seg>
<seg id="2312">Four patients (three in the Phase 3 study and one in phase 2 study) showed a marginal to low neutralizing inhibitory effect on the enzymatic Laronidase activity in vitro which seemed to impair the clinical efficacy and / or reduction of GAG in the urine.</seg>
<seg id="2313">"" "" "" "the presence of antibodies did not appear related to the incidence of unwanted drug reactions, although the occurrence of unwanted drug reactions typically coincided with the formation of IgG antibodies." "" "" ""</seg>
<seg id="2314">"" "" "" "the reason for the enzyme substitute therapy is one of the hydrolysis of the accumulated substratum, and the prevention of an additional accumulation of sufficient enzyme activity." "" "" ""</seg>
<seg id="2315">"" "" "" "after IV infusion, Laronidase is rapidly removed from the circulation and absorbed by cells into the lysosomes, most likely via manose-6 phosphate receptors." "" "" ""</seg>
<seg id="2316">"" "" "" "the safety and efficacy of Aldurazyms were examined in a randomised, double-blind, placebo-controlled Phase III study of 45 patients aged 6 to 43." "" "" ""</seg>
<seg id="2317">"" "" "" "although patients were randomised to study the entire spectrum of disease, the majority of patients were of the mean phenotype and only one patient revealed the severe phenotype." "" "" ""</seg>
<seg id="2318">Patients were recruited if they had a forced expiratory volume (FEV) of less than 80% of expected value and they had to be able to stand 6 minutes and walk 5 meters.</seg>
<seg id="2319">"" "" "" "the primary endpoints for efficacy were the percentage change of the expected FEV, and the absolute walking distance in the 6-minute walk." "" "" ""</seg>
<seg id="2320">"" "" "" "all patients were subsequently recruited for an open label extension study, where they received 100 E / kg Aldurazyme for another 3.5 years (182 weeks)." "" "" ""</seg>
<seg id="2321">"" "" "" "after 26 weeks of therapy, patients treated with Aldurazyme compared the placebo group to improve lung function and the ability to live in the following table." "" "" ""</seg>
<seg id="2322">In the open extension study showed an improvement and / or maintenance of these effects of up to 208 weeks in the Aldurazyme / Aldurazyme group and from 182 weeks in the placebo / Aldurazyme group as shown in the following table.</seg>
<seg id="2323">"" "" "" "over this period, the decrease in the expected percentage FEV is clinically not significant and the total lung capacity increased further proportionally to the size of growing children." "" "" ""</seg>
<seg id="2324">"" "" "" "from the 26 patients with a Hepatomegaly prior to treatment, 22 (85%) reached normal liver size until the end of the study." "" "" ""</seg>
<seg id="2325">"" "" "" "within the first 4 weeks, a significant drop in the GAG mirror in the urine (µg / mg of Kreatinine) was noticed, which remained constant until the end of the study." "" "" ""</seg>
<seg id="2326">Overall an improvement in 26 patients (58%) and a deterioration in 9 patients (22%) and a deterioration in 9 patients (20%) was generally observed in 26 patients (58%).</seg>
<seg id="2327">A one-year open phase 2 study was conducted in which the safety and pharmacokinetics of Aldurazyme were examined in 20 patients at the time of their inclusion in the study under 5 years old (16 patients with a severe follow-up form and 4 with the mean follow-up form).</seg>
<seg id="2328">"" "" "" "in four patients, the dosage was increased to 200 E / kg in the last 26 weeks because of increased gag- levels in the urine in week 22." "" "" ""</seg>
<seg id="2329">In several patients a size growth (n = 7) and a weight gain (n = 3) was determined after the Z-Score for this age group. the younger patients with the moderate follow-up form showed a normal mental development speed whereas the older patients with severe follow-up form had only limited or no progress in cognitive development.</seg>
<seg id="2330">"" "" "" "in a phase 4 study, investigations into pharmacogenic effects of various aldurazyms dosage schemes were performed on the GAG mirrors in the urine, liver volume and the 6-minute walk." "" "" ""</seg>
<seg id="2331">"" "" "" "100 E / kg intravenously once a week (recommended dose), 200 E / kg intravenously once a week, 200 E / kg intravenously every 2 weeks or 300 E / kg intravenously every 2 weeks." "" "" ""</seg>
<seg id="2332">"" "" "" "the dosage schedule with 200 E / kg intravenously every 2 weeks can represent a reasonable alternative for patients who have difficulties with weekly infusions, but it is not proven that the long-term clinical efficacy of these two dosage schemes is equivalent." "" "" ""</seg>
<seg id="2333">"" "" "" "the European Medicines Agency (EMEA) will review any new information available annually, and if necessary, the summary of the features of the medicine will be updated." "" "" ""</seg>
<seg id="2334">"" "" "" "the pharmacokinetic profile for patients aged 5 years was similar to that of older, less severely affected patients." "" "" ""</seg>
<seg id="2335">"" "" "" "based on conventional studies on safety macology, toxicity in one-time administration, toxicity in repeated application and reproductive toxicity, the preclinical data does not allow specific dangers to humans." "" "" ""</seg>
<seg id="2336">"" "" "" "since no tolerability studies have been carried out, this drug may not be mixed with other medicines unless listed under 6.6." "" "" ""</seg>
<seg id="2337">"" "" "" "if the ready-to-use preparation is not used immediately, it is no longer than 24 hours at 2 ° C - 8º C, provided the dilution occurred under controlled and validated aseptic conditions." "" "" ""</seg>
<seg id="2338">5 ml concentrate for the manufacture of a solution in bottle (type I glass) with stoppers (silicone-butyl rubber) and sealing (aluminium) with tear-out cap (polypropylene).</seg>
<seg id="2339">10 Prepection of the Aldurazyme infusion (using aseptic technique) • Determine the number of dilution bottles to be diluted according to body weight of the individual patient.</seg>
<seg id="2340">"" "" "" "within the specified time, the owner of the authorization for the placing on the market has completed the following study program, whose results form the basis for the annual evaluation report for the benefit-risk ratio." "" "" ""</seg>
<seg id="2341">"" "" "" "in the longer term, this tab will include safety and efficacy information for patients treated with Aldurazyme, as well as data on the natural progression of the disease in patients without this treatment." "" "" ""</seg>
<seg id="2342">"" "" "" "in patients suffering from MPS I, an enzyme called α-L-Iduronidase is found containing certain substances in the body (glycosaminoglykane), either in small amounts before or this enzyme is missing altogether." "" "" ""</seg>
<seg id="2343">"" "" "" "if you are allergic to one of the components of Aldurazyme, or if an allergic reaction occurred to laronidase in you." "" "" ""</seg>
<seg id="2344">An infusion-related reaction is any side effect occurring during infusion or until the end of the infusion-day (see Section 4 "Which side effects are possible").</seg>
<seg id="2345">"" "" "" "if you use Aldurazyme with other medicines, please tell your doctor if you are using drugs that contain Chloroquin or Procain because there is a potential risk of reduced aldurazyms." "" "" ""</seg>
<seg id="2346">"" "" "" "please inform your doctor or pharmacist if you take other medicines or have recently taken it, including non-prescription medicines." "" "" ""</seg>
<seg id="2347">"" "" "" "instructions for handling, dilution and application The concentrate for the production of an infusion solution must be diluted prior to application (see information for physicians and medical professionals)." "" "" ""</seg>
<seg id="2348">The initial infusion rate of 2 E / kg / h can be increased every 15 minutes to a maximum dose of 43 E / kg / h.</seg>
<seg id="2349">"" "" "" "in some patients with severe MPS-id-related involvement of the upper respiratory tract and lungs in prehistory, however, severe reactions occurred including bronchospasm, respiration and facial edema." "" "" ""</seg>
<seg id="2350">"" "" "" "• Frequency (occurrence of more than 1 out of 10 patients): • headaches • nausea • abdominal pain • joint disease, joint pain, back pain, pain in arms and legs • increased pulse • hypertension • less oxygen in the blood • Reaction at the infusion spot" "" "" ""</seg>
<seg id="2351">"" "" "" "the European Medicines Agency (EMEA) will evaluate any new information available annually, and if necessary, the packaging supplement will be updated." "" "" ""</seg>
<seg id="2352">"" "" "" "if the ready-to-use preparation is not used immediately, it is no longer than 24 hours at 2 ° C - 8º C, provided the dilution occurred under controlled and validated aseptic conditions." "" "" ""</seg>
<seg id="2353">"" "" "" "preparation of the Aldurazyme infusion (using aseptic technique), determine the number of dilution bottles to be diluted according to body weight of the individual patient." "" "" ""</seg>
<seg id="2354">Alimta is used together with cisplatin (another medicine against cancer) in patients who have not received chemotherapy (medicine against cancer) and "malignant" (malignant - cancer has already spread to other parts of the body) and is likely to spread easily to other parts of the body.</seg>
<seg id="2355">"" "" "" "Alimta is used in patients who have not previously been treated, in combination with cisplatin and in patients who previously received other chemotherapy as sole therapy." "" "" ""</seg>
<seg id="2356">"" "" "" "to reduce side effects, patients should take a corticosteroid as well as folic acid (vitamin B12) during treatment with Alimta." "" "" ""</seg>
<seg id="2357">"" "" "" "if Alimta is administered together with cisplatin, before or after the administration of cisplatin, an" anti-emetic "(medicine against vomiting) and liquids (to prevent a lack of water) should be given." "" "" ""</seg>
<seg id="2358">"" "" "" "in patients whose blood count changes or when certain other side effects occur, the treatment should be delayed or reduced or the dose should be reduced." "" "" ""</seg>
<seg id="2359">"" "" "" "the active form of Pemetremixed thus slows down the formation of DNA and RNA, preventing the cells to divide." "" "" ""</seg>
<seg id="2360">"" "" "" "the transformation of Pemetremixed into its active form is easier to use in cancer cells than in healthy cells, leading to higher concentrations of the active form of the drug and a longer active duration in cancer cells." "" "" ""</seg>
<seg id="2361">"" "" "" "Alimta was examined in a major study of 456 patients, who had previously received no chemotherapy for their disease." "" "" ""</seg>
<seg id="2362">"" "" "" "in the treatment of non-small cell lung cancer, Alimta's effects were compared to 571 patients with local advanced or metastatic disease previously treated with docetaxel (another medicine against cancer)." "" "" ""</seg>
<seg id="2363">"" "" "" "Alimta was also compared to gemcitabine (another medicine against cancer), both in combination with cisplatin in a study of 1,725 patients who had previously not received chemotherapy for lung cancer." "" "" ""</seg>
<seg id="2364">"" "" "" "patients treated with Alimta and cisplatin had an average of 12.1 months, compared to 9.3 months in the sole administration of cisplatin." "" "" ""</seg>
<seg id="2365">"" "" "" "in patients receiving chemotherapy first, average survival time was 8.3 months, compared with 7,9 months in docetaxel." "" "" ""</seg>
<seg id="2366">"" "" "" "in both studies, however, patients with whom the cancer did not attack the squamous epithelial cells, in the administration of Alimta extended survival time compared to the comparison drug." "" "" ""</seg>
<seg id="2367">"" "" "" "in September 2004, the European Commission granted approval to the company Eli Lilly Nederland B.V. a permit for placing Alimta in the whole European Union." "" "" ""</seg>
<seg id="2368">Each bottle must be dissolved with 4.2 ml 0.9% sodium chloride injection solution (9 mg / ml) which results in a 25 mg / ml solution.</seg>
<seg id="2369">The appropriate volume of the necessary do- sis is taken from the bottle and diluted with 0.9% sodium chloride injection solution (9 mg / ml) to 100 ml more (see section 6.6).</seg>
<seg id="2370">ALIMTA is shown in combination with cisplatin for first-line treatment of patients with locally advanced or metastatic NSCLC (see Section 5.1).</seg>
<seg id="2371">ALIMTA in monotherapy is indicated for the treatment in second-line treatment of patients with Lo- Kal advanced or metastatic non-small cell lung cancer (see Section 5.1).</seg>
<seg id="2372">The recommended dose of ALIMTA 500 mg / m ² body surface (KOF) administered intravenous infusion over a period of 10 minutes on the first day of each 21-day treatment cycle.</seg>
<seg id="2373">The recommended dose of cisplatin is 75 mg / m ² KOF as infusion over a period of 2 hours approximately 30 minutes after completion of the Pemetrexed- infusion on the first day of each 21-day treatment cycle.</seg>
<seg id="2374">In patients with non-small cell lung cancer according to previous chemotherapy the recommended dose of ALIMTA 500 mg / m ² KOF is administered intravenous infusion over a period of 10 minutes on the first day of each 21-day treatment cycle.</seg>
<seg id="2375">"" "" "" "in order to reduce the frequency and severity of skin reactions, a corticosteroid must be given on the day before and on the day after the treatment." "" "" ""</seg>
<seg id="2376">"" "" "" "during the seven days before the first dose of Pemetremixed, at least 5 doses of folic acid must be taken and the intake must be continued throughout the treatment period as well as for further 21 days after the last Pemetrexed- dose." "" "" ""</seg>
<seg id="2377">"" "" "" "patients also need an intramuscular injection of vitamin B12 (1000 micrograms) in the week before the first Pemetremixed dose, as well as after each third treatment cycle." "" "" ""</seg>
<seg id="2378">"" "" "" "in patients receiving Pemetremixed, a complete blood-pattern should be created before each application, including a differentiation of the leukocytes and a thrombocyte count." "" "" ""</seg>
<seg id="2379">The alkaline phosphatase (AP), aspartame-Transaminase (AST or SGOT) and Alanin-Transaminase (ALT or SGPT) should be ≤ 3 times the upper limit value.</seg>
<seg id="2380">"" "" "" "at the beginning of a new treatment cycle, a dose examination must take place under the conditions of fortification of the blood image or the maximum non-haematological toxicity of previous curing therapy cycles." "" "" ""</seg>
<seg id="2381">"" "" "" "after recovery, patients need to be treated according to the indications in tables 1, 2 and 3, which are used for ALIMTA as monotherapy or in combination with cisplatin." "" "" ""</seg>
<seg id="2382">These criteria comply with the definition of the National Cancer Institute common Toxicity Criteria (CTC v2.0; NCI 1998) ≥ CTC Grade 2 Blood supply.</seg>
<seg id="2383">"" "" "" "should patients not develop non-haematological toxicity ≥ grade 3 (except neurotoxicity), the therapy must be interrupted with ALIMTA until the patient has the value prior to treatment" "" "" ""</seg>
<seg id="2384">Treatment with ALIMTA must be canceled if a hematological toxicity or non-haematological toxicity of 3 or 4 occurs in patients after 2 can reductio- or non-hematological toxicity of 3 or 4 neurotoxicity.</seg>
<seg id="2385">"" "" "" "clinical studies showed no indication that in patients aged 65, or over 65 years of age, an increased side effect risk is present." "" "" ""</seg>
<seg id="2386">"" "" "" "ALIMTA is not recommended for use in children under the age of 18, due to insufficient data on safety and efficacy." "" "" ""</seg>
<seg id="2387">In clinical studies patients with a creatinin-clearing of ≥ 45 ml / min were no dose adjustments necessary which go beyond the dose adjustments recommended for all patients.</seg>
<seg id="2388">"" "" "" "the data situation in patients with a creatinin-clearing of less than 45 ml / min was insufficient; therefore, the application is not recommended (see Section 4.4)." "" "" ""</seg>
<seg id="2389">"" "" "" "however, patients with a liver function restriction of &gt; 1-fold the upper Bilirubin- limit value and / or transaminase values (in case of liver metastases) or &gt; 5.0 times of the upper limit value (for presence of liver metastases) were not studied specifically in the studies." "" "" ""</seg>
<seg id="2390">Patients must be monitored with regard to bone marosuppression and Pemetrexed must not be given to patients before their absolute neutralisation of neutrophiles has reached a value of ≥ 100,000 cells / mm ³ and the thrombocyte number has reached a value of ≥ 100,000 cells / mm ³.</seg>
<seg id="2391">"" "" "" "a can-reduction for further cycles is based on the Nadir of absolute neutrality, thrombocyte number and maximum non-haematological toxicity, as observed in previous treatment cycles (see Section 4.2)." "" "" ""</seg>
<seg id="2392">A lower toxicity and a reduction of grade 3 / 4 hematological and non-abatological toxicity such as neutropenia and neutropenia and infection with degree 3 / 4 neutropenia was treated with a pre-treatment with folic acid and vitamin B12.</seg>
<seg id="2393">"" "" "" "therefore, all patients treated with Pemetremixed must be treated with folic acid and vitamin B12 as prophy- laktic measure for the reduction of treatment-related toxicity (see Section 4.2)." "" "" ""</seg>
<seg id="2394">Patients with mild to moderate kidney failure (Creatinin-Clearance 45 to 79 ml / min) must avoid simultaneous intake of nonsteroidal antiphlogistika (NSAIDs) such as ibuprofen and acetylsaliva cyllic (&gt; 1.3 g daily) for at least 2 days after therapy with Pemetremixed (see section 4.5).</seg>
<seg id="2395">"" "" "" "all patients intended for treatment with Pemetremixed must avoid taking NSAIDs for at least 5 days before the therapy, on the day of therapy and at least 2 days after therapy with Pemetremixed (see section 4.5)." "" "" ""</seg>
<seg id="2396">"" "" "" "many patients in which these events occurred had appropriate risk factors for the occurrence of renal events, including dehydration, high blood pressure or diabetes." "" "" ""</seg>
<seg id="2397">"" "" "" "therefore, a drainage of the ergometer is recommended for patients with clinically significant fluid accumulation in the transacular space." "" "" ""</seg>
<seg id="2398">"" "" "" "5 heavy cardiovascular events, including myocardial infarction, and cerebrovascular events were occasionally reported in clinical trials with Pemetremixed if this substance was administered in combination with a different cytotoxic substance." "" "" ""</seg>
<seg id="2399">"" "" "" "for this reason, the simultaneous use of attenuated vital substances (except yellow fever, this vaccination is contraindicated) is not recommended (see Section 4.3 and 4.5)." "" "" ""</seg>
<seg id="2400">"" "" "" "since the possibility of irreversible damage to reproductive capacity is made by Pemetremixed, men should be advised to get advice regarding the sperm conservation." "" "" ""</seg>
<seg id="2401">In patients with normal renal function (Creatinin-Clearance ≥ 80 ml / min) high doses of nonsteroidal antiphlogistika (NSAIDs) and acetylsalicylic acid in high dosage (≥ 1.3 g a day) can lead to reduced Pemetremixed excretion with the result of increased occurrence of side effects.</seg>
<seg id="2402">Caution is recommended if patients with normal renal function (Creatinin-Clearance ≥ 80 ml / min) can be used in high doses of NSAIDs or Ace- tylsalicylic acid.</seg>
<seg id="2403">Ibuprofen) or acetylsalicylic acid in high dosage for at least 2 days before the therapy and at least 2 days after therapy with Pemetremixed (see section 4.4).</seg>
<seg id="2404">"" "" "" "since no data is available with NSAIDs with long semi-life cycles such as piro- xicam or Rofecoxib, simultaneous use with Pemetremixed must be avoided at least 2 days before the therapy with Pemetre- fixed." "" "" ""</seg>
<seg id="2405">The intra-individual variability of the coagulation status during the disease and the possibility of interactions between oral anticoagulants and antinoplasty requires an increased monitoring frequency of the INR (International Norised Ratio) when the decision was made to treat the patient with oral anticoagulae.</seg>
<seg id="2406">"" "" "" "there are no data for the use of Pemetremixed in pregnant women, but as with analogous antimetabolites, serious birth defects are expected during pregnancy." "" "" ""</seg>
<seg id="2407">"" "" "" "Pemetremixed must not be applied during pregnancy, except if mandatory and after careful weighing of the benefit for the mother and the risk for the foetus (see section 4.4)." "" "" ""</seg>
<seg id="2408">"" "" "" "since the possibility of irreversible damage to reproductive capacity by Pemetremixed, men should be pointed out prior to the commencement of treatment to obtain advice regarding the closure of the sperm." "" "" ""</seg>
<seg id="2409">"" "" "" "it is not known whether Pemetremixed goes into breast milk, and unwanted effects in the breastfed baby can not be excluded." "" "" ""</seg>
<seg id="2410">The following table shows the frequency and severity of adverse effects reported in &gt; 5% of 168 patients with mesothelioma and randomised Cisplatin and Pemetremixed as well as 163 patients with mesothelioma.</seg>
<seg id="2411">"" "" "" "side effects Frequency indications: very common (≥ 1 / 100 and &lt; 1 / 100), occasionally (≥ 1 / 1,000 and &lt; 1 / 1000), very rare (≥ 1 / 10,000) and not known (based on the available data from spontaneous reports)." "" "" ""</seg>
<seg id="2412">* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *</seg>
<seg id="2413">"" "" "" "for this table, a threshold of 5% was established regarding the inclusion of all events in which the reporting doctor considered a connection with Pemetremixed and cisplatin." "" "" ""</seg>
<seg id="2414">"" "" "" "clinically relevant CTC toxicity, which were reported at &lt; 1% (occasionally) of patients receiving arrhythmia and motor neuropathy, randomized to &lt; 1% (occasionally)." "" "" ""</seg>
<seg id="2415">The following table shows the frequency and severity of adverse events reported in &gt; 5% of 265 patients randomised as monotherapy with gifts of folacidire and vitamin B12 plus 276 patients randomized docetaxel as monotherapy.</seg>
<seg id="2416">* * Regarding to National Cancer Institute CTC version 2 for any toxicity level. * * Been to National Cancer Institute CTC (v2.0; NCI 1998) Hair Loss should only be reported as Level 1 or 2.</seg>
<seg id="2417">"" "" "" "for this table, a threshold of 5% was specified concerning the inclusion of all events in which the reporting doctor considered a connection with Pemetremixed for possible." "" "" ""</seg>
<seg id="2418">"" "" "" "clinically relevant CTC toxicity, which were reported at &lt; 1% (occasionally) of the patients randomized supraventricular arrhythmias." "" "" ""</seg>
<seg id="2419">"" "" "" "the clinically relevant laboratory toxicity grade 3 and 4 was compared with 3 Pemetremixed monotherapiums, except for neutropenia (12.8% compared to 5.3%) and an increase in the Alanine transaminase (15.2% compared to 1.9%)." "" "" ""</seg>
<seg id="2420">These differences are likely to lead back to differences in patient population as the phagosis 2 studies included both chemonaive and significantly pre-treated breast cancer patients with existing liver metastases and / or abnormal output values of liver function tests.</seg>
<seg id="2421">The following table shows the frequency and severity of unwanted effects that could be possible in connection with study medication; they were randomised in &gt; 5% of 839 Patients with NSCLC that were randomised to Cisplatin and gemcitabine.</seg>
<seg id="2422">11 * P values &lt; 0.05 comparison of Pemetremixed / Cisplatin and Gemcitabine / cisplatin using the Fisher Exact Test. * * * Regarding to National Cancer Institute CTC (v2.0; NCI 1998) should be reported to taste disorder and hair loss only as Grade 1 or 2.</seg>
<seg id="2423">"" "" "" "for this table, a threshold of 5% was set for the inclusion of all events in which the reporting doctor considered a connection with Pemetremixed and cisplatin." "" "" ""</seg>
<seg id="2424">Clinically relevant toxicity related to ≥ 1% and ≤ 5% (commonly) of patients randomised Cisplatin and Pemetremixed included:</seg>
<seg id="2425">Clinically relevant toxicity reported at &lt; 1% (occasionally) of patients received ran- domized cisplatin and Pemetremixed:</seg>
<seg id="2426">"" "" "" "severe cardiovascular and cerebrovascular events, including myocardial infarction, angina pectoris, cerebrovascular diseases and transitory ischemic attacks have been reported in combination with a different cytotoxic agent." "" "" ""</seg>
<seg id="2427">"" "" "" "clinical studies have occasionally reported cases of coelitis (including intestinal and rectal bleeding, including intestinal and rectal bleeding, intestinal necrosis and typhulite)." "" "" ""</seg>
<seg id="2428">"" "" "" "in clinical studies, patients with Pemetremixed treatment occasionally reported cases of sometimes fatal pneumonitis with respiratory failure." "" "" ""</seg>
<seg id="2429">"" "" "" "cases of acute renal failure in Pemetremixed monotherapy, or in combination with other chemotherapeutics, have been reported (see Section 4.4)." "" "" ""</seg>
<seg id="2430">"" "" "" "cases of Radipneumonitis in patients reported before, during or after their Pemetremixed therapy were reported (see Section 4.4)." "" "" ""</seg>
<seg id="2431">"" "" "" "ALIMTA (Pemetremixed) is an antineoplasty antifolate, which exerts its effect by interrupting weight-dependent metabolic processes that are necessary for cell replication." "" "" ""</seg>
<seg id="2432">In vitro studies showed that Pemetremixed counteracts as an antifolate with multiple attacks by using the thymidyspsynthase (DHFR) and glycinamidribonucleotidfor- myltransferase (GARFT) which are the folate-dependent key enzymes of the de novo biosynthesis of thymidine and purinnucleotides.</seg>
<seg id="2433">EMPHACIS is a multicenter, randomised, simple-blind phase 3 study of ALIMTA plus cisplatin chemonaiven patients with malignant pleuramesothelioma had a clinically meaningful benefit of a patient over median 2.8-month-prolonged survival compared to those patients who were only covered with cisplatin.</seg>
<seg id="2434">"" "" "" "the primary analysis of this study was undertaken in the population of all patients, who received the investigational medication in the arm (randomised and treated)." "" "" ""</seg>
<seg id="2435">A statistically significant improvement of clinically relevant symptoms (pain and dyspnoe) in connection with malignant pleural othelioma was demonstrated in the ALIMTA / Cisplatin arm (212 patients) compared to the cisplaine arm (218 patients).</seg>
<seg id="2436">The differences between the two treatment arms were improved by improving lung function parameters in the ALIMTA / Cisplatin arm and a reduction of lung function over time in the control arm.</seg>
<seg id="2437">A multicenter, randomised and open phase III trial with ALIMTA against docetaxel in Patients with locally advanced or metastatic NSCLC revealed a median survival time of 8.3 months in patients treated with docetaxel (ITT n = 288).</seg>
<seg id="2438">HR = 0.78; 95% CI = 0.61; 95% CI = 0.61-1.00, p = 0,047; p = 0.018; p = 0.018; p = 0.018; p = 0.047) for patients with endothelial cell carcinoma (n = 0.61; 95% CI = 0.61-1.00).</seg>
<seg id="2439">Limited data from a separately randomised controlled Phase 3 study showed that efficacy data (survival and progression-free survival) for Pemetremixed between patients with (n = 41) and without (n = 540) pre-treatment with docetaxel are similar.</seg>
<seg id="2440">The efficacy analyses of the PQ population are consistent with the analysis of the ITT population and support the non-inferiority of the ALIMTA Cisplatin combination compared to gemcitabine cisplatin combination.</seg>
<seg id="2441">For the combination ALIMTA Cisplatin (adjusted HR = 1.04; 95% CI = 0.94 - 1.15) for the combination of ALIMTA Cisplatin compared to 28.2% (95% CI = 25,0 - 31.4) for the combination of gemcitabine cisplatin.</seg>
<seg id="2442">"" "" "" "the analysis of the impact of NSCLC histology on survival showed clinically relevant differences in histology, see table below." "" "" ""</seg>
<seg id="2443">"" "" "" "CI = self-to-treat; N = Size of the total population a statistically for non-superiority, with a total context interval for HR (= Hazard ratio) significantly below the non-level limit of 1,17645 (p &lt; 0.001)." "" "" ""</seg>
<seg id="2444">Patients with ALIMTA and Cisplatin treated fewer transfusions (16.4% vs. 28,9% compared to 0.1% vs. 27.3% compared to p &lt; 0.001) and platocyte transfusions (p = 0.002).</seg>
<seg id="2445">"" "" "" "in addition, the patients required selythropoetin / Darabopoetin (10.4% vs. 18.1%, p = 0,004), and iron preparations (4.3% vs. 7.0%, p = 0.021)." "" "" ""</seg>
<seg id="2446">Pharmacokinetic properties of Pemetremixed as a monotherapist were examined in 426 cancer patients with various solid tumours in doses of 0.2 to 838 mg / m ² in infusion zones over a period of 10 minutes.</seg>
<seg id="2447">"" "" "" "Pemetremixed is mainly excreted in the urine and 70% to 90% of the administered dose are found in urine, within 24 hours of use." "" "" ""</seg>
<seg id="2448">Pemetremixed has a total output of 91.8 ml / min and the half-life time in the plasma is 3.5 hours in patients with normal kidney function (Kreatinin-Clearance 90 ml / min).</seg>
<seg id="2449">"" "" "" "in a study involving Beagle dogs, which received intravenous bolus injections for 9 months, Testikulinary changes were observed (degene- ration / necrosis of the seminificant epithelium tissue)." "" "" ""</seg>
<seg id="2450">"" "" "" "unless otherwise used, the retention periods and conditions after preparation are carried out in the user's responsibility and should not normally exceed 24 hours at 2 to 8 ° C unless the preparation / dilution has taken place under controlled and validated aseptic conditions." "" "" ""</seg>
<seg id="2451">"" "" "" "release the content of the 100 mg mug bottles with 4.2 ml 0.9% sodium chloride injection solution (9 mg / ml) without preservatives, resulting in a solution with a concentration of about 25 mg / ml Pemetremixed." "" "" ""</seg>
<seg id="2452">"" "" "" "the resulting solution is clear and the coloring ranges from colourless to yellow or greenish, without compromising the product quality." "" "" ""</seg>
<seg id="2453">"" "" "" "each bottle must be dissolved with 20 ml 0.9% sodium chloride injection solution (9 mg / ml), resulting in a 25 mg / ml solution." "" "" ""</seg>
<seg id="2454">"" "" "" "23 heavy cardiovascular events, including myocardial infarction, and cerebrovascular events were occasionally reported in clinical trials with Pemetremixed if this substance was administered in combination with a different cytotoxic substance." "" "" ""</seg>
<seg id="2455">* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *</seg>
<seg id="2456">"" "" "" "for this table, a threshold of 5% was established regarding the inclusion of all events in which the reporting doctor considered a connection with Pemetremixed and cisplatin." "" "" ""</seg>
<seg id="2457">* * Regarding to National Cancer Institute CTC version 2 for any toxicity level. * * Been to National Cancer Institute CTC (v2.0; NCI 1998) Hair Loss should only be reported as Level 1 or 2.</seg>
<seg id="2458">29 * P values &lt; 0.05 comparison of Pemetremixed / Cisplatin and Gemcitabine / cisplatin using the Fisher Exact Test. * * * Regarding to National Cancer Institute CTC (v2.0; NCI 1998) should be reported to taste disorder and loss of hair only as degree 1 or 2.</seg>
<seg id="2459">Clinically relevant toxicity reported at &lt; 1% (occasionally) of patients received ran- domized cisplatin and Pemetremixed:</seg>
<seg id="2460">HR = 0.78; 95% CI = 0.61; 95% CI = 0.61; 95% CI = 0.61-1.00; p = 0.018; p = 0.018; p = 0.047) for patients with endothelial cell carcinoma (n = 0.61; 95% CI = 0.61-1.00; p = 0.018).</seg>
<seg id="2461">"" "" "" "release 500 mg / ml of sodium chloride content (9 mg / ml) without preservatives, resulting in a solution with a concentration of about 25 mg / ml Pemetremixed." "" "" ""</seg>
<seg id="2462">"" "" "" "the resulting solution is clear and the coloring extends from colourless to yellow or greenish, without compromising the product quality." "" "" ""</seg>
<seg id="2463">Pharmacovigilance System The owner of approval for placing the market has to bear in mind that the pharmacovigilance system as described in version 2.0 contains in module 1.8.1. the approval for placing on the market is ready and operational as soon as the product is brought into circulation and while the product is on the market.</seg>
<seg id="2464">Risk Management Plan The holder of the approval of the marketing agency commits itself to the studies and the additional pharmacovigilance activities according to pharmacovigilance plan as agreed in Module 1.8.2. the approval of the entry and all subsequent updates of the RMP approved by CHMP.</seg>
<seg id="2465">"" "" "" "according to the CHMP Guideline on Risk Management Systems for human use, an updated RMP must be submitted at the same time as the next" Periodic Safety Update Report "(PSUR)." "" "" ""</seg>
<seg id="2466">"" "" "" "in addition, an updated RMP must be submitted • When new information is available which may have an impact on current security specifications, pharmacovigilance plan or risk management) milestones • On request by the EMEA" "" "" ""</seg>
<seg id="2467">ALIMTA 100 mg powder for the production of a concentrate for the production of an infusion solution ALIMTA 500 mg powder for the production of a concentrate for the production of an infusion solution</seg>
<seg id="2468">ALIMTA is used in patients who have not received prior chemotherapy for the treatment of malignant pleural othelioma (malignant disease of the rib) in combination with cisplatin and other medicines to treat cancer.</seg>
<seg id="2469">"" "" "" "if you have kidney disease or have earlier one, please discuss this with your doctor or hospital pharmacy as you may not be allowed to receive ALIMTA." "" "" ""</seg>
<seg id="2470">"" "" "" "with you, blood tests will be performed before each infusion of blood tests; it is checked whether your kidney and liver function is sufficient and whether you have sufficient blood cells to obtain ALIMTA to 49." "" "" ""</seg>
<seg id="2471">Your doctor may possibly change the dose or stop treatment if it requires your general condition and if your blood values are too low.</seg>
<seg id="2472">"" "" "" "if you also receive cisplatin, your doctor will ensure that your body contains sufficient water and you will get the necessary medicines to prevent vomiting before and after the cisplatin administration." "" "" ""</seg>
<seg id="2473">"" "" "" "if you have a fluid collection around the lungs, your doctor may decide to eliminate this fluid before you get ALIMTA." "" "" ""</seg>
<seg id="2474">"" "" "" "if you would like to educate a child during the treatment or in the first 6 months after the treatment, please talk to your doctor or pharmacist." "" "" ""</seg>
<seg id="2475">"" "" "" "interactions with other medicines Please tell your doctor if you are using drugs against pain or inflammation (swelling), such as drugs that are non-steroidal anti-inflammatory drugs (NSAIDs), including drugs which are non-prescription (such as ibuprofen)." "" "" ""</seg>
<seg id="2476">"" "" "" "your doctor will tell you what other drugs you can take, and when." "" "" ""</seg>
<seg id="2477">"" "" "" "please inform your doctor or pharmacist if you take other medicines or have recently taken it, even if it is not prescription drug han- delt." "" "" ""</seg>
<seg id="2478">"" "" "" "a hospital pharmacy, the nursing staff or a doctor will mix the ALIMTA powder with sterile 0,9% sodium chloride injection solution (9 mg / ml) before it is applied to you." "" "" ""</seg>
<seg id="2479">Your doctor will prescribe you cortisone tablets (according to 4 mg of dexamethane twice a day) that you must take on the day before and during the day following the application of ALIMTA.</seg>
<seg id="2480">Your doctor will prescribe folic acid (a vitamin) for intake or multivitamins which contain folic acid (350 to 1000 micrograms) which you must take during the application of ALIMTA a day.</seg>
<seg id="2481">"" "" "" "in the week before using ALIMTA and about every 9 weeks (according to 3 cycles of treatment with ALIMTA), you will also receive an injection of vi- tamin B12 (1000 micrograms)." "" "" ""</seg>
<seg id="2482">"" "" "" "if a side effect is described as" very frequently "in this utility information, this means that it was reported by at least 1 of 10 patients." "" "" ""</seg>
<seg id="2483">"" "" "" "if a side effect is described as" frequently ", this means that it was reported by at least 1 out of 100 patients but reported less than 1 out of 10 patients." "" "" ""</seg>
<seg id="2484">"" "" "" "if a side effect is described as" occasional, "this indicates that they have been reported by at least 1 of 1,000 but less than 1 out of 100 patients." "" "" ""</seg>
<seg id="2485">"" "" "" "fever or infection (often): if you have a body temperature of 38 ° C or over, sweating or other signs of infection (because you may have fewer white blood cells than normal, which is very common)." "" "" ""</seg>
<seg id="2486">"" "" "" "if you feel tired or weak, get fast in breath or look pale (because you might have less hemoglobin than normal, which is very common)." "" "" ""</seg>
<seg id="2487">"" "" "" "if you detect a bleeding of the gums, nose or mouth or another bleeding that does not come to a halt, or have a reddish or pink urine or unexpected bruising (because you may then have fewer blood platelets than normal, which is very common)." "" "" ""</seg>
<seg id="2488">Occasional (occurs at least 1 out of 1000 patients but less than 1 out of 100 patients) increased pulse rate colitis (inflammation of the internal lining of the colon that can be associated with bleeding in the intestines and endendim) edema (withdrawal of water into the body tissue that leads to swelling).</seg>
<seg id="2489">"" "" "" "rare (occurs in more than 1 of 10,000 patients, but less than 1 out of 1,000 patients)" Radiation Recall "(a rash similar to a severe sunburn), appearance on the skin that was previously exposed (some days to years) of radiotherapy." "" "" ""</seg>
<seg id="2490">"" "" "" "occasionally, patients with ALIMTA, usually in combination with other cancer patients, received a stroke or stroke with a lower damage." "" "" ""</seg>
<seg id="2491">"" "" "" "in patients receiving radiation treatment before, during or after their ALIMTA treatment, the inflammation of the lung tissue (scarring of the pulmonary vesicles, which is related to radiation treatment) can occur." "" "" ""</seg>
<seg id="2492">52 inform your doctor or pharmacist if any of the listed side effects are significantly impaired or if you notice any side effects that are not included in this treatment supplement.</seg>
<seg id="2493">"" "" "" "provided as prescribed, the chemical and physical stability of thinner and infusion solution for storage in the refrigerator or at 25 ° C for a period of 24 hours has been demonstrated." "" "" ""</seg>
<seg id="2494">Tél / Tel: + 32- (0) 2 548 84 84. ambulatory bid. + 359 2 491 41 40 Croweská republika ELI LILLY ČR. s.r.o..</seg>
<seg id="2495">Tel: + 420 234 664 111 Danmark Eli Lilly Danmark A / S Tlf: + 45 45 26 6100 Germany GmbH Tel. + 49- (0) 6172 273 2222 Eesti Eli Lilly Holdings Limited Eesti filiaal Tel: + 3726441100</seg>
<seg id="2496">Tel: + 34-91-623-1732 France Lilly France SAS Tél: + 33- (0) 1 55 49 34 34 Ireland Eli Lilly and Company (Ireland) Limited Tel: + 353- (0) 1 661 4377 Ísland Icepharma hf.</seg>
<seg id="2497">Tel: + 39- 055 42571 + 357 22 715000 Latvija Eli Lilly Holdings Limited atstovybė Phone: + 371 67364000 Lietuva Eli Lilly Holdings Limited atstovybė Phone. + 370 (5) 2649600</seg>
<seg id="2498">Tel.: + 48 (0) 22 440 33 00 Portugal Lilly Portugal - produtos Farmacêutist; Lda Tel: + 351-21-4126600 România Eli Lilly România S.R.L..</seg>
<seg id="2499">Tel: + 421 220 663 111 Suomi / Finland Oy Eli Lilly Sweden AB: + 358- (0) 9 7378800 United Kingdom Eli Lilly and Company Limited Tel: + 44- (0) 1256 315999</seg>
<seg id="2500">Dissolve the content of the 100 mg mug bottles with 4.2 ml 0.9% sodium chloride injection solution (9 mg / ml) without preservatives which results in a solution with a concentration of about 25 mg / ml Pemetremixed.</seg>
<seg id="2501">Solve the content of 500 mg mug bottles with 20 ml 0.9% sodium chloride injection solution (9 mg / ml) without preservatives on what makes a solution with a concentration of about 25 mg / ml Pemetremixed.</seg>
<seg id="2502">"" "" "" "the resulting solution is clear and the coloring ranges from colourless to yellow or greenish, without compromising the quality of proofing." "" "" ""</seg>
<seg id="2503">"" "" "" "it is used in overweight adults with a body measure index (BMI) of ≥ 28 kg per square metre in conjunction with a low-calorie, fat-reduced diet." "" "" ""</seg>
<seg id="2504">"" "" "" "patients who take alli and after 12 weeks do not have a weight loss, should contact their doctor or pharmacist." "" "" ""</seg>
<seg id="2505">"" "" "" "when these enzymes are inhibited, they can not break down some fats in the food, resulting in approximately a quarter of the fats contained with food undigested the intestines." "" "" ""</seg>
<seg id="2506">"" "" "" "in a third study, Alli was compared to placebo in 391 patients with a BMI between 25 and 28 kg / m2 compared with placebo." "" "" ""</seg>
<seg id="2507">"" "" "" "in the two studies in patients with a BMI of ≥ 28 kg / m2, patients who recorded an average weight loss of 4.8 kg after one year compared to 2.3 kg compared to placebo." "" "" ""</seg>
<seg id="2508">"" "" "" "in the study with Alli in patients with BMI between 25 and 28 kg / m2, no weight loss could be observed for patients." "" "" ""</seg>
<seg id="2509">"" "" "" "the most common side effects of Alli (observed in more than 1 out of 10 patients) are oily stains at the anus, flatus (winch) with studling, oily / oily chair, fluff oily (winds) and soft chairs." "" "" ""</seg>
<seg id="2510">It must not be used in patients treated with Ciclosporin (to prevent organ rejection in graft patients) or with medicines such as warfarin to prevent blood clots.</seg>
<seg id="2511">"" "" "" "it may also not be used in patients suffering from a long-term malabsorption syndrome (in which insufficient nutrients from the digestive tract are absorbed) or cholestase (liver disease), and in pregnant women or nursing mothers." "" "" ""</seg>
<seg id="2512">"" "" "" "in July 2007, the European Commission granted Glaxo Group Limited permission to import Orlistat GSK into the entire European Union." "" "" ""</seg>
<seg id="2513">Alli is indicated for weight reduction of adults with excess weight (Body-Mass Index BMI ≥ 28 kg / m2) and should be used in conjunction with a moderately hypocaloric or fatty diet.</seg>
<seg id="2514">"" "" "" "alli must not be used by children and young people under 18, as there are insufficient data on efficacy and safety." "" "" ""</seg>
<seg id="2515">"" "" "" "since orlistat is only minimal absorbed, it is not necessary to adjust the dosage in elderly and patients with reduced liver and / or kidney function." "" "" ""</seg>
<seg id="2516">• Oversensitivity to the active ingredient or any of the ingredients • Simultaneous treatment with Ciclosporin (see section 4.6) • Premature treatment with warfarin or other oral anticoagulants (see Sections 4.5 and 4.8)</seg>
<seg id="2517">The likelihood of occurrence of gastrointestinal symptoms (see section 4.8) may increase if alli is taken together with a fat-rich single meal or a fat-rich diet.</seg>
<seg id="2518">"" "" "" "as weight reduction in diabetes may be associated with improved metabolic control, patients who take a medicine against diabetes should consult a doctor or pharmacist before starting treatment with alli because the dosage of the antidiabetic needs to be adjusted." "" "" ""</seg>
<seg id="2519">"" "" "" "patients who are alli as well as medicines for high blood pressure or elevated cholesterol levels should ask their doctor or pharmacist, if the dosage of these medicines has to be adjusted." "" "" ""</seg>
<seg id="2520">"" "" "" "it is recommended to take additional pregnant precautions, in order to prevent possible failure of the oral contraception in case of serious diarrhoea (see section 4.5)." "" "" ""</seg>
<seg id="2521">"" "" "" "in a study on drug interactions, and in several cases with simultaneous use of orlistat and Ciclosporin, a lowering of the Ciclosporin plasma level was observed." "" "" ""</seg>
<seg id="2522">"" "" "" "when applying warfarin or other oral anticoagulants in combination with orlistat, the Quick-values (internationally normalized ratio, INR) could be influenced (see Section 4.8)." "" "" ""</seg>
<seg id="2523">"" "" "" "in most patients treated with orlistat in clinical trials up to 4 full years, concentrations of vitamins A, D, E and K as well as beta carotene remained in the normal range." "" "" ""</seg>
<seg id="2524">"" "" "" "however, the patient should be advised to take an additional vitamin supplement before bedtime to ensure sufficient vitamin intake (see Section 4.4)." "" "" ""</seg>
<seg id="2525">"" "" "" "after receiving a single dose of Amiodarone, a small number of healthy volunteers who were at the same time received orlistat a minor decrease in the Amiodarone plasma concentration." "" "" ""</seg>
<seg id="2526">"" "" "" "animal experimental studies showed no direct or indirect harmful effects on pregnancy, embryonic / fetal development, birth or postnatal development (see section 5.3)." "" "" ""</seg>
<seg id="2527">"" "" "" "the side effects of orlistat are mainly gastrointestinal nature and are related to the pharmacological effect of the drug, as the absorption of taken fat is prevented." "" "" ""</seg>
<seg id="2528">The gastrointestinal side effects were obtained from clinical trials with orlistat 60 mg over a period of 18 months to 2 years and were generally mild and temporary.</seg>
<seg id="2529">"" "" "" "the frequencies are defined as follows: very common (≥ 1 / 100, &lt; 1 / 100, &lt; 1 / 100), occasionally (≥ 1 / 1,000, &lt; 1 / 1000) and very rare (frequency based on available data)." "" "" ""</seg>
<seg id="2530">"" "" "" "the incidence of adverse events known after the market launch of orlistat is not known, since these events were voluntarily reported by a population of uncertain magnitude." "" "" ""</seg>
<seg id="2531">"" "" "" "† It is plausible that treatment with alli can lead to anxiety regarding possible, actual gastrointestinal side effects." "" "" ""</seg>
<seg id="2532">Doses of 800 mg orlistat and multiple doses of up to 400 mg three times daily were administered over a period of 15 days on normal and overweight subjects without significant clinical findings.</seg>
<seg id="2533">"" "" "" "in the majority of cases of orlistat overdose reported after the market launch, no side effects or similar side effects were reported as at the recommended dose of orlistat." "" "" ""</seg>
<seg id="2534">"" "" "" "based on research on humans and animals, a rapid back-formation of any systemic effects can be traced back to the characteristics of orlistat." "" "" ""</seg>
<seg id="2535">"" "" "" "in the lumens of the stomach and the upper thin intestine, the therapeutic effect is performed by covalent bonding to the active Serin-Rest of the gastrische and pankrean lipien." "" "" ""</seg>
<seg id="2536">"" "" "" "clinical studies have derived that 60 mg of orlistat, taken three times a day, blocked the absorption of about 25% of the food fetus." "" "" ""</seg>
<seg id="2537">"" "" "" "two double-blind, randomised, placebo-controlled studies in adults with BMI ≥ 28 kg / m2 determine the efficacy of 60 mg orlistat, which was used three times a day in combination with a hypocaloric, fat-reduced diet." "" "" ""</seg>
<seg id="2538">"" "" "" "the primary parameter, the change in body weight compared to the initial value (at the time of randomization), was evaluated as follows: as a change in body weight in the course of study (Table 1) and as percentage of those study participants who have lost more than 5% or more than 10% of their starting weight (Table 2)." "" "" ""</seg>
<seg id="2539">"" "" "" "although the weight reduction was observed over 12 months in both studies, the largest weight loss occurred during the first 6 months." "" "" ""</seg>
<seg id="2540">The average change in the total priestess was with orlistat 60 mg -2.4% (starting value 5.20 mmol / l) and with placebo + 2.8% (starting value 5.26 mmol / l).</seg>
<seg id="2541">The average change in LDL cholesterol was with orlistat 60 mg -3.5% (starting value 3.30 mmol / l) and with placebo + 3.8% (starting value 3.41 mmol / l).</seg>
<seg id="2542">At waist size the average change -4.5 cm with orlistat was 60 mg (starting value 103.7 cm) and with placebo -3.6 cm (starting value 103.5 cm).</seg>
<seg id="2543">Plasma concentrations of non-metabolized orlistat were not measurable 8 hours after oral administration of 360 mg orlistat (&lt; 5 ng / ml).</seg>
<seg id="2544">7 In general therapeutic doses could not be detected sporadically and at extremely low concentrations (&lt; 10 ng / ml or 0.02 µmol) and without any signs of cumulation.</seg>
<seg id="2545">"" "" "" "in a study involving adipous patients given the minimal systemic resorbed dose, two major metabolites were identified, namely M1 (in position 4 hydrolyzed Lactonring) and M3 (M1 after splitting the N-Formyl-Leucine group)." "" "" ""</seg>
<seg id="2546">"" "" "" "based on conventional studies on safety macology, toxicity in repeated application, genotoxicity, carcinogenic potential and reproductive toxicity, the preclinical data has no special risk for man." "" "" ""</seg>
<seg id="2547">"" "" "" "Pharmacovigilance System The owner of approval for placing on the market must ensure that the pharmacovigilance system, described in module 1.8.1. of the authorisation application, is applied and works before and while the product is available on the market." "" "" ""</seg>
<seg id="2548">Risk management plan The holder of approval of the marketing agency commits itself to perform the studies and additional pharmacovigilance activities as described in the pharmacovigilance plan (RMP) according to module 1.8.2. the authorisation application and all further updates of the RMPs that are agreed with the Committee on Human Use (CHMP).</seg>
<seg id="2549">"" "" "" "according to the CHMP guidelines on risk management systems for human medicines, the updated RMP must be submitted simultaneously with the next PSUR (Periodic Safety Update Report)." "" "" ""</seg>
<seg id="2550">"" "" "" "furthermore an updated RMP should be submitted: • If new information is available, the current safety guidelines, pharmacovigilance plan or risk management affected by major, drug vigilance or risk minimization • on request from the European Medicines Agency (EMEA)" "" "" ""</seg>
<seg id="2551">"" "" "" "12 PSURs In the first year after the Commission decision on the enlargement of the authorization to submit the alli 60 mg of hard capsules PSURs every 6 months, then for two years annual and thereafter every three years." "" "" ""</seg>
<seg id="2552">"" "" "" "• If you are pregnant or breastfeeding, if you are pregnant or breastfeeding, if you are hypersensitive to orlistat or any of the other ingredients, • if you are hypersensitive to orlistat or any of the other ingredients." "" "" ""</seg>
<seg id="2553">"" "" "" "take 3 times a day with each main meal that contains fat, one capsule with water. • You should take one capsule one day before bedtime, a multivitamin intet (with vitamins A, D, E and K)." "" "" ""</seg>
<seg id="2554">"" "" "" "use: take three times a day with each main meal the fat contains, one capsule with water. • You should take a multivitamin intett a day before bedtime (with vitamins A, D, E and K)." "" "" ""</seg>
<seg id="2555">"" "" "" "if you need further information or advice, consult a doctor or pharmacist for advice." "" "" ""</seg>
<seg id="2556">"" "" "" "• If any of the side effects listed you may have significantly impaired or if you notice any side effects not specified in this information information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="2557">What do you need to consider before taking alli? • Any special caution when taking alli is required • When taking alli with other medicines • In case of intake of alli together with foods and drinks • pregnancy and lactation • Well-being and operation of machines 3.</seg>
<seg id="2558">How can you prepare your weight loss? O Choose your starting point o Send a target for your calorie intake o Set your targets for your calorie and fat intake • How long should I take alli? O If you have taken alli in too large amounts o.</seg>
<seg id="2559">What side effects are possible? • Several side effects • Very frequent side effects • Frequent side effects • Effect on blood tests • How to control nutritional deficiencies?</seg>
<seg id="2560">"" "" "" "• What alli contains, how alli looks and content of the pack • Pharmaceutical entrepreneurs and manufacturers • More helpful information" "" "" ""</seg>
<seg id="2561">Alli is used to reduce weight and is used for overweight adults aged 18 years with a Body Mass Index (BMI) of 28 or above. alli should be used in conjunction with a low-fat and low-calorie diet.</seg>
<seg id="2562">BMI helps you determine whether you have a normal weight in relation to your body size or are overweight.</seg>
<seg id="2563">"" "" "" "even if these diseases initially do not cause you to feel uncomfortable, you should nonetheless ask your doctor for a check examination." "" "" ""</seg>
<seg id="2564">"" "" "" "for each 2 kg body weight, which you lose weight during a diet, you can lose an additional kilogram with the help of alli." "" "" ""</seg>
<seg id="2565">"" "" "" "please inform your doctor or pharmacist if you take other medicines or have recently taken it, even if it is not prescription medicine." "" "" ""</seg>
<seg id="2566">"" "" "" "Ciclosporin is used after transplantations, severe rheumatoid arthritis and certain severe skin diseases. • Warfarin or other medicines that have a blood diluting effect." "" "" ""</seg>
<seg id="2567">Oral contraceptives and alli • The effect of orally increasing means of contraception (pill) may be weakened or lifted under certain circumstances if you have strong diarrhoea (diarrhea).</seg>
<seg id="2568">"" "" "" "before taking alli, please contact your doctor or pharmacist if you use: • Amiodarone to treat heart rhythm disorders." "" "" ""</seg>
<seg id="2569">"" "" "" "ask your doctor or pharmacist if you take alli and if you take medicine against high blood pressure, as possibly the dosage needs to be adjusted." "" "" ""</seg>
<seg id="2570">"" "" "" "for more information on the blue pages in Section 6, learn how to define your calorific and fat limits." "" "" ""</seg>
<seg id="2571">"" "" "" "if you have a meal or does not contain any fat, do not take a capsule. alli can only act when the food contains fat." "" "" ""</seg>
<seg id="2572">"" "" "" "if you take the capsule in conjunction with a meal that contains too much fat, you risk nutrition-related accompanying symptoms (see section 4)." "" "" ""</seg>
<seg id="2573">"" "" "" "to get used to your body to the new eating habits, start before the first capsule filling with a calorie and fat-reduced diet." "" "" ""</seg>
<seg id="2574">"" "" "" "nutritional supplements are effective because you can understand what you eat, how much you eat and it will probably be easier to change your eating habits." "" "" ""</seg>
<seg id="2575">"" "" "" "in order to achieve your goal weight safely, you should set two daily targets in advance: one for the calories and one for fat." "" "" ""</seg>
<seg id="2576">"" "" "" "• In order to reduce the likelihood of diet-related accompanying symptoms (see Section 4). • Try to move more before you start taking the capsules." "" "" ""</seg>
<seg id="2577">"" "" "" "remember to ask your doctor beforehand, if you are not used to physical activity. • Stay physically active during the intake and after ending the intake of alli." "" "" ""</seg>
<seg id="2578">"" "" "" "• If you cannot detect any reduction of your weight after twelve weeks of application of alli, ask your doctor or pharmacist for advice." "" "" ""</seg>
<seg id="2579">"" "" "" "• In case of a successful weight loss, it is not necessary to change the diet only at short notice and then return to the old habits." "" "" ""</seg>
<seg id="2580">"" "" "" "• If less than one hour has passed since the last meal, take the capsule after. • If more than one hour has passed since the last meal, take no capsule." "" "" ""</seg>
<seg id="2581">"" "" "" "flatulence with and without an ovenous discharge, sudden or increased chair rang and soft chair) can be traced back to the mode of action (see Section 1)." "" "" ""</seg>
<seg id="2582">"" "" "" "severe allergic reactions • severe allergic reactions can be seen in the following changes: severe breathing, sweating, skin rash, itching, swelling in the face, heart rate, circulatory collapse." "" "" ""</seg>
<seg id="2583">29 Very frequent side effects This may occur in more than 1 out of 10 people taking alli. • Inflammatory bowel) with and without blemish • Smoking or oily chair • Weicher chair inform your doctor or pharmacist if any of these side effects are amplified or significantly impaired.</seg>
<seg id="2584">Frequent side effects This may occur in 1 out of 10 people taking alli. • stomach (abdominal) pain; • Inkontinenz (chair) • aqueous / fluid chair • Incontinence (chair) • Exercise your doctor or pharmacist if any of these side effects reinforces or significantly impaired you.</seg>
<seg id="2585">Effects on blood tests It is not known how often these effects occur. • Increasing specific liver cells • Effect on blood clotting in patients who take Warfarin or other blood-diluting drugs (anticoagulated) medicine.</seg>
<seg id="2586">"" "" "" "please inform your doctor or pharmacist, if any of the side effects listed will affect you significantly or you may notice any side effects that are not stated in this information information." "" "" ""</seg>
<seg id="2587">"" "" "" "the most common side effects are related to the mode of action of the capsules, resulting in increased fat from the body." "" "" ""</seg>
<seg id="2588">"" "" "" "these side effects usually occur within the first weeks of treatment, as you may have not consistently reduced the fat content in your diet." "" "" ""</seg>
<seg id="2589">"" "" "" "with the following basic rules you can learn to minimise the diet-related accompanying symptoms: • Begin a few days, or better a week before taking the capsules with a low-fat diet. learn more about the usual fat content of your favourite foods and about the size of portions that you normally take." "" "" ""</seg>
<seg id="2590">"" "" "" "if you know exactly how much you eat, the probability that you exceed your fat limit decreases. • Divide your recommended amount of fat evenly to the daily meals." "" "" ""</seg>
<seg id="2591">"" "" "" "save the amount of calories and fat you may take per meal, not to take them in the form of a fat-rich main court or a nutritious dessert, as you may experience it in other programs for weight loss." "" "" ""</seg>
<seg id="2592">• Keep out of the reach of children. • Do not use over 25 ° C to protect the contents from moisture. • The container tightly closed to protect the contents from moisture. • The bottle contains two white sealed containers with silica gel which serve to keep the capsules dry.</seg>
<seg id="2593">"" "" "" "do not swallow them. • You can carry your daily dose every day in the blue transport box (Shuttle), which is included in this package." "" "" ""</seg>
<seg id="2594">"" "" "" "FAMAR, 190 11 Avlona, Greece Catalent UK Packaging Limited, Sedge Close, Headway, Great Oakley, Corby, Northamptonshire NN18 8HS, United Kingdom" "" "" ""</seg>
<seg id="2595">Excess weight affects your health and increases the risk of developing various serious diseases such as: • hypertension • diabetes • heart disease • hypertension • Osteoarthritis speak to your doctor about your risk of these diseases.</seg>
<seg id="2596">"" "" "" "lasting weight loss, for example by improving diet and more exercise, can prevent serious diseases and has a positive impact on your health." "" "" ""</seg>
<seg id="2597">"" "" "" "choose meals that contain a wide range of nutrients, and gradually learn to eat healthily." "" "" ""</seg>
<seg id="2598">"" "" "" "energy is also measured in kilojoules, which you can also find in the packaging of foods. • The recommended calorie intake indicates how many calories you should take maximum per day." "" "" ""</seg>
<seg id="2599">"" "" "" "keep in mind the below tables below. • The recommended intake in grams is the maximum amount of fat you should take with every meal." "" "" ""</seg>
<seg id="2600">"" "" "" "which amount is suitable for you, refer to the information below, which indicates the number of calories you use." "" "" ""</seg>
<seg id="2601">"" "" "" "if you take the same amount of fat as before, this may mean that your body cannot process this amount of fat." "" "" ""</seg>
<seg id="2602">"" "" "" "by keeping the recommended fat intake, you can maximise weight loss and at the same time reduce the likelihood of diet-related accompanying symptoms." "" "" ""</seg>
<seg id="2603">34 This reduced calorie intake should allow you to gradually lose weight approximately 0.5 kg per week without having to develop frustrations and disappointments.</seg>
<seg id="2604">"" "" "" "the more active you are, the higher your recommended calorie intake. •" Low physical activity "means that you burn 150 kcal daily, i.e. through 3 km walking, 30- to 45 minute gardening or 2 km running in 15 minutes." "" "" ""</seg>
<seg id="2605">• For permanent weight loss it is necessary to set realistic calorie and fat targets and keep them adhered to. • Sense is a nutrition journal containing information on calorie and fat content of your meals. • Try to move more before you start taking alli.</seg>
<seg id="2606">The alli program to support weight loss combines the capsules with a diet plan and a large number of other information materials that can help you eat calory and fetal reactions and give guidelines to become physically active.</seg>
<seg id="2607">"" "" "" "in conjunction with a program tailored to your type of weight loss program, this information can help you develop a healthier lifestyle and achieve your goal weight." "" "" ""</seg>
<seg id="2608">"" "" "" "alchemotherapies are used for nausea and vomiting (like cisplatin), as well as chemotherapies, the moderate triggers for nausea and vomiting (such as cyclophosphamide, doxorubicine or carboplatin)." "" "" ""</seg>
<seg id="2609">The efficacy of Aloxi can be increased by the additional administration of a corticosteroids (a drug that can be used as antiemetic).</seg>
<seg id="2610">"" "" "" "the application in patients under 18 years of age is not recommended, because there is not enough information about the effects in this age group." "" "" ""</seg>
<seg id="2611">"" "" "" "this means that the active ingredient helps to bind a chemical substance in the body, 5-hydroxytryptamin (5HT, also known as serotonin), which prevents receptors in the intestines." "" "" ""</seg>
<seg id="2612">"" "" "" "in three major studies, Aloxi was examined at 1,842 adults who received chemotherapy for nausea and vomiting." "" "" ""</seg>
<seg id="2613">"" "" "" "for chemotherapies, the strong trigger for nausea and vomiting showed 59% of the patients treated with Aloxi (132 of 223) compared to 57% of patients treated with Ondansetron (126 of 221)." "" "" ""</seg>
<seg id="2614">Chemotherapy for nausea and vomiting showed 81% of the patients treated with Aloxi (153 of 189) compared to 69% of patients treated with Ondansetron (127 from 185).</seg>
<seg id="2615">In a comparison with Dolasetron these values were 63% for Aloxi (119 of 189 patients) and 53% for Dolasetron (101 of 191 patients).</seg>
<seg id="2616">"" "" "" "in March 2005, the European Commission issued a permit for the marketing of Aloxi in the whole European Union." "" "" ""</seg>
<seg id="2617">Aloxi is indicated: for the prevention of acute nausea and vomiting in highly emetogenic chemotherapy because of cancer and for the prevention of nausea and vomiting in moderately emetogenic chemotherapy due to cancer.</seg>
<seg id="2618">The efficacy of Aloxi for the prevention of nausea and vomiting induced by a strongly emetogenic chemotherapy may be enhanced by adding a corticosteroid given prior to chemotherapy.</seg>
<seg id="2619">"" "" "" "since Palonosetron can prolong the large intestine massage, patients with amnesty obstipation or signs of a subacute Ileus should be closely monitored after injection." "" "" ""</seg>
<seg id="2620">"" "" "" "however, as with other 5HT3 antagonists, caution is advisable at simultaneous administration of palonosetron with medicines that extend the QT interval or in patients with whom the interval is extended or which tend to be an extension." "" "" ""</seg>
<seg id="2621">"" "" "" "in addition to chemotherapy, Aloxi should not be used for the prevention or treatment of nausea and vomiting in the days after chemotherapy." "" "" ""</seg>
<seg id="2622">"" "" "" "in preclinical studies Palonosetron did not inhibit tumor activity of the five chemotherapeutic agents (cisplatin, cyclophosphamide, cyclopentine, doxorubicin and mitomycin C)." "" "" ""</seg>
<seg id="2623">"" "" "" "in a clinical trial, no significant pharmacokinetic interaction was observed between a single intravenous dose Palonosetron and a Steady State- concentration oral metoclopram, a CYP2D6 inhibitor." "" "" ""</seg>
<seg id="2624">"" "" "" "in a pharmacokinetic analysis based on a population, the simultaneous administration of CYP2D6 inductors (dexamethasone and rifampicine) and CYP2D6 inhibitors (dioxetine, kolonavir, sertraline and terbinafin) did not have a significant impact on the clearing of Palonosetron." "" "" ""</seg>
<seg id="2625">"" "" "" "experiences relating to the use of Palonosetron in human pregnancies are not present, therefore Palonosetron should not be used in pregnant women unless it is deemed necessary by the treating physician." "" "" ""</seg>
<seg id="2626">"" "" "" "clinical trials were the most frequent side effects of a dose of 250 micrograms (a total of 633 patients), which could at least be associated with Aloxi, headache (9%) and obstpation (5%)." "" "" ""</seg>
<seg id="2627">"" "" "" "very rare cases (&lt; 1 / 10,000) of hypersensitivity reactions and reactions to the administration (burning, hardening, discomfort and pain) were reported in post-marketing experience." "" "" ""</seg>
<seg id="2628">"" "" "" "in the group with the highest dosage, similar frequencies of adverse events as in the other dosage groups showed themselves; there were no dose-active relationships to observe." "" "" ""</seg>
<seg id="2629">"" "" "" "no dialysis studies were conducted, however, due to the large distribution volume a dialysis is probably not an effective therapy for alop- overdosage." "" "" ""</seg>
<seg id="2630">In two randomised double-blind studies a total of 1.132 patients received a moderately emetogenic chemotherapy with ≤ 50 mg / m2 of cyclophosphamide and 250 micrograms / m2 of cycloasetron (half-life time 7.3 hours) which was given intravenously at day 1 without dexamethasone.</seg>
<seg id="2631">In a randomised double-blind study a total of 667 patients receiving a strongly emetogenic chemotherapy with ≥ 60 mg / m2 Cyclophosphamide and Dacarbazine as well as 250 or 750 micrograms Palonosetron were compared to patients who were given intravenously 32 mg ondansetron.</seg>
<seg id="2632">"" "" "" "results of studies with moderately emetogenic chemotherapy and the study with highly emetogenic chemotherapy, are summarized in the following tables." "" "" ""</seg>
<seg id="2633">"" "" "" "in clinical trials for the indication of chemotherapy-induced nausea and vomiting (CINV), the effects of Palonosetron were comparable to blood pressure, heart rate and ECG parameters including the corresponding effects of ondansetron and dolasetron." "" "" ""</seg>
<seg id="2634">"" "" "" "following clinical examinations, Palonosetron has the ability to block the ion channels involved in ventricular de- and repolarization and extend the duration of the action potential." "" "" ""</seg>
<seg id="2635">"" "" "" "the aim of the study conducted at 221 healthy volunteers was the assessment of the ECG effects of intravenous palonosetron in single doses of 0,25, 0,75 and 2,25 mg." "" "" ""</seg>
<seg id="2636">"" "" "" "resorption After intravenous administration, a slow elimination of the plasma concentrations follows a slow elimination of the body with an average total half-life of approximately 40 hours." "" "" ""</seg>
<seg id="2637">The average maximum plasma concentration (CMAx) and the area under the concentration time curve (AUC0- ∞) are generally dosisproportional in the whole dose range of 0.3- 90 μ / kg in patients and cancer patients.</seg>
<seg id="2638">"" "" "" "after intravenous administration of Palonosetron 0,25 mg every second day for a total of 3 doses, the mean (± SD) increase in palonosetron plasma concentrations amounted to 42 ± 34%." "" "" ""</seg>
<seg id="2639">"" "" "" "pharisokinetic simulations indicate that the value measured at once daily intravenous administration of 0,25 mg Palonosetron (AUC0- ∞) was comparable to that of 0,75 mg." "" "" ""</seg>
<seg id="2640">"" "" "" "about 40% are eliminated via the kidneys and about 50% are converted into two primary metabolites, which in comparison to Palonosetron have less than 1% of the antagonistic effect on the 5HT3 receptor." "" "" ""</seg>
<seg id="2641">In vitro studies for metabolisation have shown that CYP2D6 and to a lesser extent have implicated Isoenzyme CYP3A4 and CYP1A2 on the metabolism of Palonosetron.</seg>
<seg id="2642">"" "" "" "elimination After an intravenous single dose of 10 micrograms / kg [14C] -Palonosetron, about 80% of the dose was found within 144 hours of urine, palonosetron made about 40% of the given dose." "" "" ""</seg>
<seg id="2643">"" "" "" "after a single intravenous Bolusinjektion, the total body composition was 173 ± 73 ml / min and renal clearing 53 ± 29 ml / min." "" "" ""</seg>
<seg id="2644">"" "" "" "in patients with severe liver dysfunction, the terminal Eliminationshal membranes are increased and the average systemic exposure to palonosetron increases, however, reducing the dose is not justified." "" "" ""</seg>
<seg id="2645">"" "" "" "in preclinical studies, effects were observed only by exposures that are considered sufficient over the maximum human therapeutic exposure indicating a low relevance for clinical use." "" "" ""</seg>
<seg id="2646">10 out of preclinical studies pointed out that Palonosetron can only block ion channels in very high concentrations that are involved in ventricular de- and repolarization and extend the duration of action.</seg>
<seg id="2647">"" "" "" "high doses of palonosetron (each dose corresponded to approximately 30 times the therapeutic exposure of humans), which were given daily over two years led to an increased frequency of liver tumours, endocrine, pancreas, adrenal marrow) and skin tumours in rats, but not in mice." "" "" ""</seg>
<seg id="2648">"" "" "" "the underlying mechanisms are not fully known, but due to the high dosages used and since Aloxi is determined for one-time application, the relevance of these results is regarded as low for the human being." "" "" ""</seg>
<seg id="2649">"" "" "" "" "" "" "" "the holder of this approval for the placing on the market must inform the European Commission about the plans for placing the drug approved as part of this decision." "" "" ""</seg>
<seg id="2650">"" "" "" "• If any of the side effects listed are significantly impaired or you may notice any side effects not specified in this information information, please inform your doctor." "" "" ""</seg>
<seg id="2651">• Aloxi is a clear and colorless injection solution for injecting into a vein. • The active ingredient (Palonosetron) is a group of drugs called serotonin (5HT3) antagonists. • Aloxi is used to prevent nausea and vomiting associated with chemotherapy for cancer.</seg>
<seg id="2652">"" "" "" "21 For use by Aloxi and other medicines, please inform your doctor if you are taking other medicines / applying / applied recently, even if it is not prescription medicine." "" "" ""</seg>
<seg id="2653">"" "" "" "pregnancy If you are pregnant or believe to be pregnant, your doctor will not give you Aloxi, unless it is clearly required." "" "" ""</seg>
<seg id="2654">"" "" "" "before taking any medication, ask your doctor or pharmacist for advice if you are pregnant or believe to become pregnant." "" "" ""</seg>
<seg id="2655">"" "" "" "in some very rare cases, allergic reactions to Aloxi or to burning or pain in the instituting place occurred." "" "" ""</seg>
<seg id="2656">"" "" "" "as Aloxi looks and content of the pack Aloxi Injection Solution is a clear, colourless solution and is available in a package with 1 bottle of glass containing 5 ml of the solution." "" "" ""</seg>
<seg id="2657">"" "" "" "" "" "" "" "progesterone" "" "" "" "is transmitted to a human body." "" "" ""</seg>
<seg id="2658">Latvija Pharmacy Latvia SIA 54-5: groin of the Street Riga; LV-1011 Tel: + 37167502185 Lietuva UAB Pharmaceuticals</seg>
<seg id="2659">United Kingdom IS Pharmaceuticals Ltd Office Village Chester Business Park Chester CH4 9QZ - UK Tel: + 44 1244 625 152</seg>
<seg id="2660">"" "" "" "in June 2006, the Committee for Medicinal Products (CHMP) approved a negative opinion in which the approval of the approval of the hepatitis C drug used for the treatment of hepatitis C was recommended." "" "" ""</seg>
<seg id="2661">"" "" "" "this means that Alphon should resemble a biological medicine called Roferon-A with the same drug, which is already approved in the EU." "" "" ""</seg>
<seg id="2662">Alpheon should be used to treat adult patients with chronic (long-lasting) hepatitis C (a liver disease called viral infection).</seg>
<seg id="2663">"" "" "" "in a microscopic investigation, the liver tissue indicates damage, and also the values of the liver's enzyme Glutaminotransferase (ALT) in the blood abnormality can be increased." "" "" ""</seg>
<seg id="2664">"" "" "" "it is produced by a yeast produced by a gene (DNA), which stimulates the formation of the active ingredient." "" "" ""</seg>
<seg id="2665">"" "" "" "the manufacturer of Alpheon submitted data to the comparison of Alpheon with Roferon-A (active substance structure, composition and purity of the drug, mode of action, safety and efficacy of hepatitis C)." "" "" ""</seg>
<seg id="2666">"" "" "" "in the study of hepatitis C patients, the efficacy of the optic drug was compared to 455 patients." "" "" ""</seg>
<seg id="2667">"" "" "" "the study measured how many patients spoke after 12 of a total of 48 weeks of treatment, and 6 months after the treatment was applied to the drug (i.e. no signs of the virus in the blood)." "" "" ""</seg>
<seg id="2668">(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail @ emea.eu.int http: / / www.emea.eu.int © EMEA 2006 Reproduction and / or distribution of this document is Authorised for non commercial purposes only.</seg>
<seg id="2669">"" "" "" "in addition, concerns have been expressed that the data on the stability of the drug and the marketing drug may not be sufficient." "" "" ""</seg>
<seg id="2670">"" "" "" "the number of patients with hepatitis C, which responded to the treatment with Alpheon and Roferon-A, was similar in the clinical study." "" "" ""</seg>
<seg id="2671">"" "" "" "after the treatment with Alpheleon cured the disease again in more patients than with the reference drug, Alpheleon had more side effects." "" "" ""</seg>
<seg id="2672">"" "" "" "apart from this, the test used in the study examines the extent to which the medication is immune response (i.e. the body produces antibodies - specific proteins - against the drug), not adequately validated." "" "" ""</seg>
<seg id="2673">"" "" "" "it can be used for the treatment of impetigo (a skin infection associated with crust formation) and small infected layers (cracking or cutting), abrasions and sewn wounds." "" "" ""</seg>
<seg id="2674">Altargo should not be used to treat infections that were demonstrably or presumably caused by methiciline-resistant Staphylococcus aureus (MRSA) because Alarma may not work against this type of infection.</seg>
<seg id="2675">"" "" "" "Altargo can be used in patients aged 9 months, but under the age of 18 the skin area may not be more than 2% of the body's surface." "" "" ""</seg>
<seg id="2676">"" "" "" "if the patient does not respond to treatment after two to three days, the doctor should examine the patient again and consider alternative treatments." "" "" ""</seg>
<seg id="2677">It works by blocking the bacterial ribosomes (the parts of the bacterial cell in which proteins are produced) and inhibits the growth of bacteria.</seg>
<seg id="2678">"" "" "" "in all five studies, the main indicator of efficacy was the proportion of patients whose infection was cleared after the end of the treatment." "" "" ""</seg>
<seg id="2679">119 (85.6%) of the 139 patients under Altargo and 37 (52.1%) of 71 patients under placebo discussed the treatment.</seg>
<seg id="2680">"" "" "" "in the treatment of infected Hautwunden, Altargo and Cefalexin showed similar response rates: if the results of both studies were taken together in Hautwunden, about 90% of both groups of both groups addressed the treatment." "" "" ""</seg>
<seg id="2681">"" "" "" "in these two studies, however, it was noted that Altargo was not effective enough in the treatment of abscesses (egg-filled cavities in the body tissue) or by infections that were demonstrably or presumably by MRSA." "" "" ""</seg>
<seg id="2682">"" "" "" "the most common side effect with Altargo (which was observed in 1 to 10 of 100 patients), is an irritation at the order." "" "" ""</seg>
<seg id="2683">The Committee for Medicinal Products (CHMP) concluded that the advantages of Altargo in short-term treatment of the following superficial skin infections are outweighed against the risks: • Impetigo.</seg>
<seg id="2684">"" "" "" "in May 2007, the European Commission granted Glaxo Group Ltd. approval for the placing of Altargo in the whole European Union." "" "" ""</seg>
<seg id="2685">"" "" "" "patients with no improvement within two to three days should be examined again, and an alternative therapy should be considered (see Section 4.4)." "" "" ""</seg>
<seg id="2686">"" "" "" "in the event of sensitizing or serious local irritation by using Retapamulin Salbe, treatment is canceled, the ointment must be carefully wiped out and an appropriate alternative treatment of the infection is begun." "" "" ""</seg>
<seg id="2687">"" "" "" "Retapamulin should not be used to treat infections, where MRSA is known as pathogen or suspected (see Section 5.1)." "" "" ""</seg>
<seg id="2688">"" "" "" "in clinical studies with secondary infected open wounds, the efficacy of retina in patients with infections caused by a methicillin-resistant Staphylococcus aureus (MRSA) was insufficient." "" "" ""</seg>
<seg id="2689">"" "" "" "an alternative therapy should be considered, if after 2- or 3-day treatment there is no improvement or worsening of the infected place." "" "" ""</seg>
<seg id="2690">The effect of simultaneous use of Retapamulin and other topical means on the same skin surface is not examined and the simultaneous use of other topical drugs is not recommended.</seg>
<seg id="2691">"" "" "" "due to the low plasma concentrations in humans after topical application on skimped skin or infected superficial wounds, a clinically relevant inhibition is not to be expected in vivo (see Section 5.2)." "" "" ""</seg>
<seg id="2692">3 After simultaneous oral administration of 2 times a day 200 mg of ketoconazole elevated the middle Retapamus AUC (0-24) and CMAx after topical application of 1% Retapamulin Salbe on skimped skin of healthy adult men by 81%.</seg>
<seg id="2693">"" "" "" "due to the low systemic exposure to topical application in patients, can adjustments are not considered necessary if topical Retapamulin is used during systemic treatment with CYP3A4 inhibitors." "" "" ""</seg>
<seg id="2694">Animal studies have shown reproductive toxicity after oral consumption and are insufficient regarding a statement regarding the birth and the fetal / postnatal development (see section 5.3).</seg>
<seg id="2695">Retapamulin Salbe should only be used during pregnancy when a topical antibacterial therapy is clearly indicated and the application of Retapamulin is to be preferred by the application of a systemic antibiotic.</seg>
<seg id="2696">"" "" "" "when deciding whether breastfeeding continues / terminates or the therapy with Altargo should be continued / terminates, the benefits of breastfeeding should be weighed for the woman and the benefit of Altargo therapy." "" "" ""</seg>
<seg id="2697">"" "" "" "in clinical trials involving 2150 patients with superficial skin infections, which used Altargo, the most frequently reported side effect was irritated by the administration, which concerned about 1% of the patients." "" "" ""</seg>
<seg id="2698">"" "" "" "mode Retapamulin is a semi-synthetic derivative of Pleuromutilin, a substance that is isolated by fermentation from Clitopilus fitteckerianus (formerly Pleurotus passeckerianus)." "" "" ""</seg>
<seg id="2699">The action mechanism of Retapamulin is based on selective inhibiting of bacterial protein synthesis by interaction at a specific binding site of the 50S subunit of bacterial ribosome which differs from the binding sites of other ribosomal interacting antibacterial substances.</seg>
<seg id="2700">"" "" "" "data suggests that the binding site ribosomal protein L3 is involved, and is located in the region of the ribosomal P binding site and the Peptidyltransfer Center." "" "" ""</seg>
<seg id="2701">"" "" "" "binding to this binding site, Pleuromutiline inhibits peptide transfer, blocking partial P binding interactions and preventing the normal formation of active 50S ribosomal subunits." "" "" ""</seg>
<seg id="2702">"" "" "" "due to the local prevalence of resistance to the use of retapamulin in at least some infectious forms, consultation by experts should be sought." "" "" ""</seg>
<seg id="2703">"" "" "" "there were no differences in the in-vitro activity of Retapamulin towards S.Aureus, regardless of whether the isolates were sensitive or resistant to methicillin." "" "" ""</seg>
<seg id="2704">"" "" "" "in case of failure to treat S.Aureus, the presence of tribes with additional virulence factors (such as PVL = Panton Valentine Leucocidin) should be considered." "" "" ""</seg>
<seg id="2705">"" "" "" "resorption In a study of healthy adults, 1% Retapamulin Salbe was applied daily under occlusion on intact and on skimmed skin for up to 7 days." "" "" ""</seg>
<seg id="2706">"" "" "" "of 516 patients (adults and children), who received 1% Retapamulin Salbe twice a day for 5 days for topical treatment of secondary traumatic wounds, single plasma samples were obtained." "" "" ""</seg>
<seg id="2707">"" "" "" "the sample collection occurred in the days 3 or 4 of the adult patients, before the medication and the children between 0-12 hours after the last application." "" "" ""</seg>
<seg id="2708">However the maximum individual systemic absorption on humans after topical application of 1% ointment to 200 cm2 was reduced to 200 cm2 (CMAx = 22 ng / ml; AUC (0-24) = 238 ng / h / ml) 660 times lower than the retina inulin IC50.</seg>
<seg id="2709">Metabolism The in vitro oxidative Metabolism of Retapamulin in human liver microsomites was primarily mediated by CYP3A4 with low participation of CYP2C8 and CYP2D6 (see section 4.5).</seg>
<seg id="2710">"" "" "" "in studies for oral toxicity in rats (50, 150 or 450 mg / kg) carried out over 14 days, there were signs of adaptive liver and thyroid movements." "" "" ""</seg>
<seg id="2711">In-vitro testing on gene mutation and / or chromosomal effects in mouse lymphocytes and in cultures of human peripheral blood lymphocytes and in the rats microkernel test for in-vivo analysis of chromosomal effects.</seg>
<seg id="2712">"" "" "" "there was neither male nor female rats any signs of reduced fertility at oral dosing of 50, 150 or 450 mg / kg / day, which was achieved by up to 5 times higher exposure than the highest estimated exposure in humans (topical application to 200 cm2 of skimped skin):" "" "" ""</seg>
<seg id="2713">"" "" "" "in an embryotoxicity study on rats, oral dosages of ≥ 150 mg / kg / day (corresponding to the ≥ 3-times of estimated human exposure (see above), development stolicity (reduced body weight of the fetus and delayed oscillation) and maternal toxicity were determined." "" "" ""</seg>
<seg id="2714">"" "" "" "the owner of approval for the marketing authorization must ensure that a drug vigilance system, as presented in the module 1.8.1 of the authorisation application (version 6.2) is present and works before the product is marketed and as long as the marketed product is applied." "" "" ""</seg>
<seg id="2715">"" "" "" "the owner of the authorization for the marketing agency commits itself to perform detailed studies and additional pharmacovigilance activities in the pharmacovigilance plan, as described in the version 1 of the Risk Management Plan (RMP) and all additional updates of the RMP, which are agreed with the CHMP." "" "" ""</seg>
<seg id="2716">"" "" "" "as described in the CHMP Guideline on Risk Management Systems for human use, the updated RMP is to be submitted simultaneously with the next periodic Safety Update Report." "" "" ""</seg>
<seg id="2717">"" "" "" "irritation or other signs and symptoms at the treated area, you should quit the application of Altargo and talk to your doctor." "" "" ""</seg>
<seg id="2718">"" "" "" "do not apply any other ointments, creams or lotions on the surface treated with Altargo if it was not explicitly prescribed by your doctor." "" "" ""</seg>
<seg id="2719">"" "" "" "it may not be used in the eyes, mouth or on the lips, in the nose or in the female genital area." "" "" ""</seg>
<seg id="2720">"" "" "" "when the ointment leaves on one of these surfaces, wash the place with water and ask your doctor for advice if discomfort occurs." "" "" ""</seg>
<seg id="2721">"" "" "" "after applying the ointment you can cover the affected area with a sterile dressing or a gazebo, unless your doctor has advised you to cover the surface." "" "" ""</seg>
<seg id="2722">"" "" "" "it is offered in an aluminium tube with a plastic cap containing 5, 10 or 15 grams of ointment, or in an aluminium bag containing 0.5 g ointment." "" "" ""</seg>
<seg id="2723">"" "" "" "Ambirix is used to protect against hepatitis A and hepatitis B (diseases affecting the liver) in children aged between one and 15 years, which are not immune to these two diseases." "" "" ""</seg>
<seg id="2724">"" "" "" "Ambirix is used as a vaccination plan consisting of two doses, and a protection against hepatitis B may only be achieved after the second dose is administered." "" "" ""</seg>
<seg id="2725">"" "" "" "for this reason, Ambirix can only be used if there is a low risk of hepatitis B infection during immunization, and it is ensured that the vaccination plan can be stopped from two doses." "" "" ""</seg>
<seg id="2726">"" "" "" "if a toxicity against hepatitis A or B is desirable, Ambirix can be given a hepatitis B or B vaccine." "" "" ""</seg>
<seg id="2727">"" "" "" "vaccines act by contributing to the immune system (the body's natural defense)," "" "" "" "how it can defend itself against a disease." "" "" ""</seg>
<seg id="2728">"" "" "" "after receiving the vaccine, the immune system recognizes the virus and surface antigens as" alien "and produces antibodies against it." "" "" ""</seg>
<seg id="2729">"" "" "" "Ambirix contains the same components as the Vaccine Twin Vaccine, which has been approved since 1996, and has been approved since 1997." "" "" ""</seg>
<seg id="2730">"" "" "" "the three vaccines are used to protect against the same diseases, but Twinrix adult and Twinrix children are administered as part of one of three doses of existing vaccines." "" "" ""</seg>
<seg id="2731">"" "" "" "because Ambirix and Twinrix are containing identical ingredients, some of the data that support the application of Twinrix adults were also used as evidence of the application of Ambirix." "" "" ""</seg>
<seg id="2732">The main indicator of efficacy was the share of vaccinated children who had developed a protective anti-antibody concentric one month after the last injection.</seg>
<seg id="2733">"" "" "" "in an additional study with 208 children, the efficacy of the vaccine was compared with a six month and a 12 month gap between the two injections." "" "" ""</seg>
<seg id="2734">Ambirix took between 98 and 100% of vaccinated children a month after the last injection to develop protective anti-antibody concentrations against hepatitis A and B.</seg>
<seg id="2735">The additional study showed that the degree of protecting Ambirix was similar in a six-month interval between the injections.</seg>
<seg id="2736">"" "" "" "the most common side effects of Ambirix (observed in more than 1 of 10 vaccine doses) are headache, loss of appetite, pain at the injection site, redness, fatigue and irritability." "" "" ""</seg>
<seg id="2737">"" "" "" "Ambirix can not be used in patients who may be hypersensitive to the active ingredients, one of the other components or neomycin (antibiotic)." "" "" ""</seg>
<seg id="2738">"" "" "" "August 2002, the European Commission granted GlaxoSmithKline Biologicals s.a. a permit for placing Ambirix in the entire" "" "" ""</seg>
<seg id="2739">"" "" "" "the standardization plan for pridimmerization with Ambirix is made up of two vaccines, whereby the first dose is administered at the date of choice and the second dose between six and twelve months after the first dose." "" "" ""</seg>
<seg id="2740">"" "" "" "if a localisation is desired for hepatitis A as well as for hepatitis B, vaccines can be vaccinated using the corresponding monovalent vaccines or with a combination vaccine." "" "" ""</seg>
<seg id="2741">The anti-hepatitis A surface antigen (anti-HAV) antibody-antigen (anti-HAV) antibody-antigen (anti-HAV) anti-hepatitis A virus (anti-HAV) antibody values are in the same order as after vaccination with the respective monometastatic vaccines.</seg>
<seg id="2742">"" "" "" "it is not yet fully assured if immunologically competent individuals who have addressed hepatitis C vaccination may need a refresher vaccination as protection, as they may also be protected by immunological memory even in case of no longer demonstrable antibodies." "" "" ""</seg>
<seg id="2743">"" "" "" "3 As for all injections, an anaphylactic reaction after receiving the vaccine should always be available immediately after receiving the vaccine." "" "" ""</seg>
<seg id="2744">"" "" "" "if a faster protection against hepatitis B is required, the standardization scheme with the combination vaccine is recommended, containing 360 ELISA units of formalininactivated hepatitis A virus and 10 µg recombinant hepatitis B surface antigen." "" "" ""</seg>
<seg id="2745">"" "" "" "in cases of hemodialysis patients and persons with disturbances of the immune system, there is no adequate anti-HAV- and anti-HBs antibody value, so in these cases the gift of further vaccines can be necessary." "" "" ""</seg>
<seg id="2746">"" "" "" "since intramuscular injection or intramuscular administration could lead to an optimal vaccine success, these injections should be avoided." "" "" ""</seg>
<seg id="2747">"" "" "" "with thrombocytopenia or blood coagulation disorders, Ambirix can however be injected subcutaneously, since it may result in bleeding after intramuscular administration." "" "" ""</seg>
<seg id="2748">"" "" "" "if Ambirix was administered in the second year in the form of a separate injection, tetanus, azellular, azellular, inactivated poliomyelitis- and Haemophilus-Rötel vaccine was sufficient (see Section 5.1)." "" "" ""</seg>
<seg id="2749">"" "" "" "in patients with immunosuppressive therapy or in patients with immunodeficiency, there is no need for an immune response." "" "" ""</seg>
<seg id="2750">"" "" "" "in a clinical study conducted with 3 doses of this formulation in adults, the incidence of pain, redness, swelling, maturation, gastroenteritis, headache and fever similar to the frequency observed in previous thiomery and preservative vaccine Formulation." "" "" ""</seg>
<seg id="2751">"" "" "" "in clinical trials, 2029 vaccines from Ambirix were administered to a total of 1027 vaccines ranging from 1 to 15 years." "" "" ""</seg>
<seg id="2752">"" "" "" "in a study involving 300 participants aged 12 to 15 years, the compatibility of Ambirix was compared with the 3-doses combination vaccine." "" "" ""</seg>
<seg id="2753">"" "" "" "only exceptions were the higher frequencies of pain and matureness on a basis of calculation per vaccination dose Ambirix, but not on a basis of calculation per person." "" "" ""</seg>
<seg id="2754">"" "" "" "after receiving Ambirix, pain was observed at 50.7% of the subjects compared to 39.1% in the subjects after receiving a dose of the 3-doses combination vaccine." "" "" ""</seg>
<seg id="2755">"" "" "" "after the complete vaccination cycle, 66.4% of the subjects who received Ambirix had been vaccinated against pain, compared to 63.8% in the subjects who had been vaccinated with the 3-dose combination vaccine." "" "" ""</seg>
<seg id="2756">"" "" "" "however, the frequency of matches was comparable to per volume (i.e. over the entire vaccination cycle at 39.6% of the subjects who received Ambirix) compared to 36.2% in the subjects that received the 3-doses drop-down vaccine." "" "" ""</seg>
<seg id="2757">"" "" "" "the frequency of severe pain and sensitivity was low, comparable to that observed after administration of the combination vaccine with the 3-doses-vaccine." "" "" ""</seg>
<seg id="2758">"" "" "" "in a comparison study of 1 to 11-year-old vaccines, the incidence of local reactions and general reactions in the Ambirixgruppe was comparable to that with the 3-doses drop-down vaccine with 3µg recombinant hepatitis B surface antigen." "" "" ""</seg>
<seg id="2759">"" "" "" "in the 6- to 11-year-olds, however, after vaccination with Ambirix there was a frequent occurrence of pain (at the injection site) per dose, not pro belt." "" "" ""</seg>
<seg id="2760">The portion of vaccines reported by severe side effects during the 2-doses-vaccine with Ambirix or during the 3-doses-vaccine with a combination of 360 ELISA- units decombinant hepatitis B-surface antigen was not statistically different.</seg>
<seg id="2761">"" "" "" "in clinical trials conducted for vaccines at the age of 1 to 15 years, the serum levels for anti-HAV 99.1% were a month after the first dose and 100% a month after the second dose (i.e. in month 7)." "" "" ""</seg>
<seg id="2762">The serum levels for anti-HBs were 74.2% a month after the first dose and 100% a month after the second dose (i.e. in month 7).</seg>
<seg id="2763">"" "" "" "7 In a comparative study conducted at 12- to including 15-year olds, 142 two doses Ambirix and 147 were used as standard combination vaccine with three doses." "" "" ""</seg>
<seg id="2764">"" "" "" "in the 289 persons whose immunogenicity was worthless, the rate of seroprotection (SP in the table below) against hepatitis B was significantly higher than with Ambirix in the month 2 and 6." "" "" ""</seg>
<seg id="2765">"" "" "" "the immune response, which was achieved in a clinical comparative study at 1-11 year olds one month after the full vaccination series (i.e. in month 7), are listed in the following table." "" "" ""</seg>
<seg id="2766">"" "" "" "in both studies, the vaccines obtained either a 2-doses-vaccine with Ambirix or a 3-doses-vaccine with a combination of 360 ELISA units and 10µg recombinant hepatitis B surface antigen." "" "" ""</seg>
<seg id="2767">The persistence of anti-HAV- and anti-HBs antibodies could be detected at least 24 months after immunization with Ambirix in the 0-6 months vaccine.</seg>
<seg id="2768">The immune response observed in this study was comparable to those observed after vaccination of 3 doses with a combination vaccine consisting of 360 ELISA-units formalinininactivated Hepatitiss- A-Virus and 10 µg recombinant hepatitis B surface antigen in a dose volume of 0.5 ml.</seg>
<seg id="2769">"" "" "" "in a clinical trial at 12- to including 15-year-olds, demonstrated that the persistence of anti-HAV- and anti-HBs antibodies can be compared 24 months after immunization in the 0-12 months vaccine." "" "" ""</seg>
<seg id="2770">"" "" "" "when the first dose of Ambirix was administered at the same time with the refresher of a combined diphtherial, tetanus, azellular perfect-, inactivated poliomyelitis- and 8 Haemophilus-Rötel vaccine, the immune response was sufficient to all antigens." "" "" ""</seg>
<seg id="2771">"" "" "" "a clinical study conducted with 3 doses of current formulation in adults, showed similar serum and seroze rates similar to the earlier formulation." "" "" ""</seg>
<seg id="2772">"" "" "" "the vaccine is to investigate potential foreign particles and / or physically visible changes, both before and after the reset." "" "" ""</seg>
<seg id="2773">"" "" "" "in accordance with Article 114 of Directive 2001 / 83 / EC, the state batch release is carried out by a state laboratory or a laboratory that is authorised for this purpose." "" "" ""</seg>
<seg id="2774">14 ANGABEN AUF OF OHNE NADEL 1 ready-to-use syringe WITNNE NADEL 10 ready-to-use syringe WITNNE needles 10 ready-to-use injector WITH needles 50 ready-to-use injector WITH needles</seg>
<seg id="2775">"" "" "" "suspension for injection 1: ready-to-use syringes without needles 10 ready-to-use syringes without needles 10 ready-to-use syringes with needles 50 finished syringes without needles 1 dose (1 ml)" "" "" ""</seg>
<seg id="2776">EU / 1 / 02 / 224 / 001 1 ready-to-use syringes without needles EU / 1 / 224 / 002 10 ready-to-use syringes with needles EU / 1 / 02 / 224 / 005 50 ready-to-use syringes without needles</seg>
<seg id="2777">"" "" "" "the hepatitis A virus is usually transmitted through viral foodborne foods and beverages, but can also be transmitted through other ways such as bathing in water polluted by sewage." "" "" ""</seg>
<seg id="2778">"" "" "" "you can feel very tired, have a dark urine, a pale face, yellow skin and / or eyes (jaundice) and other symptoms that might make a stationary treatment necessary." "" "" ""</seg>
<seg id="2779">"" "" "" "as with all vaccines, Ambirix can not completely protect against an infection with hepatitis B or hepatitis B virus, even if the complete vaccination series has been completed with 2 doses." "" "" ""</seg>
<seg id="2780">If you / your child are infected prior to the administration of both vaccines Ambirix already with hepatitis B or hepatitis B virus / is (although you / your child feel not uncomfortable or sick / feels) vaccination may not prevent illness.</seg>
<seg id="2781">"" "" "" "a protection against other infections that damage the liver or cause symptoms similar to those of hepatitis B or hepatitis B infection, cannot be mediated." "" "" ""</seg>
<seg id="2782">"" "" "" "• If your child already has an allergic reaction to Ambirix or any component of this vaccine, including neomycin (antibiotic)." "" "" ""</seg>
<seg id="2783">An allergic reaction can manifest itself through itching skin rash or swelling or swelling of the face or tongue. • If you have an allergic reaction to an earlier vaccination against hepatitis A or hepatitis B. • If you / your child have a severe infection with fever.</seg>
<seg id="2784">"" "" "" "• If you want to quickly protect against hepatitis B (i.e., within 6 months and before the normally scheduled date of the second vaccine)." "" "" ""</seg>
<seg id="2785">"" "" "" "at a possible risk of infection with hepatitis B between the first and second vaccination, the doctor will advise you / your child from vaccination with Ambirix." "" "" ""</seg>
<seg id="2786">"" "" "" "instead, he will recommend 3 injections of a combined hepatitis B / hepatitis B vaccine with a reduced content of effective existing hepatitis A virus and 10 micrograms of a recombinant hepatitis B surface antigen." "" "" ""</seg>
<seg id="2787">The second vaccination dose of this vaccine with reduced levels of effective components is usually administered one month after the first dose and is likely to give you / your child a vaccination protection before ending the vaccination series.</seg>
<seg id="2788">Sometimes Ambirix is injected in people who suffer from severe bleeding disorders under the skin and not injected into the muscle. • If you / your child are weakened because of a disease or treatment in your body's own defense / or if you / your child are undergoing a hemodialysis / subtract.</seg>
<seg id="2789">"" "" "" "Ambirix can be given in these cases, but the immune response of those individuals on vaccination can not be sufficient to see how strong the reaction is to vaccination." "" "" ""</seg>
<seg id="2790">21 Say to your doctor if you / she / her child are taking further medicines (including those you can get without prescription) or if you have been vaccinated or if you / your child has been vaccinated or has been planned or planned in the near future.</seg>
<seg id="2791">"" "" "" "however, it may be that in this case the immune response is not sufficient on the vaccine and therefore the person is not protected against one or both hepatitis A and B viruses." "" "" ""</seg>
<seg id="2792">"" "" "" "if another vaccine needs to be given at the same time with Ambirix, there should be vaccinated in separate places and as different limb." "" "" ""</seg>
<seg id="2793">"" "" "" "if Ambirix is to be administered at the same time or shortly before or after injection of immunoglobulins, it is likely that the reaction to the vaccine will still be sufficient." "" "" ""</seg>
<seg id="2794">"" "" "" "typically, Ambirix is not given to pregnant or breastfeeding women unless it is urgent that they are vaccinated against hepatitis A and Hepatitis B." "" "" ""</seg>
<seg id="2795">Important information on certain other components of Ambirix Please inform your doctor if you have already shown an allergic reaction to Neomycin (antibiotic) for you / your child.</seg>
<seg id="2796">"" "" "" "if you miss the agreed date for the second vaccination, talk to your doctor and arrange a new date as soon as possible." "" "" ""</seg>
<seg id="2797">"" "" "" "very common (more than 1 case per 10 linked doses): • pain or discomfort on the institch or redness • Maternity • irritability • headache • loss of appetite, lack of appetite" "" "" ""</seg>
<seg id="2798">"" "" "" "cots often (up to 1 case per 10 linked doses): • swelling at the injection site • High fever (above 38 ° C) • Reflected, gastro-intestinal disorders" "" "" ""</seg>
<seg id="2799">"" "" "" "further side effects reported that the days or weeks after vaccination with comparable combination or single vaccines against hepatitis A and hepatitis B are very rare (less than 1 case per 10,000 worn doses) are:" "" "" ""</seg>
<seg id="2800">"" "" "" "these include locally limited or extensive rashes, which can be itching or inflate, swelling of the eye area and face, startling breathing or swallowing, sudden drop of blood pressure and unconsciousness." "" "" ""</seg>
<seg id="2801">"" "" "" "influenza-like complaints, including shivers, muscle and joint pain, varicity, dizziness, misconception such as tingling, loss of sensation or movement capability of some parts, strong headaches and stiffness of the neck, disruption of normal brain functions" "" "" ""</seg>
<seg id="2802">"" "" "" "impotence and inflammations of some blood vessels may cause discomfort, loss of appetite, diarrhoea and abdominal pain." "" "" ""</seg>
<seg id="2803">23. inform your doctor or pharmacist if any of the listed side effects you / your child will significantly affect you or you may notice any side effects that are not stated in this treatment supplement.</seg>
<seg id="2804">"" "" "" "Ambirix is available in packs of 1 and 10 with or without needles, and in packs of 50 without needles." "" "" ""</seg>
<seg id="2805">"" "" "" "on the basis of the data, which has become known since the initial authorization for the entry, the CHMP advocated that the benefit-risk relationship remains positive for Ambirix." "" "" ""</seg>
<seg id="2806">"" "" "" "however, since Ambirix was published only in a Member State (in the Netherlands since May 2003), the available safety data for this medicine is limited due to the low patient exposure." "" "" ""</seg>
<seg id="2807">Ammonohydrates can also be used in patients at the age of over a month with incomplete enzyme defect or with hyperammonia encephalopathy (brain damage following high ammonia concentrations) in the prehistory.</seg>
<seg id="2808">"" "" "" "Ammonohydrates - split into several single doses to meals - blended, mixed with food or via a gastrostomieschl (through the abdominal wall into the stomach leading hose) or a nasal probe (through the nose into the stomach leading hose)." "" "" ""</seg>
<seg id="2809">"" "" "" "it was not a comparative study, since Ammony could not be compared to another treatment or with placebo (a pseudo-medicine, i.e. without substance)." "" "" ""</seg>
<seg id="2810">"" "" "" "Ammony may also lead to loss of appetite, a abnormal acid content in the blood, depression, irritability, headache, impotence, fluid retention, nausea, constipation, skin rash, uncomfortable body odor or weight gain." "" "" ""</seg>
<seg id="2811">"" "" "" "the Committee for Medicinal Products (CHMP) concluded that in patients with disruption of the urea cycle, Ammonohydrates effectively prevented ammonia levels." "" "" ""</seg>
<seg id="2812">"" "" "" "Ammony was approved under" "" "" "" "extraordinary circumstances" "" "" "" "due to the rarity of the disease at the time of admission." "" "" ""</seg>
<seg id="2813">"" "" "" "the use is indicated in all patients, where a complete enzyme shortage has already been manifested in newborns (within the first 28 days of life)." "" "" ""</seg>
<seg id="2814">"" "" "" "in patients with a late-manium form (incomplete enzyme defect, which manifests itself after the first month of life) there is an indication of the use when hyperammonia encephalopathy exists in the anamnesis." "" "" ""</seg>
<seg id="2815">"" "" "" "for infants, for children who are not able to swallow tablets or for patients with swallowing disorders, AMMONAPS is also available in granular form." "" "" ""</seg>
<seg id="2816">"" "" "" "the daily dose is individually calculated, taking into account the protein tolerance and the daily protein intake of the patient." "" "" ""</seg>
<seg id="2817">According to previous clinical experience the normal daily dose of sodium phenylbutyrat: • 450 - 600 mg / kg / day in children with a body weight of less than 20 kg • 9.9 g / m ² / day in children with a body weight of over 20 kg as well as for adolescents and adults.</seg>
<seg id="2818">The substitution of citrulline or arginine in a dose of 0.17 g / kg / day or 3.8 g / m ² / day is required for patients suffering from an early manium deficiency of carbamylphosphate synthetase or ornithintranscarbamylase.</seg>
<seg id="2819">Patients with arginine-synthetase deficiency must receive arginine in a dose of 0.4 - 0.7 g / kg / day or 8.8 - 15.4 g / m ² / day.</seg>
<seg id="2820">"" "" "" "AMMONAPS tablets may not be administered to patients with swallowing disorders, since there is a risk of the development of esophagus ulcera if the tablets do not get into the stomach immediately." "" "" ""</seg>
<seg id="2821">Each tablet AMMONAPS contains 62 mg (2.7 mmol) sodium and equivalent to 2.5 g (108 mmol) sodium per 20 g sodium phenylbutyl rate corresponding to the maximum daily dose.</seg>
<seg id="2822">"" "" "" "therefore, AMMONAPS should only be used with caution in patients with congestive heart failure and severe kidney failure and associated clinical conditions." "" "" ""</seg>
<seg id="2823">"" "" "" "as metabolism and excretion of sodium phenylbutyrat on the liver and kidneys occur, AMMONAPS should only be used with extreme caution in patients with liver or kidney failure." "" "" ""</seg>
<seg id="2824">The importance of these results regarding pregnant women is not known; the use of AMMONAPS during pregnancy is therefore contraindicated (see 4.3).</seg>
<seg id="2825">"" "" "" "in subcutaneous injection of phenylacetate to young rats in high doses (190 - 474 mg / kg), there was a slowing of neuronal proliferation and increased loss of neurons." "" "" ""</seg>
<seg id="2826">"" "" "" "there was also a delayed maturation of cerebral synapses, and a reduced number of functioning nerve endings in the brain and thus a disability of brain growth." "" "" ""</seg>
<seg id="2827">"" "" "" "it could not be ascertained whether phenylacetate is excreted in the mother's milk, and for this reason, the use of AMMONAPS during breastfeeding is contraindicated (see 4.3)." "" "" ""</seg>
<seg id="2828">"" "" "" "in clinical trials with AMMONAPS, 56% of patients had at least an undesirable event (AE) and 78% of these adverse events were assumed that they were not associated with AMMONAPS." "" "" ""</seg>
<seg id="2829">"" "" "" "the frequency is defined as follows: very common (≥ 1 / 100, &lt; 1 / 100, &lt; 1 / 10) and occasionally (≥ 1 / 1,000, &lt; 1 / 100)." "" "" ""</seg>
<seg id="2830">"" "" "" "a probable toxic reaction to AMMONAPS (450 mg / kg / day) was reported by an 18 year old anorectic patient, which developed a metabolic Encephalopathy in conjunction with lactazidosis, severe hypokalemia, armour topenia, peripheral neuropathy and pancreatitis." "" "" ""</seg>
<seg id="2831">"" "" "" "a case of overdose occurred in a 5 month old toddler, with a single dose of 10 g (1370 mg / kg)." "" "" ""</seg>
<seg id="2832">"" "" "" "these symptoms go hand in hand with the accumulation of phenylacetate, which showed a dose-limiting neurotoxicity during an intravenous administration of doses of up to 400 mg / kg / day." "" "" ""</seg>
<seg id="2833">"" "" "" "phenylacetate is an active compound, conjugated by acetylation with glutamine to phenylacetylglutamine that is excreted through the kidneys." "" "" ""</seg>
<seg id="2834">"" "" "" "phenylacetylglutamine can be seen with a urea (both compounds contain 2 nitrogen atoms); phenylacetylglutamine is therefore suitable as an alternative carrier for excretion of excess nitrogen." "" "" ""</seg>
<seg id="2835">5 Patients with disturbances in the urea cycle can be assumed that sodium phenylbutyl rate taken for each gram will be produced between 0.12 and 0.15 g phenylacetylglutamine nitrogen.</seg>
<seg id="2836">"" "" "" "it is important that the diagnosis is diagnosed early, and the treatment is immediately started in order to improve the chances of survival and clinical outcome." "" "" ""</seg>
<seg id="2837">The prognosis of the early manifest form of the disease with the onset of the first symptoms in newborns was almost always infested and the disease led to death even in the case of treatment with peritoneal dialysis and essential amino acids or with their sticking-free analogues.</seg>
<seg id="2838">"" "" "" "hemodialysis, the use of alternative methods of nitrogen elimination (sodium phenylbutyrat, sodium benzoate and sodium phenylacetate), protein-reduced diet and possibly substitution of essential amino acids was possible to increase the survival rate of newborn patients in post-partal (however within the first month of life)." "" "" ""</seg>
<seg id="2839">"" "" "" "in patients whose disease was diagnosed in the course of the pregnancy, the survival rate was 100%, but even with these patients it was time with many mental disabilities or other neurological deficits." "" "" ""</seg>
<seg id="2840">In patients with a late-manium form of the disease (including female patients with the heterozygous form of the ornithintranscarbamylase deficiency) treated by hyperammonia encephalopathy and subsequently treated with sodium phenylbutyrat and a protein-reduced diet the survival rate was 98%.</seg>
<seg id="2841">Existing neurological deficiencies are hardly reversible even in the treatment and in some patients another worsening of the neurological condition can occur.</seg>
<seg id="2842">"" "" "" "phenylacetate is oxidized to phenylacetate, which is conjugated in liver and kidney, with phenylacetylglutamine." "" "" ""</seg>
<seg id="2843">The concentrations of phenylbutyrat and his metabolites in plasma and urine were determined according to an individual dose of 5 g sodium phenylbutyrat in case of sober healthy adults and with liver cirrhosis after individual and repeated gifts of oral doses of up to 20 g / day (non-controlled studies).</seg>
<seg id="2844">The behavior of phenylbutyrat and its metabolites was also studied in cancer patients after IV administration of sodium phenylbutyl (up to 2 g / m ²) or phenylacetate.</seg>
<seg id="2845">"" "" "" "after an oral dosing of 5 g sodium phenylbutyrat in tablet form, 15 minutes after taking measured plasma concentrations of phenylbutyrat were detected." "" "" ""</seg>
<seg id="2846">"" "" "" "according to different doses of phenylbutyrat (300-650 mg / kg / day up to 20 g / day), phenylacetate in the plasma was detected in the next morning after nightly fasting." "" "" ""</seg>
<seg id="2847">"" "" "" "in three out of six patients with cirrhosis of the liver, which were repeatedly treated with sodium phenylbutyrat (20 g / day orally in three single doses), the middle phenylacetate concentrations in the plasma level were five times higher than after the first gifts." "" "" ""</seg>
<seg id="2848">"" "" "" "excretion The drug is excreted from the kidneys within 24 hours, approximately 80 - 100% in the form of the conjugated product Phenylacetylglutamine." "" "" ""</seg>
<seg id="2849">According to the results of Micronucleus tests Natriumphenylbutyrat had no complains with toxic and non-toxic doses (examination 24 and 48 h after oral administration of a single dose of 878 to 2800 mg / kg).</seg>
<seg id="2850">"" "" "" "AMMONAPS granules are either orally taken (infants and children, who can not swallow tablets, or patients with swallowing disorders) or via a gastrostomieschl or a nasal probe." "" "" ""</seg>
<seg id="2851">According to previous clinical experiences the normal daily dose of sodium phenylbutyrat: • 450 - 600 mg / kg / day with a body weight of less than 20 kg • 9.9 g / m ² / day in children with a body weight of over 20 kg as well as for adolescents and adults.</seg>
<seg id="2852">"" "" "" "the concentration of ammonia, arginine, essential amino acids (in particular branched chain amino acids), carnitine and serum protein in the plasma should be kept within the normal range." "" "" ""</seg>
<seg id="2853">The substitution of citrulline or arginine in a dose of 0.17 g / kg / day or 3.8 g / m ² / day is required for patients suffering from an early manium deficiency of carbamylphosphate synthetase or ornithintranscarbamylase.</seg>
<seg id="2854">AMMONAPS granulate contains 124 mg (5.4 mmol) sodium per gram of sodium phenylbutyl rate equivalent to 2.5 g (108 mmol) sodium per 20 g sodium phenylbutyl rate corresponding to the maximum daily dose.</seg>
<seg id="2855">"" "" "" "when rats were exposed before the phenylacetate (active metabolization of phenylbutyrat), lesions were found in the brain cells of the brain bark." "" "" ""</seg>
<seg id="2856">"" "" "" "a probable toxic reaction to AMMONAPS (450 mg / kg / day) was reported by an 18 year old anorectic patient, which developed a metabolic Encephalopathy in conjunction with lactazidosis, severe hypokalemia, armour topenia, peripheral neuropathy and pancreatitis." "" "" ""</seg>
<seg id="2857">"" "" "" "phenylacetylglutamine can be seen with a urea (both compounds contain 2 nitrogen atoms); phenylacetylglutamine is therefore suitable as an alternative carrier for elimination of excess fat" "" "" ""</seg>
<seg id="2858">"" "" "" "based on investigations about excretion of phenylacetylglutamine in patients with disturbances in the urea cycle, the sodium phenylbutyl rate taken for each gram can be produced between 0.12 and 0.15 g phenylacetylglutamine nitrogen." "" "" ""</seg>
<seg id="2859">"" "" "" "existing neurological deficiencies are hardly reversible during treatment, and in some patients another worsening of the neurological condition can occur." "" "" ""</seg>
<seg id="2860">"" "" "" "after an oral dosing of 5 g sodium phenylbutyrat in granule form, 15 minutes after taking measured plasma concentrations of phenylbutyrat were detected." "" "" ""</seg>
<seg id="2861">"" "" "" "during durability, the patient can keep the finished product unique for a period of 3 months at a temperature of not above 25 ° C." "" "" ""</seg>
<seg id="2862">"" "" "" "in this procedure the small measuring spoon contains 0,95 g, the average measuring spoon 2,9 g and the big measuring spoon 8.6 g sodium phenylbutyrat." "" "" ""</seg>
<seg id="2863">"" "" "" "if a patient has to receive the medicine over a probe, AMMONAPS can also be dissolved in water prior to use (the solubility of sodium phenylbutyrat is up to 5 g in 10 ml of water)." "" "" ""</seg>
<seg id="2864">"" "" "" "in patients with these rare diseases, certain liver enzymes are missing so that they cannot excrete the nitrogen-containing waste products that accumulate in the body after the consumption of proteins." "" "" ""</seg>
<seg id="2865">"" "" "" "if your laboratory tests are carried out, you must tell the doctor that you are taking AMMONAPS, since Natriumphenylbutyrat can influence the results of certain laboratory tests." "" "" ""</seg>
<seg id="2866">"" "" "" "if you take AMMONAPS with other medicines, please inform your doctor or pharmacist if you take other medicines or have recently taken it, even if it is not prescription medicine." "" "" ""</seg>
<seg id="2867">"" "" "" "during the lactation period, you can't use AMMONAPS as the medicine can pass to breast milk and harm your baby." "" "" ""</seg>
<seg id="2868">"" "" "" "in rare cases confusion, headaches, flaws, flaws, disorientation, memory problems and worsening of existing neurological conditions have been observed." "" "" ""</seg>
<seg id="2869">"" "" "" "if you notice any of these symptoms, you immediately contact your doctor or hospital for an appropriate treatment." "" "" ""</seg>
<seg id="2870">"" "" "" "if you forgot AMMONAPS, take the appropriate dose as soon as possible with the next meal." "" "" ""</seg>
<seg id="2871">"" "" "" "changes in blood cells (red blood cells, white blood cells, thrombocytes), decreased appetite, depression, irritability, headache, impotence, fluid retention (swelling), rash, indigestion, weight gain and anomalous laboratory values." "" "" ""</seg>
<seg id="2872">"" "" "" "please inform your doctor or pharmacist, if any of the side effects listed will affect you significantly or you may notice any side effects that are not stated in this information information." "" "" ""</seg>
<seg id="2873">"" "" "" "you may not use AMMONAPS after the expiration date specified on the board and the container, until the specified expiry date." "" "" ""</seg>
<seg id="2874">"" "" "" "as AMMONAPS looks and contents of the AMMONAPS tablets are of whitish colour and oval shape, and they are provided with the embossing" UCY 500. "" "" "" ""</seg>
<seg id="2875">"" "" "" "30 If a laboratory check is carried out, you must tell the doctor that you are taking AMMONAPS, since Natriumphenylbutyrat can influence the results of certain laboratory tests." "" "" ""</seg>
<seg id="2876">"" "" "" "if you take AMMONAPS with other medicines, please inform your doctor or pharmacist if you take other medicines or have recently taken it, even if it is not prescription medicine." "" "" ""</seg>
<seg id="2877">You should take AMMONAPS to the same single doses orally or via a stomach fever (tube that runs through the abdominal wall directly into the stomach) or a nasal probe (tube which is guided through the nose into the stomach).</seg>
<seg id="2878">31 • Take from the container a heaped measuring spoon Granules. • Remove a straight edge e.g. a knife edge over the rim of the measuring spoon to remove excess granulate. • Remove the recommended number of measuring spoon Granules from the container.</seg>
<seg id="2879">"" "" "" "angiox is used to treat adult patients with acute coronary syndrome (ACS, reduced blood supply to the heart), e.g. with unstable angina (a form of pain in the chest with different strength) or myocardial infarction (an anomaly measurement value in electrocardiogram or ECG)." "" "" ""</seg>
<seg id="2880">"" "" "" "when used to prevent blood clots in patients who undergo a PCI, a higher dose is administered and the infusion can be continued up to four hours after the procedure." "" "" ""</seg>
<seg id="2881">"" "" "" "in patients with angina or heart attack, this can contribute to maintaining blood flow to the heart and increase the effectiveness of a PCI." "" "" ""</seg>
<seg id="2882">Nearly 14 000 patients participated in the main study on the treatment of ACS in which the effect of angiox in sole administration or in combination with a glycoprotein-IIb / IIIa inhibitor (GPI) was compared with the conventional combination treatment with Heparin (another anti-coagulant) and a GPI.</seg>
<seg id="2883">"" "" "" "while PCI was often a stent (a short tube that remains in the artery to prevent a closure), and they additionally received other medicines to prevent blood clots such as Abciximab and Aspirin." "" "" ""</seg>
<seg id="2884">"" "" "" "in the treatment of ACS was angiox, with or without the administration of GPI, in preventing new events (deaths, heart attacks or revascularization) after 30 days or one year overall as effective as conventional treatment." "" "" ""</seg>
<seg id="2885">"" "" "" "in patients receiving PCI was angiox in terms of all indicators as effective as heparin, except for severe bleeding where it was significantly more effective than heparin." "" "" ""</seg>
<seg id="2886">"" "" "" "angiox should not be used in patients who may be hypersensitive to bias, other hippdine, or any of the other components." "" "" ""</seg>
<seg id="2887">"" "" "" "it may also not be used in patients who recently had a bleeding, as well as in people with high blood pressure or severe kidney problems or a heart attack." "" "" ""</seg>
<seg id="2888">The Committee for Medicinal Products (CHMP) concluded that angioxin is an acceptable replacement for heparin during the treatment of ACS and during a PCI.</seg>
<seg id="2889">"" "" "" "in September 2004, the European Commission granted the Medicines Company UK Ltd authorization to transport angiox throughout the European Union." "" "" ""</seg>
<seg id="2890">For the treatment of adult patients with acute coronary syndrome (unstable angina / non-ST) infarction (IA / NSTEMI)) during an emergency intervention or if an early intervention is provided.</seg>
<seg id="2891">The recommended initial dose of angiox in patients with ACS is an intravenous pin of 0.1 mg / kg followed by an infusion of 0.25 mg / kg / h.</seg>
<seg id="2892">"" "" "" "if a PCI is carried out in a further sequence, an additional bolt of 0.5 mg / kg should be given and the infusion for the duration of the surgery can be increased to 1.75 mg / kg / h." "" "" ""</seg>
<seg id="2893">"" "" "" "according to clinical requirements, the reduced infusion dose of 0.25 mg / kg / h can be recorded for 4 to 12 hours after clinical requirements." "" "" ""</seg>
<seg id="2894">"" "" "" "immediately before the procedure a bolt of 0.5 mg / kg is given, followed by an infusion of 1.75 mg / kg / h for the duration of the intervention." "" "" ""</seg>
<seg id="2895">The recommended dosage of angiox in patients with a PCI consists of an initial intravenous pin of 0.75 mg / kg body weight and an intravenous IV infusion with a dose of 1.75 mg / kg of body weight / h at least for the duration of the surgery.</seg>
<seg id="2896">"" "" "" "the safety and efficacy of a single Bolus gift of angiox has not been studied and is not recommended, even if a short PCI operation is planned." "" "" ""</seg>
<seg id="2897">"" "" "" "if this value (ACT for 5 minutes) is shortened to less than 225 seconds, a second pin should be 0,3 mg / kg / body weight." "" "" ""</seg>
<seg id="2898">"" "" "" "in order to reduce the occurrence of lower ACT values, the reconstituted and diluted medicinal product should be carefully shuffled before the application and administered as fast intravenously before the application." "" "" ""</seg>
<seg id="2899">"" "" "" "once the ACT value is more than 225 seconds, further monitoring is no longer required, provided that the 1.75 mg / kg infusion dose is administered correctly." "" "" ""</seg>
<seg id="2900">"" "" "" "in patients with moderate kidney function limitation (GFR 30-59 ml / min), which are subjected to a PCI (whether with bibalrudin against ACS or not), a lower infusion rate of 1.4 mg / kg / h should be used." "" "" ""</seg>
<seg id="2901">"" "" "" "if the ACT value is less than 225 seconds, a second pin dose of 0.3 mg / kg is to be administered and the ACT 5 minutes after the second pin dose should be checked again." "" "" ""</seg>
<seg id="2902">In patients with moderate kidney damage which were included in the phase III- PCI-study (REPLACE-2) which was included in the phase III- PCI-study (REPLACE-2) the ACT value was 5 minutes after the application of the biopsy-bolus without dose adjustment at an average 366 ± 89 seconds.</seg>
<seg id="2903">"" "" "" "3 In patients with severe kidney damage (GFR &lt; 30 ml / min) and also for dialysis patients, angiox is contraindicated (see section 4.3)." "" "" ""</seg>
<seg id="2904">Treatment with angiox may be initiated 30 minutes after the intravenous application of unfractionated Heparin or 8 hours after the subcutaneous administration of low-molecular heparin.</seg>
<seg id="2905">• known hypersensitivity to the active ingredient or any other component or against Hippdine • active bleeding or increased risk of bleeding due to a disorder of the hemostasesystems and / or irreversible bacterial endcarditis. • severe kidney damage (GFR &lt; 30 ml / min) and for dialysis patients</seg>
<seg id="2906">Patients are carefully monitored during treatment with regard to symptoms and signs of bleeding especially if bivalirudin is administered in combination with another anticoagulant (see section 4.5).</seg>
<seg id="2907">"" "" "" "even if in case of PCI patients under biopsy, most bleeding of arterial punctures can occur in patients suffering from a percutaneous coronary intervention (PCI), whereas the treatment in principle occurs everywhere." "" "" ""</seg>
<seg id="2908">"" "" "" "in patients who are treated with warfarin and treated with bibalrowdin, monitoring of the INR value (International Norised Ratio) should be considered to ensure that the value after settling the treatment with bivalirudin can be achieved again prior to treatment." "" "" ""</seg>
<seg id="2909">"" "" "" "starting from the knowledge of the mode of action of anticoagulants (Heparin, Warfarin, Thrombolytics or Thrombocytic inhibitors), it can be assumed that these drugs increase the risk of bleeding." "" "" ""</seg>
<seg id="2910">"" "" "" "in the combination of bibaludine with platocyte modulators or anticoagulants, the clinical and biological haemostasis parameters are to be checked regularly." "" "" ""</seg>
<seg id="2911">"" "" "" "the animal experimental studies are insufficient in relation to the effects of pregnancy, embryonic / fetal development, degeneration or postnatal development (see section 5.3)." "" "" ""</seg>
<seg id="2912">4612 were randomised to bivourudin alone; 4604 were randomised to biovalirudin plus GPIIb / IIIa inhibitor and 4603 were randomised to either unfractionated heparin or Enoxaparin plus GPIIb / IIIa inhibitor.</seg>
<seg id="2913">"" "" "" "in the bivourudin group and in the comparison groups treated with heparin, women and patients over 65 years of age were more likely to adverse events than in male or younger patients." "" "" ""</seg>
<seg id="2914">Severe bleeding was defined according to the ACUITY and Timi standards for severe bleeding such as in table 2 footnotes.</seg>
<seg id="2915">Both light and severe bleeding were significantly less frequently than in the groups with heparin plus GPIIb / IIIa inhibitor and bibalb / IIIa inhibitor (see table 2).</seg>
<seg id="2916">"" "" "" "ACUITY difficult bleeding was defined as one of the following events: intraocular, retroperitoneal, intraocular bleeding or bleeding in point area, reduction of hemoglobin mirror of ≥ 3 g / dl with well known blood supply, reoperation due to bleeding, application of blood products to transfusion." "" "" ""</seg>
<seg id="2917">"" "" "" "further, less frequently observed bleeding localizations occurring at more than 0.1% (occasionally) were" other "point positions, retroperitoneal, gastrointestinal, ear, nose or neck." "" "" ""</seg>
<seg id="2918">"" "" "" "the following information about side effects is based on data from a clinical study involving biopsy in 6,000 patients undergoing a PCI." "" "" ""</seg>
<seg id="2919">"" "" "" "in the bivourudin group and in the comparison groups treated with heparin, women and patients over 65 years of age were more likely to adverse events than in male or younger patients." "" "" ""</seg>
<seg id="2920">Both light and severe bleeding occurred significantly less often than in the comparison group under heparin plus GPIIb / IIIa inhibitor.</seg>
<seg id="2921">"" "" "" "the following side effects, which are not listed above, were reported in practice according to comprehensive application and are grouped according to system organclasses in table 6." "" "" ""</seg>
<seg id="2922">"" "" "" "in case of overdose, the treatment with biopsy must be stopped immediately and the patient is closely meshed to monitor signs of bleeding." "" "" ""</seg>
<seg id="2923">"" "" "" "angiox contains biobrudin, a direct and specific thrombininhibitor, which binds both the catalytic centre and the anion-binding region of thromboin, irrespective of whether Thrombine is bound in the liquid phase or at the tinness." "" "" ""</seg>
<seg id="2924">"" "" "" "the binding of bifimbine to thromboin, and thus its effect, is reversible because thromboin on its part splits the binding of Bivalirudin-ARG3-Pro4, which regenerates the function of the active centre of Thrombin." "" "" ""</seg>
<seg id="2925">"" "" "" "in addition, bibaludine with serum from patients with thrombocytopenia / heparin-induced thrombocytopenia (HIT / HITTS) was not induced to induce thrombocytopenia (HIT / HITTS)." "" "" ""</seg>
<seg id="2926">"" "" "" "in healthy subjects and in patients, bivourudin shows a dose and concentration-dependent anti-coagulatory effect that is evidenced by the extension of ACT, aPTT, PT, INR and TT." "" "" ""</seg>
<seg id="2927">"" "" "" "if a PCI was carried out following the patient, an additional pin of 0.5mg / kg is given and the infusion for the duration of the surgery can be increased to 1.75mg / kg / h." "" "" ""</seg>
<seg id="2928">In the arm A of the ACUITY study unfractionated heparin or eloxaparin was administered in accordance with the relevant guidelines for the treatment of acute coronary syndrome (ACS) in patients with unstable angina / non-ST lifting infarction (IA / NSTEMI).</seg>
<seg id="2929">Patients in arm A and B were also randomised to obtain a GPIIb / IIIa inhibitor either before the beginning of angiography (at the time of randomization) or PCI.</seg>
<seg id="2930">"" "" "" "in the ACUITY study, the characteristics of high-risk patients receiving angiography within 72 hours were spread evenly across the 3 treatment arms." "" "" ""</seg>
<seg id="2931">"" "" "" "approximately 77% of patients had a recurrent ischemia, 70% had dynamic EKG changes or increased cardiac biomarkers, 28% had diabetes and approximately 99% of all patients underwent angiography within 72 hours." "" "" ""</seg>
<seg id="2932">The primary analysis and results from the ACUITY study for the 30-tau and the 1 year endpoint for the total population (ITT) and for patients receiving aspirin and clopidogrel according to protocol (before angiography or before the PCI) are presented in tables 7 and 8.</seg>
<seg id="2933">ACUITY study; 30 days and 1-year risk difference for the combined ischemic endpoint and its components for patients receiving aspirin and Clopidogrel according to protocol *</seg>
<seg id="2934">Patients receiving Aspirin and Clopidogrel according to protocol received arm A arm B arm C UFH / Enox Bival B- A bival + GPIIb / IIIa + GPIIb / IIIa Risk Diff.</seg>
<seg id="2935">The frequency of bleeding both in ACUITY- and in the timi scale up to day 30 for the total population (ITT) and for patients receiving aspirin and clopidogrel according to protocol is shown in Table 9.</seg>
<seg id="2936">Patients who received Aspirin and Clopidogrel aggregate population (ITT) according to protocol BUFH / Enox Bival bival bival + + GPIIb / IIIa alone GPIIb / IIIa (N = 4604) (N = 4604) (N = 2842)%%%%</seg>
<seg id="2937">"" "" "" "* Clopidogrel before angiography or before PCI 1 An ACUITY severe bleeding was defined as one of the following events: intraocular, retroperito-neale, intraocular hemoglobin level of ≥ 3 g / dl with well known blood supply, reoperation due to bleeding, application of blood products to transfusion." "" "" ""</seg>
<seg id="2938">"" "" "" "the 30-day results, based on quadruple and triple endpoints of a randomised double blind study involving over 6,000 patients undergoing a PCI (REPLACE-2), are presented in Table 10." "" "" ""</seg>
<seg id="2939">Clinical studies with a small number of patients provided limited information on the use of angiox in patients with HIT / HITTS.</seg>
<seg id="2940">"" "" "" "the pharmacokinetic properties of bivalirudin were evaluated in patients receiving a percutaneous coronary intervention (PCI), and in patients with ACS." "" "" ""</seg>
<seg id="2941">It is expected that biodegraddin as peptide has a catabolism in its amino acid components with subsequent recycling of amino acids in the body pool.</seg>
<seg id="2942">The primary metabolic resulting from the split of the ARG3-Pro4 binding of the N-terminale sequence by Thrombin is not effective due to the loss of his affinity to the catalytic center of Thrombin.</seg>
<seg id="2943">"" "" "" "in patients with normal renal function, elimination is performed first order with a terminale half-life of 25 ± 12 minutes." "" "" ""</seg>
<seg id="2944">"" "" "" "based on conventional studies on safety macology, toxicity in repeated application, genotoxicity or reproductive toxicity, the preclinical data does not reveal any particular dangers to humans." "" "" ""</seg>
<seg id="2945">Toxicity in animals with repeated or continuous exposure (1 day to 4 weeks at an exposure to 10-faeces of the clinical steady state plasma concentration) limited to anti-shooting pharmacological effects.</seg>
<seg id="2946">"" "" "" "adverse events after prolonged physiological stress as a response to non-homeopathic coagulation were observed after short-term exposure comparable to those in clinical use, even with much higher dosage." "" "" ""</seg>
<seg id="2947">"" "" "" "if the ready-to-use solution 17 is not under controlled and validated aseptic conditions, it is no longer than 24 hours at 2 ° C to 8 ° C." "" "" ""</seg>
<seg id="2948">"" "" "" "Angiox is a freeze-dried powder in single dose glass bottles of type 1 glass to 10 ml, sealed with a butyl rubber stopper and sealed a cap of pressed aluminum." "" "" ""</seg>
<seg id="2949">"" "" "" "5 ml of sterile water for injection purposes are given in a bottle of angiox and slightly wenked until all dissolved, and the solution is clear." "" "" ""</seg>
<seg id="2950">5 ml. are taken from the bottle and diluted with 5% glucosine solution for the injection or with 9 mg / ml (0.9%) sodium chloride solution for injection in a total volume of 50 ml to obtain a final concentration of 5mg / ml bibaludine.</seg>
<seg id="2951">"" "" "" "the owner of the license agreement agrees to carry out the studies and pharmacovigilance activities presented in the Pharmacovigilance Plan, as described in version 4 of the Risk Management Plan (RMP) and in module 1.8.2 of the RMP agreed to by the CHMP." "" "" ""</seg>
<seg id="2952">"" "" "" "according to the CHMP Guideline, the revised RMP is to be submitted to the next Periodic Safety Update Report (PSUR) at the same time." "" "" ""</seg>
<seg id="2953">• Patients with chest pain caused by heart disease (acute coronary syndrome - ACS) • Patients to be operated in blood vessels (angioplasty and / or percutaneous coronary angioplasty - PCI).</seg>
<seg id="2954">"" "" "" "• You are pregnant or suspect that you might be pregnant, you intend to become pregnant - you are currently breastfeeding." "" "" ""</seg>
<seg id="2955">"" "" "" "no investigations of the effects on traffic tightness and the ability to operate machinery have been carried out, but you know that the effects of this drug are only short-term." "" "" ""</seg>
<seg id="2956">"" "" "" "if bleeding occurs, treatment with angiox is aborted. • Before starting the injection or infusion, you will inform your doctor about the possible signs of an allergic reaction." "" "" ""</seg>
<seg id="2957">Such reactions are rare (they occur in less than 1 out of 1000 patients treated). • An especially careful monitoring is performed if you have radiotherapy for the blood vessels (this treatment is referred to as beta or gamma-brachytherapy). • The dose you receive will depend on your body weight and the type of therapy you receive.</seg>
<seg id="2958">• 0.1 mg / kg body weight as an injection followed by an infusion (drip solution) with 0.25 mg / kg body weight per hour (0.1 mg / kg body weight per hour means a quarter of a milligram of the medication per kilogram of body weight per hour).</seg>
<seg id="2959">"" "" "" "probable, if angiox is administered in combination with other anticoagulant drugs (see Section 2" When applying angiox with other medicines). "" "" "" ""</seg>
<seg id="2960">These are occasional side effects (in less than 1 of 100 treated patients). • Thrombose (blood clots) that could cause serious complications such as heart attack.</seg>
<seg id="2961">"" "" "" "this is an occasional side effect (with less than 1 of 100 patients treated). • Pain, bleeding and bruising at the point point (after a PCI treatment)." "" "" ""</seg>
<seg id="2962">"" "" "" "please inform your doctor if any of the side effects listed will affect you significantly, or you may notice any side effects that are not indicated in this information information." "" "" ""</seg>
<seg id="2963">"" "" "" "after the date of expiry date, angiox should not be applied any more after the date given on the label and the carton." "" "" ""</seg>
<seg id="2964">Polska The Medicines Company UK Ltd.: + 800 843 633 26 lub + 41 61 564 1320 Landler λ: + 30 210 5281700 E-mail:</seg>
<seg id="2965">"" "" "" "Apidra is used to treat adults, adolescents and children over six years with diabetes who need treatment with insulin." "" "" ""</seg>
<seg id="2966">"" "" "" "Apidra is administered subcutaneous (under the skin) into the abdominal wall, the thighs or upper arm or as a permanent infusion with a insulin pump is administered." "" "" ""</seg>
<seg id="2967">"" "" "" "diabetes is a disease in which the body does not produce enough insulin to regulate glucose levels (sugar) in the blood, or the insulin can not be processed effectively." "" "" ""</seg>
<seg id="2968">"" "" "" "insulin lulisine differs very slightly from humanoid, and the change means that it works faster and shorter active duration than a short-effective human insulin." "" "" ""</seg>
<seg id="2969">Apidra was used in combination with a long-acting insulin for patients with type 1 diabetes in which the body cannot produce insulin in two studies with a total of 1 549 adults and in a study involving 572 children aged between four and 17 years.</seg>
<seg id="2970">"" "" "" "in type 2 diabetes, with which the body can not work effectively, Apidra was examined in a study of 878 adults." "" "" ""</seg>
<seg id="2971">The main indicator of efficacy was the change in the concentration of the substance glycosylated hemoglobin (HbA1c) in the blood that indicates how well the blood sugar is set.</seg>
<seg id="2972">"" "" "" "in the first study with type 1 diabetes, a reduction of 0.14% (from 7.60% to 7.46%) was determined in comparison to a reduction of 0.14% in insulin lisses." "" "" ""</seg>
<seg id="2973">In adults with type 2 diabetes the lowering of HbA1c concentration was 0.46% after six months with Apidra compared to 0.30% in human normal insulin.</seg>
<seg id="2974">"" "" "" "Apidra may not be used in patients who may be hypersensitive to insulin, or any of the ingredients that are already suffering from hypoglycemia." "" "" ""</seg>
<seg id="2975">"" "" "" "the doses of Apidra may need to be adjusted, if it is administered together with a number of other medicines that may affect blood glucose levels." "" "" ""</seg>
<seg id="2976">"" "" "" "in September 2004, the European Commission granted Sanofi-Aventis Germany GmbH a permit for placing Apidra in the whole European Union." "" "" ""</seg>
<seg id="2977">"" "" "" "Apidra can be used as subcutaneous injection either in the area of the abdominal wall, the thighs or the delta muscle or subcutaneous by continuous infusion in the abdominal wall." "" "" ""</seg>
<seg id="2978">"" "" "" "due to reduced glucose tolerance and reduced insulin metabolism, the insulin need for patients with a restriction of liver function can be reduced." "" "" ""</seg>
<seg id="2979">"" "" "" "any change of action, the brand (manufacturer), the insulin type (normal, NPH, zinc delayed, etc.), the type of insulin (animal insulin) and / or the method of production may change the need for insulin." "" "" ""</seg>
<seg id="2980">"" "" "" "3 A inadequate dosage or abortion of treatment, particularly in patients with insulin-based diabetes, can lead to hyperglycemia and diabetic ketoacidosis. these conditions are potentially life threatening." "" "" ""</seg>
<seg id="2981">"" "" "" "changing a patient to another type of insulin or an insulin in another manufacturer should take place under strict medical supervision, and may require a change of dosage." "" "" ""</seg>
<seg id="2982">"" "" "" "the point of occurrence of hypoglycemia depends on the active profile of the insulin used, and can therefore change when changing the treatment scheme." "" "" ""</seg>
<seg id="2983">"" "" "" "oral antidiabetic, angiotensin-converting enzyme, methotensin, chloroxifylline, propoxyphenol, propoxyphenols and sulfonamide-antibiotics are among the substances that can enhance the tendency to hypoglycemia (ACE) inhibitors." "" "" ""</seg>
<seg id="2984">"" "" "" "in addition, under the effect of Sympathy such as beta blockers, Clonidin, Guanethidin and reserves the symptoms of adrenergic counterbalance can be weakened or absent." "" "" ""</seg>
<seg id="2985">"" "" "" "animal experimental studies on reproductive toxicity showed no differences between intraembryonic and human insulin in relation to pregnancy, embryonic / fetal development, birth or postnatal development (see section 5.3)." "" "" ""</seg>
<seg id="2986">"" "" "" "it is not known whether insulin secretes into human breast milk, but generally insulin is neither absorbed into the breast milk nor is it absorbed after oral use." "" "" ""</seg>
<seg id="2987">"" "" "" "most common: ≥ 1 / 100, &lt; 1 / 100; occasionally: ≥ 1 / 100, &lt; 1 / 100; very rare: ≥ 1 / 1000, &lt; 1 / 100; very rare: ≥ 1 / 100; &lt; 1 / 100; &lt; 1 / 100;" "" "" ""</seg>
<seg id="2988">"" "" "" "cold weldiness, cool and pale skin, tiredness, nervousness or tremor, anxiety, unusual creation or weakness, confusion, lack of concentration, headache, nausea and palpitations." "" "" ""</seg>
<seg id="2989">"" "" "" "lipodystrophy is neglected to continuously change the injection unit within the injection unit, as a result, a lipodystrophy may occur at the injection site." "" "" ""</seg>
<seg id="2990">Severe hypoglycemias with unconsciousness can be treated by means of an intramuscular or subcutaneous injection of glucose (0.5 to 1 mg) administered by a given person or intravenous glucose from glucose by a doctor.</seg>
<seg id="2991">"" "" "" "after gluing, the patient should be monitored in a hospital to determine the cause of the serious hypoglycemia and to avoid similar episodes." "" "" ""</seg>
<seg id="2992">Insulin reduces blood sugar levels by stimulating the peripheral glucose (especially skeletal muscles and fat) as well as by inhibiting glucose production in the liver.</seg>
<seg id="2993">Studies with healthy volunteers and patients with diabetes have shown that at subcutaneous GA- be from insulin gulisin the effectiveness occurs faster and the duration of operation is shorter than with hu- manic normal insulin.</seg>
<seg id="2994">In a study involving 18 male individuals aged 21 to 50 with type-1 diabetes m- tus insulin-ulisin in the therapeutically relevant dosage range from 0.75 to 0.15 E / kg showed a proportional impact of the glucoseching effect as well as humanoid.</seg>
<seg id="2995">"" "" "" "insulin lulisin has twice as fast acting as normal human insulin, and achieves the total glucosechend effect approximately 2 hours earlier than human insulin." "" "" ""</seg>
<seg id="2996">"" "" "" "from the data it was obvious that in an application of insulin lulisin 2 minutes before the meal, a comparable post-dendal glycaemic control is achieved just like with human normal insulin, which is given 30 minutes before the meal." "" "" ""</seg>
<seg id="2997">"" "" "" "insulin lulisin 2 minutes before the meal was taken, a better post-denthal control was achieved than with human normal insulin, which was given 2 minutes before the meal." "" "" ""</seg>
<seg id="2998">"" "" "" "if insulin is applied in 15 minutes after the start of the meal, a similar glycemic control, like in human normal insulin, will be given before the meal (see Figure 1)." "" "" ""</seg>
<seg id="2999">Insulin-ulisin in gift 2 minutes (GLULISIN - before the start of the meal) before starting the meal (figure 1A) and in comparison to human normal insulin that was given 2 minutes (NORMAL - before) before a meal (figure 1B).</seg>
<seg id="3000">Islanisin in gift 15 minutes (GLULISIN - afterwards) after the start of the meal compared to human standard maline which was given 2 minutes (NORMAL - before) before the start of the meal (figure 1C).</seg>
</doc>
</tstset>
